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Abstract 
Health systems worldwide experience large evidence practice gaps with underuse of 
proven therapies, overuse of inappropriate treatments and misuse of treatments due 
to medical error. Quality improvement (QI) initiatives have been shown to overcome 
some of these gaps. Computerised interventions, in particular, are potential enablers 
to improving system performance. However, implementation of these interventions 
into routine practice has resulted in mixed outcomes and those that have been 
successfully integrated into routine practice are difficult to sustain.  
The objective of this thesis is to understand how a multifaceted, computerised QI 
intervention for cardiovascular disease (CVD) prevention and management was 
implemented in Australian general practices and Aboriginal Community Controlled 
Health Services and assess the implications for scale-up of the intervention. The 
intervention was implemented as part of a large cluster-randomised controlled trial, 
the TORPEDO (Treatment of Cardiovascular Risk using Electronic Decision Support) 
study. The intervention was associated with improved guideline recommended 
cardiovascular risk factor screening rates but had mixed impact on improving 
medication prescribing rates.  
In this thesis, I designed a multimethod process and economic evaluation of the 
TORPEDO trial. The aims were to:  
i. Develop a theory-informed logic model to assist in the design of the overall 
evaluation to address study aims (Chapter 3). 
ii. Conduct a post-trial audit to quantify changes in cardiovascular risk factor 
screening and prescribing to high risk patients over an 18-month post-trial 
period and understand the impact of the intervention outside of a research 
trial setting (Chapter 4). 
vi 
iii. Use normalisation process theory to identify the underlying mechanisms by 
which the intervention did and did not have an impact on trial outcomes 
(Chapter 5). 
iv. Use video ethnography to explore how the intervention was used and 
cardiovascular risk communicated between patients and healthcare providers 
(Chapter 6).  
v. Conduct an economic evaluation to inform policy makers for delivering the 
intervention at scale through Primary Health Networks in New South Wales 
(Chapter 7). 
vi. Use a new theory to explain the factors that drove adoption and non-adoption 
of the intervention and assess what modifications may be needed to promote 
spread and scale-up (Chapter 8).  
I found variable outcomes during the post-trial period with a plateauing of 
improvements in guideline recommended screening practices but an ongoing 
improvement in prescribing to high risk patients. The group that continued to have 
the most benefit was patients at high CVD risk who were not receiving 
recommended medications at baseline. The delay in prescribing recommended 
medication suggests healthcare providers adopt a cautious approach when 
introducing new treatments.  
Six intervention primary healthcare services participated as case studies for the 
process evaluation. Qualitative and quantitative data sources were combined at each 
primary healthcare service to enable a detailed examination of intervention 
implementation from multiple perspectives. The process evaluation identified the 
complex interaction between several underlying mechanisms that influenced the 
implementation processes and explained the mixed trial outcomes: (1) organisational 
mission; (2) leadership; (3) the role of teams; (4) technical competence and 
dependability of the software tools. Further, there were different ‘active ingredients’ 
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necessary during the initial implementation compared to those needed to sustain use 
of the intervention.  
In the video ethnography and post-consultation patient interviews, important insights 
were gained into how the intervention was used, and its interpretation by the doctor 
and patient. Through ethnographic accounts, the doctor’s communication of 
cardiovascular risk was not sufficient in engaging patients and having them act upon 
their high-risk status; effective communication required interactions be assessed, 
discussed and negotiated.  
The economic evaluation identified the cost implications of implementing the 
intervention as part of a Primary Health Network program in the state of New South 
Wales, Australia; and modelled data looked at the impact of small but statistically 
significant reductions in clinical risk factors based on the trial data. When scaled to a 
larger population the intervention has potential to prevent major CVD events at under 
AU$50,000 per CVD event averted largely due to the low costs of implementing the 
intervention. However, the clinical risk factor reductions were small and a stronger 
case for investment would be made if the effects sizes could be enhanced and 
sustained over time. The findings from chapters 4-6 provide insight into the intricacy 
of the barriers influencing implementation processes and adoption of the intervention.  
Taken together, these studies provide a detailed explanation of the processes that 
may be required to implement such an intervention at scale and the factors that 
might influence its impact and sustainability. The findings are expected to assist 
policy makers, administrators and health professionals in developing multiple 
interdependent QI strategies at the organisational, provider and consumer levels to 
improve primary healthcare system performance for cardiovascular disease 
management and prevention.  
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PART A 
BACKGROUND 
28 
Chapter 1: Introduction  
In 1978, the principles of primary healthcare were brought to the forefront at an 
international conference convened by the World Health Organization (WHO) and the 
United Nations Children’s Fund held in Alma Ata. This meeting marked a shift in 
thinking around the role of primary healthcare services in society.1 The Declaration 
made at Alma Ata affirmed principles of universal access, affordability, multidisciplinary 
care and community participation.2,3  
Over two decades later, Barbara Starfield’s seminal work demonstrated the importance 
of high quality primary care in improving health system performance.4 She found that 
countries with strong primary care infrastructure and a high proportion of primary care 
physicians, demonstrated improved health outcomes including reduced all-cause 
mortality, reduced health inequities and reduced health system costs.5 Starfield argued 
that ‘four Cs’ should be foundational to a strong primary care system - accessible first 
contact, continuous, comprehensive and coordinated care and that these elements 
should be present regardless of the socioeconomic, demographic or clinical 
characteristics of the population served.6,7 These elements align closely with the core 
principles of the Declaration of the Alma Ata.8,9  
Despite this evidence being established over twenty years ago, the attainment of high 
performing primary healthcare systems remains a challenge not only in low income 
countries with gross underspends on healthcare, but also in high income countries with 
relatively large financial resources.10  
In this chapter I provide a brief overview of the Australian primary healthcare system 
and outline the work I have undertaken to evaluate a complex strategy to improve 
primary healthcare quality for cardiovascular disease prevention and management.   
1.1 The Australian Healthcare System  
Australians have amongst the highest life expectancy in the world.11 Despite a steady 
downward trend in mortality, however, Australians experience the highest number of 
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years (10.9 years) with ill health amongst Organisation for Economic Cooperation and 
Development (OECD) countries.12 When looking at health system performance, 
Australia also ranks high in overall performance, but an area of concern is rising health 
inequities with Australia being amongst the lowest performing OECD countries (Table 
1.1).13 These inequities (health outcomes and access to high quality health care) are 
most strongly experienced by those living in remote and rural regions and those in the 
lowest socioeconomic groups.14,15  
The Commonwealth Fund’s report on the comparison of OECD countries’ healthcare 
system performance calculated the mean of the ‘measure performance scores’ in 
each domain and then ranked each country from 1 to 11. The overall performance 
scores and rankings were based on the mean of the five domain-specific 
performance scores and each domain is weighted equally for the overall 
performance scores. 
Table 1.1 OECD countries healthcare performance 
 
Source: Commonwealth Fund analysis13 
 
In terms of health system financing, in 2016 Australia expended over 10% of gross 
domestic product on healthcare for the first time.16 These rising costs call into question 
the sustainability of the health system going forward. Australia’s publicly funded 
universal health care scheme, Medicare, has provided coverage for Australian citizens 
and permanent residents since 1984.17 Medicare rebated services are provided in a 
variety of ambulatory care settings by specialist and general medical practitioners, 
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nurses, allied health professionals, midwives, pharmacists, dentists and Aboriginal 
Health Workers. In addition, there is a publicly funded Pharmaceutical Benefits Scheme 
(PBS) that provides subsidised access to approved medications. These two schemes 
are funded by the federal government. The other major sourcing of funding of the 
health system include state and territory governments (primarily responsible for funding 
inpatient hospital services), the Department of Veteran’s Affairs, injury compensation 
funds, private health insurers and consumers themselves (Figure 1.1).18 
Despite the obvious strengths of the current healthcare system, the Australian 
government faces major challenges of rising health expenditures, widening inequalities 
and increasing demands related to increasing burden of chronic diseases.19,20 
Strategies that support Starfield’s four C’s are of critical importance to support 
Australia’s ability to successfully tackle these challenges.  
Figure 1.1 Health Services – funding and responsibility, 2013-14  
 
Source: AIHW, Australia’s Health 2016 12 
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Primary healthcare structure 
Within Australia’s complex healthcare system, primary healthcare occurs in a diversity 
of organisations including but not limited to general practices, Aboriginal Community 
Controlled Healthcare Services (ACCHSs), state government funded services, allied 
healthcare facilities, and pharmacies.21 Services range from acute medical care, health 
promotion, prevention and screening, early intervention, treatment and management. 
My thesis focuses on three players in the primary healthcare systems – general 
practices, ACCHSs and Primary Health Networks (PHNs). 
General Practices 
General practices are the foundation of primary healthcare in Australia. Practices vary 
greatly in terms of size (ranging from solo doctor practices through to corporate 
practices with a large number of sites and doctors), location (urban, rural and remote), 
provision of multidisciplinary care, business models and co-payment charges, 
integration of care with hospital and speciality services and community outreach 
programs.22 General practices operate as gatekeepers to ‘secondary care’ provided by 
specialists. Without a general practitioner (GP) referral, specialists are generally unable 
to bill the government for reimbursement for services provided.  
Aboriginal Community Controlled Health Services 
Australia’s health system consistently performs worse for Aboriginal and Torres Strait 
Islander people compared with non-Indigenous Australians in terms of access and 
quality of care.23 In order to overcome barriers to accessing appropriate care, the first 
ACCHS was established in the early 1970s as a primary healthcare organisation 
governed and operated by the local Aboriginal community to “deliver holistic, 
comprehensive and culturally appropriate healthcare to the community which controls 
it”.24,25 ACCHSs are founded on the principle of self-determination supporting Aboriginal 
communities to control and tailor their multifaceted healthcare needs.26   
Although it is difficult to quantify the exact number of ACCHSs in Australia, in 2014-
2015, 138 ACCHSs submitted data to the Australian Institute of Welfare and Health as 
a part of their funding agreements with the Australian government.27 Using these data, 
32 
Figure 1.2 gives an overview of the number of Aboriginal and Torres Strait Islander 
peoples accessing care in comparison to the total Aboriginal population.  
 
Figure 1.2 Number of Indigenous population using ACCHSs reporting to the 
Online Service Report (OSR)27 
 
Primary Health Networks 
On July 1, 2015, thirty-one Primary Health Networks (PHNs) were established as meso-
tier, independent organisations with regional boundaries aligned to state and territory 
Local Hospital Networks.28 The PHNs’ main objectives are to improve efficiency and 
effectiveness of medical services for patients especially those with poor health 
outcomes; and to improve coordination of care between primary, secondary and 
hospital services. They are governed by a board of directors and often have community 
advisory committees.   
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PHNs play a role in identifying the health priorities of the regions they service; providing 
support and professional development for healthcare providers; integration of care with 
Local Hospital Networks; commissioning of services to address health care priorities; 
and supporting implementation of federal government programs. Flexible funding of up 
to $852 million was committed for PHNs over 3 years from 2015-2016.29 Although a 
relatively new player in the health care system, they have potential to play a major role 
in improving system performance, as has been the case in other countries such as 
New Zealand and the United Kingdom.30  
1.2 Strategies to improve quality of primary healthcare 
 
In this thesis I explore intervention strategies to improve primary healthcare quality in 
the Australian health system context. I focus on cardiovascular disease (CVD) which is 
the second leading cause of disease burden in Australia and draw particular attention 
throughout the thesis to Aboriginal and Torres Strait Islander communities who 
experience CVD at far greater rates than other Australians.31  
Evidence-based clinical guidelines play an essential role in promoting quality of care 
and minimising unwanted variation and error. These guidelines are "systematically 
developed statements to assist practitioner and patient decisions about appropriate 
health care for specific clinical circumstances”.32 Despite widely available clinical 
guidelines, their implementation into routine practice remains a challenge. Studies in 
both the United States (US) and Australia have shown that adherence to evidence-
based practices occurs only around 50% of the time.33,34 Specific to cardiovascular 
disease management and prevention, there are similar large evidence-practice gaps for 
screening and prescribing appropriately for cardiovascular disease risk prevention and 
management.35,36 The reasons underpinning these gaps are complex and operate at 
system, organisational, provider and consumer levels.37,38 
To address evidence-practice gaps, quality improvement (QI) strategies have been 
implemented to improve efficiency and processes of healthcare with the goals of 
achieving sustained health outcomes. A potential facilitator of quality improvement 
strategies is the use of health information technologies (HIT). Various forms of HIT have 
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been shown to be effective in trial settings,39-43 but questions remain about 
generalisability, transferability to different settings and cost implications.44-46 In Chapter 
2, I appraise the literature in more detail on quality improvement strategies with specific 
reference to the role of HIT. 
1.3 The importance of process evaluations 
Randomised controlled trials (RCT) are generally considered to be the gold standard for 
determining efficacy of interventions due to their ability to hold constant potential 
confounding variables, thus isolating the effects of the interventions being tested. 
However, such a design assumes interventions to be ‘fixed’ agents that can be isolated 
from the environment in which they are tested. When such interventions are 
implemented in complex social settings such as health, it is the interaction of the 
interventions and these contextual elements that need also be considered when 
assessing impact.47 Consequently, effectiveness data on its own does not sufficiently 
inform decision makers how and why interventions can be applied to different settings. 
Process evaluations embedded within trials are one potential solution to this issue. 
Process evaluations provide the ability to “assess fidelity and quality of implementation, 
clarify causal mechanisms and identify contextual factors associated with variation in 
outcomes”.48,49 Thus, the focus is on mechanisms and processes by which an 
intervention is implemented and understanding barriers to uptake at multiple levels 
within a complex health system.  
In this thesis, I designed and implemented a multimethod process evaluation of a 
computerised quality improvement intervention for improving primary care management 
of CVD in Australian general practices and ACCHSs. A multimethod approach is 
defined as “the use of two or more research methods in a single study when one (or 
more) of the methods is not complete in itself”.50 This allows the integration of findings 
from different angles, illuminating strengths and weaknesses in a diversity of methods.51   
The quality improvement intervention for CVD risk management was tested in a 
randomised controlled trial within 60 Australian General Practices and ACCHSs.52 The 
primary results paper (Appendix E) outlined mixed effectiveness in terms of clinical and 
process outcome measures without much clarity on which factors promoted or 
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hindered its impact. I designed a series of discrete but interrelated studies to provide a 
deeper understanding of the intervention’s impact and to draw broader conclusions on 
why complex health service interventions often produce equivocal effectiveness results.   
Specific aims include the following (section 1.4): 
a. Conduct a literature review of the trends and impact of quality improvement 
strategies and health information technologies in improving health systems 
(Chapter 2). 
b. Design a theory-informed logic model to assist in the planning, conduct and 
implementation of the process evaluation (Chapter 3). 
c. Quantify the efficacy of the intervention in a post-trial setting to assess 
trends in outcomes over a three-year period (Chapter 4). 
d. Describe, using a case study approach, the underlying mechanisms of 
implementation of the intervention and interaction with contextual factors 
that resulted in variable outcomes at each case study health service 
(Chapter 5).   
e. Explore through ethnographic methods, how the intervention was actually 
used in practice and how cardiovascular risk communicated and perceived 
by patients and healthcare providers (Chapter 6). 
f. Conduct a modelled cost-effectiveness analysis of the intervention to inform 
policy makers on establishing a large-scale cardiovascular prevention and 
management program delivered by Primary Health Networks in Australia 
(Chapter 7). 
The purpose of this research is to go beyond effectiveness studies and simple lists of 
barriers and facilitators to implementation of complex quality improvement 
interventions. It aims to provide a holistic understanding of what drives change in 
primary health care services, what role HIT plays in supporting that change and what 
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might be contextual factors that support or hinder the uptake of HIT into routine 
practice.  
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1.4 Structure of the thesis 
 
 
Part A: Background 
 
Chapter 1: Introduction  
 
Chapter 2: Literature review of the trends and impact of quality improvement strategies 
and health information technology 
 
 
 
 
Part B: Development of a Theory-informed Process Evaluation 
 
Chapter 3: A theory-informed logic model to assist in the planning, conduct and 
implementation of the process evaluation  
 
 
 
 
 
Part C: Sustainability, Adoption, Utilisation and Scalability 
 
Chapter 4: A quantitative study evaluating the efficacy of the intervention in a post-trial 
setting to assess trends in outcomes over three years  
 
Chapter 5: Mixed methods evaluation exploring the underlying mechanisms of 
implementation of the intervention and interaction with contextual factors that resulted 
in variable outcomes 
 
Chapter 6: Ethnographic evaluation of how the intervention was used in practice, how 
cardiovascular risk communicated and perceived by patients and healthcare providers  
 
Chapter 7: Modelled cost-effectiveness of the intervention delivered within Australian 
Primary Health Network settings 
 
 
 
 
 
Part D: Implications 
 
Chapter 8: Discussion and conclusions 
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Chapter 2: Literature review 
2.1 Chapter Overview 
The translation of research evidence into routine clinical practice is a major challenge 
faced by health systems worldwide. This chapter provides a broad overview of the 
existing literature and evidence in which my research was conducted. The first section 
reviews the international literature on quality improvement (QI) initiatives both in general 
and those with a specific focus on health information technology. The second section 
focuses on strategies implemented in Australia to improve delivery of care.  
2.2 Quality improvement strategies in healthcare 
Why the need for quality improvement strategies? 
Healthcare systems performing well below acceptable levels expose patients to wide 
variations in care despite advances in medicine and technology.1,2 In the landmark 
study on the state of the US healthcare system published in 2003, McGlynn et al found 
only 55% of patients were receiving recommended care (evidence-based clinical 
practice).3 Point-of-care evidence practice gaps accounted for more than $9 billion per 
year in lost productivity and approximately $2 billion per year in hospital costs in the US 
in 2004.4 This has sparked an urgency in improving the quality of healthcare worldwide 
along with system redesign proposals.5 The Institute of Medicine’s (IOM) seminal 
report, Crossing the Quality Chasm: A New Health System for the 21st Century, 
describes strategies to improve delivery of healthcare and address quality gaps 
focussing on underuse of evidence based practices, overuse of non-evidenced 
practices and misuse of therapies that compromise patient safety.1 
Defining quality improvement? 
QI is a well-established process to improve the efficiency and processes of health care 
with goals of achieving sustained improvements in system performance and health 
outcomes.2 The US Agency for Healthcare Research and Quality describes high quality 
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healthcare as “doing the right thing, at the right time, in the right way, for the right 
person – and having the best possible results”.3 
The concept of modern day quality improvement came to the forefront by Walter 
Shewhart in 1931 when he determined that a reduction in excessive variation and 
waste minimised inspections in manufacturing processes resulting in reduced costs.4 
His protégé Williams Edwards Deming recognised quality as a primary driver for 
industrial success when applied strategically. His framework, the System of Profound 
Knowledge, states that improvement of practice or organisation is based on four 
interdependent elements: appreciation of the system, understanding types of variation, 
psychology (importance of understanding the motivation of people), and the theory of 
knowledge (epistemology).5 At the core of these elements is his Plan-Do-Study-Act 
(PDSA) cycle of learning to continually improve and still today this remains one of the 
basic tools for implementing continuous quality improvement (CQI) programs in 
healthcare settings.  
Measuring quality in healthcare 
A systematic measurement of quality assesses whether improvement strategies: (1) 
lead to positive changes in the primary endpoints; (2) contribute to unintended 
consequences within the system; and (3) require additional resources to bring 
processes to an acceptable level of quality.6 Avedis Donabedian described key areas of 
assessment that should be considered: structure, processes, and outcomes.7 
Structural measures include the accessibility, availability and quality of resources, 
management systems and policy guidelines. Process measures assess delivery of 
healthcare services by analysing activities of health professionals over time (e.g., rate of 
unscientific care, inappropriate care, geographic variations in practice, medical injury to 
patients). Outcome measures indicate the end results of healthcare received based on 
group data such as mortality, risk factor screening, medication prescribing and patient 
satisfaction.   
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Quality improvement benchmarks 
In the 1990s, with the rise of evidence-based medicine and numerous studies 
demonstrating suboptimal quality of care, the need for systemic performance 
measurements became a priority. There was more pressure on government, decision 
makers and healthcare providers to engage in activities to measure and evaluate health 
system performance for improved accountability and understanding of the value of 
services. This led to the development of performance indicators (PIs) and measures 
that encompassed national targets for quality improvement.8 
In the US for example, in 1999, legislation was put in place for the Agency for 
Healthcare Research and Quality (AHRQ) to undertake the planning effort to develop 
systematic collection and analysis of healthcare data for greater public reporting.9 This 
would allow identification of areas of greatest need, monitor trends over time, and 
identify and subsequently replicate strategies that are successful at addressing 
deficiencies. A Strategic Framework Board was established to develop performance 
indicators for the national quality measurement and reporting system that would be 
used to analyse variation in all areas of health system delivery and care as a national 
platform for quality improvement measurements. Two reports were to be published 
annually starting in 2003, (1) National Healthcare Quality Report and (2) National 
Healthcare Disparities Report which was to be the vehicle of communication for policy 
makers, healthcare providers and the public to enhance awareness and understanding 
of quality issues, track progress of improvement initiatives and policy changes.  
Similar major initiatives to measure and report on their respective health system 
performance were taking place around the same time period in the UK (the Quality 
Outcomes Framework), Canada (Health Indicator Framework) and Australia (The 
National Health Performance Framework). In the meantime, conceptual frameworks for 
measuring performance indicators as a platform for international comparison have been 
developed for use by organisations such as the WHO and the OECD.10-12   
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Models for quality improvement  
In the last three decades, there has been a multitude of models implemented for 
measurable improvements in provision of care, health systems and population health. 
Although by no means exhaustive, three models are relevant to my thesis: Quality 
Improvement Collaboratives (QICs), the Chronic Care Model (CCM), and Patient 
Centred Medical Homes (PCMHs). 
Quality Improvement Collaboratives  
One of the earliest QI models in healthcare was the QIC (also known as learning 
collaboratives, learning communities, learning networks, and communities of practice).13 
First formed in the 1980s, such models are now used extensively to promote 
improvement in healthcare.14 A collaborative brings together multidisciplinary teams 
from different healthcare organisations to meet over several months to work towards 
identifying best practice and change strategies, applying improvement methods, 
reporting and sharing information on performance of a selected area of healthcare.15,16 
The aim is to close the gap between potential and actual performance by testing and 
implementing changes quickly across many organisations allowing for broad 
dissemination of knowledge. Going beyond PI benchmarking, this methodology is 
intended to stimulate culture change within a network and increase the likelihood that 
improvements will be sustained.  
One of the first successful QICs was the Northern New England Cardiovascular 
Disease Study Group formed in 1987.17,18 The collaboration took place among 23 
cardiothoracic surgeons in the US States of Maine, New Hampshire, Vermont, and at 
five medical centres where surgeons worked. Mortality data as endpoint of coronary 
artery bypass grafting (CABG) procedures were collected from July 1987 through July 
1993. During this time surgeons identified variability in mortality rates between centres 
and surgeons which they concluded as a “breakthrough in attitude, and notes that 
such breakthroughs are prerequisite for improvement”.14 A structured intervention was 
implemented between 1990-1991 with a 24% reduction of in-hospital morality rates 
associated with CABG. Another similar successful collaborative initiative that improved 
hospital care in the late 1980s was the Vermont Oxford Network.19 Box 2.1 outlines a 
generic set of key concepts derived from these two successful collaboratives. 
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Box 2.1 Key concepts behind multi-organisational collaborative improvement 
efforts 
 Multiple organisations 
 Quantified variability in process or outcome 
 Open sharing 
 Internal process characterisation 
 Formal benchmarking visits 
 Identification of “best practices” 
 Replication efforts 
 Measured improvement 
Source: Plsek 199714 
In 1995, the most well-known QIC model was developed by the Boston-based Institute 
for Healthcare Improvement known as the Breakthrough Series. Unlike earlier QICs, 
where participation was for several years, the Breakthrough Series was implemented 
for a shorter time-frame of 6-15 months for quicker impact.20,21 Although it has been 
continuously modified as more organisations adapt the model, the premises remain 
substantively unchanged (Box 2.2). 
Box 2.2 Breakthrough Series foundation for collaborative improvement 
Premise for Collaborative Improvement 
 A substantial gap exists between knowledge and practice in 
healthcare. 
 Broad variation in practice is pervasive. 
 Examples of improved practices and outcomes exist, but they need 
to be described and disseminated to other organisations. 
 Collaboration between professionals working toward clear aims 
enables improvement. 
 Healthcare outcomes are the results of processes.  
 Understanding the science of rapid cycle improvement can 
accelerate demonstrable improvement. 
Source: Kilo, 199820 
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QICs are being used extensively in diverse health system settings, organisational 
contexts and other countries.22,23 Quality programs based on this strategy are being 
used increasingly across the UK, Canada, Australia and European countries.  In the UK 
and Netherlands, health authorities support nationwide QICs. From 2000-2002, the UK 
National Primary Care Development Team implemented the National Primary Care 
Collaborative (NPCC) to over 2000 general practices serving 11.5 million patients, the 
largest primary health care improvement program in the world. This resulted in a 60% 
reduction in waiting time to see primary healthcare providers, reductions in delays in 
accessing secondary care, and improved care quality and reduction in mortality of 
patients with existing coronary heart disease.24,25 The successes of NPCC prompted 
the design and implementation of the Australian Primary Care Collaborative (APCC) 
program in 2003 (section 2.4).   
Despite large-scale implementation in many settings, the evidence of effectiveness, 
cost effectiveness and change are inconclusive.15,26,27 Schoueten et al. in their 
systematic review found only nine out of seventy-two studies used controlled trial 
designs to measure effects of QIC on processes of care and/or outcomes.28 Two of the 
nine studies were RCTs with one based on the Breakthrough Series which did not 
show any effects on their key processes or intermediate outcomes of care; while the 
other RCT based on the Vermont Oxford method showed significant improvements in 
processes of care and no improvement in patient outcomes. Six controlled before and 
after studies and one interrupted time series based on a mix of the Breakthrough Series 
and Vermont Oxford Network largely demonstrated modest improvements in 
processes of care. Conversely, Wells et al recently conducted a systematic review of 
literature from January 1995 to December 2015.16 Sixty-four studies were identified (10 
cluster RCTs, 24 controlled before-after studies and 30 interrupted time series studies). 
Around 85% found significant improvements in some of their intended aims, however 
there was considerable heterogeneity in outcomes, the quality of the studies reported 
was low and there is a substantial risk of reporting bias.  
Despite this mixed evidence base, QICs clearly have demonstrated potential for 
diffusion of innovation and evidence.29 However, disentangling successful components 
of QICs and the settings in which they are most likely to work are complex and 
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challenging. QICs by nature are multifaceted with variation in teams, behaviour, cultural 
and social context between organisations, complexity of the area of change, along with 
potentially requiring substantial investment of time, effort, resources and funding. These 
challenges have prompted inquiry into understanding “how and why” QICs work – 
identifying the determinants of their effectiveness.30-32 AHRQ developed a taxonomy of 
key elements derived from fifteen studies over the last two decades. The taxonomy was 
mapped to four elements (innovation, communication, time and social systems) based 
on Roger’s diffusion of innovation framework, and then further layered to other theories 
to help guide and facilitate adoption, implementation, and spread of QIC strategies 
(Box 2.3).13 Such taxonomies may be useful in assisting policy makers and funders in 
identifying which factors and approaches can promote successful collaboratives in 
specific settings.  
Box 2.3 The Agency for Healthcare Research and Quality’s learning collaborative 
taxonomy 
Primary elements Secondary elements 
Innovation Type of change 
 Degree of prescription 
 Scope 
 Supporting tools 
Communication Mode or venue 
 Directionality 
 Frequency 
 Degree of formality  
Time  Duration of learning collaborative 
 Duration of member recruitment 
 Rate of attainment or adoption 
 Sustainability of learning collaborative 
Social systems Degree of credibility of host or convener and leadership 
 Membership characteristics 
 Governance 
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 Purpose and degree of shared vision 
 Culture of the learning collaborative 
 Members’ activity level  
 Roles, process, and structure 
Source: Nix et al. 13  
 
Chronic Care Model 
Since the late 1990s, the rapid rise in chronic illnesses has posed new challenges for 
health systems as it has exposed fragmentation in care delivery systems. This 
stimulated calls for integrated physical, psychological or social medical care with a 
greater emphasis on self-management.33 Edward Wagner with support from Robert 
Wood Johnson Foundation developed the CCM as a guide for healthcare systems to 
improve the care and management of chronic illnesses.34 The model can be applied in 
diverse healthcare organisations, however the majority of health services for chronic 
illnesses are performed in primary healthcare settings. Closely aligned with Starfield’s 
‘four Cs’, the CCM has 6 essential domains to guide delivery of effective chronic care: 
(1) community resources (healthcare provider organisation needs to have linkages with 
community based resources such as exercise programs or senior centres); (2) health 
care organisation structure, goals and values need to be aligned with those of insurers, 
funders and other providers (i.e. insurance subsidies for chronic care), (3) self-
management support (educating and helping patients and their families with the skills to 
use self-management tools, e.g., blood pressure cuffs, medication use, lifestyle 
support); (4) delivery system redesign (separating acute care from planned 
management of chronic conditions by creating practice teams with division of labour 
and planned visits); (5) decision support (evidence-based clinical guidelines integrated 
with patient records or reminder system); and (6) clinical information system (reminder 
system, physician performance feedback and clinical audit reports integrated with 
reminder system).35  
QIC methods have been actively incorporated into the CCM to facilitate change in 
delivery of care. An evaluation of forty-two organisations implementing CCM alongside 
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QICs found that the model was associated with 41 organisations (98%) able to 
generate change and more closely align their system to at least five out of the six CCM 
elements; however the level of intensity (quantity and the depth of the intervention 
activities) was limited in year-long collaboratives.36 The majority of systematic reviews 
assessing effectiveness of CCM in improving health outcomes have found modest 
improvements.37-41 A limitation to the evidence base is that most studies include short-
term randomised trials or before-after studies with a short follow-up, and outcomes 
have focussed mainly on processes of care and less on health outcomes. Davy et al in 
their systematic review evaluated in more detail the change in healthcare practices 
associated with implementation of CCM from studies worldwide.42 Consistent with the 
rationale for QICs, a key finding from this review was the importance of reflective 
practice by teams creating a collegial environment to reflect, learn and adopt 
change.43,44 However the findings went further, highlighting that structural factors 
including leader support, extensive time and resources are critical for implementation 
and sustainability of the intervention. This is resonant with Donabedian’s structure-
process-outcome framework and highlights the importance of additional financial 
investment and support for practice transformation. 
Patient-centred medical homes 
The concept of “medical home” was conceived in 1967 by the American Academy of 
Paediatrics to describe holistic and dependable care for children with complex 
healthcare needs.45 Although there are variable definitions, medical homes are again 
closely aligned with Starfield’s ‘4 Cs’ and have five core attributes: (1) person-centred 
allowing patients to be maximally informed and involved in their care; (2) comprehensive 
care by a team of providers; (3) accessible- shorter wait times, after hours care and 
easy communication with providers; (4) coordinated with other elements of the system 
(e.g., hospitals and specialists); and (5) commitment to safety and quality processes 
and systems.  
Despite being proposed several decades ago, PCMHs are now gaining prominence in 
health systems worldwide as the new model for primary healthcare delivery reform.46 
Their renaissance in the 2000s was in response to highly fragmented primary 
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healthcare systems in the US, however now even countries with strong primary 
healthcare infrastructure are implementing such models.47   
Although the evidence base for PCMHs is still immature, initial studies showed 
encouraging results with improvements in care coordination of chronic conditions and 
overall cost savings.48-50 However, there remain numerous unanswered questions about 
overall effectiveness. A recent systematic review was conducted assessing the 
effectiveness of PCMH models on patient and staff experiences, provision of evidence-
based care processes, health outcomes and cost savings.51 The thirty-one studies 
included found small to modest effects on patient and staff experiences and preventive 
care and inconclusive effects on clinical and economic outcomes. Further, the 
requirements for transformation of clinical practices to become a PCMH are extensive. 
A systematic review evaluating the challenges of implementation of PCMH highlighted 
particular issues related to adopting electronic health records (EHRs), inadequate 
funding and reimbursement models to support transition to a PCMH model, and 
human resource incapacity.52  
2.3 Health information technology to support QI  
Optimal use of health information technology (HIT) is a fundamental component of QI 
strategies.53,54 HIT can be broadly defined as technologies (both hardware and 
software) that collect, store, share and analyse health information amongst consumers, 
providers, managers and payers.55 It ranges from electronic health records at the 
simplest level through to complex health information systems that incorporate multiple 
actors, system elements and information flows. Some of the earliest research evidence 
that HIT can improve care was in the area of medical error reduction.56 Three HIT QI 
interventions relevant to this thesis that have been most strongly associated with 
improvements in quality are: (1) computer decision support systems (CDSSs); (2) audit 
and feedback; and (3) computerised provider (or patient) order entry (CPOE) 
systems.55,57-59    
CDSS is defined as “a process for enhancing health-related decisions and actions with 
pertinent, organised, clinical knowledge, and patient information to improve health and 
healthcare delivery…information delivered can include general clinical knowledge and 
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guidance, intelligently processed patient data, or a mixture of both; and information 
delivery formats can be drawn from a rich palette of options that includes data and 
order entry facilitators, filtered data displays, reference information, alerts and others”.60 
It can be understood as a cognitive aide or knowledge dissemination platform that 
provides healthcare providers, patients and others with best scientific knowledge and 
patient specific information when needed continuously over time.61 Bates et al in 2003 
summarised several guiding principles for successful CDSSs. These include: speed is 
everything, anticipate needs and deliver in real time, fit into the user’s workflow, little 
things can make a big difference, recognise that physicians will strongly resist stopping, 
simple interventions work best, monitor feedback and respond, and actively manage 
the knowledge-based systems.62 There have been many systematic reviews 
documenting the effectiveness of CDSSs. Table 2.1 lists several key systematic 
reviews. 
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Table 2.1: Summary of systematic reviews on effectiveness of CDSSs 
Study Year Number 
of 
studies 
included 
Focus Findings 
Effects of computer-based 
clinical decision support 
systems on physician 
performance and patient 
outcomes: a systematic 
review 63 
1998 68 Controlled clinical trials 
assessing the effects of 
computer-based clinical 
decision support systems 
(CDSSs) on physician 
performance and patient 
outcomes 
66% (43 of 65 studies) improved physician 
performance; and 43% (six of 14 studies) 
found benefits in patient outcomes.  
Effects of Computerized 
Clinical Decision Support 
Systems on Practitioner 
Performance and Patient 
Outcomes: A Systematic 
Review 59 
2005 100 Effects of CDSSs in 
controlled trials and to 
identify study characteristics 
predicting benefit 
64% of trials improved practitioner 
performance in diagnosis, preventive care, 
disease management, or drug prescribing. 
Studies where users were automatically 
prompted to use the system and those where 
the developers of the CDSS were the authors 
of the trials performed better.  
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Improving clinical practice 
using clinical decision 
support systems: a 
systematic review of trials to 
identify features critical to 
success 58 
2005 70 Identify features of CDSSs 
critical to improving clinical 
practice  
Decision support improved clinical practice in 
68% of trials. Four features were independent 
predictors of improved clinical practice: 
automatic provision of decision support as 
part of clinician workflow, provision of 
recommendations rather than just 
assessments, provision of decision support at 
the time and location of decision making, and 
computer based decision support. Of those 
that had all four features, 94% (30/32) 
significantly improved clinical practice. In 
addition, periodic performance feedback, 
sharing recommendations with patients and 
requesting documentation of reason was 
viewed positively.  
Clinical decision support 
systems for neonatal care 64 
2005 3 Evidence from controlled 
clinical trials on the effects of 
CDSS on neonatal care 
No significant effects on short-team outcomes 
and longer-term outcomes. There was limited 
data to assess effect of CDSS.  
Systematic Review: Impact 2006 257  Evidence on the effect of HIT Increased adherence to guideline based care 
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of Health Information 
Technology on Quality, 
Efficiency, and Costs of 
Medical Care 54 
on quality, efficiency, and 
costs 
in the area of preventive health, enhanced 
monitoring and surveillance activities, and 
decreased rates of utilisation for potentially 
redundant or inappropriate care. 
Effects of computerized 
decision support systems on 
nursing performance and 
patient outcomes: a 
systematic review 65 
2007 8 Effects of CDSSs on nursing 
performance and patient 
outcomes 
The results of this study were inconsistent.   
The use and effectiveness of 
electronic clinical decision 
support tools in the 
ambulatory/primary care 
setting: a systematic review 
of the literature 66 
2008 17 Evaluation of the features of 
the CDSS, and effectiveness 
in ambulatory/primary care 
settings 
67% used CDSS for chronic disease 
management in contrast to findings published 
prior to 2000 which found CDSSs most often 
used for prevention/screening and drug 
dosing. 82% embedded within EHR and used 
with automated prompts. 83% of studies 
measured provider outcomes alone or in 
combination with patient outcomes. Patient 
outcomes were scarce due to the difficulty of 
measuring. 76% of studies had partial or 
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complete improvement in processes of care.   
The impact of health 
information technology on 
the quality of medical and 
health care: a systematic 
review 67 
2009 23 Evidence of the impact of HIT 
on the quality of healthcare, 
focusing on clinician’s 
adherence to evidence-
based guidelines resulting in 
improved patient clinical 
outcomes  
82% (14/17 studies) improved practitioners’ 
performance. There was insufficient evidence 
to statistically demonstrate change in patient 
outcomes in the limited number of studies.  
The Impact of eHealth on the 
Quality and Safety of Health 
Care: A Systematic Overview 
68 
2011 108 Systematic review of 
systematic reviews assessing 
the effectiveness and 
consequences of various 
eHealth technologies on the 
quality and safety of care 
Demonstrated benefits of eHealth 
technologies to be modest and there was no 
evidence to support cost-effectiveness.  
Computerized clinical 
decision support systems for 
chronic disease 
management: A decision-
maker-research partnership 
2011 55 To determine if CDSSs 
improve processes of chronic 
care (such as diagnosis, 
treatment, and monitoring of 
disease) and associated 
52% of (25/48) studies measuring impact on 
processes of care showed significant 
improvements. 31% (11/36) that measured 
patient outcomes demonstrated benefit. 
60 
systematic review 69  patient outcomes (such as 
effects on biomarkers and 
clinical exacerbations) 
Computerized clinical 
decision support systems for 
primary preventive care: A 
decision-maker-researcher 
partnership systematic 
review of effects on process 
of care and patient outcomes 
70 
2011 41 Review of randomised 
controlled trials assessing the 
effects of CDSSs for primary 
preventive care on process of 
care, patient outcomes, 
harms, and costs 
CDSSs improved processes of care in 63% 
(25/40) of studies. Four of 14 improved 
patient outcomes. Many trials were not 
powered to evaluate patient outcomes. Costs 
and adverse events were poorly supported.  
Can computerized clinical 
decision support systems 
improve diabetes 
management? A systematic 
review and meta-analysis 71 
2012 15 Effects of CDSSs in 
ambulatory diabetes 
management compared with 
a non-computerised CDSSs  
Results were inconclusive with no evidence 
that CDSSs enhances patient outcomes or 
practitioner performance. Study was unable to 
pool HbA1c, triglycerides and practitioner 
performance outcomes. 
Features of effective 
computerised clinical 
decision support systems: 
2013 162 Identify factors that 
differentiate between 
effective and ineffective 
CDSS improved processes of care in over 
50% of studies with marginal improvements in 
patient outcomes. 
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meta-regression of 162 
randomised trials 72 
CDSSs in processes of care 
and patient outcomes in 
randomised controlled trials 
Effectiveness of 
Computerized Decision 
Support Systems Linked to 
Electronic Health Records: A 
Systematic Review and 
Meta-Analysis 73 
2014 28 Evaluation of the impact of 
CDSSs linked to EHRs on 
mortality, morbidity and costs 
Across clinical settings, CDSSs integrated 
with EHRs did not affect mortality and 
moderately improved morbidity outcomes.  
Clinical Decision Support 
Systems and Prevention: A 
Community Guide 
Cardiovascular Disease 
Systematic Review 74 
2015 45 The effectiveness of CDSSs 
in improving screening for 
CVD risk factors, preventive 
care services and prescribing 
of treatments  
CDSSs were effective in improving processes 
of care related to screening, preventive 
services, clinical tests, and treatments. 
However results were inconsistent in 
improving CVD risk factor outcomes.  
Computer-Based Clinical 
Decision Support Systems 
and Patient-Reported 
Outcomes: A Systematic 
Review 75 
2015 15 Effect of CDSS on patient 
reported outcomes (PRO) 
and the features of CDSS 
that lead to improvement 
Three studies showed significant positive 
impact of CDSS on PRO, and no negative 
effects of any of the studies. The three 
positive studies provided decision support at 
point of care, and one study provided 
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justification to a recommendation.  
Health Information 
Technology Continues to 
Show Positive Effect on 
Medical Outcomes: 
Systematic Review 76 
2018 37 An update on previous 
systematic reviews of the 
effectiveness of HIT, and 
review of current literature of 
the association between 
adoption of HIT and medical 
outcomes 
81% of the studies improved at least one 
medical outcome as a result of adoption of 
HIT.  
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Table 2.1 highlights generally positive effects from CDSSs, particularly relating to 
processes of care. Effects on patient outcomes are more modest and there is less 
information on economic impacts. Further, there is substantial heterogeneity in the 
types of CDSS interventions implemented. These studies generally had short term 
follow-up making it difficult to interpret what should be implemented in non-trial 
settings. Several lessons have been learnt which have continued the evolution and 
increased use of CDSSs working towards addressing the current health system 
challenges around the world. However, enhancements are needed for standardising 
methods for knowledge and data representation, integration of CDSS within 
workflow at point of care, and patient data and knowledge exchange.77  
Audit and feedback is a “summary of the clinical performance of healthcare 
provider(s) over a specified period of time”.78 This approach is theorised to support 
clinical behaviour change and potentially have effects on processes of care and 
patient outcomes. Four systematic reviews conducted over the course of 10 years 
(2003 to 2013) had consistent findings that “audit and feedback generally leads to 
small but potentially important improvements in professional practice”.79-82 An update 
from the initial Cochrane systematic review on effects of audit and feedback that 
included 64 comparisons of dichotomous outcomes from 49 trials (until 2004) found 
baseline adherence to recommended practice was the main determinant in 
explaining the wide variation in effectiveness across studies. The efficacy of audit and 
feedback was larger when baseline adherence was low and intensity of the audit and 
feedback high.80 Ivers et al. found that feedback was most effective when delivered 
from a supervisor or respected colleague, presented more than once, featuring both 
specific goals and action-plans, aiming to decrease the targeted behaviour, and 
recipients were non-physicians.82  
CPOE is the process of a health professional entering instructions electronically for 
medication orders or other management instructions. It provides structured 
templates for healthcare providers to prescribe medications and order tests 
electronically which are then transferred electronically to the receiving service.83 
CPOE systems automate the ordering process with standardisation, audit trail, 
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legibility, key specifications of data, route of administration, and storage and recall of 
records.84 The potential benefits include increased safety, efficiency and quality of 
patient care. A systematic review on the effects of medication error reduction in US 
hospitals found CPOEs decrease order errors by 48%.85 Several studies have found 
that CDSSs which are integrated with CPOE systems reduce duplicate orders, 
dosage errors, drug interactions, and missed or delayed orders.86-88 However, CPOE 
systems are known to have adoption barriers that have led to abandonment of the 
system. These include making users perform new tasks, workflow problems, 
excessive system demands, increased cognitive load, generation of new kinds of 
errors, unexpected changes in provider power relations and over-dependence on the 
technology.89 Additional adoption barriers include high implementation costs, the 
need for robust integration of the CPOE into the organisational team especially in 
hospital environments, alert fatigue, lack of leadership, and provider’s resistance to 
change.83,90 The CPOE systems mentioned above are studies in hospital settings. 
There are limited studies examining impact of CPOE systems in ambulatory/primary 
care settings and although they found less prescription writing, there was no 
difference between adverse drug event rates at CPOE health services compared to 
hand writing sites.91,92 Additional research into the implementation processes and 
effectiveness of CPOE is needed especially in ambulatory care settings.  
2.4 Quality improvement strategies in Australia 
Australian Primary Care Collaboratives (APCC) 
In 2004, the Department of Health and Ageing funded $15.6 million for the APCC 
adopting the Breakthrough Series collaborative methodology. The program is run by 
a not-for-profit non-government organisation, the Improvement Foundation. There 
were seven waves of collaboratives each wave lasting 18 months.93 Initial focus areas 
included to improve chronic disease care, particularly diabetes and coronary heart 
disease (CHD) and improve timely access for patients. The first wave commenced in 
March 2005 and reported positive changes in indicators related to diabetes and 
CHD.  Later waves have also focussed on addressing chronic obstructive pulmonary 
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disease, preventive health activities, patient self-management, and Aboriginal and 
Torres Strait Islander health. Approximately 4,216 health professionals from over 
2000 health services in all states and territories within Australia have participated in 
this program. In before-after studies improvements have been reported in data 
quality, process measures and some clinical outcomes.94 Other benefits from 
participation in the program include improvements in administrative processes, team 
functioning, and accurate collection of data.  
Aboriginal and Torres Strait Islander health service quality improvement programs 
Several initiatives originating in the Northern Territory (NT) were antecedents to 
quality improvement programs in Aboriginal and Torres Strait Islander health. To 
address the high demands on Indigenous community health centres, the department 
of health and community services in NT in 1997 developed an integrated life course 
strategy (the Preventable Chronic Disease Strategy) to address chronic illnesses with 
a focus on renal disease and other associated chronic conditions.95 This was an 
evidence-based framework for early detection and management to be used in clinical 
care.  A follow-on from this was the implementation of the Coordinated Care Trials in 
1998 which had three objectives: 1) significantly increase funding and management 
of health services controlled by the community, 2) implementation of best practice 
clinical guidelines and 3) improvement of computerised information systems.96  
Following this, the Audit and Best Practice for Chronic Disease research partnership 
was formed to develop auditing tools and quality improvement strategies for primary 
healthcare services that service Aboriginal and Torres Strait Islander people. The CQI 
intervention used random case record audits entered into a web-based database, 
and PDSA cycles. It took a flexible approach, allowing health centres to adapt the 
intervention to suit their circumstances.97 The initial project ran from 2002-2006 in 12 
Aboriginal Community Controlled Health Services (ACCHSs) in the NT. The 
Cooperative Research Centre for Aboriginal Health (government funded) supported 
the project that brought together federal, state and territory government health 
agencies, ACCHSs, and research organisations. The program achieved high levels of 
acceptance and willingness to engage by primary healthcare organisations and 
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significant improvements in systems and processes of care and some intermediate 
outcomes.98 An Audit and Best Practice for Chronic Disease Extension project was 
implemented between 2005 and 2009 to inform operational and policy requirements 
for a larger scale implementation of the program and by the end of 2009 over 140 
health centres around Australia were using Audit and Best Practice for Chronic 
Disease tools.99 
There are several performance monitoring programs involving ACCHSs. The 
Queensland Aboriginal and Islander Health Council (QAIHC) represents 26 ACCHSs 
and is led by a community-elected board. In August 2008, it developed a set of 25 
indicators to provide an overview of the quality of care delivered, health status of the 
patient population, and indicators of workload, patient access and workforce-related 
issues.100 The majority of ACCHSs submit aggregated data to the QAIHC data 
repository on a monthly basis via an automated clinical audit tool. Feedback to the 
health service is provided through a web-portal and a copy is stored on the health 
services’ servers.101 The systematic collection and monitoring of performance has 
resulted in improvements in several clinical care activities. 
In the NT, a similar key performance indicator program was developed by the NT 
Aboriginal Health Forum which comprises the Commonwealth Department of Health, 
the NT Department of Health and the peak community controlled organisation in the 
NT - the Aboriginal Medical Services Alliance. A data platform provides information 
on a range of indicators comprising both government and non-government health 
services. It takes a collaborative approach to improving primary healthcare quality 
across the NT by understanding population wide trends in health outcomes, 
identifying factors that influence those outcomes and informing appropriate action, 
planning and policy development at the service and system levels.102  
A Commonwealth government key performance indicator program has also been 
implemented since 2012. Data are collected from over 200 Indigenous health 
services who received funding to provide primary health care under the Indigenous 
Australians’ Health Program. This occurs through extraction of data from clinical 
information systems and is transferred to a secure data portal. Regular reports are 
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provided by the Australian Institute of Health and Welfare for 22 process and health 
outcome indicators and has generally shown improvements in quality across most of 
these indicators.103 The New South Wales government has recently adopted a similar 
model and has started reporting on a range of preventive health, drug and alcohol 
and mental health indicators.104  
2.5 The evolution of HIT in Australia 
Like many countries worldwide and especially those in the OECD, HIT is evolving 
rapidly in Australia. In 2005, the National Electronic Health Transition Authority 
(NEHTA) was established to progress Australia’s national eHealth infrastructure and 
standards.105 Figure 2.1 provides an overview of key activities. 
Figure 2.1 Timeline of eHealth initiatives and milestones 106 
 
Glossary of eHealth programs stated in Figure 2.1: 
• ePIP – An eHealth Practice Incentives Program (PIP) to encourage general 
practices to keep up-to-date and adopt the latest digital health technology to 
improve administration processes and patient care.   
• HealthConnect Trials – Australia’s change management strategy to transition 
from paper-based towards electronic health records. 
• Wave Sites – eHealth Lead Sites to provide a community of services for 
individuals using a range of community and health service providers with 
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appropriate linkages to clinical support. Wave sites granted $14.5 million to 
support up to 243 participating general practices and 90,000 individuals. 
Pharmacies, after hours services, and out-patient services were also engaged. 
• M2N – The MyEHR-to-National (‘M2N’) Transition Project is transitioning the 
existing MyEHR Service over to the National eHealth Record System. 
• 5th Community Pharmacy Agreement – A five-year agreement between the 
Australian Government and the Pharmacy Guild of Australia to deliver to PBS 
medicines and related services. 
• Telehealth MBS Items – For patients located in remote, regional and other 
metropolitan areas to conduct consultations via video conference with medical 
specialists, known as Telehealth. 
• Healthcare identifiers - A national system that uses a unique number to match 
healthcare providers to individuals. 
• Opt out trials – rule to specify the classes of healthcare recipients who will 
participate in opt-out trials of the My Health Record system, unless they choose 
to opt-out. 
In mid-2016, NEHTA transitioned to become the Australian Digital Health Agency 
and in 2017 Australia’s first National Digital Health Strategy was released. The 
strategy outlines seven priority outcomes to be achieved by 2022:  
1) health information that is available whenever and wherever it is needed 
2) health information that can be exchanged securely  
3) high quality data with a common understood meaning that can be used with 
confidence 
4) better availability and access to prescriptions and medicines information 
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5) digitally-enabled models of care that drive improved accessibility, quality, safety 
and efficiency 
6) a workforce confidently using digital health technologies to deliver health and 
care,  
7) a thriving digital health industry delivering world-class innovation.107  
Although there are many additional building blocks to the digital health system 
(secure messaging, electronic prescription exchange services, telehealth services to 
name a few), here I review four aspects that provide important context for this thesis: 
electronic health records, auditing tools, electronic care plans and personal health 
records. 
Electronic health record (EHR) 
EHR functions are broad, ranging from documenting the delivery of care, assessing 
health outcomes, setting targets, development of patient care plans, means of 
communication with healthcare teams, financial and epidemiological.108,109 In 
Australia, 98% of general practices use EHRs according to the Bettering the 
Evaluation and Care of Health (BEACH) survey for 2013-2014.110 A 2015 
Commonwealth Fund survey comparing use of EHRs internationally from 2006- 2015 
reported 92% use in Australia which has remained relatively consistent since 2009 
(Figure 2.2).111  
 
 
 
 
 
70 
Figure 2.2: Doctors’ Use of Electronic Medical Records in OECD countries 
 
 
A key driver for early adoption of EHRs in Australia was related to government 
financial incentives similar to countries reporting use greater than Australia. These 
incentives were provided from 1998-2002 to support general practices to install 
computers and clinical software packages for prescribing and transmission of clinical 
data.112 Although a voluntary scheme, the initiative stimulated an increase in use of 
EHRs from 15% in 1997 to 70% in 2000 in general practices.113 Currently, there are 
over ten primary healthcare EHR software packages in use across Australia with 
Medical DirectorTM and Best PracticeTM being the two dominant systems, estimated 
to supply around 80% of the market.110  
71 
EHR auditing tools 
Most EHR software packages provide basic query and data extraction tools for audit 
and feedback purposes. However, for chronic disease indicators on a population and 
individual level, primary care providers tend to rely on third party software providers 
who have built data extraction software that integrate with the EHR. These tools 
provide auditing functions for chronic diseases such as diabetes, coronary heart 
disease and chronic obstructive pulmonary disease, enable identification of particular 
patient population segments that are receiving or not receiving particular care 
processes and allow for data export to custodians such as Primary Health Networks 
(PHNs) for population health monitoring. These tools have been extensively used in 
the APCCs quality improvement program described above and the majority of PHNs 
in Australia purchase a license for these tools on behalf of their member practices. 
The MedicineInsight program, run by the National Prescribing Service, also extracts 
data from over 650 general practices nationally with unique records for around 3.6 
million patients. It uses these data for a range of purposes including post-marketing 
surveillance of medications, quality improvement activities, and a range of research 
projects.114  
As mentioned above, Aboriginal and Torres Strait Islander health services have 
extensive experience in use of data extraction tools particular for reporting 
requirements to the federal government. The National Key Performance Indicator 
program (nKPIs) program commenced in 2010 to measure performance for health 
services provided to Aboriginal and Torres Strait Islander people across Australia. 
Data are uploaded from around 230 primary healthcare organisations including 
ACCHSs (58.9%), state and territory-managed organisations (34.4%), PHNs (4.1%) 
and other organisations providing services (2.5%) to Aboriginal people.103 The 
majority of the data is extracted from EHR systems to a secure portal.115,116  
Electronic care plans 
An evolving area in extending the use of the EHR relates to shared records and care 
plans. Government subsidies through Medicare claims are provided to generate 
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‘General Practitioner Management Plans’ (GPMPs). Additional subsidies are provided 
for collaboration with specialists and allied health providers as part of a ‘Team Care 
Arrangement’ (TCAs). Despite the subsidies, uptake of these services is relatively 
modest with, for example, less than 14% of patients with diabetes having a current 
GPMP and/or TCA.117 Consequently, several software vendors are developing 
electronic software tools that are integrated with EHRs to assist with generating 
management plans and allowing external care providers to contribute to these plans. 
These tools are intended to overcome the barriers of time constraints, fragmented 
communications with healthcare teams and dissemination of evidence-based 
care.118,119 Although care planning software tools have not been extensively 
evaluated, in one study there were significant improvements in processes and clinical 
outcomes for patients receiving a GPMP.120,121  However, the Diabetes Care Project, 
which was a large, federal government funded randomised controlled study that 
tested a care delivery model which combined electronic QI tools (including electronic 
shared care planning) and financial incentives found that the electronic QI tools on 
their own were not associated with improved process or clinical outcomes. Further, 
only modest improvements were noted when these tools were combined with a 
flexible funding model, and these were not considered cost-effective.122   
Personal health records 
A core component of NEHTA’s initial activities was the establishment of a personal 
health record for all Australians – now called ‘My Health Record’ (previously 
Personally Controlled Electronic Health Record (PCEHR)). Launched in 2012, and 
reliant on voluntary consent, initial adoption was slow and by March 2016 there was 
only a total of 2,642,278 active digital records (11% of Australia’s population) and a 
total of 8,139 organisations registered with majority in general practices and 
pharmacy. In June 2018, My Health Record system changed to an opt-out model. 
This model automatically provides every Australian with a My Health Record unless 
they prefer not to and opt-out.123 This is aimed at allowing for faster health and 
economic benefits such as avoided hospital admissions, fewer adverse drug events, 
reduced duplication of tests, better coordination of care, and provision of 
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recommended treatment by the end of 2018.124 As of May 20, 2018, there are 
5,804,614 consumers (54% female; 46% male), and 11,818 healthcare provider 
organisations registered.125  
My Health Record is viewed as a foundational pillar for implementation of the digital 
health strategy. In the area of new digitally enabled models of care, the Health Care 
Homes trial is currently being implemented in 200 general practices and ACCHSs 
across Australia in collaboration with ten PHNs.107 Targeting chronic and complex 
care patients, the model includes a risk stratified, bundled payment for chronic 
disease care that replaces traditional fee-for-service payments, shared care plans, 
and mandatory use of the My Health Record.   
2.6 Conclusion 
There are several promising QI strategies being implemented worldwide that can 
improve care delivery systems and address Starfield’s ‘four Cs’ (accessible first 
contact, continuous, comprehensive and coordinated care). An important enabler of 
these QI approaches is HIT. Although there is great potential for digitally enabled 
health care models to improve the effectiveness and efficiency of health services, 
there remain substantial challenges in implementation, adoption, sustainability and 
scalability.  
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Chapter 3: A theory-informed logic model to assist in the 
planning, conduct and implementation of 
the process evaluation   
 
3.1 Chapter Overview 
This chapter describes the methods of a theory-informed process evaluation of four 
discrete but inter-related studies. A multimethod approach is taken drawing on a 
logic model to assist with the planning, conduct and evaluation of the research 
components. The chapter consists of a single manuscript titled: A multifaceted 
quality improvement intervention for CVD risk management in Australian primary 
healthcare: a protocol for a process evaluation.  
This protocol allows for a multilevel analysis of implementation of the intervention 
providing both micro- and meso-system perspectives.  
3.2 Publication details 
Patel B, Patel A, Jan S, Usherwood T, Harris M, Panaretto K, Zwar N, Redfern J, 
Jansen J, Doust J and Peiris D. A multifaceted quality improvement intervention for 
CVD risk management in Australian primary healthcare: a protocol for a process 
evaluation. Implementation Science. 2014; 9:187. 
DOI: 10.1186/s13012-014-0187-8 
3.3 Author contributions 
BP, DP, and TU made substantial contribution to the conception of the process 
evaluation. BP developed the theory informed logic model. BP, DP, TU, MH, KP, NZ, 
JR, JJ, JD, and AP provided input and contributed to the overall design of the 
process evaluation. BP, AP and MH contributed to the quantitative evaluation design. 
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SJ contributed to the economic evaluation design. BP wrote the initial draft of the 
manuscript. DP provided critical review and editing of the initial draft of the 
manuscript. All authors provided advice and input on the final manuscript for 
submission. BP prepared the final draft of the manuscript for publication.  
3.4 Manuscript 
STUDY PROTOCOL Open Access
A multifaceted quality improvement intervention
for CVD risk management in Australian primary
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Bindu Patel1*, Anushka Patel1, Stephen Jan1, Tim Usherwood2, Mark Harris3, Katie Panaretto4, Nicholas Zwar3,
Julie Redfern1, Jesse Jansen2, Jenny Doust5 and David Peiris1
Abstract
Background: Cardiovascular disease (CVD) is the leading cause of death and disability worldwide. Despite the
widespread availability of evidence-based clinical guidelines and validated risk predication equations for prevention
and management of CVD, their translation into routine practice is limited. We developed a multifaceted quality
improvement intervention for CVD risk management which incorporates electronic decision support, patient risk
communication tools, computerised audit and feedback tools, and monthly, peer-ranked performance feedback via
a web portal. The intervention was implemented in a cluster randomised controlled trial in 60 primary healthcare
services in Australia. Overall, there were improvements in risk factor recording and in prescribing of recommended
treatments among under-treated individuals, but it is unclear how this intervention was used in practice and what
factors promoted or hindered its use. This information is necessary to optimise intervention impact and maximally
implement it in a post-trial context. In this study protocol, we outline our methods to conduct a theory-based,
process evaluation of the intervention. Our aims are to understand how, why, and for whom the intervention
produced the observed outcomes and to develop effective strategies for translation and dissemination.
Methods/Design: We will conduct four discrete but inter-related studies taking a mixed methods approach. Our
quantitative studies will examine (1) the longer term effectiveness of the intervention post-trial, (2) patient and
health service level correlates with trial outcomes, and (3) the health economic impact of implementing the
intervention at scale. The qualitative studies will (1) identify healthcare provider perspectives on implementation
barriers and enablers and (2) use video ethnography and patient semi-structured interviews to understand how
cardiovascular risk is communicated in the doctor/patient interaction both with and without the use of intervention.
We will also assess the costs of implementing the intervention in Australian primary healthcare settings which will
inform scale-up considerations.
Discussion: This mixed methods evaluation will provide a detailed understanding of the process of implementing
a quality improvement intervention and identify the factors that might influence scalability and sustainability.
Trials registration: 12611000478910.
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systems, Cardiovascular prevention, Cardiovascular risk, Primary healthcare, Mixed methods, Theory-based
* Correspondence: bpatel@georgeinstitute.org.au
1The George Institute for Global Health, University of Sydney, Sydney, NSW
2006, Australia
Full list of author information is available at the end of the article
Implementation
Science
? 2014 Patel et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Patel et al. Implementation Science 2014, 9:187
http://www.implementationscience.com/content/9/1/187
Background
Cardiovascular disease burden
Non-communicable diseases (NCDs)? including cardio-
vascular diseases (CVD), cancers, respiratory diseases, and
diabetes mellitus? are the leading cause of death world-
wide [1,2]. It is predicted that by 2030, NCDs will account
for 75% of all deaths with the largest proportion of deaths
attributed to CVD [3]. Globally, approximately 17 million
(30%) deaths per year and 151 million disability-adjusted
life years (DALYs) are caused by CVD [4].
In Australia, CVD is responsible for 34% of deaths
and 18% of the burden of disease and injury, making it
the largest contributor to health system expenditure
[5]. Aboriginal and Torres Strait Islander people experi-
ence a greater CVD burden than other Australians, and
this is a major contributing factor to the 10-year gap in
life expectancy [6,7]. The majority of CVD is caused by
modifiable risk factors, which include blood pressure,
lipids, diabetes, body mass index (BMI), tobacco smok-
ing, alcohol use, unhealthy diet, physical inactivity, and
psychosocial stress [8]. Recent modelling suggests that
a 25% reduction in the prevalence of six NCD risk fac-
tors alone (tobacco, alcohol, salt, blood pressure, obes-
ity, and glucose) could reduce global disease burden by
25% in the next 10 years [9].
Evidence practice gaps
International clinical guidelines recommend that assess-
ment for CVD prevention and management should be
based on a combination of risk factors (the ? absolute risk ?
approach) rather than treating risk factors such as ele-
vated blood pressure and cholesterol in isolation [10-13].
Absolute risk calculation estimates an individual ? s risk
of a CVD event over time based on modifiable and
non-modifiable risk factors such as age and gender. This
enables early identification, management, and primary
prevention of CVD for individuals at high risk. In combin-
ation with well-established secondary prevention recom-
mendations for people who have experienced a previous
CVD event, the absolute risk approach offers considerable
potential for reducing CVD burden [14].
Despite the widespread availability and consistency of
these guidelines and the availability of validated risk pre-
diction equations, there are large evidence practice gaps.
Health professionals tend to use these guidelines and
equations sporadically and inconsistently [15,16]. In the
Australian context, studies have found that only 50% of
adults attending primary healthcare have been screened
for CVD risk in accordance with guideline recommenda-
tions, and only 40% of those identified as high risk have
been prescribed recommended medications [17,18]. In-
ternational studies have similarly demonstrated that a
minority of people are being provided with appropriate
screening measures and preventive treatments [19]. The
majority of CVD events can potentially be averted with
adequate implementation of established treatments and
interventions that are effective, efficient, and universally
accessible in Australian primary healthcare settings.
Primary healthcare is the ? front-line ? for effective pre-
vention and management of the increasing burden of
chronic diseases. With 88% of Australians visiting a gen-
eral practitioner each year, the opportunities to improve
primary and secondary prevention of CVD at this level are
great [20].
Knowledge translation strategies
Given the magnitude of these evidence practice gaps in
CVD prevention, effective quality improvement (QI) in-
novations that support health services to improve their
outcomes are urgently needed. QI is a multidimensional
concept that focuses on improving the efficiency and
process of a program, service, or organisation, resulting
in improved health outcomes [21,22]. The Agency for
Healthcare Research and Quality (AHRQ) has identified
nine broad QI strategies to improve quality of care: pro-
vider reminder systems, facilitated relay of clinical data
to providers, audit and feedback, provider education, pa-
tient education, promotion of self-management, patient
reminder systems, organisational change, and financial
incentives, regulation, and policy [23]. An increasingly
important component of QI strategies is an adoption of
health information technologies (HITs). Meaningful use
of electronic health records (EHRs), computerised pro-
vider order entry systems, and electronic decision sup-
port (EDS) are increasingly recognised as key enablers to
improvements in quality and delivery of healthcare [24].
However, the overall impact of computerised QI inter-
ventions to improve CVD burden has been limited, and
effects on patient outcomes remain unclear [25-27].
Whilst QI strategies have been well characterised, there
is relatively little knowledge translation research to help
guide how these strategies can be optimally implemented
into routine practice [28,29]. The Canadian Institute of
Health Research defines knowledge translation as ? the ex-
change, synthesis and ethically sound application of know-
ledge? within a complex system of interactions among
researchers and users? to accelerate the capture of the
benefits of research for patients through improved health,
more effective services and products and a strengthened
health care system? [30]. Whilst it is critical that QI inter-
ventions are robustly assessed for effectiveness, equally
important is a detailed understanding of how those QI
interventions are implemented, using process and eco-
nomic evaluations. This will allow a deeper understand-
ing of how the intervention worked/did not work, in
which contexts was it most effective/ineffective, and why.
Given QI interventions are inevitably complex in nature,
robust evaluation requires the use of multiple theories and
Patel et al. Implementation Science 2014, 9:187 Page 2 of 12
http://www.implementationscience.com/content/9/1/187
frameworks to answer these questions. By using know-
ledge translation frameworks, we are able to better iden-
tify active ingredients of the intervention that change
behaviour, causal mechanisms of change, effective modes
of delivery, and the intended population or target [31].
This will enable promotion and integration of the inter-
ventions into clinical practice, health systems, and policy.
The treatment of cardiovascular risk in primary care using
electronic decision support (TORPEDO) study
There have been few randomised evaluations of QI in-
terventions in the Australian primary healthcare setting.
We designed a multifaceted QI intervention for CVD
risk management in Australian primary healthcare. The
intervention drew on two established QI mechanisms:
1) electronic decision support and 2) audit and feedback
(summary of the clinical performance over a specified
period of time) [32-37]. The intervention was evaluated
in the TORPEDO study, a cluster-randomised controlled
trial (cRCT) involving 60 health services. Details of the
trial are published elsewhere [38]. In brief, the system was
integrated with the healthcare provider ? s EHRs, and in-
cluded (1) a real-time decision support interface using an
algorithm derived from several evidence based national
guidelines (Figure 1); (2) a patient risk communication
interface which included ?what if scenarios? to show the
benefits from particular health risk factor improvement
during a consultation (Figure 2); (3) an automated clin-
ical audit tool for extraction of data and review of
health service performance (Figure 3); and (4) a web
portal where services can view peer-ranked perform-
ance over time (Figure 4). Healthcare providers could
use the point-of-care tool as part of a routine clinical
consultation. For the audit and feedback component,
quality indicators were developed for patients who had
visited the health service at least three times in the pre-
ceding 2 years and once in the preceding 6 months.
The population studied was based on national guideline
Figure 1 Real-time decision support interface.
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recommendations for CVD risk screening and included
Aboriginal and Torres Strait Islander people over 35 years
and all others over 45 years [38].
Data were collected for 38,725 people from the 60
health services. Overall, when compared with control,
the intervention was associated with a 25% relative (10%
absolute) improvement in CVD risk factor screening.
Overall, there was no significant difference in the pre-
scribing rates of recommended medicines to people at
high CVD risk. The intervention was, however, strongly
associated with improvements in the sub-group at high
CVD risk that was not prescribed with recommended
medicines at baseline. There were also improvements
in intensification of existing, recommended medication
regimens. There were modest improvements in attain-
ing blood pressure targets but no differences in other
clinical outcomes. The improvements in recommended
prescriptions to high risk patients were not accompan-
ied by increased prescribing rates for patients at low
risk [39].
Although the intervention exhibited significant im-
provements in some outcomes, it remains unclear how
this intervention was actually used in practice and what
factors promoted and hindered its use. Answers to these
questions are critical in order to inform future directions
for its implementation and for implementation of similar
interventions in other settings.
In this paper, we outline our protocol for a theory-
based process evaluation of the TORPEDO intervention.
The broad objectives are to understand how, why, and
for whom the intervention produced the observed out-
comes and to develop effective strategies for translation
and dissemination. The evaluation will identify which in-
tervention components promoted or had minimal impact
Figure 2 Patient-oriented risk communication interface.
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at the provider, patient, and system levels and the me-
chanism of change. It will also identify the contextual
influences on the delivery of the intervention and its
outcomes. The specific objectives are the following:
1. To understand whether intervention effects are
sustained in a post-trial setting;
2. To identify implementation barriers and enablers;
3. To understand how CVD risk is communicated in
the doctor/patient interaction both with and without
the use of the intervention; and
4. To identify cost considerations for delivering the
intervention at scale in the Australian primary
healthcare system.
Design and methods
Taking a mixed methods approach, we will conduct
four discrete but inter-related studies to address our study
objectives. Specifically, we will adopt an explanatory
sequential design whereby the qualitative data analysis
will be used to gain a better understanding of the quan-
titative findings [40].
Logic model
Drawing on the RE-AIM framework, a logic model was
developed to assist in the planning, conduct, and evalu-
ation of the research components (Figure 5) [41-44].
The model assesses five dimensions of the intervention
at different levels (individual, health service/clinic or
organisation, and community/population): (1) partici-
pant Reach; (2) Effectiveness of the intervention; (3)
Adoption by the target health service; (4) Implementa-
tion fidelity, costs, and adaptations made during delivery;
and (5) Maintenance of intervention effects over time.
The model identifies and describes inputs, activities, out-
puts, and outcomes of the intervention [45]. The four ob-
jectives have been mapped onto the relevant components
of the RE-AIM framework.
Figure 3 Automated data extraction tool? sample health service performance on CVD risk factor screening.
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The logic model will be underpinned by three theore-
tical perspectives? realist evaluation [46], the theoretical
domain framework (TDF) [47,48], and normalisation
process theory (NPT) [49,50].
Realist evaluation
Realist evaluation seeks to answer the question what
works, for whom, and in what circumstances? [46]. This
is accomplished by identifying and understanding the
underlying mechanisms by which the intervention suc-
ceeds or fails in varying contexts to produce the patterns
of outcomes. Therefore, unpacking of the underlying
generative mechanisms of the intervention and its effects
is contingent on understanding the features of the con-
text (i.e. roles and relationships of personnel at health
services, IT infrastructure, economic conditions, demo-
graphic, motivation and skills of health professionals,
etc.) [46,51,52].
Theoretical domain framework
Successful implementation of evidence-based guidelines
and QI interventions depends largely on changing the be-
haviour of healthcare professionals and patients, who are
influenced by external (i.e. organisational, environmental,
resources) and internal (i.e. motivation, capability) factors.
TDF is a consensus of numerous behaviour change mo-
dels and comprises 14 domains derived from psycho-
logical and organisational theory (knowledge, skills, social/
professional role and identity, beliefs about capabilities,
optimism, beliefs about consequences, reinforcement, in-
tentions, goals, memory attention and decision process,
environmental context and resources, social influences,
emotion, and behavioural regulation) [47,48,53].
Normalisation process theory
In order for healthcare innovation and technology to be-
come routinely embedded in every day work, we need to
Figure 4 Quality improvement portal.
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understand how the innovation is integrated within the
existing practices of a healthcare organisation. NPT assists
in understanding how health professionals implement an
intervention. NPT identified four main components: (1)
coherence (sense making by participants), (2) cognitive
participation (commitment and engagement by partici-
pants), (3) collective action (the work participants do to
make the intervention function), and (4) reflexive moni-
toring (the degree to which participants reflect on or ap-
praise the intervention [49,54,55].
Study 1: Post-trial effectiveness of the intervention
(objective 1)
Aim
To assess the effects of the intervention at one year fol-
lowing completion of the cRCT.
Methods
At the end of study follow-up visit for the TORPEDO
study, all 60 health services have the option to either
continue the use of the intervention or have the interven-
tion implemented for use in the usual care health services
for an additional 12 months. A post-trial clinical audit
data extraction at minimum of 24 months from baseline
will be conducted for the health services expressing inter-
est to use the intervention. The objective of this study is
to assess the impact of the use of the intervention over
time on the two primary outcomes: (1) proportion of
CVD risk factor screening and (2) proportion of appropri-
ate medication prescription in the high risk individuals for
the intervention arm and usual care arm at post-end of
study following baseline.
Analysis
Log-binomial regression will allow direct estimation of
risks and risk ratios (i.e. relative risks) on each outcome.
The model will be adjusted with intervention (yes vs.
no) and time (baseline, 12 and 24 month) as categorical
data where baseline is set as reference and interaction
between intervention and time. The model will be ad-
justed with the intervention (yes or no) and with a ran-
dom centre effect. Chi-square test and 95% confidence
intervals (CI) will be computed.
Figure 5 Logic model for TORPEDO process evaluation.
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Study 2: Multilevel modelling study (objective 2)
Aim
To determine what patient and health service level vari-
ables correlate with the trial outcomes.
Methods
Patient variables (age, gender, ethnicity, history of CVD,
and diabetes) will be obtained from the automated clin-
ical audit tool, and health service level variables will be
collected through Team Climate Inventory (TCI) and
Warr-Cook-Wall job satisfaction surveys, customised for
use with general practices (GPs) and Aboriginal Com-
munity Controlled Health Services (ACCHSs), adminis-
tered to all general practitioners and other practice and
health service staff at the participating 60 sites [56,57].
In addition, health service characteristics such as service
size, participation in quality improvement programs, and
type of primary healthcare (GP verses ACCHS) will be
collected at randomisation.
Analysis
TCI is a 44-item questionnaire, and items are rated on a
5-point scale [56]. Job satisfaction is a 15-item question-
naire, and items are rated on a 7-point scale [57]. Multi-
level regression model analysis will be conducted to
evaluate the influence of team climate and job satisfaction
on the primary study outcomes, controlling for patient? s
age, gender, practice size, type of PHC, and participation
in quality improvement programs. The results will be
interpreted within the context of the three conceptual per-
spectives to better understand what health service factors
(if any) are important drivers of use of the intervention in
routine practice.
Study 3: Interview study and video ethnography
(objectives 2 and 3)
Aim
To identify and understand which intervention compo-
nents promoted or had minimal impact on behaviour
change at the provider and patient levels, the mechanism
of change, and contextual influences.
Methods
Case study methods will be used to explore system chan-
ges over time, through in-depth qualitative data collection
involving multiple sources of information. The cases will
be individual GPs and ACCHSs participating in the
TORPEDO study. Quantitative data obtained from the
primary study and the studies 1 and 2 above will be
drawn on as part of the analysis of the cases, and new
qualitative data will be obtained using semi-structured
interviews, video ethnography, and surveys. This will
ensure that both intervention effects and implemen-
tation processes are comprehensively assessed. It will
identify contextual influences, and by drawing on mul-
tiple empirical data sources will increase the robustness
of the findings [58,59].
We will purposively sample health services to achieve
maximum variation in trial primary outcomes, numbers
of staff at each site, and type of service (GP versus ACCHS,
urban versus rural). We will select six cases from the inter-
vention arm (four GPs and two ACCHSs) and three cases
from the usual care arm (two GPs + one ACCHSs). There
will be two methods of data collection.
Health professional interviews
Semi-structured interviews with site staff will provide us
with their knowledge, views, and experience of the im-
plementation of the intervention at their health service.
Interview questions have been developed to explore the
realist evaluation domains of context, mechanism, and
outcome. Some questions include the following: (1)
why health staff did/did not use the intervention; (2)
how was the intervention used in routine practice and
by whom; (3) what were the contextual factors that in-
fluenced its uptake; and (4) what impact did it have on
the way personnel did their work. We will conduct ap-
proximately 20 health professional interviews with ge-
neral practitioners, nurses, managers, Aboriginal health
workers (AHWs), and administrative assistants from
within our cases. The final number of interviews will be
dependent on thematic saturation [60]. The interviews
will take place at the health service, and all interviews will
be audio-recorded and transcribed. The interviews will
take place face to face with a thematic and topic-centred
interview guide. The interview guide will be flexible to
allow exploration of emergent themes.
Video ethnography
Qualitative data obtained from ethnographic studies
can enhance our understanding of how to introduce a
technological innovation into healthcare [61,62]. In
order to augment our interview data, video ethnogra-
phy will be used to give us insight into (1) the possible
ways general practitioners used the intervention tools;
(2) how cardiovascular risk is talked about between
general practitioner and patient; (3) how patients receive
and interpret this information; and (4) what impact the
intervention tools have on the decision-making process,
particularly related to recommending and taking medica-
tion. Approximately 20% of patients video-recorded (ap-
proximately two per general practitioner) will be selected
to be interviewed after videotaping of their consultation.
Patients agreeing to participate will be interviewed at their
home or the health service at a time suitable for the
patient.
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Analysis
Framework analysis will be used to organise the inter-
view data [63]. Key issues and emergent themes will be
identified and then a coding framework will be devel-
oped to index and chart interview transcripts and videos.
Videos will be subject to fine-grain discourse analysis
[64]. NVivo 10 software (QSR International) will be used
for data management and coding of interview tran-
scripts, field notes, and videos. The analysis will occur
simultaneously with data collection. Themes will be devel-
oped both deductively (pre-defined themes) and induct-
ively (emerging themes), and then coded in an iterative
process to identify patterns, and interpret the meaning
of the themes within and across cases. Throughout this
process, we will meet regularly with a project working
group of expert researchers and collaborators to discuss
the theoretical framework within which the data will be
collected, coded, and interpreted. Reflexivity will be in-
corporated into the qualitative analysis process to take
into account personal assumptions and biases, so these
do not influence the way and the type of data that are
collected or the data analysed.
Our three chosen theoretical perspectives will be re-
gularly drawn on to assist with interpretation of the
qualitative findings. Using realist evaluation, we expect
the analysis to yield insights into particular context-
mechanism-outcome configurations that explain patterns
associated with use and non-use of the intervention. The
TDF will complement these analyses and explore to
what extent the intervention influenced behaviour change
by various actors (health professionals, managers, and
patients). Data will be used to make an assessment of
the underlying capacity, motivation, and opportunities
of these actors and the extent to which the intervention
influenced these areas. NPT will be used to provide a
better understanding of the ways in which health ser-
vices as organisational structures respond to the inter-
vention. Interview codes will be aligned with the four
NPT domains of coherence, cognitive participation, col-
lective action, and reflexive monitoring, and it is expected
this will facilitate our analyses and derivation of the key
messages.
Study 4: Cost consideration of scale-up (objective 4)
Aim
The cost implications for health services to adopt the
intervention, and deliver at scale in Australia.
Summary
A business model will be developed for health services
to adopt and maintain the intervention. We will both
quantitatively and qualitatively explore the factors that
will influence costs for the various types of health services
(i.e. large, medium and small health services, patient load/
GP, etc.), capacity constraints within individual practices,
the investment needed to adopt the intervention, and the
potential returns to the practice in terms of patient care.
These will be assessed across a diverse range of practices.
This evidence will be obtained through clinical audit
data, surveys, and health professional semi-structured
interviews. The findings will be used to determine the
economic viability of the widespread adoption and im-
plementation of this intervention and inform policy by
ascertaining the support that individual practices will
need to accomplish these tasks and ultimately the costs
to government of scaling up.
Ethical considerations
The study is approved by The University of Sydney
Human Research Ethics Committee (2012/2183) and
the Aboriginal Health & Medical Research Council
(AH&MRC) of New South Wales (778/11). Participa-
tion agreements were signed between the participating
health services and the coordinating research institute.
De-identified patient level data is being extracted from
health service software systems to analyse post-trial
outcomes (study 1) and assess health service utilisation
costs (study 4). Participants in the TCI and job satisfaction
surveys (study 2) and the qualitative study components
will be provided with an information sheet and asked to
provide written informed consent to participate. Partici-
pants will be reassured of the confidential nature of any
data collected, and they will be identified by a unique
identification number only. Participants will be reminded
that they can opt not to answer any questions or can stop
interviews or videotaping at any time, and they will have a
right to withdraw consent and cease involvement in the
study without penalty.
Trial status
Data collection is underway. Preliminary qualitative data
analysis is being conducted contemporaneously with data
collection. Quantitative data analysis has not commenced.
Discussion
Addressing the challenges of CVD burden requires im-
plementation strategies for increasing the uptake of well-
established evidence into practice. Our attempt to address
this with a multifaceted QI intervention was moderately
but not uniformly successful, suggesting the need for a
rigorous process evaluation to understand how and in
what ways it was taken up in practice. Such evaluations
are crucial to understanding how implementation strat-
egies should be applied in non-trial settings.
Multifaceted interventions, by their nature, invariably
lead to complex usage patterns which can make inter-
pretation of study outcomes difficult. In order to maxi-
mise understanding that is relevant to other settings,
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process evaluation is therefore critical. The strength of
our process evaluation is its multicomponent, multi-
theory approach combining diverse study designs to
make sense of how this particular knowledge translation
strategy was adopted into practice. Further, by examining
implementation from multiple perspectives (provider,
patient, health services, and system) the findings are ex-
pected to provide both micro- and macro-system per-
spectives which will be of interest to policy makers and
implementers. There are two key limitations to our ap-
proach (1) the majority of the data collection will occur
toward the end of the trial and in the post-trial phase
and may miss critical insights gained from early phase
adoption processes; and (2) the study setting is limited
to Australian primary healthcare settings and therefore
may be only of relevance to health systems with similar
contexts, financing, workforce structures, and adoption
of electronic medical records.
Despite these caveats, the adoption and successful
implementation of computerised QI interventions and
strategies are the key challenges for healthcare systems
worldwide. In 2009, the US government passed the
Health Information Technology for Economic and Cli-
nical Health Act as a stimulus to promote and adopt
?meaningful use ? of information technologies. The Act
provided incentive payments to hospitals and individual
practices totalling $14 ? 27 billion to adopt EHRs within
3 years to avoid financial penalties. This unprecedented
investment is a reflection of the importance of informa-
tion technology adoption for health systems reform. In
Australia, the National E-Health Transition Authority
was established in 2010 with a government investment
of over $467 million to develop and implement e-health
systems nationally. Despite such large publicly funded
investments, there remains uncertainty around the fac-
tors that will promote successful adoption of compu-
terised QI strategies.
This mixed methods process evaluation, grounded in a
theoretical framework, will evaluate the impact of a com-
plex, multifaceted intervention and help us to understand
the knowledge translation considerations for use of com-
puterised QI interventions in clinical practice.
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Chapter 4: A quantitative study evaluating the efficacy 
of the intervention in a post-trial setting to 
assess trends in outcomes over three years   
4.1 Chapter overview 
This chapter reports the results of an observational study assessing the changes in 
cardiovascular disease (CVD) risk factor screening, prescribing to high-risk patients 
and patients outcomes in the post-trial period of implementation of the intervention. 
The chapter consists of a single manuscript titled: Impact of Sustained Use of a 
Multifaceted Computerized Quality Improvement Intervention for Cardiovascular 
Disease Management in Australian Primary Health Care. 
The study demonstrated that there was no change in CVD risk factor screening in 
the post-trial period when compared with the end of the trial period. Conversely, for 
patients at high CVD risk, there were statistically significant improvements in 
recommended prescriptions at the end of the post-trial period.  
The post-trial study complements the TORPEDO trial looking at impact when trial 
support is scaled back. The findings of the observational study suggest that 
implementation of the quality improvement intervention may take some time for 
healthcare providers to initiate medications, and the potential impact of the 
intervention beyond trial settings.  
4.2 Publication details  
Patel B, Peiris D, Usherwood T, Li Q, Harris M, Panaretto K, Zwar Z, Patel A. Impact 
of Sustained Use of a Multifaceted Computerized Quality Improvement Intervention 
for Cardiovascular Disease Management in Australian Primary Health Care. Journal of 
the American Heart Association. 2017; 6: e007093. 
DOI: 10.1161/JAHA.117.007093   
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conducted the data collection, interpretation of the results and writing of manuscript. 
BP, AP and QL contributed to the statistical analysis plan. QL conducted the 
statistical analysis with advice from AP and BP. BP interpreted the data with input 
from AP, QL and DP. BP wrote the initial draft of the manuscript. AP and DP 
provided critical review and editing of the initial and subsequent drafts of the 
manuscript. All authors provided advice and input in preparation of the final 
manuscript. BP prepared the final draft of the manuscript for publication.   
4.4 Manuscript 
Impact of Sustained Use of a Multifaceted Computerized Quality
Improvement Intervention for Cardiovascular Disease Management in
Australian Primary Health Care
Bindu Patel, MPH; David Peiris, MBBS, MIPH, PhD; Tim Usherwood, MBBS, MD; Qiang Li, MBiostat; Mark Harris, MBBS MD;
Kathryn Panaretto, MBBS, MPH; Nicholas Zwar, MBBS, PhD; Anushka Patel, MBBS, SM, PhD
Background-—We evaluated a multifaceted, computerized quality improvement intervention for management of cardiovascular
disease (CVD) risk in Australian primary health care. After completion of a cluster randomized controlled trial, the intervention was
made available to both trial arms. Our objective was to assess intervention outcomes in the post-trial period and any heterogeneity
based on original intervention allocation.
Methods and Results-—Data from 41 health services were analyzed. Outcomes were (1) proportion of eligible population with
guideline-recommended CVD risk factor measurements; and (2) the proportion at high CVD risk with current prescriptions for
guideline-recommended medications. Patient-level analyses were conducted using generalized estimating equations to account for
clustering and time effects and tests for heterogeneity were conducted to assess impact of original treatment allocation. Median
follow-up for 22 809 patients (mean age, 64.2 years; 42.5% men, 26.5% high CVD risk) was 17.9 months post-trial and 35 months
since trial inception. At the end of the post-trial period there was no change in CVD risk factor screening overall when compared
with the end of the trial period (64.7% versus 63.5%, P=0.17). For patients at high CVD risk, there were signiﬁcant improvements in
recommended prescriptions at end of the post-trial period when compared with the end of the trial period (65.2% versus 56.0%,
P<0.001). There was no heterogeneity of treatment effects on the outcomes based on original randomization allocation.
Conclusions-—CVD risk screening improvements were not observed in the post-trial period. Conversely, improvements in
prescribing continued, suggesting that changes in provider and patient actions may take time when initiating medications.
Clinical Trial Registration-—URL: http://www.anzctr.org.au. Unique identiﬁer: 12611000478910. ( J Am Heart Assoc. 2017;6:
e007093. DOI: 10.1161/JAHA.117.007093.)
Key Words: cardiovascular disease prevention • computer decision support systems • health information technology
• intervention • long-term use • primary health care • quality improvement
Q uality issues affecting healthcare organizations world-wide include inadequate access to healthcare services,
suboptimal provision of evidence-based preventive services
and treatments, and poor coordination of care across health-
care systems.1,2 Our previous work found that only around one
half of adults routinely attending Australian primary healthcare
providers are screened for CVD risk in accordance with
guideline recommendations, and only about 40% of those
identiﬁed at high CVD risk are prescribed recommended
medications.3,4 Meaningful use of health information technol-
ogy (HIT) has the potential to be an important enabler in
increasing the quality of healthcare delivery.5,6 Two such HIT
tools are computer decision support systems and computer-
ized audit and feedback tools (the provision of summarized
clinical performance indicators to healthcare provider(s) over a
speciﬁed period of time). There is a well-established evidence
base demonstrating that these tools improve processes of care
and modestly improve clinical outcomes.7–10 Despite this
evidence, there remain substantial challenges in implementing
these tools in routine clinical care.11,12
We designed a computerized multifaceted quality improve-
ment (QI) intervention for CVD risk management in Australian
primary health care. The intervention, termed HealthTracker,
comprised 4 elements: (1) real-time decision support
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integrated with the patient electronic record utilizing a
guidelines-based algorithm; (2) a patient risk communication
interface that included “what if scenarios” to show the
potential beneﬁts from particular health risk factor modiﬁca-
tions during a consultation; (3) an automated clinical audit
tool for extraction of data and review of health service
performance; and (4) a web portal where services could view
peer-ranked performance over time. Details of the interven-
tion have been published.13
HealthTracker was evaluated between 2011 and 2013 in
the TORPEDO (Treatment of Cardiovascular Risk in Primary
Care Sing Electronic Decision Support) study, a cluster-
randomized controlled trial (cRCT) involving 38 725 people
from 60 primary healthcare services. Detailed results of the
study have been previously published.14 In brief, when
compared with services that did not have HealthTracker
installed, and after a median of 17.5 months follow-up,
services with HealthTracker demonstrated a 25% relative (10%
absolute) improvement in CVD risk factor screening. There
was no signiﬁcant difference overall in prescribing rates of
recommended medicines for people at high CVD risk.
However, for the subgroup of individuals at high CVD risk
who were not prescribed optimal recommended medicines at
baseline, the intervention was associated with a 59% relative
(17% absolute) improvement in prescribing rates.
At the completion of the trial, health services in both trial
arms were offered access to HealthTracker and invited to
participate in a post-trial evaluation. Randomized controlled
trials generally have short-term follow-up periods, and
evidence of sustained impact in nontrial settings is
sparse.15,16 In this observational study, we analyze changes
in CVD risk factor screening, prescribing to high-risk patients
and patient outcomes in this post-trial period to improve our
understanding of the impact of integration of the intervention
into routine clinical care.
Methods
Intervention
Forty-ﬁve of the original 60 primary health services (29
general practices [GPs] and 16 Aboriginal community
controlled health services) agreed to participate in the
post-trial study (Figure 1). Fifteen health services chose not
participate because of the health service closing or moving
(n=4); limited resources (n=3); concerns about HIT tool
slowing down their computer system (n=3); changing to an
incompatible electronic health record software system
(n=3); using another online CVD risk tool (n=1); and lack
of interest (n=1). Four services later withdrew because of
concerns about resources required to support intervention
use and the effects of the software on the speed of their
systems, leaving 41 services (21 intervention and 20
control) included for evaluation purposes. The study popu-
lation comprised Aboriginal and Torres Strait Islander
people aged ≥35 years and all others aged ≥45 years,
who were regular attendees of the health service. Regular
attendance was deﬁned as having visited the health service
at least 3 times in the preceding 2 years and once in the
preceding 6 months.
Health services that had been previously randomized to not
receive HealthTracker were trained in use of the intervention
at the end of the cRCT. The health services previously
randomized to receive HealthTracker were given a refresher at
the end of the cRCT period, if requested. Ongoing training and
technical support was provided to the health services on
request, but this was minimal during the post-trial period. An
average of 13-minute support per month comprising on-site
training, remote clinical Webinars, and IT helpdesk services
was provided during the post-trial period, 35 minutes less
than during the cRCT. All software was provided free of
charge.
Data Collection
Nonidentiﬁable data extracts were obtained from each service
using a validated extraction tool17 at 3 time points—(1) at
baseline for the cRCT; (2) at the end of the cRCT; and (3) at
the end of the post-trial period. Data extractions were either
conducted by the research team through a virtual remote log-
in system or by health service staff themselves. Data were
sent via a secure ﬁle transfer protocol or encrypted email to
the coordinating research institute. An encrypted identiﬁer
code was added to each patient’s data, and this was used to
enable longitudinal follow-up of individual patients.
Clinical Perspective
What Is New?
• This observational study examines the impact of a multi-
faceted computerized quality improvement intervention to
reduce cardiovascular disease risk beyond the randomized
trial period.
• The intervention in a post-trial period was associated with
maintenance of trial-related improvements in screening of
cardiovascular disease risk and ongoing improvements in
prescribing recommended medicines to patients at high
cardiovascular disease risk.
What Are the Clinical Implications?
• The study demonstrates evidence of potential longer-term
impact of a computerized quality improvement intervention
on primary prevention of cardiovascular diseases.
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We invited all general practitioners (GPs) from the inter-
vention health services to complete an end-of-study survey.
The survey obtained information on GP use of the intervention
along with their professional and health service characteris-
tics and prior use of information technology.
The study was approved by The University of Sydney
Human Research Ethics Committee (2012/2183) and the
Aboriginal Health & Medical Research Council of New South
Wales (778/11). Participation agreements were signed
between the participating health services and the coordinat-
ing research institute.
Study Outcomes
The follow-up study outcomes were prespeciﬁed and corre-
spond to those reported in the TORPEDO study. Co-primary
61 health services randomized  
31 randomized to intervention 
(21GPs, 10 ACCHSs)
• 1 GP withdrew from the study shortly 
after randomization 
30 randomized to control 
(20 GPs, 10 ACCHSs)
30 health services analyzed at end of cRCT
• Median follow-up - 17.3 months (IQR 
15.3-18.0)
30 health services analyzed at end of cRCT
• Median follow-up - 17.7 months (IQR 
14.3-18.3)
23 health services agreed to participate in 
post-trial period
22 health services agreed to participate in 
post-trial period
2 withdrew (1 
limited resources; 
1 concerns about 
system slowness
2 withdrew (1 
limited 
resources; 1 
organizational 
change)
21 health services analyzed at end of post-trial 
• N = 12, 534
• Median follow-up in post-trial phase 
17.7 months (IQR 15.5-20.8)
20 health services analyzed at end of post-trial
• N =  10, 275
• Median follow-up in post-trial phase  
18.5 months (IQR 15.6-23.1)
8 – did not wish 
to participate
(2 closed/moved; 
2 limited 
resources, 2 
concerns about 
system slowness; 
1 changed to 
incompatible
software system; 
1 using another 
online CVD risk 
tool)
7 – did not wish 
to participate
(2 closed; 1 
limited resources, 
1 concerns about 
system slowness; 
2 changed to 
incompatible
software system; 
1 not interested)
Figure 1. Study ﬂow diagram. ACCHS indicates Aboriginal Community Controlled Health Service; cRCT,
cluster randomized controlled trial; CVD, cardiovascular disease; GP, general practice; IQR, interquartile
range.
DOI: 10.1161/JAHA.117.007093 Journal of the American Heart Association 3
Long-Term Use of a Complex eHealth Intervention Patel et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on January 27, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
outcomes are 1 and 2, and secondary outcomes are 3 and 4
below:
1. The proportion of eligible patients who received appropri-
ate screening of CVD risk factors. Appropriate screening
was deﬁned as smoking status recorded at least once;
systolic blood pressure recorded in the previous
12 months; and total cholesterol and high-density lipopro-
tein recorded in the previous 24 months.
2. The proportion of eligible patients deﬁned at baseline as
being at high CVD risk, receiving recommended medica-
tions. This was deﬁned as (1) current medication of at
least 1 blood pressure (BP)–lowering drug and statin for
high-risk patients without established CVD, and (2) current
medication of at least 1 BP–lowering drug, statin, and
antiplatelet agent (unless contraindicated) for patients
with established CVD. This outcome was evaluated in the
overall high-risk cohort, as well as the subgroup of high-
risk individuals who were undertreated (deﬁned as those
not prescribed guideline-recommended medications at
baseline).
3. Escalation of prescription medication (either newly pre-
scribed or additional numbers of antiplatelet, BP–lowering
or lipid-lowering medications) among patients at high CVD
risk.
4. Change in BP and serum lipid levels among people at high
CVD risk.
Based on Australian guidelines, high CVD risk was deﬁned
as (1) history of CVD (diagnosis of coronary heart disease,
cerebrovascular disease, or peripheral vascular disease); (2)
the presence of any guideline-stipulated clinically high-risk
conditions such as diabetes mellitus and age >60 years,
diabetes mellitus and albuminuria, stage 3B chronic kidney
disease, or extreme individual risk factor elevations: systolic
BP ≥180 mm Hg, diastolic BP ≥110 mm Hg, total cholesterol
>7.5 mmol (290 mg/dL); or (3) a calculated 5-year CVD risk
of >15% based on the Framingham equation.18
Statistical Analysis
Analyses were performed on the cohort of patients for whom
data were recorded at baseline, end of the cRCT, and end of
the post-trial period. Descriptive data are presented as mean
(SEs) or proportions. Patient-level analysis was conducted
using generalized estimating equations to account for clus-
tering of patients within services with exchangeable correla-
tion structure. A v2 test for categorical variables was used to
test for comparison between intervention and control health
services since they are at the cluster level. The P value for
patient characteristics was obtained from the generalized
estimating equations model, taking into account the cluster-
ing effect using log link for binary variables and identity link
for continuous variables. The random allocation was the
independent variable in the model. Study outcome analyses
were conducted using generalized estimating equations
regression model for continuous outcome, assuming Gaussian
distribution and binary outcomes assuming binomial distribu-
tion with a log link function. Effect estimates between
intervention and usual care health services for the primary
and secondary outcomes were obtained from the generalized
estimating equations model with adjustments made for
baseline measurements, size of service, type of service, and
current participation in QI initiatives. Given that the event rate
is higher in our prospective study, the log link function was
used to produce a rate ratio between intervention and usual
care group rather than deriving an odds ratio using a logit link
function. Although odds ratios produced by logit link tend to
be equivalent to rate ratios produced by log link when the
event rate is small, they may overestimate the relative risk
when event rate is high.
Trend analysis was conducted using data from 2 time
points: end of cRCT and end of post-trial period. Additionally,
paired comparisons were performed to evaluate the effects
of receiving the intervention during the post-trial period. For
outcomes in the post-trial period, P values were calculated
based on change from end of the cRCT to the end of the
post-trial period. For the post-trial period, heterogeneity in
effects between the previously randomized intervention and
control groups was assessed based on the signiﬁcance of
interaction term in the model. Statistical analyses were
carried out using SAS enterprise guide 7.1 (SAS Institute Inc,
Cary, NC).
Results
Cohort
The original TORPEDO cRCT included 38 725 individuals from
60 health services with a median follow-up of 17.3 months for
the intervention group, and 17.7 months for the control
group. Of these, 22 809 patients from 41 health services
were followed up in the post-trial period. Twenty-one services
(n=12 534) were originally randomized to the intervention
and 20 services (n=10 275) to control (Figure 1).
For the screening outcome, data from the 3 extraction
periods for the overall post-trial cohort (22 809 patients) were
analyzed. For the prescribing outcome, data from the 3
extraction periods were analyzed for those patients identiﬁed
as high CVD risk patients at baseline in the cRCT (6106
patients in total and 3039 patients who were undertreated).
The median post-trial follow-up was 17.7 months for the
intervention group and 18.5 months for the control group.
Recruitment into cRCT commenced in September 2011 and
the ﬁnal health service data collection for the post-trial period
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was completed in February 2015 (total median follow-up of
34.8 and 35.0 months for the intervention and control
groups, respectively).
Demographics
For those health services participating in the post-trial
period, there were no signiﬁcant differences in baseline
health service characteristics between the intervention and
control groups (Table 1). There was no difference in risk
factor screening and appropriate prescriptions for high CVD
risk patients based on our 3 prespeciﬁed health service
characteristics of health service type (Aboriginal Community
Controlled Health Service versus general practice), service
size (<500 and ≥500), and if health service participated in a
QI program prior to randomization. Table 2 compares patient
characteristics at baseline and at the end of the cRCT. With
the exception of albuminuria rates, the variables with
signiﬁcant between-group differences at the end of the
cRCT were similarly observed at baseline. Further, there
were no differences in the health services and patient
characteristics of those who participated and those who did
not participate in the post-trial period.
Survey on Attitudes to the Software Tools
Thirty-two GPs within 21 intervention health services (70%)
completed the end of study survey. Of these, 6% reported
always using the intervention, 25% used it more than half of
the time, 53% used it less than half of the time, and 15% never
used it for our study patient population. The majority of GPs
had positive attitudes to all intervention components (Fig-
ure 2).
Outcomes
There were no differences in appropriate CVD risk factor
screening rates during the post-trial period when compared
with rates at the end of the cRCT ([64.7% versus 63.5%
overall; P-trend=0.17] Figure 3). There was also no hetero-
geneity of effects by original intervention allocation group
(P=0.18). Thirty-ﬁve percent of patients were not screened
appropriately according to guideline recommendations at the
end of the post-trial period. Of these, 31.1% had insufﬁcient
data to calculate absolute CVD risk, 39.8% were low-risk
patients with missing or out-of-date information, and 29.1%
high-risk patients with missing or out-of-date information
among high-risk patients. The main driver for this was an out-
of-date or missing lipid value, which accounted for 71.3% of
the screening gap.
There was a signiﬁcant improvement in prescription rates
for patients at high CVD risk in the post-trial period when
compared with rates at the end of the cRCT ([65.2% versus
56.0% overall; P-trend<0.001] Figure 4). There was no
heterogeneity of effects by original intervention allocation
group (P=0.57).
There were signiﬁcant absolute increases in medication
escalation (new prescriptions or increased numbers of
medications) for patients at high CVD risk in the post-trial
period. An absolute improvement of 15.8% was observed for
antiplatelet drugs (P<0.01); 14.8% for lipid-lowering medica-
tions (P<0.01); and 19.0% for BP-lowering medications
(P<0.01). There was no heterogeneity in these outcomes by
original intervention allocation group.
For the high CVD risk patients who were undertreated (not
prescribed guideline-recommended medications) at baseline,
the prescribing rates of recommended medications prescrip-
tions in the post-trial period was signiﬁcantly higher overall
compared with the rates at the end of the cRCT (42.1% versus
33.4%, P-trend<0.001). This improvement was apparent in
both the intervention and control groups (44.9% intervention
Table 1. Baseline Health Service Characteristics
Health Service
Characteristics (n=41)
Intervention
(N=21,
n=12 534)
Control
(N=20,
n=10 275) P Value
Eligible population
<500 9/21 (42.9%) 9/20 (45.0%) 0.89
≥500 12/21 (57.1%) 11/20 (55.0%)
Type of services
Aboriginal
community
controlled health
service
6/21 (28.6%) 6/20 (30.0%) 0.92
General practice 15/21 (71.4%) 14/20 (70.0%)
Medical software used
Best practice 5/21 (23.8%) 7/20 (35.0%) 0.43
Medical director 16/21 (76.2%) 13/20 (65.0%)
Information technology support
Both local and
external
2/21 (9.5%) 8/20 (40.0%) 0.07
External 12/21 (57.2%) 8/20 (40.0%)
Local 7/21 (33.3%) 4/20 (20.0%)
Staff currently using data extraction tools
Most 1/21 (4.8%) 0/20 (0.0%) 0.38
None 9/21 (42.9%) 6/20 (30.0%)
Some 11/21 (52.4%) 14/20 (70.0%)
Current participation in a quality improvement initiative
No 14/21 (66.7%) 12/20 (60.0%) 0.66
Yes 7/21 (33.3%) 8/20 (40.0%)
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versus 37.8% control at post-trial period; Figure 5); however,
there was signiﬁcant heterogeneity by original intervention
allocation group (P=0.03), with greater effects observed in the
control arm. There were no changes in BP or cholesterol levels
in the post-trial period compared with mean levels at the end
of cRCT for either high-risk patients or undertreated high-risk
patients. There was no heterogeneity between patient
outcomes based on original randomization.
0
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improve quality of 
care
Recommendaons 
for screening helped 
me to improve 
quality of care
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Figure 2. General practitioner’s opinion on HealthTracker intervention use. CVD indicates cardiovascular
disease.
Figure 3. Patients receiving appropriate screening of their CVD risk factors. CVD indicates cardiovascular
disease; cRCT, cluster-randomized controlled trial.
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Discussion
Implementation of HealthTracker, a multifaceted QI interven-
tion, in a post-trial setting was associated with maintenance
of trial-related improvements in CVD risk factor
measurements and ongoing improvements in prescription of
appropriate medications to patients at high CVD risk.
Sustainability of health innovations has been deﬁned as “the
extent to which desired health beneﬁts are maintained or
improved upon over time after initial funding or support have
Figure 4. High CVD risk (>15% and with CVD) patients receiving recommended medications. CVD
indicates cardiovascular disease; cRCT, cluster-randomized controlled trial.
Figure 5. Undertreated high CVD risk (>15% and with CVD) patients receiving recommended
medications. CVD indicates cardiovascular disease.
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been withdrawn.”19,20 From this perspective, our ﬁndings
provide some indication of sustainability of the HealthTracker
intervention in the Australian primary healthcare environment.
A post-trial plateauing in CVD risk factor screening rates
was observed at health services in both trials arms. Despite
our evidence-based QI intervention being available, there
remained an overall CVD screening gap of 35%. The plateau-
ing of CVD risk factor screening is suggestive of a “ceiling”
effect.18 There are some factors that partly explain this
phenomenon. Of the 35% screening gap, the vast majority had
an out-of-date or missing lipid value. The majority of out-of-
date values were from those identiﬁed at low CVD risk, and
providers may have not considered it necessary to re-screen
these patients within a 2-year timeframe. Although absolute
CVD risk assessment is recommended 2-yearly for low-risk
individuals in Australia,18 some guidelines recommend lipid
screening every 5 years.21 For those at moderate to high risk
who are lacking lipid measurements, there are possibly
patient factors (eg, difﬁcult-to-reach populations, refusal to be
tested) and provider factors (active disregard or passive
omission) at play.
Conversely, there was a signiﬁcant improvement in
recommended prescribing of appropriate treatments among
those at high CVD risk in the post-trial period both for the
intervention and control groups. The delayed onset of
improvement in the intervention group might be related to
doctors not prescribing recommended medications immedi-
ately following institution of lifestyle change recommenda-
tions or initiatives, or a generally more cautious approach to
introducing or accepting new treatments.22 The improvement
in prescriptions in the control group during the post-trial
period suggests the intervention had an impact outside the
trial setting, although there are obvious limitations in making
this assertion given the observational and uncontrolled nature
of the study design. The secular effects of wider distribution
of a new guideline advocating for an absolute risk approach to
management of cardiovascular risk may have also had
relevance to the observed change.18,23
The group that continued to have the most beneﬁt was the
undertreated high CVD risk patients. The intervention group
had signiﬁcant improvements in prescribing recommended
treatments both in the trial and post-trial period and the
control group signiﬁcantly improved in prescribing after
introduction of the intervention.
HealthTracker contains components known to improve
processes of care and outcomes in trial settings.9,24,25 Key
features include real-time, computer-guided decision support
that is integrated into routine clinical workﬂows, patient-
speciﬁc recommendations and management rather than
assessments alone, screening and therapy alerts, and regular
audit and feedback advice to practitioners.14 The continued
escalation of medication in those at high CVD risk suggests
the possibility that the intervention was able to address
doctor therapeutic inertia (deﬁned as failure to initiate or
increase medication when treatment goals are not being
met).26 Given the multifaceted nature of the intervention, it
can be difﬁcult to assess what were the “active ingredients”
that may have promoted improvements in prescribing
recommended treatments.
An important study limitation is that for technical reasonswe
were unable to obtain usage data for the various intervention
tools. Based on GPs’ opinions on use of the intervention in the
end-of-study survey it would, however, appear that the inter-
vention was partially used and when used the GPs viewed the
intervention favorably. To better understand implementation
issues, a detailed mixed-methods process evaluation of both
the trial and post-trial phases is under way to better understand
which intervention components promoted or had minimal
impact on behavior change at the provider, patient, and system
levels. We are capturing insights on usage patterns through
staff surveys, in-depth practitioner and patient interviews, and
ethnographic analyses of videotaped consultations.27,28 A
realistic evaluation approach is being taken to analyze the
mechanisms of change, contextual inﬂuences, and the resultant
outcomes.28,29 Preliminary ﬁndings indicate a complex inter-
action between the intervention, organizational mission and
values, the role of leaders and teams, and the technical
competence of the software tools. Understanding these
interactions is expected to shed further light on why mixed
outcomes are often observedwith implementation strategies to
improve healthcare quality.
Despite an abundance of research on HIT interventions,
most studies are limited by examining short-term impact.
Consequently, knowledge on their implementation into routine
practice and sustainability of their use is sparse.30 Studies have
found that implementation of interventions outside of a trial
setting is inﬂuenced by several inter-related factors including
hardware and software computing infrastructure, clinical con-
tent, human–computer interface, people, workﬂow and com-
munication, internal organizational policies and procedures and
culture, external rules and regulations and pressures, and
system measurement and monitoring.31 Some of these factors
will be addressed in the process evaluation. For future HIT
studies, these factors need to be evaluated on an ongoing basis
for successful implementation of HIT.
Study strengths include pragmatic implementation of the
intervention within routine clinical practice, evaluation in a
large cohort, and longer follow-up after initial implementation
during the post-trial period. The representativeness of the
general practices and Aboriginal community controlled health
services in Australia32,33 helps strengthen the generalizability
of the ﬁndings to similar healthcare environments in Australia.
The main study limitation is related to the lack of a
comparable control group during the post-trial period.34 This
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limits our ability to make causal inferences from the data
extracted in the post-trial period. In addition, the 2 groups
(intervention and control) experienced different exposure
periods to the intervention and levels of support. Another
limitation relates to the use of electronic medical records and
data extraction tools to evaluate the effects of the interven-
tion. This meant that (1) lifestyle advice, which is often
entered as free text in the record, was not able to be captured
and we were unable to assess effects on diet and physical
activity (although there were no effects observed on body
mass index and smoking status); (2) the data extraction tool
only extracts data for active patients who meet the criteria for
being a regular attendee and if a patient were to die during the
trial period from our cohort, they would not be included in the
follow-up period; and (3) information on medication adherence
was not able to be captured, and this may be an important
driver in achieving BP- and lipid-lowering reductions. Given
this intervention targeted practitioner rather than patient
behavior and adherence barriers are complex, it is quite likely
that such interventions need to be companioned with
additional patient-focused interventions in order to achieve
reductions in CVD biomarkers.
This observational study, despite being weak in study
design compared with rigorous randomized control trials, has
the beneﬁts of demonstrating the impact of the intervention
beyond trial settings and assessing integration into clinical
care.35 It demonstrates some evidence of potential longer-
term impact of a multifaceted QI intervention on management
of CVD risk. Further research on understanding how best to
implement the intervention in various complex health systems
and social/economic settings is needed. This would provide a
broad range of stakeholders and funders key information
needed to allocate resources and to understand the best
strategies for implementation and modiﬁcation of interven-
tions to maximize the use of technology-driven, QI strategies.
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Chapter 5: Mixed methods evaluation exploring the 
underlying mechanisms of implementation 
of the intervention and interaction with 
contextual factors that resulted in variable 
outcomes 
 5.1 Chapter overview 
This chapter reports the results of a mixed methods evaluation to identify and explain 
the underlying mechanisms by which the intervention did and did not have an impact 
amongst the participating case study health services. The chapter consists of a 
single manuscript titled: What drives adoption of a computerised multifaceted quality 
improvement intervention for cardiovascular disease management in primary 
healthcare settings? A case study analysis using Normalisation Process Theory. This 
manuscript has been resubmitted after initial comments to Implementation Science 
and is currently under review.  
The use of Normalisation Process Theory within the UK Medical Research Council 
framework assisted in explaining how contextual factors influence the work that is 
done by individuals and teams when implementing a multifaceted computerised 
intervention. The study provided insight into the complexity and multiple levels of 
interactions between implementation processes and several contextual factors 
affecting uptake of the intervention. 
Overall the study found that there were four spheres of influence that appeared to 
enhance or detract from adoption of the intervention: organisational mission and 
history, leadership, team environment and technical integrity of the intervention.  
5.2 Manuscript details 
Patel B, Usherwood T, Harris M, Patel A, Panaretto K, Zwar N and Peiris D. What 
drives adoption of computerised quality improvement tools by primary healthcare 
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providers? An application of Normalisation Process Theory. Implementation Science 
(Under review).  
 
5.3 Author Contributions 
BP, DP, TU, and MH made substantial contribution to the conception of the mixed 
methods evaluation. All authors contributed to the overall study design of the 
process evaluation. BP developed the interview guides and consent forms for ethics 
submission, implemented the study, conducted the data collection and analysis. All 
authors contributed to the interpretation of the results as part of the project working 
group. MH advised on the to data analysis of the surveys. BP wrote the initial draft of 
the manuscript. DP provided critical review and editing of the manuscript. All authors 
provided advice and input to prepare the manuscript for journal submission. BP 
prepared the final draft of the manuscript for publication.  
5.4 Submitted manuscript 
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ABSTRACT  
Background 
A computerised, multifaceted quality improvement (QI) intervention for cardiovascular 
disease (CVD) management in Australian primary healthcare was implemented and evaluated 
in a cluster randomised controlled trial (cRCT). The trial improved CVD risk factor screening 
but did not increase prescribing of guideline-recommended medicine for patients at high 
CVD risk. The aim of this study was to conduct a process evaluation of the cRCT 
(TORPEDO trial) to identify and explain the underlying mechanisms by which the 
intervention did and did not have an impact amongst the participating health services.  
Methods/Design 
A conceptual framework based on Normalisation Process Theory (NPT) was used to 
understand factors that supported or constrained normalisation of the intervention into routine 
practice. We applied a case study methodology in which health services were our cases. Six 
of the 30 participating intervention health services were purposively sampled to obtain a mix 
of size, governance, structure and performance. Multiple quantitative and qualitative data 
sources from both cases and other sites were drawn on including trial outcome data, surveys 
of job satisfaction and team climate (246 health professional participants within 39 (65%) 
health services), a survey of attitudes to the intervention (32 doctors within 21 (70%) of 
intervention health services), and health professional interviews (n=19). These data were 
primarily analysed within cases but also compared with findings in other trial sites.  
Results 
We found a complex interaction between implementation processes and several contextual 
factors affecting uptake of the intervention. There was no clear association between team 
climate, job satisfaction and intervention outcomes. There were four spheres of influence that 
appeared to enhance or detract from normalisation of the intervention: organisational mission 
and history (e.g. strategic investment to promote a QI culture enhanced cognitive 
participation), leadership (e.g. ability to energise or demotivate others influenced coherence), 
team environment (e.g. synergistic activities of team members with different skill sets 
influenced collective action) and technical integrity of the intervention (e.g. tools that slowed 
computer systems limited reflective action).   
Discussion 
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Use of NPT helped explain how certain contextual factors influence the work that is done by 
individuals and teams when implementing a novel intervention. Although these factors do not 
necessarily distil into a recipe for successful uptake, they may assist system planners, 
intervention developers, and health professionals to better understand the trajectory that a 
health service may take when developing and engaging with complex interventions.  
 
Australian Clinical Trials Registry 12611000478910. 
Keywords 
Quality improvement, health information technology, primary healthcare, health service, 
Normalisation Process Theory, process evaluation, mixed methods, adoption  
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Background 
In the area of cardiovascular disease (CVD) risk management, around 50% of adults 
attending primary healthcare are adequately screened for CVD risk and only around 40% of 
those identified at high risk are prescribed recommended medications [1-3]. To address these 
entrenched gaps the US National Academy of Medicine recommended changing the 
healthcare environment in four ways: increasing the uptake of evidence in healthcare 
delivery, leveraging information technology, aligning payment reform with quality 
improvement, and enhancing workforce support [4, 5].  
 
Quality improvement (QI) is a well-established process to improve the efficiency and 
processes of healthcare with goals of achieving sustained improvements in health outcomes 
and system performance [6, 7]. Three inter-related QI strategies are pertinent to this paper. 
The first is the Chronic Care Model, particularly the sub-domains of decision support and 
optimising clinical information systems. Several evaluations of varying quality have 
indicated contributions to improved processes of care and patient health outcomes [8, 9]. The 
second is the Breakthrough Series Collaborative model organised around principles of 
closing evidence-practice gaps, minimising unwanted variation in care, disseminating and 
diffusing best practice activities, fostering collaborative work ethics, and implementing rapid 
evaluation and action (plan-do-study-act) cycles [10][11]. There have been relatively few 
randomised evaluations of collaborative models and outcomes have been mixed [12]. Third, 
health information technology (HIT) is a key enabler of the Chronic Care Model and the 
Collaborative model to improving QI. HIT strategies with the strongest evidence base include 
computerised clinical decision support systems and audit and feedback of performance to 
providers. These have been shown to improve processes of care with a modest impact on 
healthcare outcomes [13-17].  
 
Development of the intervention 
Drawing on the above literature, we developed a multifaceted QI intervention for CVD 
management in Australian primary healthcare. A sociotechnical approach was taken in the 
design of the intervention, recognising that integrating technology into practice requires 
human work to re-contextualise knowledge for different uses within complex social settings 
[18]. Influential theories and previous literature that helped guide the development of the 
intervention included: (1) Lipsky’s concept of street-level bureaucrats which in this context 
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relates to the ways in which GPs expeditiously process large workloads and technological 
tools can influence this process [19]; (2) Kawamoto’s systematic review of decision support 
systems that found the timing of advice when decisions are being made was important [20]; 
and (3) Gabbay and Le May’s concept of ‘mindlines’ which are professionally sanctioned 
codes of practice that may or may not relate to evidence based guidelines [21]. 
  
The intervention, named ‘Health Tracker’, has been described in detail elsewhere [22]. It 
incorporated two “in-consultation” tools which included real-time decision support integrated 
with electronic medical records to support workflow when clinical decisions are being made; 
and an interactive risk communication tool to support conversations between provider and 
patient about CVD risk during the consultation. It also included two “out of consultation” 
tools to support reflective practice. These included an automated clinical audit tool which 
provided feedback to providers on their performance and allowed them to identify patients 
who were potentially not being treated according to guidelines; and a web portal which 
provided peer-ranked performance trends using a technical platform that is used in the 
Australian Primary Care Collaboratives (APCC) programme [23].  
 
During the cRCT, as part of the intervention, health services received introductory training 
visits from staff in use of the software and a clinical lead researcher conducted both face to 
face and training webinars on the management of CVD risk. The technical help desk support 
was also provided for any software related problems. During the post-trial period this support 
was scaled back and mainly restricted to technical software support. All software licences and 
technical support associated with the intervention were provided free to intervention sites 
during the trial period, and to all sites participating in the post-trial phase. Patient and practice 
costs associated with patient care occurred as per usual practice. 
 
Clinical effectiveness evaluation 
The intervention was evaluated between September 2011 and June 2013 in the TORPEDO 
(Treatment of Cardiovascular Risk in Primary Care Using Electronic Decision Support) study 
- a cluster-randomized controlled trial involving 38,725 people (40 general practices and 20 
Aboriginal Community Controlled Health Services (ACCHSs) [22]. At completion of the 
cRCT, the intervention was provided for a further 18 months to end 2015 to both intervention 
and control sites.  The primary outcomes of the cRCT and the post-trial period have been 
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previously published and related to guideline-recommended CVD risk factor screening and 
prescribing of recommended medicine to those identified at high CVD risk  [24, 25]. In the 
cRCT, when compared with services that did not receive the intervention, and after a median 
of 17.5 months’ follow-up, intervention services had a 25% relative improvement in CVD 
risk factor screening. There was no significant difference in prescribing rates of 
recommended medicines for people at high CVD risk. However, for the sub-group of 
individuals at high CVD risk who were not prescribed optimal recommended medicines at 
baseline, the intervention was associated with a 33% relative improvement in prescribing 
rates and significant improvements in intensification of existing blood pressure and blood-
thinning medications.  In the post-trial evaluation period there was a plateauing of 
improvement in measurement of recommended risk factors but an ongoing improvement in 
prescribing of recommended medicines in both intervention and control arms of the trial [25].  
 
The objective of this study was to conduct a process evaluation of the TORPEDO trial to 
identify the underlying mechanisms by which the intervention did and did not have an impact 
on trial outcomes amongst health services participating in the study. It forms part of a broader 
multimethod process evaluation in which several studies are being conducted to examine the 
implementation and impact of the intervention. 
 
Methods and design 
The process evaluation was designed prior to the commencement of the cRCT by a project 
working group which comprised researchers who were involved in the trial development and 
external researchers not involved in the intervention. The logic model, which articulates all 
the component studies of the process evaluation, has been previously published in this journal 
and has been included here as an additional file [26]. The mixed methods analysis in this 
paper refers to study 2 in the logic model which included semi-structured health professional 
interviews and quantitative survey data. 
For this study we applied a case study methodology. This approach facilitated exploration of 
implementation processes within the health service by answering “how” and “why” questions 
from multiple sources and taking into account contextual influences [27, 28]. ‘Cases’ refer to 
the intervention arm health services who agreed to participate in this study. ‘Non-case 
intervention sites’ are intervention health services that were not selected as cases. ‘Control 
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sites’ are health services that were assigned to the usual care arm of the cRCT, whose 
quantitative data were used as a comparison for the trial outcomes. In determining case 
selection, we purposively invited intervention health services that exhibited a broad variation 
in trial primary outcomes, numbers of staff at each site and type of service (general practice 
versus ACCHS, urban versus rural and size). We took a “small N” approach where six 
intervention health services were followed to understand how various influential factors 
interacted with one another and why the intervention played out differently in some places 
compared to others.  
Theoretical framework 
Nilsen identified a wide range of theories, models and frameworks that have been applied to 
understand implementation of complex interventions including process models, determinant 
frameworks, classic theories, implementation theories and evaluation frameworks [29]. We 
used a framework (the UK Medical Research Council (MRC) guidance on process 
evaluations for complex interventions) [30]  and a theory (Normalisation Process Theory 
(NPT)) to understand the factors and mechanisms involved in implementation of the 
intervention.  
The MRC guidance provides practical guidance on designing and conducting evaluations to 
assess implementation (fidelity, dose, and reach) of complex interventions, explain causal 
mechanisms (how change is produced) and identify contextual factors (anything external to 
the intervention) associated with variation in outcomes [31, 32].  NPT seeks to understand the 
implementation processes and the extent to which an intervention became “normalised” in the 
service environment [33, 34]. NPT is focused on the work people do individually and 
collectively to implement, embed and integrate new interventions into their physical and 
social context. This is characterised by four generative mechanisms of coherence (‘what is 
the work?’), cognitive participation (‘who does the work?’), collective action (‘how does the 
work get done?’) and reflexive monitoring (‘how is the work understood?’). By embedding 
NPT within the MRC guidance, we sought to understand the interaction between health 
service context, the generative mechanisms related to the implementation of the intervention 
and the outcomes observed in the cRCT. 
Data collection  
Multiple quantitative data sources were used:  
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1. To assess effectiveness of the intervention on the trial outcomes within cases, data 
from electronic medical records were collected using a validated extraction tool at 
baseline, end of trial and end of post-trial phase. 
2. To assess the support requirements provided by the project staff, support time was 
calculated based on contact time logged by both the technical helpdesk and the 
research team.  
3. To assess acceptability and fidelity of the intervention staff were invited to complete 
three surveys at the end of cRCT - (1) An end of study mail survey was conducted 
asking about satisfaction with the intervention and frequency of use. Although we had 
intended to look at usage analytics to look at intervention fidelity, due to technical 
problems with the software database we were unable to generate accurate usage logs 
and therefore had to rely on staff self-report. Drawing on the NPT sub-domain of 
“collective action” in which team members work together to incorporate and 
innovation into practice, a Team Climate Inventory (TCI) [35] survey was 
administered. This is a 44-item questionnaire which assesses team vision (11 items); 
participative safety (12 items); task orientation (7 items); support for innovation (8 
items) and social desirability (6 items) with each item rated on a five-point Likert 
scale.  
4. In order to assess if job satisfaction may be an influential factor in driving outcomes, 
the Warr-Cook Wall job satisfaction survey was administered [36]. Based on previous 
work [37], this 10-item questionnaire assesses physical work conditions, income, 
amount of responsibility given, freedom in the job, variety, work colleagues, 
opportunity to use abilities, recognition, and hours of work. The internal reliability of 
the scale is well established with rank order correlation between item-whole values 
for each item in the scale averaging 0.95.  It was validated and adapted for use with 
general practices and ACCHSs using a 7-point Likert scale [37].  
The TCI and job satisfaction surveys were either distributed by mail or in person during 
the end of trial data collection period. Health services were followed up one week later by 
telephone on expected completion timeframe. For surveys not received within the month, 
a second attempt to follow-up was made.  
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In addition to these quantitative data sources, semi-structured interviews were conducted by 
two researchers with staff between May 2013 and February 2014 at each of the cases. A 
purposive sample of staff were asked about their knowledge, views and experience of the 
intervention. We sought a diverse mix of general practitioners, nurses, managers, Aboriginal 
health workers (AHWs) and administrative assistants to participate. Interviews took place at 
the health services towards the end of the trial and during the post-trial phase to not overly 
influence the implementation phase of the intervention. Interviews were audio-recorded and 
professionally transcribed. The interview questions were aligned with NPT domains. Broad 
domains of inquiry included the following: (1) why health staff did/did not use the 
intervention; (2) how was the intervention used in routine practice (3) how did the 
intervention help use of guidelines (4) how was the intervention integrated at the health 
service (5) what impact did the intervention have on the way personnel do their work (see 
additional file for the interview guide). During the process of conducting the interviews, 
questions were modified in light of earlier interviews to allow exploration of emergent 
themes in consultation with the project working group.  
Data analysis  
We conducted a mixed methods analysis adopting an explanatory sequential design whereby 
both survey and qualitative data were analysed to gain better understanding of the processes 
of implementation and the resultant quantitative outcomes [38]. The systematic integration of 
qualitative and quantitative data within a single case allowed for examination of rich 
empirical data through varied perspectives.  
Effectiveness data were analysed using SAS Enterprise Guide V4.5. Contact time with 
services was tabulated in a spreadsheet and simple frequency analyses conducted. The 
satisfaction survey results were reported as frequencies or proportions. For the TCI, mean 
scores were calculated for each sub-domain and a total mean score was calculated across all 
domains (maximum score 44) [39]. For the job satisfaction survey, each of the seven domains 
were equally weighted and a total mean score (maximum score 7) was calculated [40, 41]. 
Scores were reported for each case and overall mean scores were calculated to compare three 
groups: case study sites, non-case study intervention sites and control sites. Associations 
between the TCI and job satisfaction survey scores and trial outcomes overall and for these 
three groups were analysed using univariate analyses of variance. Although we intended to do 
a multilevel regression model analysis (as per our published study protocol); the univariate 
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analyses of these surveys did not reveal any substantive associations between Team Climate 
Inventory and Job Satisfaction survey scores and the trial outcomes.   
Interview data were analysed in three stages and assisted by Nvivo 11 (QSR International 
Melb. Vic). An initial familiarisation stage was conducted in which five interviews from 
three cases (cases 1, 2 and 6) were analysed and discussed with the project working group. 
Following this an initial thematic coding framework was developed that consisted of both 
descriptive codes derived from the initial thematic framework and new codes that were 
inductively developed as we became more familiar with the data. Thematic saturation was 
achieved after interviewing nineteen health professionals with no new codes being created. 
Several meetings with the project working group were held to discuss the findings and their 
significance. The NPT constructs were continuously drawn onto assist with the interpterion 
of the findings. In particular May and Finch’s outline of the mechanisms, components and 
investments to understand and identify “the trajectory and outcomes of implementation 
process” [34, 42]; and Mair and colleagues’ meta-review of implementation of e-health 
interventions using an NPT-based explanatory framework was used to evaluate barriers and 
facilitators [43]. Key elements of the framework are summarised in Table 1.  
[insert Table 1] 
 
RESULTS 
Eight intervention health services were approached towards the end of the trial phase with six 
agreeing to participate (4 general practices and 2 ACCHSs). Figure 1 summarises key 
characteristics of the cases and figures 2 -7 provide detailed summaries of the health service 
context, attitudes to and use of the intervention and the trial and post-trial outcomes.  
 
Table 2 shows the mean TCI and Warr-Cook Wall job satisfaction scores for the cases, the 
other intervention health services, and the control arm health services. There were no 
statistically significant differences overall in mean TCI and job satisfaction scores between 
the cases and other participating intervention and usual care health services. There were also 
no statistically significant associations found between trial outcome variables and either the 
TCI or job satisfaction scores, and no heterogeneity between groups (cases, non- case 
intervention and control arm sites). There were also no significant associations in terms of 
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size of health service, type of health service (general practice vs ACCHS), location and 
previous participation in a continuous quality improvement (CQI) program. 
 
[insert Table 2] 
 
A total of 19 interviews were conducted (9 general practitioners (GPs), 4 practice managers 
(PMs), 3 Aboriginal health workers (AHWs), 1 practice nurse (PN), 1 health information 
officer (HIO), and 1 administrative assistant/practice manager (AA/PM)) from the six health 
services (‘cases’) (Table 3). Key findings for each of the cases organised by NPT domains are 
summarised below and in figures 2 -7. More detailed findings with supporting quotes are 
shown in Additional file 2. 
 
[insert Table 3] 
 
Case 1 (Figure 2) 
Context and outcomes 
Case 1 was a small, urban general practice in a socioeconomically disadvantaged region of 
Western Sydney. Staff members were the full-time GP owner and a practice manager (PM) 
who had both worked there for over 30 years with part time clinical and administrative staff. 
Screening and prescribing outcomes significantly improved over the trial period but then 
plateaued with a slight decrease in prescribing in the post-trial period. The practice was 
strongly dependent on the research team to stay engaged with the intervention. There was 
approximately 10 hours of training and technical support provided during the trial phase and 
negligible support provided in the post-trial phase. There were multiple visits to the practice 
by the project officer to assist both the PM and GP but little dedicated training for any of the 
other staff.  
 
Mechanisms of implementation 
The high level of understanding of the objectives (coherence) and engagement (cognitive 
participation) for the two main staff members (GP and PM) in combination with support from 
the research team strongly influenced implementation of the intervention. The GP and PM 
valued different aspects of the intervention – the former using the tools to enhance 
communication with patients, while the latter assessed aggregated data for monitoring 
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practice performance. Despite the clear appeal of different intervention components for each 
of these staff, overall there was a lack of collective action at this practice. There was little 
evidence of modifications to prevailing policies, procedures and resourcing. The PM was 
influential in encouraging the GP to use the decision support tool, providing feedback on his 
performance, however other practice team members were almost completely non-engaged. 
Consequently, there was little evidence of enhanced interactions or relations between team 
members. The PM had tried to engage receptionist staff in use of the tools, however, there 
appeared to be little interest, possibly due to a lack of coherence for these staff. Further, there 
was little evidence of ongoing appraisal and evaluation of the use of the interventions, setting 
goals and/or strategies to overcome any barriers. These factors may provide some explanation 
as to why the outcomes may have declined in the post-trial setting.  
 
Case 2 (Figure 3) 
Context and outcomes 
Case 2 was a small urban, residential Sydney general practice with a full-time GP owner, 
several part-time GPs, administrative staff and no practice nurse. Much of the practice 
management was handled by the owner GP and there was a high degree of turnover of 
administrative staff. The owner GP had a strong interest in use of software interventions to 
improve health care quality, however, there was little formal participation in QI programs 
prior to participation in this research project. Total support time was 12 hours (mostly IT 
support) and this was mainly during the trial period with minimal support provided in the 
post-trial period. Trial outcomes were significantly improved over the trial period for both 
screening and prescribing and then plateaued and slightly declined in the post-trial period for 
screening.  
 
Mechanisms of implementation  
The intervention had a high degree of coherence for the owner GP who was strongly 
interested in appraising performance at his practice compared to other general practices 
involved. Improvement in peer-ranked performance was the major motivation to participating 
in the study for this GP. However, sustained engagement was a major barrier, where major 
software technical issues were encountered resulting in prolonged periods where the tools 
were inaccessible despite multiple calls to helpdesk support. This led to sporadic engagement 
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and diminished any possibility of systematically incorporating usage into every day work. 
There was virtually no evidence of collective action at this practice with staff members 
working in isolation of one another. Although the owner GP became highly competent in 
using the intervention, these skills were not transferred to other staff members. One other 
part-time GP expressed interest in using the tools following a training visit, but in the face of 
the technical barriers rapidly lost interest. Consequently, the substantial trial period 
improvements appear to be almost entirely attributed to the activities of the owner GP. In the 
post-trial period, his motivation to remain engaged was diminished and this may explain the 
plateau in outcomes.  
 
Case 3 (Figure 4) 
Context and outcomes 
Case 3 was a solo GP practice with a full-time manager/receptionist in a diverse Sydney 
community near a major business district. The GP had been in practice for over twenty years 
but had little experience with QI programs. Initial implementation of intervention and 
training to this GP was provided by the GP principal investigator and only one additional 
onsite training visit was provided by the research team. Total support time was approximately 
3 hours. Trial outcomes were above average at baseline. Screening rates decreased but overall 
remained broadly unchanged by the end of the post-trial period. There were improvements in 
prescribing rates over both the trial and post-trial periods.  
 
Mechanisms of implementation  
The intervention lacked coherence for both the GP and PM. The GP found the initial training 
session to be overwhelming with trying to fit in patient consultations during the training. 
Although he appreciated the relevance of CVD risk screening and management, he did not 
readily see what value this intervention provided in addition to his usual practice. He also felt 
that his patients had a low level of understanding of absolute CVD risk scores and that it was 
not appropriate to engage them in the risk communication tools (interactional workability). 
Consequently, over time he saw the intervention primarily as a laborious data collection 
exercise with little utility and no financial compensation. This lack of coherence and 
cognitive participation was further compounded by technical issues midway through the trial 
where the decision support software appeared to be slowing down performance of his 
computer systems and at times cause disruptions to clinical practice (contextual integration). 
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The PM was not encouraged to be involved in use of the intervention and consequently there 
was limited collective action evident at this practice (relational integration and skill set 
workability). A key driver for increased engagement was related to financial incentives. The 
lack of a sustainable business case meant that the work of engaging in the intervention was 
primarily to benefit the research team and not the practice or his patients.  
 
Case 4 (Figure 5) 
Context and outcomes 
Case 4 is a mid-sized teaching general practice in a rural outer Western Sydney suburb. The 
owner GP established the practice over 30 years ago and has been active in supervising GP 
registrar training for many years. There is a full-time practice manager, part-time nurse and 
up to three full-time training GP registrars who generally did 6-month placements at the 
practice. Despite extensive involvement in teaching and supervision, the practice has not been 
involved in any formal QI programs. There was extensive onsite training provided by project 
officers throughout the trial period with frequent refresher courses when new GP registrars 
commenced at the practice. Total support time was approximately 11 hours. Trial outcomes 
were below average at baseline. Screening rates improved substantially over the trial period 
but deteriorated in the post-trial period. There were steady improvements in prescribing rates 
over both the trial and post-trial periods.  
 
Mechanisms of implementation  
The owner GP found value in the intervention as a teaching tool to train GP registrars. The 
GP had moderate coherence because of his specific interest in the use of tools to assess CVD 
risk and was interested in gauging his practice performance. Although he himself had low 
confidence in using computer tools in his practice, he saw it as an inevitable aspect of future 
clinical practice. Consequently, cognitive participation was high as a clear expectation was 
set by the owner GP that staff learn how to use the tools. Weekly staff meetings were used as 
a teaching platform and team-building forum. At these meetings, the intervention and 
performance outcomes were discussed intermittently throughout the trial period. The major 
barrier to integration across team members was the high turnover of GP registrars. The owner 
GP lacked capacity and confidence to train new staff and consequently this was left to the 
research team staff. The decline in screening performance in the post-trial period may in part 
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relate to the high turnover as newer registrars commenced, and research team support was 
less intensive. Although relational integration between the doctors appeared high, there was 
little evidence of engagement with the practice nurse or practice manager in the intervention. 
There was some evidence of appraisal with both the practice manager and owner GP pleased 
with the performance improvements relative to peers. 
 
Case 5 (Figure 6) 
Context and outcomes 
Case 5 was a large ACCHS in a remote region with strong Aboriginal community 
representation on its all Aboriginal governing board. The service was over 20 years old and 
received funding from both state and federal governments. It had a chronic disease strategy in 
place for 12 years which included a strong focus on CQI programs. Initial training was 
conducted by the GP principal investigator over three separate sessions for a total of 23 staff 
including GPs, nurses, Aboriginal Health Workers (AHWs) and a health information officer 
(HIO). Additional support was provided via webinar and phone when required over the 
course of the trial and minimal support in the post-trial period. Total support time was 
approximately 12.5 hours. TCI and job satisfaction scores were lower than average compared 
to other cases, especially in the TCI subgroup regarding ‘Vision’ and ‘Task Orientation’. The 
health service had a high baseline performance in the trial outcomes reflective of its extensive 
involvement in CQI programs. Trial outcomes in prescribing increased during the trial period 
and subsequently plateaued, and screening stayed relatively unchanged.  
 
Mechanisms of implementation  
There was strong overall coherence by all levels of staff in understanding the objectives of 
the intervention and its alignment with existing activities. This in turn fostered immediate 
action to engage with the intervention (cognitive participation). These actions and processes 
were variably implemented because management decided to not provide non-GP clinical staff 
with the tools due to concerns of it impacting on existing workloads. This impacted relational 
and contextual integration of the intervention into the organisation. Some GPs would have 
preferred AHWs to use the tools to engage patients as part of their existing role in performing 
frontline screening assessments prior to seeing the GPs. Despite this limitation, the HIO 
played a central role in cognitive participation, collective action and reflexive monitoring. 
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Use of the service’s existing monitoring and evaluation platform assisted in communal 
appraisal. Regular team meetings were held where data and performance were reviewed with 
a specific focus on improving GP prescribing to the high CVD risk patient population. This 
likely played a key role in the increase in prescribing during the trial period. 
 
Case 6 (Figure 7) 
Context and outcomes 
Case 6 was a large urban ACCHS in the state of Queensland. The service has two clinic 
locations with the main branch in a mixed residential and commercial area; and a smaller 
clinic located in a shopping centre. The service was over 20 years old and is governed by an 
all Aboriginal and Torres Strait Islander board of directors. There were around 26 staff in 
total with 5 GPs (3 full-time and 2 part-time) with the following staff participating in the 
semi-structured interview: 3 full time GPs, 2 AHWs, practice manager and nurse/practice 
manager. The service had been regularly involved in a CQI collaborative run by an external 
state-based organisation representing Aboriginal and Torres Strait Islander health services 
(peak body), but at the time of the study, this program was not actively being implemented. 
Initial implementation of intervention and training was conducted by two project officers in a 
group forum and then individually to each staff member. Additional training support was 
provided via webinar and phone when required over the course of the trial. As with Case 5, 
TCI and job satisfaction scores were lower than average compared to other cases, especially 
in the TCI subgroup regarding ‘Vision’ and ‘Task Orientation’. Total support time was 17 
hours. Slightly above average performance in screening and prescribing was observed at 
baseline and this largely remained unchanged throughout the trial and post-trial periods.   
 
Mechanisms of implementation  
All levels of staff appeared to have moderate understanding (coherence) of the intervention 
and its objectives.  AHWs were enthusiastic about using the tool for screening and patient 
risk communication with support from lead GPs. Most staff used the patient risk 
communication graph component only and were less confident in using the other 
components. Many described time constraints in using the tools. In addition, IT infrastructure 
and technical issues were major barriers at this service. This prevented long-term use of the 
intervention by all staff and greatly diminished any prospects of collective action. Only the 
lead GP remained enthusiastic in use of the tool over time, however this required extensive 
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time with the IT helpdesk to resolve software problems. Further, although this GP was the 
senior clinical lead, he lacked the authority to make managerial decision as this is the role of 
the chief executive officer. Another factor that inhibited collective action was a perception 
the data extracted from the audit tool was unreliable and this discouraged use by the PM and 
a newly employed GP. This also inhibited opportunities for reflexive monitoring despite the 
research team’s efforts to provide performance feedback reports and explain the reasons for 
data quality issues. This lack of collective action and reflexive monitoring are likely drivers 
in no change in the screening and prescribing outcomes.  
 
Discussion  
This process evaluation of a multifaceted computer-guided QI trial in Australian primary 
healthcare settings sought to better understand why there was increased CVD risk factor 
screening and no effect on the prescribing rates in the intervention health services compared 
to the usual care during the trial. In depth examination of six case studies revealed a complex 
interaction between implementation processes and several contextual factors.  The findings 
complement previous work highlighting the multiple barriers to uptake of health technologies 
into routine practice. These include knowledge-related barriers, sufficient training, specific 
features of the technologies themselves, the external environment, coherence for both 
providers and patients, and organisational context [44-47]. 
 
Despite knowledge of these barriers the challenge remains in identifying strategies to 
overcome them. Given the diversity of the cases and the contextual circumstances in which 
they operated, there is clearly no one recipe for success or failure. The findings illustrate that 
there may be different factors at play during initial implementation compared to those that are 
needed to influence sustained use of the intervention. There appear to be spheres of influence 
that when aligned enhance normalisation of the intervention into routine practice. The first 
broadly relates to the mission of the health service, its organisational culture and the 
antecedents to participating in this project. The second related to the leadership structures and 
the role of influential leaders in changing the activities of others. The third relates to the team 
environment and the extent to which certain actors within the team influence the activity of 
others. The fourth relates to the tools themselves and the degree to which they are fit-for-
purpose from content, workflow and technical perspectives.  
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Organisation mission and history – One of the ACCHSs (case 5) had prioritised use of CQI 
processes over 10 years and this was evident in strategy documents, staffing allocations and 
prior use of various CQI tools. Its high baseline performance is reflective of this commitment. 
However, the intervention was strategically determined by CEO to prioritise use of the tools 
by GPs only to the exclusion of other clinical staff. This supported improved performance in 
prescribing outcomes (the domain of GPs) and less movement in screening outcomes (the 
domain of nurses and AHWs). Such strategic choices were made explicit in this large 
organisation and could be linked to its policies and procedures around QI processes. In the 
smaller general practices, such strategic processes were less explicit but still played an 
important role in driving engagement with the intervention. For example, the teaching 
practice (case 4) had made as part of its mission a long-standing commitment to teaching 
excellence. Consequently, the intervention tools were avidly promoted to GP registrars as a 
part of this overall organisational commitment. NPT describes the alignment of the 
innovation and organisational mission as contextual integration and in our cases this was a 
driving factor [48]. 
 
Leadership – A recent systematic review of the impact of clinical leadership on adoption of 
health information technologies found that the leader’s attributes and behaviours strongly 
influenced engagement [49] which supports Bodenheimer’s notion of ‘engaged leadership’ 
being the foundational building block of a high performing primary care [50]. We found that 
the influence of leaders varied greatly. Although in case 1 there was strong motivation from 
the GP to improve CVD risk management practices, this alone appeared insufficient. 
Importantly when the motivated leader’s interests were aligned with those of his trusted 
practice manager then engagement in the new practice was enhanced. However, this also 
appeared to be insufficient and when the support provided by the research team was removed 
the intervention rapidly ‘de-normalised’ and was used infrequently emphasising the 
importance of ongoing provider training. Cases 2 and 3 represented ‘one-person shows’ 
where utilisation of the intervention was entirely dependent on the GP owner. In the former 
case, utilisation was high and strongly driven by a desire to outperform peers. In the latter 
case, utilisation was low from the outset and over time came to be seen as a nuisance. In both 
cases the intervention had little prospect of normalising across the practice once the study 
was completed. Curiously, however, in case 3 where the GP was least enthusiastic about the 
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intervention there were large sustained improvements in prescribing outcomes suggesting 
some behaviour change had occurred despite antipathy for the intervention. In case 6, 
although the GP leader was strongly engaged in some elements of the intervention and 
encouraged staff to use the intervention, he did not appear to take on a role of 
mentoring/training other staff. Further, organisational goals were more focused on individual 
patient care rather than CQI. This limited the impact of the audit and feedback and peer-
ranked performance tools which are intended to make organisational performance more 
transparent.  
 
While in case 5, the long history of leadership in CQI, supported by the governing board and 
CEO, influenced improvements in trial outcomes but it did not translate to normalisation of 
the intervention. This highlights the importance of ‘special people’ as key to successful 
implementation of HIT [51]. We found that these ‘special people’ include both clinical 
champions and non-clinical staff who have the ability to both broker and stifle engagement 
with an innovative practice. The findings suggest that when implementing QI interventions, it 
is important to identify and support ‘engaged leaders’ early to maximise potential for 
embedding new practices. 
 
Team work – Although teamwork is a key ingredient to enhance uptake of innovative 
practices [52, 53], the influence of teams manifested in complex ways in the case studies. 
There was no evidence of association between the team climate or job satisfaction scores and 
uptake of the intervention or trial outcomes. Indeed, in some cases where these scores were 
lower than average, performance was higher than average (case 5) and vice versa (case 3). 
This contrasts with previous studies which have shown that team climate scores are positively 
associated with staff satisfaction, and improved quality of care [41, 54]. NPT conceives 
healthcare as a collective activity requiring a multitude of interactions between professionals, 
patients, managers and others. Rather than affecting only one individual or group a 
‘successful chain of interactions’ is required [55] such as leadership, strong managerial 
relations, readiness for change, a culture of staff training and resource availability. Where 
teams are small and aligned (e.g. practice manager and solo GP in Case 1) the chain of 
successful interactions may be less complex, making the work of integration less onerous. 
Conversely, in large teams (e.g. multidisciplinary care teams and several administrative staff 
in ACCHSs) with multiple roles the intervention appeared less likely to influence staff 
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interactions. Cases 5 and 6 (ACCHSs) had low ‘team vision’ and ‘task orientation scores’. 
These measures relate to a shared sense of purpose, belief in the team objectives and 
reflective action on the outcomes that the innovation is generating.  Even in case 4 (a general 
practice) where there was strong alignment of mission, leadership and shared purpose by the 
team, the high turnover of training GPs was an important barrier. Further, there was little 
engagement with practice nurses despite chronic disease screenings often being a core role 
for these staff. The intervention components were viewed mainly as GP and management 
tools rather than whole-of-practice tools.  
 
It was clear from this study that support provided by the research team played a central role 
in driving engagement and it is not surprising that there was a plateauing of trial outcomes in 
many cases once support was reduced in the post-trial period. A recent systematic review of 
decision support systems for prescribing highlighted that lack of training and limited 
computer skills were significant barriers to uptake [56]. In addition, several studies have 
found that the most effective training is tailored to specific provider’s needs [57], offers a 
variety of training formats, and is provided on an ongoing basis [47, 58]. This suggests that 
there is an important role for external practice facilitators to reduce the work that insiders 
may have to do to support uptake [59]. In Australia, primary health networks [60] employ QI 
support officers to provide such a role, however, the degree to which they are accepted into 
practice processes is currently unknown.  
 
Tools that are fit-for-purpose – One appealing feature of the tools was their multifaceted 
nature targeting gaps at the system, provider and patient level [61]. In case 1 the tool 
components were synergistically incorporated into the practice with the manager taking 
ownership of the audit tool and the GP focussing on the in-consultation decision support tool. 
and this facilitated normalisation. Certain staff gravitated to features of the intervention 
(clinical managers using the audit tools and GPs using the decision support and risk 
communication tools) with lack of cohesiveness within the health service staff to integrate 
these features collectively. This prevented reinforcement of the value of the intervention to 
others in the health service. Although in majority of cases, the tools had high appeal in terms 
of content and usefulness, there were two cases (case 3 and case 6) where technical problems 
grossly impacted its use and led to early abandonment. In case 3 the low level of initial 
interest combined with frustrations that the tool was slowing software systems virtually 
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eliminated any prospect of it being used (enrolment). In cases 2 and 6 it was only the high 
level of motivation by the lead GPs to solve the software installation problems that enabled 
sustained use over the trial period. In addition, time constraints and lack of financial 
incentives was a major issue in using the intervention during the trial and beyond. Both cases 
2 and 3, stated that financial incentives would have helped to sustain the use of the 
intervention. 
 
Strengths and limitations  
Applying NPT both in the design of the process evaluation and coding framework provided a 
practical way to understand key activities involved individually and collectively in investing 
and enacting on the meaning, commitment, effort and appraisal of the intervention over time 
and across diverse primary healthcare settings. Our findings provide important insights into 
the interaction of context and mechanism (socio-technical change) to produce the resultant 
outcomes. It enabled us to systematically analyse complex social and behavioural processes 
through several different ‘lenses’ moving beyond psychological theories of behaviour [62]. 
There are multitude of theories, models and frameworks to gain insight into how 
implementation of complex and multifaceted interventions can succeed beyond trial settings 
[29] and identify how these processes influenced the overall trial outcomes. NPT provided an 
explanatory focus through its emphasis on human agency [63]. By elucidating differences in 
implementation processes over time and between settings and various actors, we have been 
able to develop a nuanced understanding of intervention fidelity moving beyond whether it 
‘worked’ or not.  
 
A number of limitations need to be mentioned. The process evaluation was implemented 
toward the end of the trial and whilst this was intentionally planned so as to not unduly 
influence conduct of the trial providers may have limited recall of the intervention in its early 
stages. The cases studied clearly represent a limited snapshot of Australian primary care, 
particularly given most general practices were located in an urban setting, two cases did not 
agree to participate due to time constraints and only selected providers were interviewed. 
Consequently, there may be other important phenomena that influence intervention 
normalisation in different settings that we did not observe. Further, by focussing mainly on 
staff, we were not able to fully appraise how the tools influenced the interactions between 
patients and health professionals (interactional workability). Another important issue was that 
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the lack of usage analytics (for reasons described in the methods) limited our ability to look 
more closely at adoption and fidelity measures. As part of the overall process evaluation, we 
conducted a video ethnography study and post-consultation patient interviews to provide 
insights into how the intervention tools were drawn upon in the clinical encounter. Initial 
discourse analysis has been published and further analyses are currently underway [64]. We 
also did not explore technical support staff perspectives which may have shed more light on 
the technical challenges encountered at some sites. Finally, resource constraints are likely to 
be major barriers to the “work” done by staff members and we did not conduct detailed 
analyses of existing IT infrastructure, budget allocations to support use of IT tools and 
staffing allocations for quality improvements.    
 
Conclusion 
This study evaluated the processes by which primary healthcare services engaged in a 
multifaceted computerised intervention. In doing so we identified key mechanisms of why 
particular outcomes were observed highlighting the complex interaction of the tool and the 
environments in which they are implemented. These processes do not necessarily distil into a 
formula for successful uptake and improved outcomes. Rather, they may help to determine 
what trajectory a service is likely to take when engaging with such interventions. The 
findings suggest that there needs to be sufficient lead time at the health service to identify and 
act on any organisational changes that are needed prior to the intervention being implemented 
(e.g., management processes, resource allocation, and staff roles and duties routines). An 
organisational mission that embraces quality improvement, engaged leadership and activation 
of all team members, dedicated quality improvement personnel, financial support, strong IT 
infrastructure and regular appraisal of outcomes are all key contextual enablers. Greater 
appreciation of these factors can yield important information for intervention designers, 
academics, providers and policy makers to assist in adoption of computerised, quality 
improvement initiatives.  
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Table 1: Coding framework: context and mechanism influencing outcomes of implementation of computerised QI intervention  
 
Case description  
COMPONENTS CONTEXT  MECHANISM OUTCOMES 
 
 
 
 
 
 
 
 
 
 
 
Components (1) 
Immediate work 
 
 
 
 
 
 
 
 
 
 
Components (2) 
Organising work 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Physical 
environment/setting 
of health service:  
 
General description of 
the health service 
 
Size of health service 
 
Description of the type 
of health service 
 
 
 
 
 
 
 
 
 
Roles, interactions 
and relationships: 
 
# of Staff  
 
Training and support 
received 
 
Use of HT 
Coherence 
(sense-making work) 
Cognitive participation 
(relationship work) 
Collective action 
(enacting work) 
Reflexive monitoring 
(Appraisal work) 
 
 
 
 
 
 
 
 
 
 
 
 
Process and work of sense-
making and understanding that 
individuals and organisations 
have to go through in order to 
promote or inhibit the routine 
embedding of practice. 
 
Differentiation 
Is there a clear understanding 
of how a new e-health* service 
differs from existing practice? 
 
Individual Specification 
Do individuals have a clear 
understanding of the aims, 
objectives and expected 
benefits of the e-health* 
service? 
 
 
 
Communal Specification  
Do individuals have a shared 
understanding of the aims, 
objectives and expected 
benefits of the e-health 
service? 
 
Internalisation  
Do individuals understand the 
value, benefits and importance 
of the e-health* service? 
 
 
 
Process and work that 
individuals and organisations 
have to go through in order 
to enrol individuals to 
engage with the new 
practice 
 
Initiation 
Are key individuals willing to 
drive the implementation? 
 
Legitimation 
Do individuals believe it is 
right for them to be 
involved? 
 
 
 
 
 
 
Enrolment 
Do individuals “buy into” the 
idea of e-health* service? 
 
Activation 
Can individuals sustain 
involvement? 
 
 
 
 
 
 
 
The work that individuals and 
organisations have to do to enact 
the new practice. 
 
Interactional Workability (IW) 
Does the e-health* service make 
people’s work easier? (The impact 
that a new technology or practice 
has on interactions, particularly the 
interactions between health 
professionals and patients 
(consultations).) 
 
Relational Integration (RI) 
Do individuals have confidence in 
the new system? (The impact of the 
new technology or practice on 
relations between different groups 
of professionals.  A positive impact 
on RI is more likely if the 
technology does not disrupt 
current lines of responsibility and 
accountability.) 
 
Contextual Integration (CI) 
Is there organisational support? 
(The fit between new technology 
and the overall organisational 
context.  This includes the goals of 
the organisation, morale, 
leadership and resources.) 
 
Skill Set Workability (SSW) 
How does the innovation affect 
roles and responsibilities or training 
The work inherent in 
informal and formal 
appraisal of a new practice 
once it is in use, in order to 
assess its advantages and 
disadvantages, and which 
develops users’ 
comprehension or the 
effects of a practice. 
 
Systematisation 
How are benefits or 
problems identified or 
measured? 
 
Individual Appraisal 
How do individuals 
appraise the effects on 
them and their work 
environment? 
 
 
Communal Appraisal 
How do groups judge the 
value of the e-health 
service? 
 
Reconfiguration  
Do individuals try to alter 
practice to incorporate 
new e-health service? 
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Investments 
 
 
 
 
 
Meaning  
(insert quote) 
 
 
 
 
 
Commitment  
(insert quote) 
needs? (The degree to which the e-
health service fits with existing 
working practices, skill sets, and 
perceived job role.) 
 
Effort 
(insert quote) 
 
 
 
 
 
Comprehension 
(insert quote) 
*e-health = electronic health  
Sources: 
May, C. and T. Finch (2009) 
Mair, F. S., C. May et al. (2012)  
Finch et al (2102) 
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Table 2: Team Climate Inventory (TCI) and Warr-Cook Wall Job satisfaction scores 
 
  TCI sub-domains Mean total 
TCI score 
(max = 44) 
Mean job 
satisfaction 
scores  
(max = 7) 
 Sum of 
health 
professionals 
completing 
the surveys  
Participant 
Safety  
(max = 12) 
Support for 
Innovation (max = 8)  
Vision  
(max = 11) 
Task 
Orientation 
(max = 7) 
Social 
Desirability 
(max = 6) 
Case 1 4  9.2 6 9.8 6.5 4.5 36.0 5.7 
Case 2 3  10 6.4 10 6.5 4.8 37.7 5.9 
Case 3 2  9.8 6.8 9.5 6.8 5.2 38.1 6.8 
Case 4 8 9.3 6.6 9.2 6.4 4.8 36.3 6 
Case 5 34 9.1 6 8.4 5.8 4.6 33.9 5.7 
Case 6 17 8.5 5.9 8.3 5.4 4.5  32.6 5.5 
Mean score of all 
cases (n*=6) 
68 9.3 6.3 9.2 6.2 4.7 35.8 6.0 
Mean score of other 
intervention sites 
(n=18) 
113 8.6 5.9 8.3 5.7 4.4 33.2 5.4 
Mean score of 
control sites (n=15) 
65 9.5 6.4 8.8 5.7 4.7 35.0 5.7 
n* = health services  
max = maximum score 
TCI and Job Satisfaction surveys were completed in year 2013 during end of cRCT data collection through the end of the post-trial phase. 
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Table 3. Interview participants’ characteristics  
 
 Case 1  Case 2 Case 3 Case 4 Case 5 Case 6 
Participants GP PM GP GP  PM GP  PM/ 
receptionist 
GP  PM GP  AHW  HIO GP GP GP PM PM/
N 
AHW AHW 
Employment status                    
Full- time x x x   x x x x x x x x x x x x x x 
Part-time    x x               
Age group                    
20-29            x        
30-39       x  x x x    x   x  
40-49 x x x x x           x   x 
50-59             x x      
60-69      x  x         x   
70+                    
Gender                     
Male x  x   x  x  x x  x x x   x  
Female   x  x x  x  x   x    x x  x 
Years worked in 
primary healthcare 
in Australia (years) 
9 30 17  8 5 40 10 34 7 1.5 1.5  5.5 26 5.5 1 6.5 46 5 5 
Length of time at 
current health 
service (years) 
9 30 5 1 5 8 8 7 7 1.5 1.5  18 5.5 1 6.5 16 5 5 
Given access to 
HealthTracker-CVD 
(yes or no) 
yes no yes yes no yes no yes no yes no yes yes yes yes no yes yes yes 
GP = general practitioners, PM = practice managers, AHW = Aboriginal health workers, HIO = health information officer, N = nurse 
 
 
 
 
 
Figure 1. Primary healthcare service characteristics  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Training/Support is dependent on size of primary healthcare service, staff availability and technical issues 
ⱡ CQI = continuous quality improvement  
 
 
Case 1 Case 2 Case 3 
cas 
Case 4 Case 5 Case 6 
General Practices  Aboriginal Community 
Controlled Health Services 
Location – Urban 
Size – Small  
Rural 
Medium 
Rural/remote 
Large 
Urban 
Large 
CQI involvement 
prior to study 
No CQIⱡ involvement prior to study 
IT-Off site 
On site 
(Main 
doctor) 
Off site Off site On site Off site  
Training 
/Support: 
10 hours 
Training 
/Support: 
2.6 hours 
Training 
/Support 
11.4 hours 
Training 
/Support 
12.5 hours 
Training 
/Support 
6.1 hours 
Training 
/Support: 
12.4 hours 
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Figure 1 
:  
 
 
   
 
 
  
 
 
 
 
 
 
  
Figure 2. Case 1 
• Small general practice  
• 305 eligible patients (4.3% Aboriginal and 
Torres Strait Islander) 
• 1 full time GP, 2 part-time GPs, 1 part-time 
nurse, 1 full time PM, and 3 part-time 
receptionists  
• Previous use of data extraction tools 
• Communication/rapport good between staff 
• PM – 30 years at general practice 
• 4 hrs - training; 6 hrs - tech support 
• The principal GP reported using the 
intervention less than 50% of the time, found 
easy to use and recommendations provided to 
be valuable. 
 
General Practice 
 
 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
baseline end of RCT end of post-
trial period
Trial outcomes - Case 1
Screening Prescribing
Coherence  Cognitive 
participation 
Collective action Reflexive monitoring 
Differentiation *** 
Individual specification *** 
Communal specification *** 
Internalization *** 
Initiation *** 
Legitimation *** 
Enrolment *** 
Activation * 
 
Interactional Workability ** 
Relational Integration ** 
Contextual Integration * 
Skill Set Workability ** 
 
Systematization ** 
Individual appraisal ** 
Communal Appraisal * 
Reconfiguration * 
Meaning 
GP: useful tool in the 
sense of knowing how 
to, sort of how to reduce 
the patients’ risks with 
cardiovascular disease 
and kidney disease and 
so on.   
 
Commitment 
GP: the routine 
of checking for 
the 
microalbumin is 
something I 
didn’t do 
before, and now 
I realise its 
benefits. 
 
Effort 
PM: I’m going to be 
running these lists and I 
know who’s going to be 
looking at these people 
and cleaning that data 
and it is a really, I mean 
it’s actually quite 
exciting when you do it.  
And I actually quite like 
doing that and I think if 
at the end of the day 
you’re helping that 
patient you know, that’s 
the best thing about it.  
 
Comprehension 
PM: having the 
patient coming in, 
that[HealthTracker] 
coming up and the 
doctor being able to 
better treat the 
patient would be, I 
would say, the main 
impact ...referred to 
the nurse and 
obviously, she’s then 
got the data that the 
doctor’s put in and 
makes her life a bit 
easier as well...  
Overall caring of the 
patient I think, it really 
has improved 
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       Figure 3. Case 2 
• Medium sized general practice  
• 503 eligible patients (0.4% Aboriginal and 
Torres Strait Islander) 
• 1 full time GP, 1 part-time GP, 2 consultant 
GPs (paediatrics), 1 part-time PM, multiple 
part time receptionists (>5) 
• Main GP responsible for overall management 
and operations 
• 2.7 hrs – training; 9.7 hrs - tech support 
• The principal GP reported using the 
intervention less than 50% of the time, found 
easy to use and recommendations provided 
to be very valuable. 
•  
 
General Practice 
 
 
Coherence  Cognitive 
participation 
Collective action Reflexive 
monitoring 
Differentiation *** 
Individual specification ** 
Communal specification ** 
Internalization ** 
Initiation *** 
Legitimation ** 
Enrolment ** 
Activation * 
Interactional Workability ** 
Relational Integration * 
Contextual Integration * 
Skill Set Workability * 
Systematization ** 
Individual appraisal * 
Communal Appraisal * 
Reconfiguration * 
Meaning 
Main GP: there are 
certainly increased 
vigilance to screen the 
patient who is supposed 
to have the screening 
done.  To look at their 
risk factors in a more 
comprehensive way 
because HealthTracker 
itself is look at it in a 
comprehensive, give you 
an assessment risk of a 
five-year period. 
 
Commitment 
Main GP: it strikes 
me as a good trial to 
get involved, to look 
at how robust my 
practice is, or was 
during the trial.  And 
is not a big area 
analysis, it’s a small 
area of clinical 
practice. That’s why 
I think I could get 
involved.  It’s only 
the cardiovascular 
side of it and it’s got 
an existing tool that 
you can use and you 
just see how we use 
it, how good it is 
and so on. 
 
Effort 
Main GP: It cannot be 
based on just me to do 
the analysis all the time, 
which is impractical at 
the end of it...fully 
integrated in terms of 
not just the doctors are 
using it, the staff are 
using it at the same 
time.  So you need a bit 
of education for the 
staff, show them how to 
install it, how to log in, 
how to logout, where to 
get the information, 
which area they should 
be looking at, maybe 
even our administrative 
side of it, to help the 
doctors maybe. 
Comprehension 
Main GP: No, I don’t 
[think] it’s 
integrated very well 
at the moment, 
because one is I 
haven’t allocated a 
task to my staff to 
use it, we haven’t 
trained the staff to 
train once or twice. 
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Figure 4. Case 3 
 
• Solo general practice 
• 333 active patients (0.3 % Aboriginal and 
Torres Strait Islander) 
• 1 full-time GP and 1 full-time 
PM/receptionist 
• Appointments available 7 days/week 
• 1.1 hrs – training; 1.5 hrs – tech support 
• The principal GP reported it always, found easy 
to use and recommendations provided to be  
very valuable. 
 
 
General Practice 
 
 
Coherence  Cognitive 
participation 
Collective action Reflexive monitoring 
Differentiation ** 
Individual specification * 
Communal specification * 
Internalization * 
Initiation ** 
Legitimation * 
Enrolment * 
Activation * 
 
Interactional Workability ** 
Relational Integration * 
Contextual Integration * 
Skill Set Workability * 
 
Systematization * 
Individual appraisal * 
Communal Appraisal * 
Reconfiguration * 
Meaning 
GP: I could see that it 
was specific to most of 
my patients.  Now, most 
of my patients had to do 
with heart disease and, 
of course, you could 
incorporate kidney 
disease as well in that.  
 
Commitment 
GP: this one 
here, bugger, 
it’s just a 
matter of 
collecting 
data.  That’s 
how it feels, 
you see, so I 
haven’t got 
any, how 
shall I say it, 
enthusiasm 
about it.  
 
Effort 
GP: “Oh, I’m all right.  
I’m doing okay so all I 
have to do is just carry 
on doing what I’m 
doing”. 
Comprehension 
GP: it’s a bit of a 
nuisance and apart from 
the fact that it is 
beneficial in terms of 
putting figures down 
and calculating it, it 
appears as if I’m 
working for somebody 
else with no 
compensation and no 
recompense and it’s very 
annoying sometimes, 
especially when the 
thing clogs my computer 
now. 
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Figure 5. Case 4 
Coherence  Cognitive 
participation 
Collective action Reflexive monitoring 
Differentiation *** 
Individual specification ** 
Communal specification ** 
Internalization ** 
Initiation ** 
Legitimation ** 
Enrolment ** 
Activation * 
 
Interactional Workability ** 
Relational Integration *** 
Contextual Integration ** 
Skill Set Workability * 
 
Systematization ** 
Individual appraisal * 
Communal Appraisal ** 
Reconfiguration * 
Meaning 
Main GP: I’ve been 
looking for non-paper 
based prompts for 
cardiovascular or chronic 
illness prevention.  And 
that’s one reason.  And 
secondly because I 
thought it’s something 
which was good to be 
measured.  And thirdly I 
just wanted to see 
maybe overall how we 
were performing.   
Commitment 
Main GP:  you 
had a tool 
where you 
could instantly 
see what an 
evidence base 
risk calculator 
shows and you 
were able to 
modify it.  
Right, okay.  
And that was 
some of the 
other features 
like bringing up 
the feedback 
online and so 
on, “Let’s do 
this, remember 
the password, 
do this, it’s the 
internet’s slow.  
Bugger it.  I’m 
going to go 
have lunch”. 
Effort 
Main GP: I remember 
you and xxx [chief 
investigator] would 
come around and you’d 
explain things and there 
would be things that I 
would see the benefit of, 
and then it was like 
“Okay, I’ve learned 25 
new things.  I remember 
three very well, I know 
how to use five, and I 
know I can sort of do this 
but I don’t quite 
remember how to do it”, 
and then after three 
weeks you’d think “Was 
there something like 
that there or not?”  And 
you thought “Okay, I can 
go for a walk or I can sit 
here for half an hour and 
work out how to do it.  
I’ll go for a walk”. 
Comprehension 
Main GP: It’s 
integrated well, and 
there needs to be still 
more work.  Look it’s a 
tool, and it’s a tool 
which has very, very 
many uses, and quite 
a lot of potential.  
 
 
 
• Medium sized teaching general practice 
• 765 eligible patients (0.3 % Aboriginal and 
Torres Strait Islander) 
• 1 full time GP, 3 full time registrars, 1 part-
time nurse, 1 full time PM, and 2 receptionists 
• Regular team meetings 
• High GP turnover due to GP registrars 
• 6 hrs – training; 5.4 hrs – tech support 
• The principal GP reported using the 
intervention less than 50% of the time, found 
easy to use and recommendations provided to 
be valuable. 
 
 
General Practice 
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Figure 6. Case 5 
  
Coherence  Cognitive 
participation 
Collective action Reflexive monitoring 
Differentiation *** 
Individual specification *** 
Communal specification *** 
Internalization *** 
Initiation *** 
Legitimation *** 
Enrolment ** 
Activation ** 
 
Interactional Workability ** 
Relational Integration ** 
Contextual Integration ** 
Skill Set Workability ** 
 
 
Systematization *** 
Individual appraisal ** 
Communal Appraisal *** 
Reconfiguration * 
Meaning 
GP: It's helped my practice 
individually because I can 
get an accurate complex 
summary that takes into 
account all these 
additional factors and 
other relevant history, all 
the numbers, it gives me 
the reassurance that I'm 
getting an accurate 
cardiovascular risk, the 
most accurate really that 
I've seen by a long way.  So 
it gives me confidence to 
prescribe the medicines 
that I prescribe knowing 
that my cardiovascular risk 
is accurate. 
Commitment 
GP: if I was 
running my own 
practice I'd pay 
for this 
software even if 
I was charged 
to use it and I'd 
use it often. 
 
Effort 
GP: It's got a big 
potential to help the 
practice but you've got 
to have people willing to 
use the computers and 
have the time in the 
consultation to go 
through it with the 
patient and 
unfortunately that 
hasn't been the situation 
in the last six to nine 
months at xxx [ACCHS 
name]. 
Comprehension 
HIO: …for example 
only 30% of the high 
risk patients are being 
prescribed with triple 
therapy and they go, 
whoa, you know.  So 
they really like that, 
and we can then 
actually provide them 
with the names of 
people, you know, and 
then sort of next time 
they present to the 
service they can have 
a quick look at their, 
you know, medication 
management. 
 
 
• Large Aboriginal Community Controlled Health 
Service (ACCHS) 
• 454 active patients (76.4% Aboriginal and 
Torres Strait Islander) 
• > 4 full-time GPs, multiple AHW, multiple 
nurses, CQI staff, multiple administrative 
assistants 
• Team based care/diverse skill set 
• Use of data extraction and other eHealth tools 
• Strength in Indigenous capacity building 
• 10.4 hrs – training; 2.1 hrs – tech support 
• Two GPs reported using the intervention less 
than 50% of the time or never and were 
indifferent to the tool. 
 
 
ACCHS 
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Figure 7. Case 6 
Coherence Cognitive 
participation 
Collective action Reflexive monitoring 
Differentiation *** 
Individual specification ** 
Communal specification ** 
Internalization ** 
Initiation ** 
Legitimation ** 
Enrolment *** 
Activation * 
Interactional Workability *** 
Relational Integration ** 
Contextual Integration * 
Skill Set Workability * 
 
Systematization * 
Individual appraisal ** 
Communal Appraisal * 
Reconfiguration * 
Meaning 
Lead GP: it sets the bar 
high and it does, it’s a 
great programme and I 
guess the constraints are 
just the time constraints.  
But it’s something that you 
need to look at, you know, 
if you’re going to do a 
good general practice and 
you’re going to do primary 
prevention you’ve got to 
use something like 
this…using something like 
this it’s got to be part of 
your practice otherwise 
you’re just doing reactive 
medication.  
Commitment 
Lead GP:  I’d 
still go looking 
for it [when 
HealthTracker 
disappeared].  
You know, the 
benefits 
outweigh the 
problems…I’m 
very much an 
advocate of it.   
 
Effort 
Main GP: focused on case 
conferences and individual 
cases, and we don’t so 
much look at public health.  
… not a lot of 
remuneration for it 
immediately, so maybe 
we’re chasing the cash 
cow a little bit that way 
rather than stepping back 
and getting a bit 
academic.  
Comprehension 
AHW2: there was 
no follow up with it 
[intervention] within 
xxx [ACCHS] itself to 
say, ‘How’s 
everyone going with 
this?’ ‘Are you using 
it?’ like, ‘Was it 
useful?’ and stuff 
like that.  There was 
nothing 
 
 
 
• Large ACCHS (2 locations) 
• 507 active patients (52.1% Aboriginal and 
Torres Strait Islander) 
• 3 full time GPs, 3 part-time GPs, multiple 
AHWs, 1 PM, 1 PM/practice nurse (2nd 
location), multiple nurses, multiple 
administrative staff, transport care teams  
• Previous CQI  
• Off-site IT support 
• 13 hrs – training; 4.8 hrs – tech support 
• The principal GP reported using the 
intervention less than 50% of the time, found 
easy to use and recommendations provided to 
be valuable. 
 
ACCHS 
 
 
Additional file 1: Adapted - Center TRT Evaluation Framework 
 
 Grey shaded portions represent the CDC evaluation framework  
 
 
 
 
Problems 
• High prevalence of 
CVD  
• Lack of screening for 
CVD risk & provision 
of recommended 
treatments 
• Unaware of latest 
guidelines and 
recommendations 
Solutions 
• Multifaceted QI 
intervention  
• Evidenced based 
approach on use of 
absolute risk 
• Use of point of care 
electronic decision 
support system  
• Use of audit and 
feedback tool for 
practice level 
improvements 
• Engaging patients 
• Training and support 
by experts  
Stakeholders/ 
Politics 
• PHC -GPs and ACCHSs 
• Healthcare providers 
(HP) 
• Administrative staff 
• Patients and 
communities 
Other 
• Existing policies/ QI 
programs 
• Administrative 
structures  
• IT infrastructure 
• Incentives for HP and 
patients 
• Material resources 
• Monitoring health 
services 
 
Short Term (1-3 years) 
 
 
 
 
 
Long Term Goal 
(Public Health 
Impact) 
(4-9 years) 
 
• Increase in CVD 
screening and 
prescribing 
 
• Increase control 
of CVD risk 
factors 
 
• Decrease in CVD 
incidence 
 
• Improved 
quality of life 
 
• Increase 
efficiency in the 
primary health 
care system 
 
Equitable 
distribution of 
improvements 
across population 
subgroups, 
particularly those 
at greatest risk 
 
Minimal/ no 
unintended 
consequences 
 
Continuous Engagement of Stakeholders, Intended Users  
 Outcomes/Effectiveness 
3. Implementation 
  
 
 
 
 
TORPEDO Study (cRCT) 
[Peiris et al. 2012; 
Peiris et al. 2015] 
2. Enactment 
• Engage stakeholders 
• Enact plan  
 
• Enacted plans and 
policies  
• Type and number of 
resources leveraged 
 
• Reach to health 
professionals and 
patients (intended 
population) 
 
• Adoption by PHC 
(settings/sectors) 
 
• Implementation as 
intended & acceptable/ 
feasible/ 
affordable 
 
4. Maintenance/ 
    Modification 
• Maintain relationship 
with PHC 
• Monitor performance  
• Ongoing training and 
support by experts 
• Establish partners and 
vendors for 
implementation & 
evaluation 
• Proposed plans  
• Maintenance of 
funding, 
partnerships, 
implementation, 
enforcement & 
reach  
  
• Modifications for 
intervention and 
implementation 
based on Studies 1-4 
 
Disseminate & utilize findings 
                        Gather credible evidence  
Justify conclusions 
1. Formulation 
• Review evidence 
• Pilot study (Peiris et al. 
2009 & 2011) 
• Modify QI intervention 
Inputs Activities Outputs 
Study 2 – 
Quantitative/Qualitative 
Multi-level modeling/health 
professional interviews  
 
 Study 3 – Qualitative 
Video-ethnography of actual 
clinical encounters and post- 
consultation patient 
interviews 
Study 4 – 
Quantitative/Qualitative 
Cost consideration of scale-up 
If implemented by an 
Australian Primary Health 
Network 
 
Study 1 – Quantitative 
Post cRCT effectiveness 
 
Data sources 
Primary outcome evaluation 
from RCT 
 
10% absolute increase in 
recommended CVD risk screening. 
No improvement in prescription 
of recommended treatments 
overall 
 
 
Study 1: 
Plateauing of CVD risk factor 
screening performance in the 18 
months post completion of the 
RCT. Ongoing improvement in 
prescribing performance in both 
control and intervention arm 
practices 
 
Study 2: 
Subject of this paper 
 
 
 
 
 
Study 3 
Doctor’s communication of CVD 
risk alone is not sufficient to 
engage patients. Rather, effective 
communication required skilled 
interactions on the part of both 
doctor and patient to enable 
meaningful use of risk 
communication tools 
 
Study 4 
Modelling intervention in PHN 
population demonstrated ICER 
<$50,000 threshold 
 
Plateauing of CVD risk factor 
screening performance in the 18 
months post completion of the 
RCT. Ongoing improvement in 
prescribing performance in both 
control and intervention arm sites 
 
Study 2: 
Subject of this paper 
 
 
 
 
 
Study 3 
Doctor’s communication of CVD 
risk alone is not sufficient to 
engage patients. Rather, effective 
communication required skilled 
interactions on the part of both 
doctor and patient to enable 
meaningful use of risk 
communication tools 
 
Study 4 
Modelling intervention in PHN 
population demonstrated ICER 
<$50,000 threshold 
 
 
S j ct f t is a r 
 
 
 
 
Doctor’s communication of CVD 
risk alone is not sufficient to 
engage patients. Rather, effective 
communication required skilled 
interactions on the part of both 
doctor and patient to enable 
meaningful use of risk 
communication tools 
Incremental costs of 
implementation <$15AUD per 
person. 
If optimal effect sizes could be 
sustained over 5 years, the 
incremental cost per CVD event 
averted would be <$20,000AUD 
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Additional file 2: Health professional interview findings and quotes 
 
Case 1 – Small urban general practice   
Interview date: August 22, 2013; Time of interview: 11 am (PM) and 12:30 pm (GP) 
 
MECHANISM  
Coherence 
(sense-making work) 
Cognitive participation 
(relationship work) 
Collective action 
(enacting work) 
Reflexive monitoring 
(Appraisal work) 
Differentiation 
The main two staff (the GP and PM) both had 
a clear understanding of HealthTracker (HT) 
and Clinical Audit Tool (CAT) and how it 
differs from existing practice.  GP focused on 
HT and PM on CAT. PM encouraged GP to 
use HT and to populate data in correct fields 
within EHR for CAT to be accurate. 
 
Individual specification 
After participation in webinar, GP had good 
overall understanding of the HT intervention 
and reason for use.  
 
For PM, CAT could assist in data quality and 
helped other staff (i.e. nurse) with chronic 
disease management.  She believes that 
audit tools help improves data quality and 
assess outstanding patient indicators. She is 
a promoter of audit tools.  
 
PM: ….he’s taking blood pressures all the 
time but what was happening he actually 
wasn’t putting in the right spot in Medical 
Director….by using that audit tool you can go 
“hold on”. 
 
Communal Specification 
Both PM and GP collectively understood that 
value and benefits of the tool was to 
improve patients’ health and their 
Initiation 
The PM is the main driver in helping 
coordinate implementation of intervention.  
PM is familiar with e-health and its benefits of 
improving patient care through data being 
linked with various e-health tools.   
 
PM is familiar with the intricacies of all the GPs 
and staff work/habits and use of technology.  
 
Legitimation 
Both GP and PM found the study to be 
valuable to the practice in different aspects; GP 
got involved initially to improve CVD 
management/knowledge, and PM was 
sceptical. PM later was a believer in the 
intervention due to the substantial 
improvement in data quality at the health 
service.  
 
GP: I could see it was going to be beneficial for 
me and the practice.  So, it was really good.   
 
Enrolment 
GP used HT routinely for screening which 
became routine.  Other components of HT 
were not used to their full potential due to 
unawareness and lack of confidence in tool.  
 
Both GP and PM use their respective tools (HT 
and CAT). PM uses it to inform others of data 
Interactional workability 
HT aides in communicating CVD risk. Patients find graphs 
to be helpful and enlightening. The GP uses the heart-
age projectile graph to communicate CVD risk to 
patients. 
 
GP was not familiar and comfortable with all the 
features of HT and only used the traffic light assessment 
prompts and heart-age projection graph.  He does not 
completely understand absolute risk % and therefore 
does not use to explain to patients. Further, he was not 
familiar with CAT or IF portal in relation to intervention. 
He did view the peer ranked graphs distributed to him 
by study team member.  
 
GP: Visual presentation of what they can do with it. It’s 
much easier to show them, you know, you can tell them, 
but to actually for them to see where they should be 
ideally, and then where they are at the moment, that 
does make them realise what a big difference that is 
there.  
 
Relational integration 
PM assesses GPs’ data quality and outstanding CVD risk 
screening using CAT. She gives main GP feedback on his 
use of HT.  
 
The intervention has made the GP and PM’s jobs more 
efficient.    
 
Systematisation 
CAT tool helped health 
service assess how they 
were performing, and if 
there were any issues 
with their data quality.  
The tool assisted the PM 
to cleanse data and 
identify any issues.  
 
Individual appraisal 
PM gives GP reassurance 
that he is performing well 
in screening his patients 
using HT. 
 
GP: seeing their 
cholesterol going down 
and their kidney functions 
improving, you know, 
that’s the real, yeah, 
when those results come 
through that makes me 
happy. 
 
Communal Appraisal 
GP received reports of 
peer ranked graphs to see 
how they were 
performing compared to 
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knowledge of care processes. 
 
Internalisation 
GP and PM are motivated by 
improving quality of care and 
patient outcomes.  
 
GP convinced more than before of treating 
early for high risk without CVD. 
 
PM believes that CAT helps entire health 
system inevitably helping patients attain 
better quality of care.  
 
GP: …focus on improving the 
patients’ sort of health, and 
improving my knowledge of it  
as well. ….Greater service, a better 
service to patients, especially 
those with chronic health 
problems and with CVD risk.  I 
think it’s really good.  
 
Meaning 
GP: useful tool in the sense of knowing how 
to, sort of how to reduce the patients’ risks 
with cardiovascular disease and kidney 
disease and so on.   
 
 
 
 
quality and can see how it can affect data 
being uploaded to the hospital and benefit the 
patient.  PM sees the bigger picture of use of e-
health interventions.  
 
PM is training one receptionist on why and 
how to use CAT.  Other GPs are not familiar 
with HT. One part-time GP after several years 
recently started to use EHR and other GP is 
only involved in women’s health. PM 
suggested main GP to train part-time GPs.  
 
PN could benefit from HT however not using it.  
She was not approached to participate in the 
study despite her main role taking care of 
chronic disease patients. 
 
 GP: …highlighted the issues that’s important in 
treating these patients, and so it’s becomes 
second nature now to know what to do and 
how to do it.  
 
Activation 
With regular support and training for GP and 
PM, the intervention can be sustained.  Need 
all staff to be involved to be able to be sustain 
completely and integrate into routine work.  
 
Commitment: 
GP: the routine of checking for the 
microalbumin is something I didn’t do before, 
and now I realise its benefits. 
 
PM:  It helps our nurse, so then we ah look, this person 
hasn’t had such and such for a while wo when you’re 
doing a chronic disease management say for 
cardiovascular or diabetes or anything like that, that all 
shows up as well.  And so then we can then say to Dr. 
XXX (main GP) well look this hasn’t been done either 
because he might not have seen that patient in that last 
six months….so it’s like feedback from the nurse and also 
the doctor as well.  
 
Contextual integration 
GP would prefer HT to be incorporated within MD.  He 
finds it frustrating that it is separate.  Also, SideBar is too 
large and must minimise the tool which causes GP to 
forget to open to use with patients.   
 
GP had problems signing in and needed regular extra 
support. He would prefer someone to call to check in on 
how things are progressing with the intervention. 
 
CAT would stop working occasionally.  PM would have to 
call PEN support.  Needed a reminder on using it and 
how to use it on a regular basis. 
 
When tools were working properly, GP and PM found it 
to have integrated within their routine work. 
 
GP: It’s not, it [HT] doesn’t really take any more time or 
effort; you get to the stage where you can use it without 
even thinking anymore 
 
PM: they’ve [patients] come to the doctor and said look 
can you, you know, send a report up into the clouds, so if 
they end up in the hospital or the hospital can send 
things to us.  But now you have that you need to have 
the right data in there, you need to make sure that the 
medications are up to date, their last blood pressure and 
you know, the pathology that you know, whatever their 
chronic condition is, it needs to be equalling whatever is 
in the system.  So to be able to get rid of the old 
other health services. He 
found it beneficial to 
know how they were 
performing relative to 
other practices; however, 
doesn’t put too much 
emphasis on comparing 
themselves to other 
health services. Further, 
the report was not 
discussed with health 
service team members. 
 
Reconfiguration 
There was no 
reconfiguration of the 
health service. 
 
Comprehension 
PM: having the patient 
coming in, that [HT] 
coming up and the doctor 
being able to better treat 
the patient would be, I 
would say, the main 
impact … referred if so to 
the nurse and obviously, 
she’s then got the data 
that the doctor’s put in 
and makes her life a bit 
easier as well...  Overall 
caring of the patient I 
think, it really has 
improved 
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prescriptions out of there or the people who are no 
longer patients I wouldn’t have been able to find that 
any other way. 
 
 
Skill set workability 
GP given the capability of the knowledge and reasoning 
behind the tool and its benefit by a ‘champion’ via 
webinar.  This motivated GP and gave him confidence to 
use two components of HT: prompt (traffic light) and 
patient risk communication.   
 
PM was proficient in using another audit tool (Canning) 
therefore she had the skills and knowledge to learn CAT 
quickly.   
 
GP and PM operationalised part of the intervention that 
was appropriate for their skills and role. 
There is partial collective participation.  Not all staff are 
involved and trained. 
 
GP: …eventually I’ll get to the stage where I’ll want to 
use them also for my resources and guidelines as well.  
It’s just a matter of time, just get used to it because, you 
know, just once I get the hang of it and it gets more 
useful I guess I just need to expand what I’m using, 
because I guess it can offer me so much more than what 
I’m using it for. 
 
Effort 
PM: I’m going to be running these lists and I know who’s 
going to be looking at these people and cleaning that 
data and it is a really, I mean it’s actually quite exciting 
when you do it.  And I actually quite like doing that and I 
think if at the end of the day you’re helping that patient 
you know, that’s the best thing about it.  
 
November 7, 2017 
 
Case 2: Small urban general practice 
Date of interview: January 22nd and 23rd 2014 (main GP); January 30, 2014 (PM); January 31, 2014 (part-time GP) 
MECHANISM  
Coherence (sense-making work) Cognitive participation (relational work) Collective action (enacting work) Reflexive monitoring (appraisal work) 
 
Differentiation 
Main GP and part-time GP see the 
benefits of using absolute risk and 
believe this is a better way for CVD 
prevention and management.  
Both GPs saw the benefits of HT and it’s 
use with patients.    
 
Main GP: Prior to the Torpedo trial I used 
a fair bit of that [online absolute risk 
calculation].  Very similar in terms of 
what to do.  But they are a bit more 
tedious.  You got to punch in the 
information and so on.  Whereas the 
HealthTracker can just extract the 
information much quicker.  So those 
guidelines I look at more often.  I haven’t 
looked at a lot of other cardiovascular 
guidelines...normal practice you might 
not consciously go in and do it.  Being 
having a HealthTracker sitting there, 
giving you a prompt and say “You need 
to go look at it”. 
 
Individual specification 
Data quality is important to the main GP. 
He saw the benefits and value of CAT for 
data cleansing. However, other staff 
were not involved and did not know 
what value it would add to the practice. 
 
Main GP wanted to see how his practice 
was doing regarding CVD management 
compared to others as main reason for 
Initiation 
Main GP was the main driver of 
implementation of the intervention at 
the practice. GP has the knowledge and 
skills to be a ‘champion’ of the 
intervention for his staff and patients. 
However time and resource constraints 
prevented him from using it regularly.  
 
Legitimation 
GP liked HT and the risk communication 
component however only used for 
patients he thought of as high risk. 
Participation in the trial gave GP an 
incentive to use during trial period. HT 
allowed GP to become more vigilant in 
screening and prescribing according to 
guidelines. 
 
Part-time GP uses other CVD risk tools on 
a regular basis and if this had worked for 
her, she would have incorporated into 
her daily work.  She found the 
intervention to be novel and easy and 
beneficial for the care of the patients.  
 
PM is not interested in any additional 
work besides what has been delegated to 
her due to time constraints. 
 
Enrolment 
Part-time GP was excited about the 
prospect of using HT.  Using absolute risk 
and risk projectile graphs is common 
Interactional workability 
‘What If” CVD risk graphs were helpful to 
communicate to the patients their heart risk.  Patient 
resources could have been better 
if more concise and on one page.  Patients were 
impressed with graphs and found resources useful 
when GP found time to use.  
 
HT tool wasn’t used frequently by main GP because of 
time constraints. Further it was dependent on if 
patient were high risk or not. 
 
Due to technical issues, part-time GP was not able to 
use HT.  She uses similar patient risk communication 
tool online at her other practice. 
 
Main GP: Explaining to the patient, the graph is quite 
good.  But I have to admit that I haven’t used it very 
often.  
 
Main GP: I’ve moved away from using single factors a 
few years back now.  Is to use a combined risk factors.  
And it’s always championed to me that is the better 
way to analyse to the patient.  But I find that they’re 
harder to explain to the patient with a number. 
 
Relational integration 
There was lack of relational integration.  GP is only 
staff using HT and CAT. GP has mentioned it to the PM 
however she is not keen on taking on any extra tasks 
outside her current role due to time and resource 
constraints. 
 
Systematisation 
Main GP found peer ranked reports to 
be beneficial in assessing how he is 
doing compared to other GP practices. 
He used a few times during the year.   
 
He prefers someone to come in and tell 
him how he is doing and where he is 
regarding the study indicators. Time 
constraint prevents him from analysing 
data on a regular basis, and lack of a 
dedicated staff member. 
 
Individual appraisal 
Data illumination from CAT and IF 
portal reports for main GP.  He was 
motivated by data quality.  
 
Part-time GP has reviewed reports that 
main GP has given her however does 
not motivate her because not aware of 
the bigger picture of the study.  The 
reports informed the GP they are an 
average practice. 
 
Main GP think HT helped improve their 
data.  
 
Main GP: I did tell someone halfway 
through that I was a bit embarrassed 
about our data of how many patients 
are supposed to have blood pressure 
pills and they’re not on blood pressure 
pill.  And that I think there was another 
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participation in the trial.  Thought tool 
would be good platform to view how he 
was performing.  This would assist in 
picking up additional patients that have 
incomplete screening and prescribing. 
Motivated by competition.   
 
Both GPs recognized the benefits of 
using HT to improve patient care and 
data quality. 
 
PM does not see the benefits or value of 
the intervention for the health service 
due to lack of interest and capacity to 
participate.  
 
Part time GP: it is something that 
[absolute risk calculations] we do as 
common practice, I do it in the other 
practice but it’s not the same, just that 
online one and we discuss it with a 
patient and do implicate whatever it is.  
So I do use, like to use it [HT], and I was 
really very excited. 
 
Communal Specification  
Both GPs used absolute risk as method of 
managing CVD risk. They both saw value 
and benefits in HT tool for the 
assessment/care of their patients. 
 
Part-time GP did not get involved in 
other parts of the intervention and was 
not aware of their objectives for the 
study. 
 
Other staff were not made aware of the 
purpose of the intervention and study. 
 
Internalisation 
practice for the GP at her other surgery.  
She was persistent in trying to use HT at 
different periods of the trial.  However 
never could overcome technical issues.   
 
Other staff not involved in the study due 
to time constraints.  They did not seem 
to think it was something they should be 
concerned about with their roles and 
responsibilities.  GP didn’t want to 
overburden them with other work. 
 
Accreditation for all GPs or financial 
incentive for compulsory use of HT and 
CAT can help motivate the use of the 
intervention.  
 
Main GP is more vigilant in prescribing 
after awareness of guidelines.  
 
Main GP: belief that if not using HT, 
numbers [screening] would have dropped 
or stayed steady. Prompts are helpful. 
 
Activation 
Main GP is the sole user of all 
components of intervention.  Due to time 
constraints, he is unable to sustain long-
term use of HT beyond the study. He 
needs more external incentives to get 
others at practice involved.  
 
Main GP became more vigilant on using 
HT and CAT during the trial period; 
however, he believes there is more work 
that is needed to improve the 
intervention.  Further, he needs allocated 
person to assist in implementation and 
maintenance of the intervention.  
 
There are no formal meetings on CQI programs or 
studies that practice is involved with.  They have 
meetings only for big policy or system changes, 
otherwise meeting once a year on a weekend.  A lot of 
corridor chat.    
 
Main GP:  the administrative side of it needs 
improvement.  If you ask the doctor to just go and look 
at it [CAT] himself every three months or so I think 
you’ll be hitting the wall.  Okay.  But if you get an 
allocated person to say “Well I’ve been allocated this 
task, and so every three months I do it [review CAT]. 
 
Main GP: A good single person allocated, keep 
monitoring, keep going, these tools will be very, very 
good.  Yeah. 
 
Contextual integration 
Ongoing technical issues with HT and CAT prevented 
integration of the tool at the health service. Part-time 
GP had the intentions to use the intervention; 
however ongoing issues discouraged use.  
 
Main GP sees the value in HT however does not see it 
as a “robust” intervention.  The intervention needs 
improvement.  He would like it to be used quickly and 
efficiently.  Time constraint and lack of resources is a 
factor.  
 
Part-time GP: Every time I do the data on that [HT], it 
is just, it’s frozen up so I don’t think I have any input in 
their things.  That’s what I you know, was a bit of, 
because I didn’t, you know I used it in the beginning 
but every time then it was a struggle and then we tried 
to fix it and it didn’t work, then I just stopped doing 
it….They [Developers] come but we tried it many times 
but then that’s it, we give up like after a while, I 
couldn’t, it’s always, it didn’t work 
 
group, there was discussion and they 
say, I say “But after I look at all the 
other practices and I wasn’t feeling too 
bad, even though it was bad”.  Even 
though the number was quite low, and I 
said that I’m not far difference. 
 
Main GP:  …others [GP practices] who 
improved.  Improvement is a much 
better of course, so I know that yes, you 
can do better, by using all this Health 
Trackers and looking at the CAT tools 
and so on. 
 
Communal Appraisal 
For communal appraisal at the practice, 
there needs to be regular formal 
meetings. Also, there needs to be an 
allocated person driving the monitoring 
and evaluation of the goals of the trial 
and intervention.  
 
Main GP: get the person allocated to 
analyse and then feedback and say 
“Well we’ve extracted our data.  This is 
the pictures.  This is what it is” and you 
can just read that summary quickly and 
say “I need to concentrate on my, say, 
blood pressure documentation for this 
groups of patients”, or “My 
microalbumin has not been done for 
groups of patients and there’s too many 
that are not being done” and the data 
will come out with the summary.  And 
that each three months or six months 
you would get a little bit of summary “I 
better do better in this area.  Or this 
area’s missed out, or this area missed 
out”.  
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Main GP initially participated to improve 
health service patient data quality 
however realised the importance of HT in 
screening and prescribing according to 
guidelines.  
 
Meaning: 
Main GP: there are certainly increased 
vigilance to screen the patient who is 
supposed to have the screening done.  To 
look at their risk factors in a more 
comprehensive way because 
HealthTracker itself is look at it in a 
comprehensive, give you an assessment 
risk of a five-year period. 
 
 
 
 
 
 
Screening and prescribing that have 
become somewhat routine for the main 
GP as a result in participation in the 
study. 
 
Main GP: I’d like to use it more.  
Unfortunately timing issues.  But at the 
end of the day if there are some criteria 
that are set, that it becomes compulsory 
for accreditations, that could be a way of 
forcing all the doctors and the staff and 
the nurses, if you have one, to look at it 
at the regular fashion.  And if you come 
out and say “Yes, the CAT tools are good” 
you’re supposed to be doing what is 
supposed to be doing, is good enough to 
be applied to 80% of the surgery for 
example, and we want at least 80% of 
the surgery using it to do it regularly, 
maybe at the three-monthly fashions, 
and extract the data,  
 
Commitment:  
Main GP: it strikes me as a good trial to 
get involved, to look at how robust my 
practice is, or was during the trial.  And is 
not a big area analysis, it’s a small area 
of clinical practice.  That’s why I think I 
could get involved.  It’s only the 
cardiovascular side of it and it’s got an 
existing tool that you can use and you 
just see how we use it, how good it is and 
so on. 
 
PM: I simply don’t have enough time because I have to 
do the recall while attending to the phone calls and 
receiving the patients.  I don’t think it’s feasible.  It 
wouldn’t be effective.  
 
Skill set workability 
GPs have the skills and knowledge to promote the use 
of the intervention. Regular training/support over the 
phone for part-time GP and face 
to face for main GP would encourage its use and 
provide confidence.  Both GPs learn best by hands on 
training. Our training was sufficient initially. 
 
Other staff were not trained on use of TORPEDO or 
any of the components of the intervention. 
 
GP performed work from administrative, IT and regular 
patient care.   
 
Main GP: I haven’t allocated a task to my staff to use it 
[intervention], we haven’t trained the staff. 
 
Effort 
Main GP: It cannot be based on just me to do the 
analysis all the time, which is impractical at the end of 
it…fully integrated in terms of not just the doctors are 
using it, the staff are using it at the same time. So you 
need a bit of education for the staff, show them how to 
install it, how to log in, how to logout, where to get the 
information, which area they should be looking at, 
maybe even our administrative side of it, to help the 
doctors maybe. 
Reconfiguration 
Main GP worked with developers to fix 
problems so both GPs can use the 
intervention, however ongoing 
technical barriers deterred GPs from 
using or changing their practice to 
improve their data any more than it 
had.  
 
Main GP would like intervention to be 
quicker, integrated within EHR and 
have an allocated staff to help drive the 
intervention at the practice to use long 
term.  
 
No delegated person/point person to 
present ongoing reports of the study 
indicators (CAT and IF reports), trouble 
shooting of intervention with 
developers or study personnel, and 
organising training.   
 
Comprehension 
Main GP: No, I don’t [think] it’s 
integrated very well at the moment, 
because one is I haven’t allocated a task 
to my staff to use it, we haven’t trained 
the staff to train once or twice. 
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Case 3: Small urban general practice 
Interview date: February 16, 2014; ~ 10:30-11:45 am (GP) and 12:15 pm (Practice manager/receptionist)  
 
MECHANISM 
Coherence (sense-making work) Cognitive participation (relational 
work) 
Collective action (enacting work) Reflexive monitoring (appraisal work) 
 
Differentiation 
GP has a personal interest in kidney disease. 
HT was a tool that was going help GP to be 
more aware of risk factors for diagnosis and 
treating kidney disease.   
 
Prior to using HT tool GP did not use absolute 
risk calculations since it was too complicated 
and time consuming.  Tried to assess CVD risk 
from individual risk factors. The tool assisted in 
assessing overall risk and kidney disease risk.  
 
GP did not know the purpose for other 
components (audit tool and web-based portal) 
of the intervention; therefore, did not use.  He 
used portal initially but did not see much point.   
 
PM was not involved in the study therefore did 
not know the purpose. 
 
GP: we couldn’t complete that [absolute risk 
calculation prior to HT].  We could simply say 
to him, “You are in the bad department” … 
 
…It [absolute risk calculation] was tedious, it 
was hard work.  It still is like that but that gives 
us a bit more about absolute risk calculations.  
 
Individual Specification 
GP lacks knowledge of the specifics and 
purpose of all components of the intervention.  
He is familiar with HT assessment and “what if’ 
graphs.     
Initiation 
GP is the solo driver of all programs 
and studies including patient care. GP 
works autonomously.  He used HT tool 
for kidney disease and cardiovascular 
patients and those he suspected of 
being high CVD risk. 
 
GP: I began looking at everybody with 
kidney problems.  I do lots and lots of 
blood tests.  
 
Legitimation 
GP has a difficult time convincing high 
risk patients in taking medication.  This 
is a regular occurrence and assumes 
patients wouldn’t be interested so 
doesn’t bother trying.  
 
Further, he believes he a high 
performing site and didn’t need to 
change much after initial training from 
implementation team.  
 
Enrolment 
GP believes the concept of the tool is 
good; however, does not know how to 
use it properly. Needs incentive to use 
intervention to have impact, and needs 
further training. 
 
GP: difficult to convince patients to 
take the medication, although 
Interactional workability  
At his practice, he wants to give his patients “total 
patient care”.  
 
He initially used HT tool however went back to 
practicing the way he was prior to the 
implementation of the tool. 
 
Doesn’t find the graphs helpful in explaining to 
patients their risk.  The mathematics of is too 
complicated for the patients, unless patient shows 
interest.   
 
GP: occasionally when a patient is a bit difficult to 
understand and difficult about realising that he has 
got a risk with cardiovascular disease, then I 
produce the file in the hope of convincing them 
they have to do something about it.  
 
… “I’m quite happy with that.  That’s a good sign.  
Thanks, Doctor.  Thanks very much, you know, 
you’re the first one who showed me”.  So, you 
know, things like that do happen.  Out of the 10 
patients that I would use that with, about seven of 
them would say that. 
 
Relational integration 
PM finds the study interesting.  She has seen the 
audit tool, and peer ranked reports when study 
research team visited the practice.  She would like 
to learn and be involved but her assumption from 
what GP has said in past is that he doesn’t want 
Systematisation 
GP did not know how to use and read 
the peer ranked graph provided by the 
study team or use the web-based 
portal.  He needed additional training.  
Therefore, there was no measure of 
health service performance of the 
study indicators.  
 
There are no systematic method or 
practice of identifying benefits or 
issues with the intervention. 
 
Individual appraisal 
There was lack of interest in assessing 
how the intervention was impacting his 
overall performance in CVD 
management.  He was happy with his 
initial performance of being above 
average compared to other general 
practices.  
 
GP: I was more keen on this fact that I 
was doing almost as well, then I wasn’t 
paying too much attention to the later 
graphs that came. 
 
GP:  Well, looking at this [performance 
on web portal], for example, where the 
red one is, it applies to me.  I’d rather 
be on the other end like I did in the first 
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GP: HealthTracker made it more attractive 
because that showed that I was doing 
something and I was going somewhere, 
whereas all the others, just collect this, collect 
this, collect this.  
 
Communal Specification 
The PM did not know purpose of the 
intervention or study.  GP did not believe she 
was interested; and PM believes GP did not 
want PM involved.  
 
Patients found it useful however GP not able 
to convince patients of changing their 
behaviour or medications for high CVD risk 
patients without CVD. 
 
Internalisation 
Saw overall benefits of using HT tool for 
cardiovascular patients and incorporating 
kidney screening. His personal influence of 
using a tool to screen for kidney disease was a 
major factor in its use.  
 
GP: I have prescribed for people to whom I can 
demonstrate that something is wrong and they 
need to fix it.   
 
GP: it’s worthwhile knowing, however when it 
comes to treating people, they want to be 
looked upon as individuals and they want to be 
shown where they are going, not relative to 
somebody else 
 
Meaning 
GP: I could see that it was specific to most of 
my patients.  Now, most of my patients had to 
admittedly I understand the benefits of 
it [prescribing to high risk patients].  
 
…It’s a very good tool.  It’s a very good 
system and I know it is developing 
because it’s looks newer, different each 
year and the use is just a matter of 
having to use it.   
 
Activation 
GP’s method of patient care is face to 
face without focus on the computer.  
He uses computer to see if patients 
need further assessments and what 
was discussed previously.  
 
GP set in his ways in patient care.  He 
needs a lot of hand holding to become 
comfortable with new method of 
assessing CVD risk.    
 
GP: It’s a good tool.  It’s a good tool.  If 
it is put to proper use it’s, the use will 
eventually serve the purpose for which 
it was built… 
 
 …now that I’ve used the thing for a 
little while, I’m aware, I’m conscious of 
its, of the management, of the use of it.  
 
Commitment 
GP: this one here [HT], bugger, it’s just 
a matter of collecting data.  That’s how 
it feels, you see, so I haven’t got any, 
how shall I say it, enthusiasm about it.  
 
 
her involved. GP excludes PM from anything 
related to software system. 
 
GP thinks she is not “keen” on the study and stated 
he would ask her.   
 
PM: I think he doesn’t like me doing it, he wants to 
do it himself, that’s why.  So I have no idea what 
he’s doing. 
 
GP: Time factor is primarily that.  You are right, if I 
could train xxxx(PM) to do it, I suppose she’d do it, 
but essentially, I didn’t know what it is for.   
 
Contextual integration 
The tool slowed down his whole system.  This 
caused him to dislike the intervention.  
 
GP lacks time and resources to fully implement and 
embed the intervention.  
 
GP: Slows the damn thing down.  It’s very 
annoying.  
 
Skill set workability 
GP needs additional training and support to 
understand the rationale and use of the 
intervention.  He found the initial training to be 
overwhelming. Incremental training and delegated 
time flagged explicitly with administrative 
assistant.  
 
Doesn’t feel comfortable using absolute risk to 
prescribe.  Needs more training and skill 
development. Age is a barrier in using health 
information technology 
 
GP: I wasn’t paying 100% attention to that 
[study/intervention training] because these were 
time, like this one. …I suppose I didn’t 
know how to change that.  
 
Communal appraisal 
Participants including patients did not 
appraise the intervention and its value.  
They gave some positive feedback 
initially when GP was using the ‘What 
If” graphs however impact was 
unknown. 
 
Reconfiguration 
There was nothing done to 
accommodate the intervention. 
Financial incentive would have helped 
use of the intervention.  
 
There was lack of reflexive monitoring 
at the practice.  
 
Lack of understanding of the study and 
intervention.  Initial purpose to be 
involved was to assess kidney disease 
more efficiently. 
 
Comprehension 
GP: it’s a bit of a nuisance and apart 
from the fact that it is beneficial in 
terms of putting figures down and 
calculating it, it appears as if I’m 
working for somebody else with no 
compensation and no recompense and 
it’s very annoying sometimes, 
especially when the thing clogs my 
computer now. 
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do with heart disease and, of course, you could 
incorporate kidney disease as well in that.  
 
just not appointment type attendances.  Somebody 
just blew in and began talking about this 
[intervention] and I, so my patients are used to 
waiting but I don’t like them waiting.  
 
…you’re really given a utensil and you don’t know 
too much about how to use it.  
 
Effort 
GP: “Oh, I’m all right.  I’m doing okay so all I have 
to do is just carry on doing what I’m doing”.  
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Case 4: Medium rural general practice 
Date of interview: July 17, 2014; time of interview: ~11 am (PM) and ~12 pm (GP) 
 
Mechanism 
Coherence (sense making) Cognitive participation (relationship work) Collective action (enacting work) Reflexive monitoring 
(appraisal work) 
Differentiation 
Benefits of using HT as CVD risk management and 
teaching tool.  Provided evidence for teaching 
registrars.  
 
Main GP sees the benefits of having the best 
quality improvement tools at his health service 
however using the e-health tools has its obstacles.  
 
Main GP: was using it [HT] as a risk measurement 
tool and as a patient teaching tool that people 
would, we would, a registrar would say “Gee I’ve 
just seen somebody who’s come in, who’s new, and 
have got a cholesterol of this and a blood pressure 
of this, and their sugar’s a bit high but they claim 
they’re not diabetic.  What do I do?” and instantly 
we’d use it to say “Okay, let’s have a look at the 
risk.  Let’s see what things we can modify.  What 
can we do straightaway?  What can we do down 
the track?  What’s what?  What can be, which 
order do you do it in” and so on.  And at times 
what’s the evidence for it?  Use it to teach wider 
range.  
 
Individual Specification 
Due to the practice having mainly registrars with 
the owner being the main full time GP, it was a 
good way to train and teach doctors on best 
practice based on evidence-based practice, and 
use of new technology to enhance patient care.   
 
Main GP values prompts to help screen and 
Initiation 
In order for all GPs to use HT, main GP needs 
to be a ‘clinical champion’ for using 
intervention.  
 
Main GP dislikes computers therefore didn’t 
use as often as he may have wanted to and did 
not know the full capabilities of HT. 
 
Main GP used in meetings as teaching tool and 
had research team attend meetings to train all 
the GPs.  Registrars were keen to use. 
 
Main GP: ..my age range is against me.  It was, 
I’m not someone who’s intuitively familiar.  So I 
attempt to use [HT], as I say I really hate 
computers…I tend not to sort of sit and say 
“Ooh I wonder what this will do” or “I wonder if 
I can find out this?  I wonder if I can find out 
that?”….therefore if that’s my approach then 
it’s difficult for me to pass that on to other 
people [GPs]. I can’t sort of say go and do this 
[use HT] when I don’t usually do it [use HT].   
 
Legitimation 
Main GP finds the tool to be beneficial but 
does not use regularly due to his confidence in 
computer tools.  He needs additional training 
for him to promote it within his health service.  
 
PM: I think the younger doctors found it [HT] 
useful, so that made things, the pop up 
reminders, “Okay, this person needs this 
Interactional workability 
For the main GP, the - ‘What-if” graph – he only 
showed the graph and didn’t manipulate since didn’t 
feel comfortable with explaining rationale. The graph 
was engaging for the patients.  
 
Main GP: People are interested.  It’s a mode of 
engaging people.  
 
Relational integration 
Practice has good staff rapport. Have regular weekly 
meetings as a teaching and team-building forum. HT 
was used to teach about difficult cases and its use 
with patients.   
 
Main GP...often will use it in case discussions in 
teaching that use it to actually say “Look, it’s there.  
You can use it and you can calculate and you can use 
it as a teaching tool for the patient, and you can use 
it as a prompt for yourself, what you can modify”. 
 
Contextual integration 
Uses regular weekly team meetings to standardise 
practice and ‘continuing medical education’.  Both 
administrative and clinical staff are invited to the 
meeting where both areas will be discussed.  
 
The need of permanent GP staff could enhance the 
use of the intervention.  Main GP was an advocate 
for the use of PCHR however doctor’s ineptness for 
computer was affecting its use.  Young registrar soon 
to be permanent doctor had tips for using it more 
Systematisation 
Used IF peer ranked 
reports to view the 
practice’s performance. 
Values feedback about 
how service is doing 
regarding screening and 
management of patients. 
 
 
Individual appraisal 
Peer ranked reports that 
identify progress needs to 
be summarised concisely 
via email in order for 
main GP to view the 
report. 
 
Main GP: it was most 
likely once again, having 
a very, very short simple 
summary [IF report]. This 
kind of reporting is good 
where you sit down and 
have the introspection.  
 
Communal Appraisal 
PM can add reviewing 
peer ranked reports at 
the Thursday meetings on 
a regular basis.  This was 
done a few times 
however not regularly. 
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manage CVD and chronic diseases. 
 
PM understood what the study was about 
however was not engaged in it due to time 
constraints. 
 
Communal Specification 
Main GP works on being the ‘clinical champion’ 
during team meetings. GP is an expert on diabetes 
management, and works at a diabetic clinic. 
 
Other GP registrars saw the benefits of HT; 
however unaware of the frequency of use. Due to 
staff turnover, interest and awareness of the 
intervention was unknown. 
 
Internalisation 
Main GP valued it as a good platform to teach 
registrars and use to communicate risk to patients.  
 
Meaning 
Main GP: I’ve been looking for non-paper based 
prompts for cardiovascular or chronic illness 
prevention.  And that’s one reason.  And secondly 
because I thought it’s something which was good 
to be measured.  And thirdly I just wanted to see 
maybe overall how we were performing.   
checked, this person needs that checked”, that 
was useful for them. 
 
Enrolment 
Theoretical concept was great however lack of 
confidence and knowledge with computer 
affected use of tool.  Young keen and proactive 
doctors would be more apt to use.  
 
PM not involved in the study and did not use 
CAT component for the study. PN could have 
been better able to assist with CAT. 
 
Activation 
Young doctors would likely be proactive and 
use HT; however due to staff turnover 
(registrars), use of HT was variable at the 
practice. 
 
Main GP was less likely to use HT unless he felt 
confident in the rationale and knowledge of 
using it properly.  
 
Commitment 
Main GP:  you had a tool [HT] where you could 
instantly see what an evidence base risk 
calculator shows and you were able to modify 
it.  Right, okay.  And that was some of the 
other features like bringing up the feedback 
online and so on, “Let’s do this, remember the 
password, do this, it’s the internet’s slow.  
Bugger it.  I’m going to go have lunch”.  
 
efficiently. Main GP was impressed and learned from 
young GP. 
 
Three permanent GPs to join health service which 
could increase engagement in the intervention. 
 
Non-GP staff were not involved and not interested. 
This would have assisted in overall use of the 
intervention and integration. 
 
Main GP needs incremental training for him to use 
the tool regularly. 
 
Skill set workability  
Further training for main GP, PM and PN needed.  
Incremental training and once a month phone call 
for support would enhance use of the intervention. 
Possibly an online training demonstration could help. 
 
High staff turnover is a cause of lack of collective 
action. 
 
 
GP: the sole barrier was familiarity.   
Effort 
Main GP: I remember you and xxx [chief investigator] 
would come around and you’d explain things and 
there would be things that I would see the benefit of, 
and then it was like “Okay, I’ve learned 25 new 
things.  I remember three very well, I know how to 
use five, and I know I can sort of do this but I don’t 
quite remember how to do it”, and then after three 
weeks you’d think “Was there something like that 
there or not?”  And you thought “Okay, I can go for a 
walk or I can sit here for half an hour and work out 
how to do it.  I’ll go for a walk”.  
PM has shown/given the 
reports to the Main GP.   
 
Reconfiguration 
There has been minimal 
alteration in the health 
service to ensure regular 
appraisal and use of the 
intervention.  This 
occurred a few times 
during team meetings.  
 
Main GP: …use of the 
tools was increased 
obviously.  Right, okay.  
But my use, or my way of 
using the guidelines really 
didn’t change.  
 
Comprehension 
Main GP: It’s integrated 
well, and there needs to 
be still more work.  Look 
it’s a tool, and it’s a tool 
which has very, very 
many uses, and quite a 
lot of potential.  
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Case 5: Large remote Aboriginal Community Controlled Health Service  
Date of interview: May 28-29, 2013; Time: ~10 am (GP); after lunch (AHW); May 29th at 10 am (HIO) 
 
Mechanism 
Coherence (sense making) Cognitive participation (relationship work) Collective action (enacting work) Reflexive monitoring 
(appraisal work) 
Differentiation 
Staff that were introduced to the 
intervention saw the benefits of using the 
point of care component of the intervention.  
They saw the benefits of having easy access 
to the CVD risk screening profile and 
absolute risk displayed with ‘one click’.  
 
The screening team and GPs had already 
been using the Doctor’s Control Panel (DCP) 
however the tool lacked calculation of 
absolute risk and patient risk 
communication.  It was more of a screening 
tool.  Therefore, they were keen on using HT.   
 
AHW: it is just the way it tabulates so much 
more information than what our other 
options have been.  So again, it gives us a 
real accurate point of where they are with 
their risk assessments. 
 
Individual Specification 
GP was an advocate in calculating absolute 
CVD risk, and prescribing according to their 
risk.  HT made GP aware of prescribing 
guidelines and gave him confidence to 
prescribe “early”.  Further GP had 
professional development motives for using 
the audit tool and absolute risk calculations.  
 
AHW: I liked it where we could show the 
predictions if they’d changed this or done 
that.  Even though I know that doctors would 
Initiation 
HIO worked exclusively on CQI programs and health 
system reports.  She was the delegated staff working 
on TORPEDO and driving the implementation of the 
tool.   
 
GP found the tool to be valuable and when possible, 
GP registrar would demonstrate the HT tool to other 
GPs.  GP promoted and educated about the tool to 
colleagues.  He would like AHWs who are at the 
frontline screening patients to use the HT tool.  
 
Legitimation 
HIO reviewed TORPEDO data on a regular basis (1-2 
times per month).  However, after trial completion, 
she did not review data as frequently.  Driven by trial 
participation. 
 
HIO used audit tool more often than peer-ranked web 
portal. Web portal was used to give an overview of the 
health service.  
 
AHW was keen on using HT with his patients. He 
screens chronic disease patients before they see the 
GP, so it would have been valuable for him to show the 
visual presentation to the patient.  
 
AHW: I think as I work in that clinical sort of direct 
patients and really working close with doctors and all 
that, it could be a great tool for me to use.  Someone in 
the community might be, it’d still be good for them but 
they wouldn’t have that, I think the visual tool, and 
Interactional workability 
Patients appreciate the ‘what-if’ graph and being 
able to see their risk visually.  GP used 
infrequently due to time constraints.  He thought 
it was valuable component.  Time constraint is a 
big barrier at the health service for GPs. 
 
GP: if you're going to go through all this you 
actually, you've got to be prepared to have a 
good 10 minute chat with the patient because 
you actually want to engage them and help them 
understand where they're at and make a 
difference and that's the time. So it's not the 
program time it's actually alright we're going to 
have a proper chat today…..that's what takes the 
time.  So to just have that chat without this tool 
would, you know you'd be drawing all sorts of 
pictures over the paper and the patient might get 
the point but not really.  But with this tool if 
you've got the time you can really get your 
message across.  Yeah but it's that, sort of that 
10 minutes to have a proper chat with the 
patient that I haven't, yeah. 
 
Relational integration 
HIO worked with GPs to install HT, set up training 
and report on performance at meetings.  
 
There was lack of use of HT across different roles 
despite interests.  If non-GP staff used tool, it 
would be beneficial to GPs and overall patient 
outcome.  
Systematisation 
HIO would report to GPs their 
performance in TOPREOD 
especially prescribing to high 
risk patients quarterly at the 
GP meetings.  She would 
have lists of patients that 
were not properly managed.  
GP were illuminated by the 
reports from HIO.  They were 
keen to review patients that 
were suboptimally treated.  
 
Individual appraisal  
GP suggested providing all 
GPs with reports of 
performance of study 
indicators by point person, 
and then reviewing the data 
with GPs to motivate use of 
HT.  This will demonstrate the 
benefits of using absolute 
risk.   
 
At quarterly meetings, HIO 
presents data from CAT and 
IF portal on performance of 
all study indicators.  GPs are 
very receptive.   
 
Communal appraisal 
Health service’s focus is on 
seeing how they are doing 
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go through that, I think also having an 
indigenous person as a health worker who 
only help maybe on that cultural side to say, 
well this is what this means, and it will be 
really handy in screening ‘cause not all our 
patients want to go through to a doctor. 
 
Communal Specification 
GP was an advocate of using guidelines.  He 
took on the responsibility of sharing 
guidelines with other GPs by making multiple 
photocopies. 
 
AHW thought the ‘what-if’ graphs would be 
valuable in giving patients an Indigenous 
perspective.  
 
HIO: we do conduct business using absolute 
cardiovascular risk as our means to 
determine, you know, who’s looked after by 
what team  
 
Internalisation 
HT provided evidence based medicine for 
CVD management which was a key reason 
for participation in the study.  Everyone 
introduced to the intervention at the start 
really believed it would be beneficial to the 
health service.  
 
HIO: I think it’s a very good tool to have 
added to our kit.  The fact that it’s electronic, 
the fact that it integrates with the medical 
record, I certainly see its value and purpose.  I 
think the doctors certainly see its value and 
it’s, you know, sort of streamlined their 
consultations from the what do I need to do 
point of view, and then extended their 
consults on the how to engage with a patient 
 
that’s probably what I’m looking is that it’s just a great 
visual tool for me to use with my patients 
 
Enrolment 
GP used tool to help reassure himself of his diagnosis 
and risk calculation, and management of high CVD risk 
patients.  GP would buy the tool if he owned his own 
practice.   
 
AHW wanted to use the tool; however never given 
access.  He was not aware of reason for not being able 
to have access.  He was disappointed.  
 
GP: it did change my prescribing criteria and having 
the Health Tracker tool available to help me calculate 
that reassured me that I was doing what is perceived 
to be the right thing. 
 
AHW: it was interesting though that we were still 
shown it [intervention], and, so, you know.  So you sort 
of, look we’ve got this great tool here, but guess what, 
you can’t use it.  It was sort, that’s what it felt like to 
me. 
 
Activation 
The intervention can become embedded and 
integrated if non-GP staff are given access to HT.  And 
regular support and training is offered to GPs and non-
GP staff. 
 
Commitment 
GP: if I was running my own practice I'd pay for this 
software even if I was charged to use it and I'd use it 
often. 
 
 
There are multiple care teams that work with 
different patient cohorts.  There was lack of 
implementation of the intervention within these 
groups.  
 
There was staff turnover that affected use of the 
intervention with new GPs.  
 
Contextual integration 
GP would like to see HT move information from 
HT into the EHR.   
 
There was an issue with the resource and time 
constraints.  
 
It would be valuable, and increase capacity for 
change if non-GP staff used HT tool. 
 
GP: it's like a one way street and doesn't come 
back.  And so if I wanted to get any of these nice 
documents into my notes I don't really know how 
to do it apart from print it out then type it all in.  
And I'm not going to do that. 
 
AHW: I don’t know whether from management 
and whether they thought it was for the safety 
sake, you know, patient’s safety and the safety of 
us workers, you know, maybe too much stuff I 
think.  But as we’re involved clinically I think it’s 
still, it’d be great to have access [HT]. 
 
The ACCHS has a strong foundation of CQI 
programs.  Our intervention fit in with other 
already integrated programs.  
 
Skill set workability  
Skill set depends on age of the doctor.  Young 
doctors are more ‘IT savvy’.  
 
amongst themselves.  Less 
concerned with comparing 
themselves with others.  
Focus in improving patient 
outcomes and quality.  
 
HIO: will extract the 
information out and then put 
it into our own, you know, 
xxxx [ACCHS name] looking 
report, and then report that 
back to the staff.  Because 
only the GPs here use that we 
usually tie it into the GP 
meeting, so they’re held 
quarterly and we might not 
put TORPEDO on every 
quarter, but maybe, you 
know, it’s six monthly to 
allow for, you know, a bit 
more, so certainly I think, 
yeah, they’ve had at least two 
to three reports it must be, 
handed back to the GPs. 
 
Reconfiguration  
HIO incorporated reporting 
on CVD risk factor indicators 
at GP meeting. HIO worked to 
check regularly that training 
was provided to new staff.  
 
GP: I've seen these graphs 
[peer ranked web portal 
reports] before in 
presentations, when 
presentations have been 
given, but I've never accessed 
it myself. 
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Meaning 
GP: It's helped my practice individually 
because I can get an accurate complex 
summary that takes into account all these 
additional factors and other relevant history, 
all the numbers, it gives me the reassurance 
that I'm getting an accurate cardiovascular 
risk, the most accurate really that I've seen 
by a long way.  So it gives me confidence to 
prescribe the medicines that I prescribe 
knowing that my cardiovascular risk is 
accurate. 
 
It would be beneficial to have follow up calls and 
training session within 2 weeks of initial training.  
Follow up training and support is crucial in 
helping GPs use HT. 
 
HIO, delegated CQI staff had experience using 
the audit tool and found web-portal as an 
important avenue of relaying information to the 
GPs.  
 
HIO: I think it’s just about that training.  So, and 
then following up, you know, so for example, the 
doctor has training, you know, following up a 
month later just do we need not a re-training 
but, you know, any questions.  What we find is 
most of the doctors when they go to the initial 
training session they’ve, you know, they may not 
even have a login so they’ve never actually seen 
Health Tracker at all…. they really benefit from 
having maybe a following up session.  But, yeah, 
sometimes I feel that, you know, the time delays 
are really too far gone and they actually need 
complete re-training again. 
 
Effort  
GP: It's got a big potential to help the practice 
but you've got to have people willing to use the 
computers and have the time in the consultation 
to go through it with the patient and 
unfortunately that hasn't been the situation in 
the last six to nine months at xxxx [ACCHS name] 
Comprehension 
HIO: …for example only 30% 
of the high risk patients are 
being prescribed with triple 
therapy and they go, whoa, 
you know. So they really like 
that, and we can then 
actually provide them with 
the names of people, you 
know, and then sort of next 
time they present to the 
service they can have a quick 
look at their, you know, 
medication management. 
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Case 6: Large urban Aboriginal Community Controlled Health Service  
Date of interview: November 25th-27th 2013 and February 6, 2014 
# of staff: Large health service with multiple staff at two locations. (3 full time GPs and 2 part-time GPs) 
Mechanism 
Coherence (sense making) Cognitive participation (relationship work) Collective action (enacting work) Reflexive monitoring (appraisal work) 
 
Differentiation  
GPs, PN, AHWs, and PMs, saw the 
benefits of the intervention and impact 
it could have on patients with one click.  
 
Lead GP: you’ve just got an 
independent source and it’s new data 
so it’s just refreshing your minds 
because the guidelines are always 
changing, the targets are always 
changing, blood pressure targets, lipid 
targets, so I, yeah, just brings 
everything, gives you a fresh review of 
everything, and it’s on your computer, 
it’s on your desktop. 
 
AHW: Well, usually when a patient 
goes in for a consult, they don't usually 
see anything like this.  They might get a 
bit of paper with their care plan on it 
that's written in medical jargon and 
they don't understand it.  When you've 
got something as basic and 
straightforward as that, it's an easy to 
read tool for anyone.  
 
Individual specification  
Lead GP was sceptical at first due to 
technical nature; however, he is an 
advocate for managing patients based 
on absolute risk. HT provided a simple 
explanation for patients through the 
Initiation 
PM worked with research team to install 
HT and scheduling training; however, no 
delegated person for ongoing training or 
trouble shooting. 
 
Lead GP and GP2 were an advocate of 
AHWs and nurses using HT as part of their 
screening practice.  However, GP3 does not 
think others should have access to HT only 
because this will cause more time 
constraints. 
 
AHW: I've been there a couple of times 
with GP x [lead GP] doing this [‘what if’ 
graphs].  And he's entered in the data.  And 
then it showed on the projection.  What 
would they do if they changed this, you 
know, change their smoking and then 
change that and then change this and 
watch it come down and see the patient's 
reaction to that?  And even that for me, 
'cause I'm a smoker [laughs], yeah, and 
there was a considerable jump in the risk 
when he just took away the smoking.  So, 
yeah, it was a bit of an eye-opener.  And it's 
pretty easy to read graph 
 
Legitimation 
All staff believe that this intervention can 
improve quality of care. However many are 
not aware of the full capabilities of the 
intervention.  
Interactional workability  
The ‘what-if’ graphs have impacted 
positively in helping patients understand 
their CVD risk profile.   
 
Engaging and easy for clinical and non-
clinical staff to explain graphs.   
 
Lead GP: you can look at the specific risk 
factors and what you can do about it, 
and see how you can change your risk.  
And so I like using, in that instance I love 
using the graph, I love using the change, 
the smoking status, to look at how you 
can change your heart age, and I’ll say, 
“If we put you on a statin it will drop your 
cholesterol from 6.9 to 4, and here’s 
what happens to your cardiovascular risk; 
your heart age drops to this, or it has 
relatively no change.”  So yeah, just 
looking at the what-ifs. 
 
GP2: pictures make more for impact than 
the words, kind of thing.  So they were 
more affected by that.  And some of them 
made the decision to, you know, to stop 
smoking, for example.  And yeah, so that 
was a good effect. 
 
…Advantages, definitely showing the 
patient on a graph [What if graph] is 
effective. Because it’s a picture, they 
can’t, it’s clear, it’s not complicated, the 
Systematisation 
PN/PM working on data quality and clinical audits.  
PN works at new smaller location. This affects 
communication of data quality results.   
 
Main GP sees value in CQI programs but no 
incentives to participate.  Patient care is focus. 
 
Individual appraisal 
There was partial self-monitoring on performance 
after using intervention.  Staff would see benefits if 
there was an impact on patient lifestyle after viewing 
‘what if’ graphs.  
 
PM: Find these [peer-ranked reports from web 
portal] very valuable in looking at how we’re going 
compared to other services, and whether or not 
we’re actually getting to the potential risk factors in 
the patients that we’re seeing. 
 
Communal appraisal 
Main GP/CEO would like a delegated point person, 
preferably GP, to report on study progress at team 
meetings.  
 
New GP working on CKD audit, and used this as 
educational session on UACR screening and kidney 
disease. 
 
PM: I’m just really, really pleased that you’re 
continuing for another 12 months, because I think for 
the first six months of the project no one got it right, 
and I will be even more interested to see how much 
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‘what-if’ graphs.   
 
All GPs gained knowledge and skills on 
screening and prescribing based on 
absolute risk  
 
PM, PN and two AHWs believed that 
HT would be beneficial for their patient 
population at the HS. They were 
excited about the prospect of using the 
risk communication component.    
 
PM: Initially, when we first got the side 
bar [HT], I was really impressed, and I 
did like the fact that it reminded you 
that things needed to be done, or not 
that needed to be done, but things that 
hadn’t been done that perhaps could 
be done, and I found that really helpful.  
 
GP3: I think it’s [intervention] definitely 
made an impact.  It’s helped me with 
my clinical practice.  It saves me having 
to manually input all the things into the 
calculator, the Framingham risk 
calculator, and it’s a good reminder 
tool. 
 
Communal Specification 
All staff using intervention found risk 
communication ‘what if’ graphs to 
have the most impact on patient 
outcomes.  
 
Internalisation 
GP and non-GP staff see the overall 
value in intervention being a 
preventive care tool.  
 
 
Lead GP: routinely I would use it [HT] when 
I’ve done some, I’ve done a health check 
and I’ve done their bloods and they’re 
coming back and they’re looking at their 
lipid results, and people get a bit fixated on 
why is that number up, why is that number 
down or whatever, “Do I need to fix that?”  
And so you give them a holistic view of 
cardiovascular risk. 
 
 
Enrolment 
All staff trained found the ‘what-if’ graphs 
to be powerful and engage patients. It was 
easier to explain to patients their CVD risk 
in pictures.  They did not use often due to 
time constraints. 
 
Activation 
One GP and AHWs stopped using HT after 
it disappeared one day. AHWs were too 
busy to follow up.  They were using for 
screening purposes. 
 
Lead GP was more computer savvy and 
proactive in trying to fix issues on his own 
or call/email research team. However 
worked mostly autonomously due to his 
personality. 
 
Commitment 
Lead GP:  I’d still go looking for it [when HT 
disappeared].  You know, the benefits 
outweigh the problems…I’m very much an 
advocate of it.   
 
 
 
graph.  So you can actually see with a 
simple explanation and it’s effective.  It’s 
impressive. 
 
Relational integration 
Non-GP staff were provided assess and 
training to HT.  Those screening patients 
used HT till it disappeared.  Main GP and 
GP2 an advocate for AHWs to use HT for 
CVD assessment. 
 
GP3: At the moment there’s no one doing 
that role [CQI officer], so everyone’s just 
busy seeing patients and no one’s really 
looking into quality improvement. 
 
Contextual integration 
Problems with audit tool not extracting 
data from EHR accurately.  This 
discouraged GP3 and PM/PN from using 
for data quality purposes.  PN used CAT 
frequently for audit purposes and study 
reporting.  Due to working across two 
locations, there were issues with data 
accuracy. 
They were unable to resolve the issue 
 
Most staff did not use the intervention to 
its full capabilities. There was lack of 
knowledge of what comprised TORPEDO 
components.   
Team meeting on a regular basis with 
focus on case conferences.   
 
Lead GP: advantages are it’s on the side 
of the screen and it’s interacting with 
your software… 
 
improvement we’ve made at the end of the next 12 
months.  
 
Reconfiguration 
CEO requested one of the GPs to focus on CQI once a 
week which can enhance intervention use. Need 
regular reporting of performance of TOPREDO study 
indicators at meetings.   
 
Lead GP: [GP3] got a whole day a week that he’s 
supposed to do this [data review extracted from 
audit tool], then that’s the place because I don’t 
really know what he does on most days, and I 
occasionally ask him and then I drift off when he tells 
me.  So I think that’s, you’ve got him being paid one 
a day a week, you know, that’s where it should 
happen.   
 
Comprehension 
AHW2: there was no follow up with it [intervention] 
within xxxx [ACCHS] itself to say, ‘How’s everyone 
going with this?’ ‘Are you using it?’ like, ‘Was it 
useful?’ and stuff like that.  There was nothing.  
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AHW: It saves you heaps of time 
because in a blink of an eye you can see 
what they're due and what they're not, 
whether or not it could be save a load 
of time and provide a better care for 
the patient, making sure we're not 
missing anything. 
 
GP2: Torpedo, as I said, when I see 
those graphs that I’m sharing with the 
patients, yes, for example I change, I 
change the medication like blood 
pressure medication from one level to 
two more levels, like three combination 
medications instead of just giving one.  
So it’s still one tablet, but three 
medications in it to improve the blood 
pressure. 
 
Meaning 
Lead GP: it sets the bar high and it 
does, it’s a great programme and I 
guess the constraints are just the time 
constraints.  But it’s something that 
you need to look at, you know, if you’re 
going to do a good general practice 
and you’re going to do primary 
prevention you’ve got to use something 
like this…using something like this it’s 
got to be part of your practice 
otherwise you’re just doing reactive 
medication.  
 
… disadvantages ..it did take a little while 
to load if you didn’t have it running 
already, and just a few software glitches, 
not with your programme but mainly 
with Medical Director, because most of 
the time the questions about this come 
up during a health assessment, 
Aboriginal and Islander health 
assessment which is a horrible 
programme in Medical Director that runs 
alone and you can’t move from it to any 
other programme.  So you’ve almost got 
to hand write your little notes and then 
come back to at the end, and you always 
run out of time.  So that’s just an 
unfortunate part of Medical Director, but 
no, that’s about all. 
 
AHW: Just because of some discrepancies 
of where it's pulling information from, it's 
really let itself down.  I mean, it saves you 
using the assessment tool.  It saves you 
heaps of time because in a blink of an eye 
you can see what they're due and what 
they're not, whether or not it could be 
save a load of time and provide a better 
care for the patient, making sure we're 
not missing anything, you know. 
 
Lead GP: then when the print status 
came up that was good because I could 
give people a hard copy to take with 
them. 
 
GP3: It didn’t pick up all the patients, so 
for example say in April of last year I tried 
to see how many Aboriginal patients we 
saw for that entire month.  And it came 
up with a number of about 20 or 30 
something, which is not right because I 
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had to, I went through manually all the 
patients for that month, and it turned out 
to be about 200.  So it was not picking up 
all the patients.  I don’t know why that’s 
happening.  But I couldn’t use the clinical 
audit tool to verify my numbers, because 
it’s underestimated by a lot. 
 
 
Skill set workability  
Main GP trained GP2; didn’t provide in-
depth training. Newer GP did not receive 
formal training. He was given training 
over the phone by webinar.  
 
Need for additional follow up training 
and support on regular basis.  Computer 
literacy is variable.   
 
100% staff turnover for AHWs during 
middle of the trial.  Lack of transfer of 
training and knowledge about HT and 
study.  
 
Main GP: I mean I think you guys came 
around and did a few live tutorials, and 
that was helpful, and especially when 
new doctors came on board they could 
hear it from someone else; they don’t 
want to hear it everything from me.  I’m 
not very good at explaining things, just 
ask my kids.  
 
Effort 
Main GP: focused on case conferences 
and individual cases, and we don’t so 
much look at public health.  … not a lot of 
remuneration for it immediately, so 
maybe we’re chasing the cash cow a little 
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bit that way rather than stepping back 
and getting a bit academic. 
 
Additional file 3: Job Satisfaction survey data 
Warr-Cook-Wall Scale of Job 
Satisfaction  
Case 1 
(4) 
Case 2 
(3) 
 Case 3 
(2) 
 Case 4 
(8) 
Case 5 
(34) 
 Case 6 
(17) 
All cases (n=6); 
68 participants 
 Other 
Intervention 
HS (n=18); 
113 
participants 
 Other 
Control HS 
(n=15); 65 
participants 
Amount of Responsibility 5.75 6.3 6.5 6.5 5.5  5.5 6 5.7 6 
Freedom 6.25 6.3 7 7 5.8 5.7 6.3 5.6 5.9 
Amount of Variety 5 6.7 7 5.75 5.7  5.5 5.9 5.8 6.1 
Colleagues & Fellow Workers 6 6 6.5 5.6 6.2 5.7 6 5.5 5.8 
Physical Work Conditions 5.75 5.7 7 6.6 5.5  5.7 6 5.4 5.9 
Opportunities to use abilities 5.5  6 7 6.25 5.7  5.4 6 5.7 5.9 
Your Income 5.5  4.3 6 4.75 5.2 4.7 5.1 4.8 5.3 
Recognition 5 4.7 7 5.9 5.5  5.1 5.5 5 5.3 
Hours of work 6 6.3 7 5.6 5.7  5.8 6.1 5.4 5.8 
Everything Consideration 6 6.3 7 6 5.8  5.8 6.2 5.5 5.9 
Overall score (mean) 5.7 5.9 6.8 6.0 5.7  5.5 6.0 5.4 5.7 
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TORPEDO 
Health Professionals Interview Guide  
 
DATE Health Service  Name Health Service # Participant Code Interviewer Name 
 
    /      / 13 
 
 
 
  
 
 
 
 
Job Title…………………………………………………………………….............. 
 
Locations currently working at:………………………………………….............. 
 
Do you have access to HealthTracker-CVD tool on your computer? Yes/No (if yes, answer question below) 
 
Sampling Matrix: 
 
Type of Health Service  General Practice (GPs) Aboriginal Community Controlled 
Health Service (ACCHSs) 
Urban 
Rural 
EHR Medical Director     Best Practice      
Change in CVD 
screening Outcome 
Large (>10% ) Medium (5-
10%) 
Small to None 
(<5%) 
Large (>10%) Medium (5-10%) Small to none (<5%) 
Complexity of HS 
 staff 
# of 
GPs 
# Full 
time 
PM (Y/N) # of 
PNs 
# Full 
time 
# of 
GPs 
# Full 
time 
PM/(Manager 
type) (Y/N) 
# of 
Nurses 
# 
Full 
time 
# of 
Healthworkers 
# Full 
time 
# Part-
time 
# Part 
time 
# Part 
time 
# 
Part 
time 
# Part 
time 
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Social-demographic   
 
Age 20-29 30-39 40-49 50-59 60-69 70+   
Gender  
First language  
Other languages  
Country of medical graduation. 
Postgraduate medical qualifications 
 
Years worked in general practice  
Years worked in Aboriginal Health  
Length of time at current ACCHS/General 
practice 
 
Social-demographic  AHW, Nurse, and other Health Profesionals 
 
Age 20-29 30-39 40-49 50-59 60-69 70+   
Gender  
First language  
Other languages  
Time in practicing as Nurse, AHW, other 
HP 
 
Time at site   
Highest level of education Year 10 or below                                                        
Year 11-12                    
College diploma or similar                         
Undergraduate university degree               
               Postgraduate university degree           
Formal Cross cultural training CALD                                      Indigenous  
 
Notes 
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TORPEDO - Health Professionals Interview Guide  
 
Area of Interest  Initial Broad Descriptive 
Questions 
Possible Probing Questions (These are a guide only. It is not expected that you ask all these 
questions) 
[1] 
Views of the reason 
for outcomes 
Reviewing your results from 
your health service, what do 
you think might be the reason 
for these outcomes? 
 
 
 
 
 
 
 
 
 
 
Now, let’s take a look at your 
data in CAT.  We will then open 
up your last data extraction, and 
review your data?   
- show them their randomization results and their monthly progress from the IF portal data 
(print out EOS feedback report) 
- Did you use the TORPEDO portal for viewing your data? Why/why not? 
- How often did you use the IF portal? 
- If you did use it, how useful did you find it?  
- What benefits did the IF portal have at your practice or health service?   
- Do you see a value in using IF portal?  What would influence your use of the portal more 
often? 
- How did you use the TORPEDO portal feedback reports given to you by the project officers?  
How was this discussed with the team or other GPs involved? 
 
 
- Did you use the CAT? Why/why not? 
- If you did use it, how useful was it?  How often did you use it? 
- Did you use it only for HT or did you use it for other health outcomes and data quality 
information?  
- For what purpose would you use CAT at your health service?  Who would be the main 
person using CAT?  How would information be relayed to the team at the Health Service?   
[2a] 
Use of HealthTracker-
CVD tool 
 
 
 
 
 
 
 
 
Can you remember the last 
patient you used HealthTracker 
for? And how did you use 
HealthTracker for this patient? 
 
 
 
 
 
 
 
- What purpose do you use HT for? 
- Roughly how often do you use HT in a day for your patients? 
- What kinds of patients do you use HT with? 
- How was using the HealthTracker tool at point of care different from when you would not use 
the tool?  Did you at a later time assess if use of HealthTracker improved care?How long did 
it take you to use the tool confidently? How confident are you in your knowledge and skills in 
using HealthTracker-CVD? 
- What do you see as major advantages of using the HT tool? 
- What do you see as the major disadvantages or barriers of using the HT tool? 
 
                                                                                                                                                                              
MASTER_TORPEDO_Health Professionals Interview Guidelines_V2.4_December 13, 2013_clean 
 
 
 
 
[2b] Use of Risk 
Projection graph 
 
 
 
 
 
 
 
[2c] Implementation of 
Guidelines 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
How did you use the risk 
communication graph for your 
last patient? 
 
 
 
 
 
 
To what extent were you using 
the National Vascular Disease 
Prevention Alliance Guidelines 
in patient care before 
participating in our Study? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- Did you use the risk projection graphs? Why/why not? 
- If you did use it, what did the patient think of the “What if” graphs? 
- How did the patients find the print outs of their risk summary and recommendations?   
- Did you give your patients print outs of resources?  What type of impact do you think the risk 
summary and resources print out has on patients (if applicable)? 
- At a later visit from the patient, did you review again with the patients their risk score? 
 
 
 
- What recommendations in the guidelines were you implementing and using? 
 
- Are you aware of the new updated NVPDA guidelines on absolute risk management? If yes, 
what are your thoughts on the guidelines? 
 
- How did you generally access the NVDPA guideline?  Hardcopy, electronically, other doctors, 
meeting, etc? 
 
- How has HealthTracker helped you to use NVDPA guideline?  Or any other guidelines used in 
HealthTracker?   
 
- What knowledge in relation to the NVPDA guideline or any other guidelines have you gained after 
using HealthTracker? 
[3]- For GPs Only 
Knowledge and use of 
absolute risk 
calculation and  
management 
What are your views about 
absolute risk calculation in the 
management of your patients?  
 
 
 
 
 
 
- Have you been using absolute risk calculations to calculate patients estimated risk of heart 
attack or stroke?  If yes, how do you find this useful in managing/treating patients CVD? 
- How did absolute risk score in HealthTracker-CVD facilitate treatment or care of the patient? 
How would you normally treat patients if you did not have access to HealthTracker? 
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How have they changed in your 
prescribing methods as a 
consequence of taking part in 
TORPEDO? 
 
- What are your thoughts on prescribing to high risk patients who do not have established 
disease? 
 
- What are your thoughts on prescribing to low risk patients who may have high BP or 
cholesterol who do not have established disease? 
 
- How do you prescribe to those patients you have co-morbidities? 
 
- How do you handle patients who need blood pressure and/or cholesterol medication and do 
not want to take any medication?  What steps do you take to help them understand their 
condition when they don’t have an visible systoms? 
[5a] 
Support/training  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[5b] 
Prior knowledge and 
skills of electronic 
health technology 
What barriers did you/your 
practice face in taking part in 
the study? In using HT? 
 
 
 
 
 
 
What were the facilitators? 
 
 
 
 
 
 
 
 
Had you used any e-health 
tools, such as SideBar and 
Clinical Audit, Doctor’s Portal, 
before taking part in TORPEDO? 
 
 
 
Software:  
- Were there any issues installing SideBar on your practice staffs’ computers 
o Once SideBar was installed, did you have any issues using HealthTracker-CVD? 
o How did SideBar perform after any updates from PEN Computer systems?  How did the 
update affect you?  
o What types of issues, if any, did you have overall with performance of SideBar and/or 
HealthTracker tool?  
Support Training: 
- Were you provided with enough information and support from study staff to confidently use 
the tool? If not, what do you think you would have wanted to happen? 
- How did the initial training impact your use of the tool? 
- How did you find the support/training from the study team? Who at the health service was 
dedicated to work with the study team, resolving issues, and communicating to software 
provider if needed? 
Prior use of e-health tools: 
- If yes, which tools and how long have you been using them? 
- How long have you been using electronic health records? 
- Do you have knowledge of electronic decision support tools?  If yes, what have you heard 
about EDS tools?  
- How confident are you in general with new computer programs? 
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Have you started using any e-
health tools since then? 
 
 
[6] Workability and 
integration of 
HealthTracker-CVD at 
practice/HS 
What helped you/your practice 
take part in the study? How was 
HealthTracker-CVD integrated 
within your practice/HS?  
Staff at Health Service: 
 
- How do you work with other GPs and staff at your Health Service?  (if applicable) 
 
- What incentives do GPs receive to participate in studies?   
 
- What type of support is given to non-GP staff?  Are there incentives at your health service for 
the staff?  If yes, what types of incentives? 
  
- What was the % of staff turnover in the last year? 
 
- At your health service, do you have regular meetings with team?  If yes, what is discussed at 
these meetings? 
Resources:  
- Did you have competing work demands and time constraints while participating in the study?  
If yes, how did you handle competing work demands and time constraints? 
- What type of financial support do you receive at your health service, if any?  
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- Do you have any external management groups involved at your health service? 
- How would you describe your financial stability at your health service?   
 
Involvement of programs to improve health services: 
 
- What types of continuous quality improvement programs is your health service involved in?   
- What are your thoughts on continuous quality improvement programs? 
- If you have not been involved in continuous quality improvement programs, would you be 
interested in participating?  How do you think this will impact your health service?  What 
types of incentives would encourage you to participate in CQI programs? 
 
[7] 
General Impact of the 
Study on the health 
service? 
 
To understand how the 
study integrated into 
everyday practice 
In what ways do you think the 
ACCHS/general practice (in 
which you work) has changed 
as a result of participating in the 
study? 
- What was the impact on you and your health service in choosing to be a part of this study?   
- Were there any benefits to you and your health service of participating in the study?  If so 
please explain? 
- Were there any problems with you and your health service in participating in the study?  If so 
please explain? 
- What impact did HealthTracker have on the consultation process? 
- How did it impact on the length of the consultation?   
[8]-For GPs Only 
 
Motivation to 
participate 
 
What were your reasons for 
taking part in the TORPEDO 
study? 
- Were there any benefits to you and your practice in participating in the study?  If so, explain? 
- Do you think you would take part in a similar study in future? 
- What factors would make you more likely to take part? 
- What factors would make you less likely to take part? 
[9]-For GPs Only 
 
Attitudes to e-health 
E-health is becoming a major 
government priority.   
 
 
- What are your thoughts on electronic decision support tools as best practice use in primary 
health care? 
- What types of resources, support, and training do you think would be needed to change 
primary health care to use more e-health tools? 
- What advice would you give to government on implementation of HealthTracker-CVD in 
primary health care? 
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[9] 
Final comments 
- Is there anything else you would like to add that we have not discussed in this interview? 
 
Note: Some questions in the guidelines will be modified in response to participant’s answers and themes emerging from the data. 
 
 
Thank you for your participation. 
Notes: 
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Chapter 6: Ethnographic evaluation of how the 
intervention was used in practice, how 
cardiovascular risk communicated and 
perceived by patients and healthcare 
providers 
6.1 Chapter overview 
This chapter contributes to real-world context of how and when the intervention was 
used by the doctor and how patients perceived it. This chapter consists of a single 
published book chapter titled: ‘It’s just statistics … I’m kind of a glass half-full sort of 
guy’: The Challenge of Differing Doctor-Patient Perspectives in the Context of 
Electronically Mediated Cardiovascular Risk. 
Successful dissemination of the intervention in a real-world context requires 
understanding of how it is used in practice. How is the intervention deployed 
strategically in doctor-patient interaction to communicate cardiovascular risk? What 
are the factors that support or hinder its impact? Taking a case study approach that 
combines fine-grained discourse analysis of video-recorded consultations in which 
cardiovascular disease risk is discussed with insights derived from interviews with 
participants, this research examines consultations use and non-use of the 
intervention.   
The findings suggest a step-wise, strategic and cumulative use of the intervention as 
valuable entry point for engaging patients in discussion of their CVD risk. The 
discourse analysis reveals doctor’s commitment to addressing risk relies upon 
interpersonal engagement between doctor and patient as well as cognitive 
engagement with the topic of risk. 
6.2 Book chapter details 
O’Grady C., Patel B., Candlin S., Candlin C.N., Peiris D., Usherwood T. (2016) ‘It’s 
just statistics … I’m kind of a glass half-full sort of guy’: The Challenge of Differing 
192 
Doctor-Patient Perspectives in the Context of Electronically Mediated Cardiovascular 
Risk Management. In: Crichton J., Candlin C.N., Firkins A.S. (eds) Communicating 
Risk. Communicating in Professions and Organizations. Palgrave Macmillan, London. 
https://doi.org/10.1057/9781137478788_17 
6.3 Author contributions 
BP developed the methodology for the video ethnography, conducted the video 
recording of all consultations, and conducted the patient and doctor interviews. CO, 
CNC and SC designed the discourse analysis and BP, DP and TU provided detailed 
insights into the overall study and the health service context for each video. All 
authors contributed to the design of the discourse analysis of the video recordings 
and interpretation of the findings. CO wrote the initial draft of the manuscript in close 
consultation with BP. All authors contributed to the final draft. 
6.4 Book chapter  
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‘It’s just statistics ... I’m kind 
of a glass half-full sort of guy’: 
The Challenge of Differing 
Doctor-Patient Perspectives in the 
Context of Electronically Mediated 
Cardiovascular Risk Management
Catherine O’Grady, Bindu Patel, Sally Candlin, Christopher 
N. Candlin, David Peiris and Tim Usherwood
Introduction
Best practice guidelines for the prevention and management of cardio-
vascular disease recommend that management decisions be informed 
by estimation of a patient’s ‘absolute risk’ of a cardiovascular event 
over time. Such a risk calculation is based on a combination of non-
modifiable factors such as age and gender and modifiable factors that 
include blood pressure, lipids, diabetes, body mass index (BMI), tobacco 
smoking, alcohol use, unhealthy diet, physical inactivity, and psycho-
social stress.
In Australia, a quality improvement intervention has been devel-
oped to assist general practitioners to calculate an individual’s ‘abso-
lute risk’ at the point of care and to engage the patient in considering 
factors that might modify this risk (Peiris et al., 2009). Integrated 
with the healthcare provider’s electronic health record, the interven-
tion, known as ‘HealthTracker’, includes a real-time decision support 
interface using an algorithm derived from evidence-based guidelines, 
a patient risk communication tool including ‘what if’ scenarios to 
show benefits from risk factor improvement, as well as mechanisms 
for provider audit and feedback. Robust, trial-based evaluation of this 
electronic intervention indicates that its use is associated with a 25% 
relative improvement in cardiovascular risk factor screening (Peiris et 
al., 2015).
J. Crichton et al. (eds.), Communicating Risk
© The Editor(s) 2016
286 Catherine O’Grady, et al.
Successful dissemination of the intervention in a post-trial context 
requires understanding of how it is used in practice. How is the inter-
vention deployed strategically in doctor-patient interaction to com-
municate cardiovascular risk? What are the factors that support or 
hinder its impact?
In this chapter we focus on a single case study drawn from a com-
prehensive post-trial evaluation of the intervention (Patel et al., 2014) 
to offer a response to these questions. Taking an interactional socio-lin-
guistic approach (Gumperz, 1999; Roberts & Sarangi, 2005), we combine 
fine-grained analysis of the discourse of a transcribed, video-recorded 
primary care consultation in which the intervention is used with ethno-
graphic interviews that bring the perspective of the participating patient 
and doctor to bear on our analysis.
Findings indicate the potential of the intervention as a valuable entry 
point for engaging a patient in discussion of their CVD risk. Discourse 
analysis brings to light the doctor’s role as mediator between risk 
knowledge made available by HealthTracker and the patient. It uncov-
ers the doctor’s strategic, step wise deployment of HealthTracker as a 
means to focus the patient’s attention on the cumulating factors that 
contribute to his overall risk. In particular, analysis reveals the doctor’s 
skilled use of tool outputs that display risk calculations and estimations 
of heart age for the patient in graphic numerical and visual formula-
tions. Yet, as Alaszewski (2010, p. 104) points out ‘Individuals are not 
passive recipients of [risk] information …’. Ethnographic findings from 
a post-consultation interview with the patient reveal how he reframes 
and reformulates the HealthTracker risk calculations in light of his own 
experience and perspective to dilute their significance.
It appears that the value of risk calculations is not fixed and immuta-
ble but subject to differing interpretations informed by different values 
and perspectives (Sarangi & Candlin, 2003). Risk communication that 
emphasises the one-way flow of knowledge from doctor to patient 
albeit enhanced by HealthTracker cannot take such different perspec-
tives into account. Effective risk talk and the effective deployment of 
HealthTracker may rely upon the negotiation of disparate participant 
values and experiences by way of collaborative, co-constructed doctor-
patient interaction.
The computer in the consultation
By examining an instance of electronically mediated risk communica-
tion our case study is also illustrative of the worldwide phenomenon 
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of the computer in the primary care consultation. In Australia 
computerisation in general practice is all but complete with 93% of 
doctors using a computer on their desks for a range of functions includ-
ing decision support (Pearce, Dwan, Arnold, Phillips, & Trumble, 2009). 
In the UK computerisation of the clinical encounter has long been in 
progress and the electronic patient record is now used pervasively 
in general practice to support patient care (Swingelhurst, Roberts, & 
Greenhalgh, 2011).
The presence of the computer in the general practice consultation has 
changed the nature of doctor-patient interaction placing new demands 
on the communicative expertise of doctors. The computer’s presence 
introduces a potential third party into the previous dyadic relationship 
of doctor and patient opening the way for a variety of complex rela-
tional configurations and reconfigurations that would not otherwise 
have been possible. For example, within the newly configured ‘par-
ticipation framework’ (Goffman, 1981) of doctor, patient and computer 
the doctor may act to position the computer as a ‘bystander’ (Goffman, 
1981) to the interaction as he or she engages with the patient. 
Alternatively, prompted by the computer the doctor may side-line the 
patient to interact with the screen. The presence of the computer also 
provides the patient with the opportunity to disengage from what is 
going on as doctor and computer interact. Yet the triadic participation 
structure that the computer affords is of itself neither advantageous nor 
disadvantageous to the interpersonal relationship between doctor and 
patient nor to the purposeful trajectory of a consultation. The computer 
is an inanimate actor in the consultation. Whilst not devoid of influ-
ence it is a neutral tool that is brought into the interaction and enabled 
to play its part largely by the strategic work of the doctor but potentially 
by the actions of the patient as well. ‘Integrating technology … always 
requires human work to re-contextualise knowledge for different uses 
within complex social settings’ (Greenhalgh et al., 2009 in Swingelhurst 
et al., 2011, p. 4).
In our case study we bring to light the discursive work that the doctor 
does as he strives to integrate HelathTracker purposefully and strategi-
cally into the consultation so as to persuade the patient of his CVD 
risk. We then go on to look beyond the immediate context of the con-
sultation to the patient’s social setting so as to access those life-world 
perceptions, values and attitudes that shape the patient’s response to 
risk. Finally, in light of insights derived from analysis of the discourse 
of the consultation as well as from our ethnographic interview with 
the patient, we consider the nature of communicative expertise that is 
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required for the effective integration of tools such as HealthTracker into 
the clinical encounter.
The case study
Clinical context
The patient is a 66 year-old-man who has been taking medication for 
high blood pressure for 40 years. He has been seeing the participating 
GP for two years. He is visiting the doctor today for a blood pressure 
check following change of medication and for comprehensive blood 
tests including a fasting blood sugar test following a previous high 
blood sugar reading.
The computer as participant
Throughout the consultation the doctor is seated in a swivel chair that 
allows for easy shifts in body orientation and gaze between the patient 
in person and ‘the patient inscribed’ (Robinson, 1998) in records and 
data on the computer screen. The patient is seated at the end of the desk 
and to one side of the computer. His line of vision towards the screen is 
unimpeded. This configuration allows for potential triadic engagement 
between doctor, patient and HealthTracker. Tracker is a mutually avail-
able information resource.
Space however is more complex than physical layout or physical envi-
ronment. Space is socially constructed and participants in interaction 
‘do’ or ‘enact’ space through their relationships with each other, with 
objects and with what is going on at a particular moment (Jones, 2010). 
Through the meanings they assign to various tools introduced into the 
consultation space such as blood pressure monitor, computer screen or 
HealthTracker, doctor and patient create and circumscribe a ‘sphere of 
attention’ (Jones, 2010). This sphere of attention may expand or con-
tract or otherwise diversify as they shift their orientation to objects to 
each other and to what it is that is going on.
Thus, for a time in this consultation the doctor enacts a ‘participa-
tion framework’ (Goffman, 1981) or ‘relational space’ (Jones, 2010) 
that sidelines the computer screen as he engages exclusively with the 
patient. At other times his sphere of attention narrows to exclude the 
patient or expands to encompass patient and HealthTracker so that all 
are potential participants in the interaction. The patient too is engaged 
in these shifting reconfigurations of space that display his engagement 
or disengagement with HealthTracker and with the talk of risk that is 
going on.
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Doctor as mediator
As the consultation gets under way, the patient raises concern about 
symptoms associated with withdrawal from a longstanding migraine 
medication. Once the doctor has reassured the patient about this mat-
ter, he turns to the tasks of taking the patient’s blood pressure and 
extracting blood. We pick up the interaction from this point, focusing 
on three ‘critical moments’ (Candlin, 1987) to trace a risk talk trajec-
tory that culminates in the deployment of HealthTracker to provide the 
patient with visual formulations of his absolute CVD risk and heart age. 
In this way we bring to light the doctor’s discursive responses to the 
challenge of mediating between HealthTracker and the patient.
Consultation extract 1: Introducing risk factors
Talk Action Screen 
information
23 D Let’s see D swivels chair to face desk 
drawers at patient’s side
P’s electronic 
health record 
open on screen
23 I guess because the sugar 
was a bit high there’s a 
very high chance that 
you might have diabetes 
so that’s why the three 
sugar tests today yeah :
Takes tools for extracting 
blood from drawer as speaks 
24 P Yep
25 D (inaudible) Puts tools on desk; places 
hands on knees. Directs 
gaze towards Blood 
Pressure monitor but legs 
and torso are oriented to P
D One fifty five seventy 
six so that’s a bit high
26 P ((nods)) P looks into middle 
distance; Barely perceptible 
nod
27 D What have we got you 
on at the moment (.) 
we’ve got the ten one 
sixty yeah 
D turns head to glance at 
screen; legs, torso remain 
oriented towards P as fits 
tourniquet 
28 P I don’t know what the 
dosage is 
(continued)
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29 D I only give you two 
packs last time yeah :
30 P Yeah two packs
31 D ( might have to go) to the 
higher strength one yeah 
What I’m going to do 
today (.) is using one of 
the software called health 
Tracker (.) have a look at 
your cardiovascular risk 
factors yeah :
D swabs arm of P in 
preparation for extracting 
blood
32 P Yeah
33 D Because looks like you’re 
probably at a high risk 
anyway
D prepares syringe; P with 
head raised directs gaze 
towards middle distance; 
arm extended awaiting 
insertion of needle
D … blood pressure’s a 
bit high you’re being 
overweight and let’s see 
sugar being a bit high 
yeah
D continues to prepare 
syringe. P shifts body very 
slightly away from D and 
raises eyes towards ceiling
Throughout this sequence the computer is open on the desk display-
ing the patient’s electronic health record. Whilst the doctor glances 
momentarily towards the screen (27) to check the dosage of the patient’s 
blood pressure medication his legs and torso remain directed towards 
the patient, communicating that his primary orientation is to the 
patient and the tasks at hand. The computer that houses HealthTracker 
remains largely outside his sphere of attention. It is positioned as a 
‘bystander’ (Goffman, 1981) to the interaction that is going on.
Yet CVD risk and the potential for usefully deploying HealthTracker 
in this consultation are clearly on the doctor’s mind as the following 
extract from his post-consultation interview confirms.
… I was thinking I’d done the blood pressure, I was about to take the 
blood and I may be thinking about ‘Hey you know this fellow you know 
you can see he’s obese, he’s got blood pressure and his sugars so there 
you go he’s the cardiovascular risk guy (.) maybe we can use the Tracker.
From turn 23 the doctor works to bring the topic of risk factors into the 
discourse of the consultation. As he goes about the task of preparing to 
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extract blood, he simultaneously uses the strategy of ‘thinking aloud’ 
(Dowell, Stubbe, Scott-Dowell, Macdonald, & Dew, 2013) to share his 
reasoning about the likelihood that the patient has diabetes (23), and 
to refer to the elevated blood pressure reading (25) that might neces-
sitate an increase in medication. Against the backdrop of these cumu-
lating risk factors, he refers to HealthTracker as a tool for examining 
the patient’s level of risk (31), bringing the sequence to a close with a 
summarising statement of known factors that already place the patient 
in the high risk category (33).
However this risk talk has no observable effect on the patient. Whilst 
he acknowledges the likelihood of a diagnosis of diabetes with an 
immediate and unqualified ‘yep’ (24), his responses to the doctor’s 
utterances are otherwise minimal. At turn 26 he receives news of his 
elevated blood pressure reading with a barely perceptible nod. Further, 
across this sequence he directs his gaze into the middle distance as if to 
create a private interactional space that enables him to disengage from 
the interaction.
This apparent disengagement from talk of risk might be accounted for 
by the patient’s discomfort with the process of having blood taken. As 
Heath (2006) has shown, patients almost invariably maintain a ‘middle 
distance orientation’ whilst subject to clinical procedures as a means 
to detach themselves from what is going on. Talk at such moments of 
detachment is unlikely to have impact as the following extract from the 
patient’s interview suggests:
Interviewer:  … and how did you feel when he said that you’re prob-
ably high risk
Patient: Oh
Interviewer: Have you been have you heard that before
Patient:  I don’t remember him even saying that. I think when 
you’re facing a needle in the eye, you know (.) you tend 
not to tend (laughs) I’m more worried about getting 
jabbed in the arm than (.) you know
But it also appears that the patient is somewhat immured against risk 
talk. He goes on to explain that he constantly hears about his risk. The 
likelihood that he is at high risk is not news to him.
Patient:  I mean I hear things like high risk all the time you 
know. Waking up in the morning’s always a positive 
thing for me.
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For the discourse analyst the patient’s apparent disengagement from 
interaction as the doctor talks of risk represents a moment of uncer-
tainty where the patient is difficult to read. Can his disengagement be 
accounted for by his need to detach himself from the process of hav-
ing blood extracted as Heath (2006) would suggest? Or is he indeed 
hardened against risk talk and taking a fatalistic stance as ethnography 
implies?
Similarly, the patient’s action at this particular moment may pre-
sent a problem of interpretation for the participating doctor. What is 
the patient thinking? How can the doctor raise the stakes so that the 
patient is more likely to engage with the matter of risk? Will bringing 
HealthTracker into the interaction have some impact?
Deploying HealthTracker
As the consultation proceeds, the doctor turns his attention to 
HealthTracker as a means to involve the patient with the matter of risk. 
Following a number of turns in which the doctor completes the task 
of extracting the patient’s blood, revisits the need for a urine test and 
provides the patient with a sugar drink in preparation for his upcom-
ing blood sugar test, he initiates an interactional sequence in which, 
prompted by HealthTracker, he gathers data that the Tracker will use to 
update and modify the patient’s risk profile.
Consultation extract 2: Gathering risk data
Up until this point in the consultation the computer that houses 
HealthTracker has been sidelined from a ‘participation framework’ 
(Goffman, 1981) encompassing doctor and patient only. But now 
the doctor moves to reconfigure this framework so as to bring 
HealthTracker into the interaction as an active and ‘ratified participant’ 
(Goffman, 1981).
Talk Action Screen 
information
57 D And while you’re 
doing that (inaudible) 
might use this software 
to have a look at your 
cardiovascular risk
D swivels chair towards 
computer; directs gaze to 
computer screen P turns head 
slightly towards screen; sugar 
drink in hand
Tracker is 
sitting on right 
hand side of 
screen awaiting 
activation
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We use the Health 
Tracker which is on 
trial with the university 
under the torpedo study 
(…) when you (.)finish 
off that drink first
D turns head briefly towards 
P then returns gaze to screen
58 P ((nods)) P nods; continues drinking 
from bottle; D attends to 
screen tracing screen prompts 
with left index finger
P directs gaze to middle 
distance
59 D Does anyone in your 
family have a very 
high cholesterol level?
D’s index finger on screen. D 
turns head to address patient 
then back to screen
Tracker 
prompts 
60 P Cholesterol not that 
I’m aware[ of
P continues to drink; gaze 
directed at middle distance
61 D  [not that you’re aware 
of ok
62 P I mean I’ve got members 
of my family that have 
got heaps of other 
problems but not that 
I’m aware of cholesterol
P sustain gaze at middle 
distance
63 D Right ok and none of 
your family is probably 
(inaudible) forty five or 
fifty five with heart attack 
(.) coronary heart disease
D gazes to screen Tracker prompts
64 P My father died at fifty 
seven
D directs gaze towards P then 
back to screen
65 D Fifty seven
66 P With heart attack P places empty bottle on desk
67 D First degree; did he 
have a lot of chest pain 
before :
D sustains gaze on screen as P 
responds to questions
68 P Yeah always had chest 
pain
P redirects gaze to middle 
distance as he answers questions
69 D For a few years before 
that=
70 P =yep P sustains gaze at middle 
distance
71 D So that’s probably early 
coronary [heart disease
D looks at screen
(continued)
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72 P [Yep coronary that’s 
what he had
P raises head slightly as gazes 
to middle distance
73 D Younger than sixty yeah
74 P Yep=
75 D = so that’s your father=
76 P =yep
77 D So that’s a tick for that Swivels chair to face patient. 
Takes tape measure from 
drawer
Tracker prompts 
D to check BMI 
and waist
At turn 57 the doctor swivels his chair towards the computer, commu-
nicating a shift in his dominant physical orientation from the patient 
to the screen. In this way he signals the inclusion of HealthTracker as 
an active participant in the interaction. In the same turn the doctor 
works strategically to ratify HealthTracker, that is to invest it with the 
authority to act as a bona fide participant in risk talk. By deploying the 
inclusive institutional pronoun form ‘we’ he invokes an ‘institutional 
identity’ (Sarangi & Roberts, 1999) to speak as a member of the insti-
tution of general practice rather than as an individual. In this way he 
invests use of HealthTracker with institutional authority. In the same 
utterance, HealthTracker is further endorsed with reference to the uni-
versity study of which it is a part.
At turn 58, the patient acknowledges this endorsement of HealthTracker 
with a nod. Then, as the doctor attends to the screen, tracing the Tracker 
checklist with his index finger, the patient redirects his gaze into the middle 
distance, a position that is sustained across the entire sequence. However, 
this shift in gaze does not appear to signify the patient’s disengagement 
from the interaction or from the activity of risk information gathering 
that is going on. As Greatbatch (2006) points out the diverting of gaze by 
a patient whilst the doctor is engaged with computer related tasks can be 
seen as a means to reduce the interactional demands on the doctor. Here 
the patient’s sustained middle distance gaze functions to free the doctor 
to attend to the prompts and checklist questions as they appear on the 
HealthTracker screen. Yet, despite their physical misalignment doctor and 
patient continue to occupy the same ‘relational space’ (Jones, 2010). As the 
doctor orients to the screen and the patient looks into the distance they 
engage with each other and with HealthTracker as they go about the task 
of co-constructing the risk information that Tracker requires.
From turn 59, prompted by HealthTracker the doctor initiates a 
question answer sequence to explore risk factors associated with the 
patient’s family history including high cholesterol level (59) and early 
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age heart attack (63). At turn 64 the patient states that his father died 
at 57. This prompts the doctor to redirect his gaze momentarily from 
screen to patient in an action that displays that this news is of sig-
nificance to him. Then, across ensuing turns he pursues confirmation 
of this newly disclosed risk information with reiterated confirmation 
checks (65, 67, 69, 71, 73, 75) to ascertain that a family history of early 
coronary disease involving a first degree relative is indeed a risk fac-
tor for his patient. The patient’s latched and overlapping responses to 
the doctor’s confirmation checks (70, 72, 75) indicate his involvement 
in the interaction and with the risk factor topic. At this point in the 
consultation he is engaged in the collaborative task of building his risk 
profile. HealthTracker’s diagnostic prompting, mediated by the doctor 
has enabled a collaborative conversation in which doctor and patient 
are mutually involved with factors that may place the latter at high risk.
In the moments that follow, and prompted by HealthTracker the doctor 
weighs the patient so as to calculate his body mass index (BMI) and meas-
ures his waist circumference. Doctor and patient then resume their seats 
as the doctor enters new and updated risk factor data into the computer 
so that HealthTracker might calculate the patient’s absolute CVD risk.
Mobilising HealthTracker to communicate risk
The stage is now set to mobilise HealthTracker to the task of engaging 
the patient in recognising his current level of absolute risk as well as his 
risk projections.
As the consultation proceeds the doctor draws upon the combined multi-
modal resources of wording, gesture, gaze, pausing and silence as he works 
to deploy HealthTracker calculations and semiotic tools in a way that might 
impact on the patient. His communicative expertise in mediating between 
HealthTracker risk information and the patient is now on display.
Consultation extract 3: Mobilising HealthTracker
Talk Action Screen 
information
85 D So let’s go back and 
have a look at this
D indicates data on screen with 
left hand. P shifts torso slightly 
and turns head to direct gaze 
to screen. Arms unfold and 
then fold again as he leans a 
little closer towards screen
Tracker open 
on screen 
(continued)
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D Ahh cardiovascular risk 
profile I need to add 
on your family history 
because that hasn’t (.) 
before sixty yeah (…) 
and we haven’t got your 
urine yet so when we 
check that yeah 
D inputs data Tracker 
calculates
D So looking at that 
you’re (…) just refresh 
that (inaudible) 
D presses key to refresh screen
86 D Your risk is sitting at 
about nineteen to twenty 
percent at the moment 
yeah 
Indicates data on screen with 
left hand; turns head towards 
patient
Tracker 
calculation on 
screen
87 P Ok P sustains gaze on screen
88 D In terms of getting a 
heart attack over the 
next five years (pause)
P nods
89 D Or a stroke (pause) D keeps index finger on data; 
sustains focused gaze on 
patient’s face
P slow repeated nods
90 D Twenty percent is about 
one in five (pause)
Sustains gaze towards patient’s 
face. Left hand closes but 
remains at screen. P sustains 
gaze on screen. Nods; slight eye 
brow rise
91 D So that’s (.) if you look 
at the colour you’re in 
the red zone
D’s hand moves across screen 
to indicate relationship 
between data and visual on 
screen. D looks to P and then 
to screen
P gazes at screen
Tracker risk 
projection 
visual on 
screen
92 P (nods)
93 D Now this is (.) not adding 
on the diabetes here.
If you are having 
diabetes jump to twenty 
five percent easily I 
would think
Indicates screen with finger
Directs gaze towards patient’s 
face
And this is a little 
picture we can show 
you (.) your heart which 
is here 
Indicates patient’s projection 
on graph with left hand
P sustains gaze l towards screen
Heart age 
graph on 
screen
(continued)
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compared with the 
general population(..) at 
your age
Slides finger across screen 
to indicate line for general 
population
94 P mm
95 D So your heart is about 
(…) seventy five years old 
(.) even though you’re 
only sixty five
Directs gaze towards patient’s 
face then back to screen then 
back to patient. Finger remains 
on screen
96 P Yeah ↑ P looks at screen
97 D =Yeah this is taking all 
these [risk factors that we 
collected into[ account
98 P  [Yeah yeah
99 D Your smoking history 
your blood pressure and 
of course we haven’t got 
the urine we haven’t 
got the (.) I’m just going 
to save this (.) haven’t 
got the urine results yet 
(inaudible) I’ll see if I 
can print one out for 
you to look at yeah (.) 
I’ll just print the picture 
instead (inaudible) 
cardiovascular 
projection
P gazes at screen
D So this is give you an 
idea about where you 
are at yeah :
Runs finger over screen
P looks to screen
D What we need to 
monitor you here yeah :
Runs finger over screen
P continues to gaze at screen
At turn 85, using his left hand to draw attention to the screen, 
the doctor employs the inclusive form ‘Let’s’ to invite the patient to 
join him in examining the HealthTracker outputs. In response the 
patient reorients to the screen, shifting his torso slightly towards 
the computer, redirecting his gaze and leaning forward to display 
his attention. At the same time he unfolds and refolds his arms in a 
move that suggests he is settling in to take in the information that 
HealthTracker is about to offer. Doctor and patient are mutually 
engaged with Tracker.
Then, as the HealthTracker calculation appears on the screen, the 
doctor turns his head towards the patient, representing the calculation 
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verbally to state that the patient has a 19–20% chance of having a heart 
attack or stroke over the next five years. By way of strategic pausing he 
fragments this statement into a series of discrete utterances that draw 
attention to each aspect of the message (86, 88, 89). Whilst the patient’s 
responses are largely minimal, including the minimal acknowledge-
ment token ‘OK’ and a single slight nod, the slow repeated nods (89) 
with which he receipts news of possible stroke suggest that he is not 
simply attending but absorbing and considering this information.
In the next turn (90) the doctor moves to intensify the patient’s 
engagement by reformulating the HealthTracker calculation of a 20% 
risk as a one in five chance. This reframing of the patient’s risk projec-
tion in more accessible terms is accompanied by the doctor’s sustained 
gaze towards the patient’s face. Gaze direction together with a further 
strategically placed pause invests the doctor’s risk reformulation with 
added importance. The patient’s raised eyebrow response (90) signifies 
that it has had some effect.
In light of these signs of the patient’s receptiveness, the doctor 
acts to mobilise the semiotic formulations of the patient’s risk that 
HealthTracker affords. At turn 91 he directs the patient’s attention to 
the visual representation of his risk projection that places him in the 
high risk red zone. Then, as the patient nods, gaze fixed on the screen 
the doctor redirects his own gaze from patient to screen and back to the 
patient. As his gaze settles on the patient’s face in a way that intensifies 
his message, he states that if the patient has diabetes his risk will jump 
to 25% (93). Whilst the patient continues to gaze at the screen, he offers 
no verbal or visual response.
In a final move the doctor mobilises HealthTracker’s visual represen-
tation of the patient’s heart age in relation to the general population. 
Once again he strategically deploys gesture, gaze direction, and verbal 
reformulation to strengthen the effect of HealthTracker’s message. As 
turn 93 continues he uses his index finger to trace the heart age projec-
tions on the screen so as to highlight the contrast between the patient’s 
projection and that for the general population. The patient attends 
but responds with a minimal ‘mm’. Finally (95) as the doctor redirects 
his gaze from patient to screen and then back to the patient in order 
to emphasise his message, he brings his deployment of HealthTracker 
towards its completion with an upshot that summarises what this risk 
information means:
So your heart is about (…) seventy five years old (.) even though you’re 
only sixty five.
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This simply formulated upshot appears to have considerable impact on 
the patient. The patient’s response ‘yeah’ (96), marked by a sharp rise in 
tone constitutes a relatively strong ‘news receipt’ (Heritage, 1984) that 
displays recognition of the significance of this news.
As the consultation draws to its close it seems that doctor and patient 
are in alignment with each other in their mutual understanding of the 
significance of the patient’s high CVD risk status. Such apparent mutu-
ality is the foundation upon which doctor and patient might go on to 
make shared decisions about how the patient’s risk is to be managed.
But as Candlin points out (2002, p. 25) ‘… mutual understanding 
is always a shifting and temporary matter’ and mutual agreement 
is ‘… an unstable state of becoming’. Alignment with the medical 
perspective during a consultation cannot be taken as evidence of 
on-going concordance. Behind the risk calculations and projections 
communicated to this patient in the context of the consultation lies 
his life-world accessed through ethnography. As finding from the 
post-consultation interview with the patient suggest, the meaning and 
value of risk calculations are not fixed and immutable but subject to 
reinterpretation by the patient in light of his values, attitudes, and 
life-world perceptions.
The patient’s perspective
To what extent has HealthTracker generated knowledge of the patient’s 
absolute cardiovascular risk been made tractable for the patient by the 
actions of the doctor? What value does the patient bring to this knowl-
edge? What is its importance to him?
During the interview conducted with the patient in the days follow-
ing his consultation he consistently reframes HealthTracker calculations 
and projections in ways that dilute their significance. For example, 
when asked to comment on the projection of a one in four chance of 
having a heart attack or stroke in the next five years he takes a positive 
stance to reformulate this calculation as a three in four chance that he 
will not experience such an event.
… I’m not a gambling person, but I know statistics reasonably well, 
and I know that, you know, okay, you’ve got one chance in four, 
but that means you’ve also got three chances in four that you’re not 
going to get it, so the odds are, you know, statistically, you’re alright 
(laughs) you know, so you’ve got more chances of not having a 
heart attack or a stroke than you have.
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For the patient the upshot of this statistical information is that his 
chance of not having a cardiovascular event far outweighs the chance 
that he will. In a similar way, he takes the HealthTracker calculation of 
his heart age that seemed to have considerable impact during the con-
sultation and reframes it in a positive light.
… you know I’ve only got a heart of a 75yearold and not a 95-year-
old. I’m kind of a glass half-full sort of a guy, you know.
Clearly, this patient is not a passive recipient of risk information. 
Whilst he does not refute the risk calculations and projections that have 
been presented to him, the meaning that he invests in them is at odds 
with the medical perspective. Patient and doctor frame risk knowledge 
in different ways to give risk calculations different valence and such 
disparate perspectives are likely to affect the patient’s commitment to 
management advice as the following interview extract suggests:
… it’s no good saying we’ll change your lifestyle … I’m 66 years old … 
I have a lifestyle, you know. I’m not an alcoholic (.) I don’t over-drink (.) 
I don’t you know I don’t overeat. I’m just, just a big bloke. … Look, 
I didn’t walk out of there thinking, oh, I’m only going to eat salad and, 
you know, drink water for the rest of my life.
HealthTracker has afforded the patient the opportunity to consider 
those statistical calculations and projections that are indicative of his 
CVD risk. But it appears that contemplation of health risk as repre-
sented in statistical terms may not lead easily in a linear fashion to 
mutual management decisions or to determination to take action to 
reduce that risk. Whilst the patient appeared to defer to the authority of 
HealthTracker during the consultation, in the post-consultation period 
his life-world perceptions intervene and the impact of risk knowledge 
begins to decay.
Concluding comment
In this case study, discourse analysis has brought to light the doc-
tor’s skilled use of language and other semiotic means to mobilise 
HealthTracker to the task of informing the patient about his absolute 
CVD risk. Yet, as ethnographic accounts have shown, HealthTracker risk 
information mediated by the doctor has not been sufficient to engage 
the patient in acknowledging and acting upon his high risk status. Risk 
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is not absolute but subject to different interpretations and the impact 
of risk knowledge on the patient is tempered by his own perceptions.
What then is the nature of communicative expertise required for the 
effective deployment of tools such as HealthTracker? The participating 
doctor in this case study adheres largely to a ‘rational model of risk com-
munication’ (Alaszewski, 2010, p. 103) that characterises risk commu-
nication as the flow of risk knowledge from the knowledgeable expert, 
in this case HealthTracker mediated by the doctor, to the less informed 
patient. But such a one-way flow of information does not allow for the 
patient’s perspective to enter the discourse of the consultation.
The effective communication of risk may require that tools such as 
HealthTracker be integrated into collaborative co-constructed interac-
tion whereby the patient’s perceptions and accounts can be accessed, 
discussed, and negotiated.
As Candlin and Candlin state (2002, p. 103) ‘Expertise in the manage-
ment of risk is not solely – or even primarily – a matter of knowledge but 
of discursive negotiation among participants’ values and experiences’.
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Appendix
Table A17.1 Transcription conventions
 [ A square bracket indicates the point at which a current speaker’s 
utterance is overlapped by the talk of another.
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= Where the turns of two different speakers are connected by two 
equal signs, this indicates that the second followed the first with 
no discernable silence between them, or was ‘latched’ to it.
(.) A dot in parenthesis indicates a micro-pause that is hearable but 
not measurable.
: : Colons indicate the stretching or prolonging of the sound that 
immediately precedes them. 
Yes: If the letters preceding a colon are underlined, this indicates that 
there is a falling intonation contour; you can hear the pitch turn 
downwards.
Yes: If the colon itself is underlined, this indicates a rising intonation 
contour; you can hear the pitch turn upward.
↑ An arrow indicates a strong fall or rise in pitch in accordance with 
the direction of the arrow.
(( )) Double parenthesis are used to mark descriptions of events e.g. 
((telephone rings)).
(word) Words in parenthesis indicates uncertainty on the transcriber’s 
part but represents a likely possibility. 
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Chapter 7. Modelled cost-effectiveness of a multifaceted 
health information technology delivered 
within an Australian Primary Health 
Networks setting to improve cardiovascular 
disease prevention 
7.1 Chapter overview  
This chapter reports the cost effectiveness of HealthTracker over a 5-year period 
delivered by the Primary Health Networks (PHNs) in the state of New South Wales 
(NSW), Australia.  
7.2 Introduction  
Quality issues plague Australia’s primary healthcare system with large deficiencies in 
guideline recommended care.1 The need for high quality health systems is a major 
focus of the Australian government’s healthcare reform.2 The ultimate goal is to 
improve population health outcomes and address health inequities by providing 
continuous, effective, efficient and accessible care. The establishment of 31 
government-funded PHNs Australia-wide to replace Medicare Locals in July of 2015 
was a major effort of the Australian government’s healthcare reform. PHNs main 
objectives are to improve efficiency and effectiveness through coordination of care 
between the primary healthcare sector and local hospital networks (LHNs).3  
A major role of the PHN is to act as a commissioning agency working closely with 
general practitioners and other primary healthcare services to adopt quality 
improvement (QI) initiatives with the aim of improving care delivery and health 
outcomes while reducing hospital costs.4,5 Booth and Boxall define commissioning as 
“strategic purchasing decisions based on local health needs, priorities and service 
availability and quality” with the main activities being strategic planning, contracting 
services and monitoring and evaluation (figure 7.1).6  PHNs receive funding from the 
Australian Federal government after they have approved the ‘needs assessment and 
service planning’ documents for their local regions. The primary emphasis is on the 
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delivery of high quality, low-cost services through acquiring funding for specific 
programmes from a competitive and limited pool of flexible funding.7  
Figure 7.1: Commissioning elements8 
 
Cardiovascular disease (CVD) is a leading cause of death and disability and one of 
the biggest health problems facing the Australian population and their health systems 
despite improvements in diagnosis and treatments in the last few decades.9,10 
Aboriginal and Torres Strait Islander people experience rates of CVD hospitalisation 
and death that are twice as high compared to other Australians. Healthcare 
expenditure – for hospital services, out-of-hospital medical care and pharmacological 
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agents – resulting from cardiovascular diseases (CVDs) represents a level of 
economic burden that exceeds that of any other disease group in Australia (12% of 
all allocated healthcare expenditure).11,12  One study found, approximately one-fifth of 
the Australian population aged 45-74 years (~1.4 million people) were at high risk of 
developing a CVD event within the next five years.13 A large proportion of these 
events are preventable by interventions that target both the population and 
individuals in assessing and managing absolute CVD risk in primary healthcare 
settings.14  
One of the major barriers to prevention of CVD is lack of evidence-based risk 
assessment and prescribing of recommended preventive medications to the high 
CVD risk population. Australian clinical guidelines recommend that assessment for 
CVD prevention and management should be based on a combination of risk factors 
(the “absolute risk” approach) rather than treating risk factors such as elevated blood 
pressure and cholesterol in isolation.15,16 This enables early identification and 
treatment for primary prevention of CVD for individuals at high risk at the primary 
healthcare level. In combination with well-established secondary prevention 
recommendations for people who have experienced a previous CVD event, the 
absolute risk approach offers an efficient strategy from a population perspective for 
reducing further CVD events (mortality and morbidity) with recommended 
medications.17  
Adherence to clinical guidelines for CVD assessment and management at a primary 
healthcare level is suboptimal. Studies have found that only 50% of adults attending 
Australian primary healthcare are screened for CVD risk factors according to best 
practice, and only 40% of those identified as high risk for CVD are prescribed 
preventive medications optimally consistent with guideline recommendations.18,19 
These studies indicate a large evidence practice gap in CVD management, and the 
inadequacy of current CVD prevention programs in Australia. Therefore, identifying 
cost-effective quality improvement strategies that encourage increased uptake of 
absolute risk management by healthcare providers are warranted in primary 
healthcare settings.  
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The US Community Preventive Services Task Force has demonstrated, through a 
systematic review, sufficient evidence that clinical decisions support systems 
(CDSSs) are effective in improving screening for CVD risk factors, clinical tests, and 
prescribing recommended treatments with larger effects when CDSS is combined 
with other interventions.20-22 However, the results are inconsistent in improving CVD 
risk factors such as systolic and diastolic blood pressure, total and low-density 
lipoprotein (LDL), and haemoglobin A1C levels (HbA1C). This could be a result of 
sparse data collection and insufficient statistical power for clinical outcomes. Still, it is 
hypothesised that multifaceted CDSS preventive strategies could reduce CVD risk 
factors that would in turn reduce morbidity and mortality and increase the quantity 
and quality of years lived. Health information technology (HIT) is being recognised 
worldwide as a key enabler in transforming healthcare systems to control costs and 
improve outcomes.23,24  
The Task Force also conducted a systematic economic review of CDSSs on CVD 
prevention and what drives intervention costs and benefits from published literature.25 
Three US-based studies performed long term cost-effectiveness analysis of 
randomised controlled trials of CDSS interventions to improve diabetes care through 
improvements in clinical risk factors. The multifaceted interventions included the 
provision of personalised management recommendations in primary healthcare 
settings that improved intermediate risk factors, such as HbA1C, systolic blood 
pressure (SBP), and LDL, resulting in modest improvements in long-term health 
outcomes.26-28 Two interventions were considered cost-effective, with incremental 
cost-effectiveness ratios of $16,500 and $49,000 per quality-adjusted life year 
(QALY) saved, whilst another was not cost-effective at $143,000 per quality-adjusted 
life year saved.26-28 Similar time horizons were used for net cost and adjusted life 
years lived, and only one study did not include annual operating cost of the 
intervention.25,26 The interventions that demonstrated cost effectiveness also included 
financial incentives to the physicians in using the CDSS27 and diabetes consultation 
by practice nurse, recall system, and feedback on performance.28 However, the 
variation in value of the interventions could not be fully explained. These studies 
demonstrated potential of the multifaceted nature of the interventions to reduce 
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morbidity and mortality over large populations at relatively low cost,29,30 yet the cost-
effectiveness of CDSS on CVD prevention in an Australian context has been limited.  
To avoid repetition, the details of the intervention, HealthTracker, are presented in 
chapters 3-5. For relevance to this chapter, I present information necessary for the 
cost-effectiveness analysis. The intervention was evaluated in The Treatment of 
Cardiovascular Risk using Electronic Decision Support (TORPEDO) study, a cluster-
randomised controlled trial  in the Australian primary healthcare settings.31 Health 
services with the intervention demonstrated a 25% relative (10% absolute) 
improvement in CVD risk factor screening and a 33% relative (5% absolute) 
improvement in prescribing rates for individuals at high CVD risk who were not 
prescribed optimal recommended medicines at baseline. The study was not 
powered for effects on modifiable risk factor levels, however trials have consistently 
demonstrated that use of blood pressure and blood cholesterol lowering treatments 
lead to a relative risk reduction in both CVD morbidity and mortality.32 The 
intervention aimed at optimising recommended treatments in high CVD risk patients 
who attend primary healthcare.  
The TORPEDO trial did not demonstrate significant improvements in prescribing to 
high CVD risk patients attending those health services that had the provision of 
HealthTracker compared to those that continued with usual care. In the post-hoc trial 
analysis, undertreated high CVD risk patients had a significant increase in prescribing 
in the intervention group as mentioned above. The findings in my previous chapters 
highlight several issues that contributed to this result; in particular the complexity of 
implementation and adoption of the intervention at the organisational, healthcare 
provider/staff and patient levels. With an appropriately implemented intervention, a 
modelled cost-effectiveness analysis will be able to provide the economic viability to 
inform health policy in Australia.   
As I have mentioned in chapter 2, a priority for the Australian government is the 
commitment to investing in implementation of sustainable multifaceted HIT as an 
enabler for transforming healthcare delivery. However, there are limited cost-
effectiveness analyses on large scale trials of HIT to improve CVD outcomes in 
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Australian primary healthcare. The basis of my economic evaluation provides a ‘linear 
approximation’33 on potential impact the intervention can have within a PHN 
population. We examine both the total costs of the intervention and its cost-
effectiveness over a 5-year period, incorporating CVD related morbidity for the high 
CVD risk population. 
7.2 Methods  
Study design and setting 
We conducted a modelled cost-effectiveness analysis of HealthTracker compared 
with usual care from the perspective of the Australian health system for individuals at 
high CVD risk. This perspective was chosen to assess long-term benefits of the 
intervention and the value of implementing the intervention in primary healthcare 
settings via the PHN. This will inform healthcare providers, health services and policy 
makers of the resource allocation and health benefits provided by implementing the 
intervention. 
Definition of high CVD risk 
Based on Australian guidelines, high CVD risk was defined as (1) history of CVD 
(diagnosis of coronary heart disease, cerebrovascular disease, or peripheral vascular 
disease); (2) the presence of any guideline-stipulated clinically high risk conditions 
such as diabetes mellitus and age >60 years, diabetes mellitus and albuminuria, 
stage 3B chronic kidney disease, or extreme individual risk factor elevations: systolic 
BP ≥ 180 mm Hg, diastolic BP ≥ 110 mm Hg, total cholesterol > 7.5 mmol [290 
mg/dL]); or (3) a calculated 5-year CVD risk of >15% based on the Framingham 
equation.16  
Intervention 
In brief, HealthTracker was integrated with healthcare providers’ electronic health 
record (EHR) and used for any regular patients attending the 30 intervention health 
services.  
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Comparator 
The usual care primary healthcare services continued with their usual practice of their 
current systems, including any access to cardiovascular related tools or participation 
in continuous quality improvement programs already implemented as routine patient 
care.  
Health outcomes 
The health outcome of interest was the number of CVD events measured over a 5-
year period. As per current CVD management guidelines,16 the Framingham risk 
equation was used at baseline to predict the number of CVD events over a 5-year 
period for both groups. Changes in 5-year CVD risk were based on reductions in 
intermediate risk factors (LDL-C and SBP) using results from the TORPEDO trial over 
a 17-month period.  
Target population 
The population of interest was the number of high CVD risk individuals within an 
average-sized PHN. The high CVD risk cohort was derived from the TORPEDO trial.31 
In line with CVD prevention guidelines, adults aged 45 years and over (35 years and 
over for Aboriginal and Torres Strait Islanders) were included in the analysis. The 
prevalence of high CVD risk was 20.3% for non-Aboriginal and 6.3% for Aboriginal 
peoples in the TORPEDO population.32 We calculated the mean high CVD risk 
population for all NSW PHNs using the PHN demographic data in 2015.34  
Economic model  
A decision analytic model was developed to estimate the costs and benefits over a 
5-year period. Individuals at high CVD risk, Framingham risk scores, prescribing 
patterns and changes in intermediate risk factors were based on TORPEDO end of 
trial data. We divided high risk individuals into primary (those without a prior CVD 
event) and secondary (those previously experiencing a CVD event) prevention 
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groups. The model ran in annual cycles and costs were discounted using a 3% 
discount rate.35,36 
Efficacy and assumptions 
The model was based on the effect of the intervention on improving prescribing 
patterns in the high CVD risk population compared to usual care at the end of the 
trial (Table 7.2) and applied over five years.  
Baseline CVD risk assumptions   
Baseline 5-year absolute CVD risk was calculated using Framingham risk scores 
based on the mean population characteristics: (1) for the primary prevention group 
the risk was estimated to be 20%, (2) for the secondary prevention group, 5-year 
CVD risk was conservatively estimated to be 30%. Reductions in 5-year absolute 
CVD risk were based on the point estimates of the differences in the change from 
baseline in LDL-C and SBP between the intervention and control groups, stratified by 
primary and secondary CVD prevention categories after a 17-month follow-up period 
in the TORPEDO trial (Table 7.2). Numerous trials and meta-analyses demonstrate 
relative risk reductions in LDL and SBP associated with pharmacological treatment 
leads to a reduction in CVD events and death.37,38 These are described in detail 
below. 
Blood pressure lowering treatment effects 
We used a recent meta-analysis of trials assessing blood pressure lowering 
treatment effects on reduction of total major CVD events or death based on 
individual’s absolute risk.39 For each 5mmHg reduction in SBP, an expected risk 
reduction of 15% was assumed. 
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Lipid lowering treatment effects  
A meta-analysis of randomised trials assessed statin effects on reduction per in 
major vascular events. For each 1.0 mmol/L LDL cholesterol reduction a 22% 
reduction in major vascular events was assumed.40 
Antiplatelet effects 
A meta-analysis of aspirin in primary and secondary prevention found, a 19% risk 
reduction (RR = 0.81) in secondary prevention of any vascular events. This effect size 
was assumed for the evaluation.41  For primary prevention as aspirin is not currently 
routinely recommended in Australian guidelines, we took a conservative approach 
and did not include this in the modelled effects. 
Adherence 
It is well known that patients stop taking recommended medication or take it less 
than prescribed making them nonadherent.42 By focusing on blood pressure and lipid 
levels in the trial at baseline and 17-month follow-up, this in effect takes sub-optimal 
adherence into account. Adherence rates for individuals taking aspirin for secondary 
prevention were based on a large meta-analysis of 376,162 patients from 20 studies 
assessing adherence using prescription refill frequency.43 Based on these data, the 
adherence rate to aspirin was assumed to be 66% for the secondary prevention 
group.   
Costs  
Intervention costs were derived from the TORPEDO trial associated with the 
implementation and maintenance of the tool within general practices and ACCHSs 
and patient level costs (hospitalisation as a result of CVD and prescription of drugs) 
(Table 7.3). The costs of software licenses, implementation and maintenance are 
assumed to be borne by the PHN and were estimated at $500 per health service per 
year. The costs were calculated as long-term average costs of implementation and 
exclude development and research costs. For medication costs, CVD medications 
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were categorised into 3 groups: lipid lowering, blood pressure lowering and 
antiplatelets/anticoagulants. We used the dispensed price for maximum quantity 
(DPMQ) and number of dispensed scripts from the Pharmaceutical Benefits 
Schedule 44 to estimate the annual average weighted cost of each group for the 2015 
calendar year. The estimated hospital costs related to major vascular events were 
based on Australian Institute for Health and Welfare from 2015-2016.45  
Sensitivity analysis  
A series of one-way sensitivity analyses were conducted on: the discount rate (0% 
and 7%); assumptions on the continuing lowering of medication costs as a result of 
the expiration of patent protection on statins (25% and 75% reduction); and the 
lower and upper limits of 95% confidence intervals (CI) for changes in LDL-C 
between the intervention arm compared to usual care for the two high CVD risk 
groups (primary and secondary prevention). Although I had planned to conduct a 
sensitivity analyses using the lower limits of the 95% CIs for SBP, the difference in 
the change from baseline was non-significant and consequently usual care is 
assumed to be dominant under this scenario. 
7.3 Results  
Table 7.1 describes our hypothetical population and different treatment categories 
based on TOPREDO data and assumptions based on literature. We estimated the 
average sized eligible NSW PHN population to be 62,723, with 15,963 (25.4%) and 
15,398 (24.5%) classified as primary and secondary high CVD risk individuals, 
respectively. Optimal medication use was 55.3% and 48.5% in the primary and 
secondary intervention groups, compared to 48.4% and 44.3% in the control groups 
respectively. 
The provision of HealthTracker intervention was hypothesised to increase guide-
recommended prescribing, thereby, reducing LDL-C and SBP levels. The trial results, 
showed a small but significant LDL-C difference in the change from baseline for both 
primary (0.05; 95% CI: 0.00-0.09) and secondary prevention groups (0.05; 95% CI: 
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0.01-0.10) compared to usual care. For SBP the intervention was associated with a 
non-significant difference in the change from baseline (0.12 mmHg; 95% CI: -0.98 to 
1.23) in primary and (1.09 mmHg; 95% CI: -0.03 to 2.21) in secondary prevention 
groups.   
Table 7.4 summarises the results in the base case. It was estimated that 168 major 
CVD events would occur per 1000 persons in the primary prevention population over 
5 years in PHNs using HealthTracker compared to 176 CVD events in those PHNs 
not using the intervention (8 major CVD averted events per 1000 persons). Similarly, 
for the secondary prevention population, it was estimated that 259 major CVD events 
would occur per 1000 persons in the PHNs using HealthTracker intervention 
compared to 267 in those PHNs not using the intervention (8 repeat CVD events 
averted per 1000 persons).  
The costs for medication per person will be more in the intervention group compared 
to the usual care as a result of increased prescribing, however this is partially offset 
by the reduction in hospitalisation costs for both primary and secondary prevention. 
The net healthcare costs per person for those PHNs with the provision of 
HealthTracker intervention was estimated to be $59.25 and $142.11 for the primary 
and secondary prevention groups, respectively. The estimated incremental cost 
effectiveness ratio (ICER) is $7,406 and $17,988 per CVD event averted for the 
primary and secondary prevention groups, respectively.  
The sensitivity analyses are summarised in Table 7.5. One-way sensitivity analysis 
showed ICER to be moderately sensitive to the change in LDL-C using lower limits of 
the 95% CI in the secondary prevention group. This impacted on the number of CVD 
events and subsequently, hospitalisation costs. The ICERs in the primary (ICER, 
$7,610.83) and secondary prevention (ICER, $27,667.72) groups if using the lower 
limit change in LDL-C. An assumed reduction in statin costs due to patent expiration 
of 75% reduced the ICER to $5,104 per CVD event averted in the primary group and 
$14,661 per CVD event averted in the secondary group. 
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7.4 Discussion 
Modelling implementation of HealthTracker within a NSW PHN population indicated 
potential health benefits by preventing major CVD events that could lead to 
improvement in population health at under AU$50,000 per DALY threshold. The 
estimated ICER for HealthTracker was $7,406 and $17,988.16 per CVD event 
averted for the primary and secondary prevention groups, respectively. The findings 
are limited by the following: (1) the TORPEDO trial may not have been adequately 
powered for changes in risk factor levels; and (2) as stated in findings from chapters 
4 to 6, there are several factors at the health service, healthcare provider and patient 
levels that influence implementation processes and adoption of the intervention.  
The effects sizes reported here were small but given the low costs of the intervention 
when scaled to a larger population it does result in a potentially cost-effective 
intervention. Clearly, a more intense effect size could make the case more 
compelling. The TORPEDO trial did not identify significant increases in prescribing to 
the high CVD risk population overall, although there was a significant increase in 
prescribing in the post-trial phase. There are several potential reasons for this 
outcome as stated in previous chapters. Chapter 4 suggests that doctors may be 
cautious in prescribing immediately after assessment of risk. Doctors may opt for 
lifestyle change before commencement, and patient acceptance of taking 
medications may take time. Chapters 5 and 6 reveal the complexity of the primary 
healthcare organisations, implementation processes, the people and risk 
communication in implementing and adopting HealthTracker. The mixed methods 
process evaluation in chapter 5 found a complex interaction between contextual 
factors and implementation processes that produced suboptimal effects of the 
intervention with different factors at play during the trial and those needed to 
influence sustainability of the intervention. The discourse analysis in chapter 6 found 
the use of the intervention as a valuable entry point to discuss CVD risk which 
requires skilled knowledge of the tool and absolute risk by the healthcare provider. 
The impact of effective risk communication on the patient required the healthcare 
provider to understand the patient’s values and experiences in order to 
collaboratively discuss and negotiate CVD management or prevention options. 
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This chapter suggests that there is guarded potential for HealthTracker to be low 
cost and improve CVD outcomes, but this depends on it being implemented 
optimally. The results of this study, along with the findings from Chapters 4, 5 and 6 
suggest that HealthTracker requires a comprehensive assessment of both 
quantitative and qualitative outcomes to enhance several factors in improving optimal 
medication uptake and reducing intermediary CVD risk factors. This will aid in 
allocating appropriate resources for successful implementation of HIT for prevention 
and management of CVD. In Australia, CVD accounts for a substantial share of 
national health expenditures11 which can be drastically reduced with effective HIT 
strategies to prevent and control major risk factors for CVD.46 HIT is being promoted 
around the world as an enhanced model to improve delivery of care and quality while 
reducing health care expenditures.47,48 This has resulted in OECD countries heavily 
investing in HIT,49 however there is paucity in data demonstrating business value 
from these investments.50 There is a significant need to understand the mechanisms 
around how HIT can generate business value.   
The analyses have several limitations. As the perspective was taken from the health 
system, other costs such as lost productivity for individuals due to premature 
morbidity and mortality were not captured. The day to day ‘operating cost’ of the tool 
according to the Community Preventive Services Task Force requires staff time and 
other resources. These costs were not captured due to the complexity and variation 
of health services. However, the intervention could improve care processes and 
possibly reduce resources needed to care for patients once intervention is optimally 
implemented. Finally, the major limitation is the assumption that the observed 
improvements in trial would be sustained over time without any variation. The model 
assumes no changes in adherence and compliance to prescribing in the 5 years after 
the trial period. It is unknown how these assumptions will be maintained into the 
future especially within a complex health system that “is adaptive to changes in its 
local environment, is composed of other complex systems and behaves in a 
nonlinear fashion”.51 
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Conclusions  
The five-year modelling of cost effectiveness demonstrates potential to increase the 
value of HealthTracker if implemented by PHNs optimally. This will result in benefits 
for the broader health system. To further increase the potential cost-effectiveness of 
the intervention, it is important to take into account macro, -meso and -micro health 
system level components that influence adoption and sustainability. Understanding 
the circumstances under which the intervention is or is not cost-effective will be an 
important determinant of efficient resource allocation in the implementation process. 
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Table 7.1 Input variables  
Estimated NSW PHN population  62,723  
High CVD risk (established CVD) – 
medication profile 
HealthTracker-
CVD 
Usual care Reference 
Estimated PHN population  15398 15398 Information sourced 
from the TORPEDO 
trial No treatment 1817 (11.8%) 
2094 (13.6%) 
Antiplatelets/anticoagulants 493 (3.2%) 585 (3.8%) 
Blood pressure lowering 354 (2.3%) 493 (3.2%) 
Blood pressure lowering & 
antiplatelets/anticoagulants  816 (5.3%) 
1032 (6.7%) 
Lipid lowering  1216 (7.9%) 1540 (10.0%) 
Lipid lowering & 
antiplatelets/anticoagulants 
1355 (8.8%) 1355 (8.8%) 
Lipid lowering and blood pressure 
lowering  832 (5.4%) 
862 (5.6%) 
Optimal (All three medications) 8517 (55.3%) 7445 (48.5%) 
High CVD risk (> 15% and clinically 
high risk)  
 
Estimated PHN population  15963 15963 
No treatment 3097 (19.4%) 3608 (22.6%) 
Blood pressure lowering 1596 (10.0%) 1516 (9.5%) 
Lipid lowering 3528 (22.1%) 3767 (23.6%) 
Optimal (lipid lowering and blood 
pressure lowering) 7732 (48.4%) 
7065 (44.3%) 
  
Assumptions Reduction Risk reduction  
Systolic blood pressure (SBP) 5 mmHG 
15% 
 
The Blood Pressure 
Lowering Treatment 
Trialists’ Collaboration 
Lancet 2014  
LDL Cholesterol 1 mmol/L 22% 
Cholesterol Treatment 
Trialists’ (CTT) 
Collaboration 
Lancet 2010 
Aspirin 
Newly 
commenced 
treatment 
19% 
Antithrombotic Trialists’ 
(ATT) Collaboration 
Lancet 2009 
Baseline 5-year absolute risk – High 
CVD Risk (with CVD) 30% 
Baseline 5-year absolute risk – High 
CVD risk (without CVD) 
20% 
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Table 7.2 TORPEDO trial prescribing rate and intermediate outcome mean 
differences   
Prescribing high risk 
patient due to 
established CVD 
HealthTracker-CVD 
Usual care 
Statins  71.8% 65.9% 
BP lowering  77.3% 73.8% 
Antiplatelets/anticoagulants 71.8% 67.7% 
 
Prescribing high risk patient due >15% + clinically high risk 
 
Statins  58.5% 53.7% 
BP lowering  70.6% 67.9% 
Change in mean lab 
values from baseline to 
end of study 
Mean difference 
from baseline (SD) 
Mean difference 
from baseline (SD) 
Difference 
(95% CI) 
 
 
High CVD risk due to CVD 
 
Mean low-density lipoprotein 
cholesterol (LDL-C) 0.11 (0.81) 0.06 (0.63) 
0.05 (0.01,0.10) 
Mean Systolic BP (SBP) 
mmHg 0.54 (18.8) 0.42 (19.7) 
0.12 (-0.98, 
1.23) 
 
 
Total high risk due to >15% + clinical high risk 
 
Mean low-density lipoprotein 
cholesterol (LDL-C) 0.18 (0.80) 0.13 (0.74) 
0.05 (0.00, 0.09) 
 
Mean Systolic BP (SBP) 
mmHg 4.01 (19.4) 2.92 (20.5) 
1.09 (-0.03-2.21) 
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Table 7.3 Costs of patient level and intervention implementation  
 Unit price 
(2015 AUD$) 
  
Source  Assumptions 
Pharmaceutical costs (annual costs) 
Lipid-lowering 
medications 
$292.42 PBS cost and 
quantity in 2015 
 
Average annual cost weighted by 
scripts for standard daily dose for all 
lipid lowering drugs (simvastatin, 
rosuvastatin, atorvastatin, pravastatin, 
fluvastatin, fenofibrate, gemfibrozil, 
simvastatin and ezetimibe, etc) 
Blood pressure 
lowering 
medications 
$217.11 Average annual cost weighted by 
scripts for standard daily dose for all 
types of blood pressure lowering 
drugs (beta blockers, calcium channel 
blockers, ACE inhibitors, angiotensin II 
antagonists, diuretics, etc)  
Antiplatelet 
medications  
$288.32  
Hospitalisation costs for CVD events 
Average cost – all 
CVD events (per 
person per year) 
$10,872.29 AIHW 2015 
 
Average weighted cost 
Intervention implementation (annual costs) 
Software license per 
health service 
$500 Software 
developer 
Through discussion with software 
developer, the price of software 
license per year per health service. 
(average - 283 Health services per 
PHN) 
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Table 7.4 Costs, outcomes and the incremental cost-effectiveness ratio per CVD event 
averted compared to usual care 
CVD disease events and 
economic outcomes 
HealthTracker-
CVD 
Usual Care  Difference (% 
reduction/gain) 
Costs and outcomes per person 
High CVD risk (with CVD) 
CVD events per 1000 over 5 
years 
259 267 8 
Medication costs $2,576,864.95 
 
$2,411,612.23 $165,252.72 
Hospital costs for CVD events $2,268,676.08 
 
$2,337,768.38  ($69,092.30) 
Intervention cost (based on 283 
health services per PHN) 
$45,946.04 ---- $45,946.04 
ICER per CVD event averted  
(3% discounting)  
  $17,988.16 
High CVD risk (without CVD) 
CVD events per 1000 over 5 
years 
168 176 8 
Medication costs $1,571,509.10 $1,486,612.44 $84,896.65 
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Hospital costs for CVD events $1,468,429.89 $1,538,396.77  ($69,966.88) 
 
Intervention cost  $44,321.23 
 
--- $44,321.23 
ICER per CVD event averted  
(3% discounting)  
  $7,406.38 
CVD events, coronary heart disease, cerebrovascular disease, peripheral vascular disease, or death; 
ICER, incremental cost-effectiveness ratio
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Table 7.5 One-way sensitivity analysis for alternative scenarios  
 # of 
CVD 
events 
averted  
Medication 
costs difference 
CVD event 
costs difference 
(hospitalisation)  
ICER  
High CVD risk (without CVD) 
Base case analysis 8 $84,896.65 
 
($69,966.88) 
 
$7,406.38 
Scenario 1 –95% CI of 
the difference of LDL 
(lower limit) 
8 $84,896.65 ($69,092.29) $7,610.83 
Scenario 1 – 95% CI of 
the difference LDL (upper 
limit) 
12 $84,896.65 ($103,201.15) $2,204.81 
Scenario 2 – 0% 
discounting 
8 $89,988.22 
 
-$72,043.28 
 
$7,783.27 
Scenario 3 – 7% 
discounting  
8 $78,959.46 
 
-$67,349.76 
 
$6,991.37 
Scenario 4 – 25% 
reduction in statin costs  
8 $82,151.43 
 
-$69,966.88 
 
$7,063.22 
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Scenario 5 – 75% 
reduction in statin costs 
8 $66,477.86 
 
-$69,966.88 
 
$5,104.03 
High CVD risk (with CVD) 
Base case analysis 8 $165,252.72 ($69,092.30) $17,988.16 
Scenario 1 –95% CI of 
the difference of LDL 
(lower limit) 
7 $165,252.72 ($63,844.78) $27,667.72 
Scenario 1 – 95% CI of 
the difference of LDL 
(upper limit) 
14 $165,252.72 ($124,191.121) $6,127.29 
Scenario 2 – 0% 
discounting 
8 $175,163.53 
 
-$69,341.66 
 
$19,710.12 
Scenario 3 – 7% 
discounting 
8 $153,695.88 
 
-$64,824.14 
 
$17,508.80 
Scenario 4 – 25% 
reduction in statin costs 
8 $161,536.88 
 
-$67,343.12 
 
$18,199.97 
Scenario 5 – 75% 
reduction in statin costs  
8 $134,283.59 
 
-$67,343.12 
 
$14,660.59 
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PART D 
IMPLICATIONS 
242 
Chapter 8: Discussion and conclusions 
In this thesis I took a multimethod approach to understanding how and why a 
technology-enabled quality improvement intervention generated mixed outcomes 
when implemented in Australian general practices and Aboriginal Community 
Controlled Health Services (ACCHSs). Factors influencing uptake of technological 
innovations are often listed in terms of barriers and facilitators. While this is valuable, 
it does not explain the interplay between these factors and the environments in which 
they are tested. Greenhalgh’s seminal paper on diffusion of innovations in service 
organisations states, “it is not individual factors that make or break a technology 
implementation effort but the dynamic interaction between them”.1 The component 
studies in this thesis aimed to better understand what is already known about the 
implementation of technology based quality improvement interventions (Chapter 3), 
how a specific intervention (HealthTracker) was sustained in a post-trial setting 
(Chapter 4), how various interactions between the technology and the health service 
environments in which it was placed influenced adoption (Chapters 5 and 6), and 
what are the economic considerations for implementing the intervention at scale 
(Chapter 7).2  
In this discussion, I use Greenhalgh and colleagues’ recently published framework, 
the Nonadaptation, Abandonment, Scale-up, Spread, and Sustainability (NASSS) 
framework, to synthesise the main findings from the thesis.3 NASSS was derived 
from a narrative systematic review of theory-informed frameworks and aims to 
identify and address challenges of non-adoption and abandonment of health 
technologies over time (Figure 8.1). It consists of seven domains, each of which may 
be simple (few components, predictable), complicated (many components but still 
largely predictable) or complex (many components interacting in a dynamic and 
unpredictable way). NASSS was designed to be used both retrospectively to 
understand the degree to which complexity influenced uptake of technology and 
prospectively as a means of systematically appraising and potentially reducing 
complexity to enhance adoption and minimise non-adoption. 
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Figure 8.1. The NASSS framework for considering influences on the adoption, non-
adoption, abandonment, spread, scale-up, and sustainability of health technologies.3  
 
8.1 Findings 
The component chapters of the thesis identified numerous complicated and complex 
factors that influenced the impact of the HealthTracker intervention. These are 
addressed below using questions that Greenhalgh has posed within each domain of 
the NASSS framework. 
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The Condition/Illness 
a) To what extent is the illness or condition predictable and straightforward? Does 
the condition affect everyone in the same way? Does everyone receive the same 
treatment? If not, are there tests that can stratify people reliably?   
Cardiovascular disease (CVD) represents a cluster of illnesses with multiple 
interacting risk factors. The conditions and their common risk factors are well 
recognised by health professionals and there is a robust evidence base for what 
interventions (both drug and non-drug) are effective in reducing CVD disease 
burden.4 For primary prevention of CVD, however, the ‘condition’ is more complex to 
characterise and the multiplicative nature of the risk factors makes CVD risk 
detection more complex. Most guidelines internationally recognise that assessment 
of a person’s total or absolute CVD risk should be based on multiple risk factors and 
this approach is superior to assessment of single risk factors.5,6 Despite this strong 
evidence base, risk prediction equations are more complex to understand than 
simple single risk factor threshold-based definitions like hypertension. The difficult 
nature of assessing CVD risk generates different responses from health practitioners, 
some defaulting to the time-honoured single risk factor paradigm, others embracing 
risk-based approaches but finding it difficult to incorporate into routine practice,7-10 
and others “eye-balling” the people most at risk. Taking all these factors into account 
the condition is complex but with appropriate tools and resources can be managed. 
The underlying premise of HealthTracker was that a decision support tool integrated 
with clinical software systems would remove some of the complicated steps of 
assessment and management of CVD risk. However, this was seen as an enabling 
factor only for some of the participating GPs. Many were not comfortable with all the 
features of the intervention. For example, one GP found the statistical concepts 
underpinning absolute CVD risk calculation too complicated to explain to patients 
(Chapter 5). Further, although patients seemed to appreciate the interactive features 
of the tools, meaningful communication required a high level of background 
proficiency on the part of both GP and the patient (Chapter 6).  
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b) What other illnesses may coexist with the one targeted? How are these likely to 
affect management? In particular, would co-morbidities or sociocultural influences 
affect use of the technology? 
The presence of other comorbid conditions is common with CVD, particularly in the 
elderly, Aboriginal and Torres Strait Islander people, and those that experience 
socioeconomic hardship. CVD, diabetes and chronic kidney disease have shared 
common risk factors and often occur together.11 Some of these comorbidities are 
variably recorded in electronic medical records and consequently manual data entry 
fields for family history and other comorbidities were included in the decision support 
tool. However, general practitioners (GPs) found this time-consuming and there were 
difficulties with saving these data back into the primary electronic health record 
(EHR). This could lead to reduced provider engagement on two fronts; both because 
some GPs felt it did not capture all the necessary information for comprehensive 
management and because the workaround solution to address it was not fit for 
purpose (Chapter 5).  
c) How might (for example) the illness and its management be affected by age, 
poverty, IT literacy, health literacy, system literacy, English proficiency or 
citizenship status? How might these factors affect management?  Is the standard 
treatment available and acceptable to all social and cultural groups?  If not, what 
else needs to be taken into account? 
For patients, concepts of CVD risk and risk stratification are also vague. This 
suggests that achieving a mutual understanding between provider and patient may 
require both to have high levels of general literacy and specifically health and digital 
literacy (Chapter 6). There are also challenges with applying a ‘one size fits all’ 
approach to heterogenous populations and the absence of validated equations for 
Aboriginal and Torres Strait Islander people, in particular, is seen as a barrier to using 
these equations more widely. Although this is a known limitation of current equations, 
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we did not observe this to be a major factor in influencing adoption in Aboriginal 
Community Controlled Health Services. 
The technology 
a) What are the technology’s material features? Is it dependable? Is it easy to use? 
Is it freestanding or already interoperable with other relevant technologies and 
systems? 
HealthTracker drew on two extensively studied technological components.12-15 It 
incorporated “in-consultation” tools (real-time decision support integrated with 
electronic medical records and an interactive risk communication tool) and “out of 
consultation” tools to support reflective practice (automated clinical audit tool and a 
web portal of peer-ranked performance trends). The major selling point of the system 
was its integration with clinical software thereby reducing data entry and providing 
quick access to tailored guideline recommendations at the time during the clinical 
encounter when management decisions needed to be made. There were several 
examples, however, of where the technology was difficult to install, health service 
information systems with low operating capacity slowed down on initial installation, 
and frequent technical fixes were required even when initial installation barriers were 
overcome (Chapter 5). In some sites this led to early abandonment as first 
impressions of the new technology were strong determinants of future use.  
Additionally, it would appear that while certain staff gravitated to particular features of 
the software (clinic managers using the audit tools, GPs using the risk 
communication tools) there was a lack of cohesiveness within the health service to 
integrate these features collectively. This diluted the potential for different users 
reinforcing the value of the intervention to others in the service. It was rare that 
people used the intervention collectively e.g. team meetings looking at audit 
performance to formulate strategies to address performance gaps (Chapter 5). 
Achieving collective action is driven by factors such as leadership, strong managerial 
relations, readiness for change, a culture of staff training and resource availability.16 
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The mix of these organisational attributes in the services participating in TORPEDO 
were highly variable and this strongly influenced the level of engagement with 
HealthTracker. 
b) What knowledge or support is needed to use the technology? Could anyone 
learn to use the technology with simple instructions or an introductory course?  
Ongoing training and support was provided during the trial period by the research 
team, technical helpdesk and a clinical champion. During the post-trial phase, 
training was scaled back to an initial training and installation session and then 
ongoing support if requested (Chapter 4 and 5).  Many expressed the need for 
ongoing support, refresher courses, troubleshooting and staged training to 
progressively understand the full capabilities of the software. This training would need 
to be flexibly delivered according to individual staff circumstances. In Chapter 7, I 
estimated the running costs for Primary Health Networks to support this program. 
Although I found the median support time during the trial to be quite low, it is likely 
that in a non-research setting additional support resources would need to be 
provided to cover ongoing training needs.  
c) Do the data generated by the technology reliably and transparently reflect changes 
in the condition? Or are these data obscure, partial and/or contested by 
clinicians? What kind of data does the technology NOT provide (or what data 
does it implicitly over-ride)? 
Most health professionals found the data generated to be reliable and trustworthy, 
particularly because it was developed by a university research institution. Many sites 
initially received pathology data in an unstructured format and when the audit tool 
was initially used resulted in management gaps larger than they actually were. This 
may have had an impact on perceived trustworthiness of the data, however, the 
project support team were able to explain this issue, implement the necessary 
technical fixes, and this was then reflected in improved performance on subsequent 
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data extractions. On balance, this was a simple problem to solve and had minimal 
impact on adoption as the solutions were pre-empted, easily explained, easy to fix 
and the results were obvious within a short time frame. A more complex issue, 
however, arose when practitioners actively rejected the guideline recommendations 
as not being appropriate for a particular patient. It was frustrating for them to be 
continually reminded via a red traffic light that something was missing. There was a 
need for greater flexibility in being able to dynamically alter recommendation prompts 
for specific individuals. The use of computer templates is known to render patients in 
a particular way and privileges the population over the individual.17   
d) What is the technology supply model? Is the technology generic, ‘plug-and-play’ 
or customisable-off-the-shelf – or does it require a bespoke contract? 
The technology supply was dependent on an existing commercial software platform 
that is inter-operable with commonly used Australian medical record systems. This 
meant that the fortunes of HealthTracker were intimately connected with those of the 
commercial software platform. There was initially great appeal in housing 
HealthTracker within this particular platform as the software vendor had entered into 
a partnership with the Royal Australian College of General Practitioners to provide the 
software to all its members. However, over the life of the trial, this partnership was 
abandoned and therefore the potential for easily reaching large numbers of GPs was 
diminished. As a consequence, a ‘software-agnostic’ approach is now being taken 
to work with multiple software vendors to diminish the risk of relying on any one 
system.  
The Value Proposition 
a) What is proposed about the technology’s supply and demand side value? If the 
technology is still being developed, does the business case rest on sound, 
independently verifiable assumptions and predict a good return for investors 
within a reasonable timescale? Is the technology something that patients are likely 
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to want and need? Has it been subject to health technology assessment and 
shown to be both efficacious and cost-effective? Are clinicians agreed on the 
robustness of the evidence base? 
The perception of value of this type of technology product is likely to vary for different 
stakeholders including policy makers, regulatory agencies, public and private payers, 
healthcare providers and patients.18 The economic modelling study conducted in 
Chapter 7 assessed the potential value of the program if paid for and administered 
by a Primary Health Network. In terms of input costs, it is clear that quality 
improvement programs of this nature are cheap to implement at scale and could be 
reasonably accommodated within the budget allocations of these organisations. The 
cost-effectiveness of the program, however, was inconclusive and clearly depends 
on a stronger signal of effect than was achieved in the trial. Although the trial-based 
estimates of reductions in blood pressure and cholesterol were small, the modelling 
work from Chapter 7 found that if these small effect sizes could be sustained over 
time, interventions of this nature are highly cost-effective. Further work is needed to 
understand the potential value to other actors in the health care system. 
Healthcare providers and staff generally valued the intervention and expressed 
interest in using it long term (with the caveat that amendments be made to technical 
aspects of the software and that ongoing training and support is provided). Some 
GPs talked about the need for government subsidised CVD risk assessments as 
occurs for other chronic diseases such as diabetes. Although additional program 
considerations such as these incur financial costs they are likely to raise perceived 
value to providers (Chapter 5).  
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Adopters (Staff, Patient, Caregivers) 
What is expected of professional staff and the patient? Can the staff member use the 
technology within their capability, doing their existing job in the way they currently do 
it? Or will they be expected to fundamentally change what they do? 
Most GPs found the tools fairly straightforward to use and it aligned with their current 
modes of practice.  However, time constraints and lack of financial incentives was an 
issue in using the intervention regularly. In the interviews, GPs reported that the 
length of time they spent with the intervention ranged from a few minutes to ten 
minutes which is a substantial time commitment to incorporate into a standard 
clinical consultation. For other members of staff there were mixed levels of 
engagement. Practice nurses engaged minimally with the intervention despite it being 
designed such that the initial screening component could be completed by nurses. 
This suggests that the decision support was predominantly viewed as a GP tool and 
did not enhance team collective action.19 
The case study analysis highlighted the need for staff with a dedicated quality 
improvement role in the organisation. This may require creation of new roles and 
realigning of responsibilities for non-GP staff such as practice managers and nurses 
to incorporate implementation of the intervention, coordination of training and 
support and use of audit and feedback in their daily activities. In sites where these 
roles already existed the intervention was easier to adopt (e.g. case 5 in Chapter 5). 
However, such sites tended to be larger and these models would not be possible to 
replicate in small general practices.  
The acquisition of new knowledge, particularly in adopting the absolute risk 
approach, was influenced by ‘special people’ that included both clinical champions 
and non-clinical staff who could motivate and engage other staff (Chapter 5). It is well 
known that people learn faster and are more effective in spreading knowledge when 
working in a social group (Chapter 2).20,21 Identifying and recruiting these ‘special 
people’ as central members of these social groups is under-recognised. This 
resonates with Gabbay and Le May’s concept of ‘mindlines’ which are professionally 
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sanctioned codes of practice that may or may not relate to evidence-based guidelines.22 
There were only a few examples of where health professional teams, both within and 
across health service sites, were involved in knowledge exchange activities. These 
were sporadic in nature and not systematically implemented. Greater emphasis on 
stimulating professional networks and use of top-down structural support combined 
with bottom-up participation is likely to have an impact on adoption.23 
In terms of patient engagement, the findings from a single care consultation 
encounter in Chapter 6 provided some insight on what might be required for patients 
to engage in these tools. This was influenced by the manner in which the doctor 
deploys the intervention with the patient, the skills required by the doctor to introduce 
it strategically at multiple critical moments during the encounter, and the skills 
required by the patient to interpret the information and apply it to their 
circumstances. Although HealthTracker was designed for in consultation use, one 
key factor that might promote a higher degree of patient engagement is offline 
access to the tools post-consultation. A follow-on project is currently underway to 
assess the impact of a consumer portal that provides HealthTracker information and 
other content linked to a patient’s electronic health record.24  
The Organisation(s) 
a) What is the organisation’s capacity to innovate? Does the organisation have 
strong leadership, flat hierarchies, good managerial relations, slack resources that 
can be channelled into new projects and a climate that encourages trying out 
new things? What changes will be needed in organisational routines?  Will the 
technology fit with existing care pathways and linked organisational routines?  
Chapter 5 illustrated the importance of a health service’s commitment to CQI 
programs, an engaged leader with an interest in trying new approaches, cohesive 
teams, and strong information technology infrastructure and support. In sites without 
these elements there was greater dependency on the research project officers to 
252 
sustain engagement and this was clearly a factor in how much the tools were used in 
the post-trial period.  
Although most services participating in the trial saw value in the tools being tested, 
there was generally no sense of urgency for change within these services. In the 
preparatory work for commencing the trial, all services received an audit report 
highlighting baseline performance. With some exceptions, these reports 
demonstrated large evidence practice gaps that were not previously known by the 
organisation. Although certain individuals were highly motivated by these findings, on 
balance most services did not respond by making it a priority. Further, engagement 
with non-clinical managers was variable in the trial, some reluctantly participating 
because the GP was keen to be involved. This lack of interest toward participation 
was a factor in preventing adoption of the intervention (e.g., when software bugs 
needed attention the manager may have placed this low on the priority list) 
As described above in the adoption domain, GPs were not expected to make many 
changes to their organisational routines, however this may not have been the case 
for other staff. In organisations that lacked existing processes for adopting new 
technology, use of audit tools and engaging in collaborative work to improve 
performance was a daunting and time-consuming task for some staff who had 
minimal exposure to such approaches. The lack of reflexive monitoring in almost all 
of the case sites studied in Chapter 5 suggests that such processes are challenging 
to incorporate into existing routine methods of work. In places where there is 
substantial organisational inertia to overcome, the benefits of the intervention are 
remote. Early wins with improvements in data quality were often used to increase 
engagement. While this was apparent in many sites, for others there was little 
capacity to evaluate and monitor improvements. This further demotivates people 
who were not necessarily convinced of the initial value of the intervention. 
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The wider context for the programme 
What is the political/policy context? Is there a ‘policy push’ for this innovation?  What 
is the regulatory and legal context? What is the position of professional bodies? What 
is the position of patients, citizens and the public? 
The Australian primary health care system is making small, incremental steps to 
reform its current fee-for-service dominant model. This includes an increased focus 
on improving care for people with chronic and complex care needs, strategies to 
enhance integration of care between primary care and hospital sectors and large-
scale deployment of a national personal health record system that is interoperable 
with electronic health record systems. Payment reforms are currently being made 
which reflect these changes and there is much emphasis on meso-tier organisations 
(Primary Health Networks and Local Hospital Networks) to support implementation of 
these reforms. All of these initiatives make ‘plug and play’ tools like HealthTracker 
appealing, however they should be viewed as only one enabling factor amongst 
many others that are needed to improve system performance. 
There are potential regulatory issues with widespread implementation of decision 
support tools. However, the US Federal Drug Administration recently released 
guidance on clinical and patient decision support software suggests that rule-based 
tools that provide guideline-based recommendations do not constitute a device and 
therefore do not require regulatory oversight.25 This remains a grey area and it is not 
yet clear whether the Australian Therapeutic Goods Administration takes a similar 
view on this issue. 
Professional bodies are unlikely to have major issues with supporting such tools. 
Although such organisations are commonly asked to endorse clinical guidelines, 
there do not exist clearly defined processes for formally endorsing clinical software. 
As mentioned above one of the motivations for building HealthTracker with one 
particular software vendor was related to their existing collaboration with the Royal 
Australian College of General Practitioners. Such connections could be considered a 
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‘nice to have’ for supporting adoption but are likely to be less influential than the 
other domains discussed here.  
Although this research focussed mainly on health service and provider factors 
supporting and hindering adoption, the patient interview data suggests that patients 
have at best a moderate interest in the use of such tools. However, as major 
initiatives are being implemented to support uptake of the national personal health 
record, it is possible that over time patients will start to become more engaged in 
such tools, particularly if they are interoperable.  
Adaption Over Time 
Can the technology and the programme evolve and adapt over time? Or is the 
technology ‘as supplied’, dependent on rigid roles and interactions, and likely to 
become obsolete before long?  
During the randomised trial the technology and implementation strategy were 
somewhat static. This highlights the challenges of using this evaluation design for 
interventions that need to adapt as user feedback is gathered and the digital health 
environment changes.26 Since trial completion, however, there have been major 
changes to the software including expansion of scope of decision support to cover 
other conditions such as diabetes and atrial fibrillation. The software platform 
provided by the commercial partner has also undergone major changes in response 
to some of the technical barriers encountered during the trial. New implementation 
strategies are also being trialled including: (1) the program is being supported by a 
Primary Health Network as part of a CVD focussed quality improvement 
collaborative;27 (2) the intervention strategy is being supplemented with a pharmacy 
support program to maximise quality use of medicines for people at high CVD risk;28 
and (3) a companion consumer portal (described above) is being trialled to make 
HealthTracker information more accessible to patients outside of the clinical 
encounter.24 Given the outcomes observed in TORPEDO and in the post-trial period 
were modestly positive, new strategies to refine the tools and the implementation 
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strategy will help build a stronger understanding of the factors driving adoption, scale 
and spread. 
8.2. Strengths and limitations  
The strength of this research was a theory-informed approach that drew on multiple 
data sources to understand the complexity of a technology intervention. While the 
trial-based evaluation provided an ‘on-average’ assessment of the impact of the 
intervention, it fails to understand the wide variation that occurred within individual 
services. This thesis tried to address this by providing insight on the factors 
influencing implementation and adoption at the patient, provider and organisational 
levels. Although I started with a somewhat simplified logic model that looked at 
particular ingredients, activities and outcomes, I finished with a more nuanced 
understanding that is less linear and predictable. By focussing on the messy 
narratives that occur within health services, it helped me to get to the important 
question of why things play out differently in some contexts compared to others. The 
rigorous multimethod process evaluations of a multifaceted health information 
technology are not routinely done, and my work is critically important to address this 
knowledge gap in the literature. My thesis provides novel and extensive evidence on 
the adoption and sustainability of technology interventions beyond a trial setting and 
sheds light on the conditions required for investing in such interventions to improve 
CVD outcomes. It will contribute to a broader conversation about the role of such 
quality improvement strategies for policymakers, administrators and health care 
providers.  
The limitations associated with each study are discussed in each chapter. On a 
broader level, the research was only conducted in the Australian primary healthcare 
context with a particular emphasis on urban general practices and ACCHSs in two 
Australian states. While the findings are likely to be of relevance to other health 
systems, the specific health system constraints and opportunities in other countries 
will inevitably create different results (e.g., countries with different primary health care 
systems and differing levels of maturity with digital health). Another potential limitation 
was that my “insider-outsider” status in the research may have resulted in me taking 
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a particular lens to the evaluation that would be quite different to that of an 
independent evaluator. Working closely with the architects of the HealthTracker 
intervention may have fostered a certain degree of investment in its success and it 
was important to maintain a high degree of reflexivity in the process. The main 
strategy I took to mitigate this risk was engagement with a range of multidisciplinary 
researchers who were not involved in the development of the intervention. As 
mentioned in Chapter 5, most of the data collected for the process evaluation was 
done toward the end of the trial and therefore failed to capture the dynamic evolution 
of the intervention and how people reacted to it over time. 
8.3 Conclusion 
Implementation of digital health strategies are a policy priority in Australia and for 
most health systems internationally. Digital health has great potential to improve 
health system performance on may dimensions (e.g. access, quality, efficiency) 
however the benefits remain inconsistent and poorly understood. Even when digital 
health policies are strongly supported, there remain major adoption challenges. 
Without a detailed understanding of these challenges, the full potential of a digitally 
enabled health system is unlikely to be realised.  
This thesis goes beyond a checklist approach to understanding factors that influence 
adoption of technology interventions. It highlighted the complex interaction of these 
interventions and the environments in which they are placed. It uncovered factors 
that are inherently not knowable or predictable but dynamic and emergent. In so 
doing, it provides important information on where investments need to be made both 
with the technical aspects of the intervention and the human elements that are critical 
to driving adoption. 
Both bottom-up approaches within health service organisations and top-down 
enablement with support from the wider system is needed. This results in multiple 
overlapping and layered strategies that address different facets of the target health 
conditions, the technology, the adopter system (patients, providers, managers), 
organisational context and broader system enablers (policy, financing etc). Although 
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no one strategy is likely to be a magic bullet for success, collectively and 
incrementally these strategies may generate small influences that when scaled can 
lead to a large impact.  
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APPENDIX A: Policy, submission of PhD theses 
containing published work 
Thesis with publications (Thesis and Examination of Higher Degrees by Research 
Policy 2015) 
 
(1) The University will accept for examination a thesis which contains previously 
published material provided that: 
Thesis and Examination of Higher Degrees by Research Policy 2015 Page 9 of 21  
(a) the thesis makes an original and substantial contribution to the field of knowledge;  
(b) the thesis forms a consistent, coherent and unified whole;  
(c) the previously published material relates to research undertaken during the 
candidature and was published during the candidature; and  
(d) in addition to the published material, the student provides, at the minimum: (i) an 
introduction which argues for the aim(s) of the thesis and contextualises the research 
problems it purports to address; and  
(ii) a conclusion which draws together the findings of the studies in the context of the 
stated aims of the thesis.  
(2) The student may also provide other separate chapters to supplement the 
published papers such as a literature review, background information, or description 
of the methodology used.  
(3) Acceptable publications (including material already published, accepted for 
publication, or submitted for publication) include: (a) papers in refereed journals;  
(b) book chapters;  
264 
(c) conference papers;  
(d) a documentary record of an exhibition or installation mounted during candidature 
which is not part of the creative or artistic component of a thesis.  
(4) A blog is not an acceptable publication.  
(5) A collection of disparate publications, no matter what their quality, must not be 
approved for the award of a higher degree by research if they do not meet the criteria 
for the award.  
(6) A thesis containing published material must be examined using the same criteria, 
and by the same process, as one which does not.  
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APPENDIX B: Ethics Approval Letters 
 
a) University of Sydney Human Research Ethics Committee approval letters 
b) Aboriginal Health and Medical Research Council Ethics Committee approval 
letters 
RESEARCH INTEGRITY 
Human Research Ethics Committee 
Web: http://sydney.edu.au/ethics/ 
Email: ro.humanethics@sydney.edu.au 
 
Address for all correspondence: 
Level 6, Jane Foss Russell Building - G02 
The University of Sydney 
NSW 2006 AUSTRALIA 
 
 
Manager Human Ethics 
Dr Margaret Faedo 
T: +61 2 8627 8176 
E: margaret.faedo@sydney.edu.au 
 
Human Ethics Secretariat: 
Ms Patricia Engelmann T: +61 2  8627 8172 E: patricia.engelmann@sydney.edu.au 
Ms Karen Greer  T: +61 2  8627 8171 E: karen.greer@sydney.edu.au 
Ms Kala Retnam T: +61 2  8627 8173 E: kala.retnam@sydney.edu.au 
 
 ABN 15 211 513 464 
CRICOS 00026A 
 
Ref:  MF/PE 
 
7 April 2011 
 
Dr David Peiris 
The George Institute for Global Health 
Missenden Road 
CAMPERDOWN  NSW  2050 
Email:  dpeiris@georgeinstitute.org.au 
 
 
Dear Dr Peiris 
 
Thank you for your correspondence dated 6 April 2011 addressing comments made to you by the 
Human Research Ethics Committee (HREC).   
 
I am pleased to inform you that with the matters now addressed your protocol entitled “Treatment 
of cardiovascular risk in primary care with electronic decision support - The TORPEDO 
study” has been approved. 
 
Details of the approval are as follows: 
 
Protocol No.:  13533 
 
Approval Period:  April 2011 to April 2012 
 
Authorised Personnel: Dr David Peiris 
   Associate Professor Kathryn Panaretto 
   Professor Mark Harris 
   Professor Tim Usherwood 
   Dr Jenny Hunt 
   Ms Faith Koh 
 
Documents Approved: 
GP Health Professional Information and Consent Sheet Version 1 25/1/11 
GP Patient Information and Consent Form Version 2 6/4/11 
Interview Guide for Health Professionals Version 1 21/1/2011 
Interview Guide for Clients/Patients Version 1 21/1/2011 
 
The HREC is a fully constituted Ethics Committee in accordance with the National Statement on 
Ethical Conduct in Research Involving Humans-March 2007 under Section 5.1.29. 
 
The approval of this project is conditional upon your continuing compliance with the National 
Statement on Ethical Conduct in Research Involving Humans. A report on this research must be 
submitted every 12 months from the date of the approval or on completion of the project, 
whichever occurs first. Failure to submit reports will result in withdrawal of consent for the project to 
proceed. Your report is due by 30 April 2012.  
 
 
 
 
 
 
 
     
 
Special Condition of Approval 
 
Approval is given only for the General Practice component of the study.  It is a condition of 
approval that letters of support are received from all participating Divisions of General Practice. 
(We note that letters of support have been received from Nepean Division of General Practice, 
South Eastern Sydney Division of General Practice Limited, Central Sydney GP Network Ltd and 
the University of New South Wales). 
 
Chief Investigator / Supervisor’s responsibilities to ensure that: 
 
1. All serious and unexpected adverse events should be reported to the HREC within 72 
hours for clinical trials/interventional research. 
 
2. All unforeseen events that might affect continued ethical acceptability of the project should 
be reported to the HREC as soon as possible. 
 
3. Any changes to the protocol must be approved by the HREC before the research project 
can proceed. 
 
4. All research participants are to be provided with a Participant Information Statement and 
Consent Form, unless otherwise agreed by the Committee. The following statement must 
appear on the bottom of the Participant Information Statement: Any person with concerns 
or complaints about the conduct of a research study can contact the Manager, Human 
Ethics, University of Sydney on +61 2 8627 8176 (Telephone); + 61 2 8627 8177 
(Facsimile) or ro.humanethics@sydney.edu.au (Email). 
 
5. You must retain copies of all signed Consent Forms and provide these to the HREC on 
request. 
 
6. It is your responsibility to provide a copy of this letter to any internal/external granting 
agencies if requested. 
 
7. The HREC approval is valid for four (4) years from the Approval Period stated in this letter. 
Investigators are requested to submit a progress report annually.  
 
8. A report and a copy of any published material should be provided at the completion of the 
Project. 
 
Please do not hesitate to contact Research Integrity (Human Ethics) should you require further 
information or clarification. 
 
Yours sincerely 
 
 
 
Dr Margaret Faedo 
Manager, Human Ethics 
On behalf of the HREC 
 
  
Copy: Ms Faith Koh fkoh@georgeinstitute.org.au 
 Research Integrity 
Research Portfolio 
Level 6, Jane Foss Russell 
The University of Sydney  
NSW 2006 Australia 
T +61 2 8627 8111 
F +61 2 8627 8177 
E ro.humanethics@sydney.edu.au 
sydney.edu.au 
ABN 15 211 513 464 
CRICOS 00026A 
 
 
Research Integrity 
Human Research Ethics Committee 
 
Wednesday, 27 February 2013 
 
Mr David Peiris 
The George Institute for Global Health; Sydney Medical School 
Email: david.peiris@sydney.edu.au 
 
Dear David 
 
Your request to modify the above project submitted on 12 February 2013 was considered by the 
Executive of the Human Research Ethics Committee at its meeting on 20 February 2013. 
 
The Committee had no ethical objections to the modification/s and has approved the project to 
proceed. 
 
Details of the approval are as follows: 
 
Project No.: 2012/2183 
 
Project Title: Treatment of cardiovascular risk in primary care with electronic decision 
support - The TORPEDO study 
 
Addition of Authorised Personnel: Ms. Shannon Mckinn 
 
Approved Documents: 
 
Date Uploaded Type Document Name 
11/02/2013  Participant Consent Form  ACCHSs Patient Information and Consent_clean  
11/02/2013  Participant Consent Form  ACCHSs Patient Information and Consent_tracked  
11/02/2013  Interview Questions  Approved Health Professional Interview Guide  
11/02/2013  Interview Questions  Approved Patient Interview Guide  
11/02/2013  Questionnaires/Surveys   End of study survey  
11/02/2013  Participant Consent Form  Health Professional Interview information and 
consent_clean  
11/02/2013  Participant Consent Form  Health Professional Interview information and 
consent_tracke  
11/02/2013  Participant Consent Form  Health Professional video information and 
consent_clean  
11/02/2013  Participant Consent Form  Health Professional video information and 
consent_tracke  
11/02/2013  Participant Consent Form  Patient Information and Consent form_clean  
11/02/2013  Participant Consent Form  Patient Information and Consent form_tracked  
11/02/2013  Interview Questions  Revised Health Professional Interview Guide  
11/02/2013  Interview Questions  Revised Patient Interview Guide  
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Please do not hesitate to contact Research Integrity (Human Ethics) should you require further 
information or clarification. 
 
Yours sincerely 
 
 
 
 
Dr Stephen Assinder 
Chair 
Human Research Ethics Committee 
 
 
 
This HREC is constituted and operates in accordance with the National Health and Medical 
Research Council’s (NHMRC) National Statement on Ethical Conduct in Human Research 
(2007), NHMRC and Universities Australia Australian Code for the Responsible Conduct of 
Research (2007) and the CPMP/ICH Note for Guidance on Good Clinical Practice. 
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AH&MRC ETHICS COMMITTEE 
28
th
 April 2014 
 
 
Dr David Peiris 
Program Head - Primary Health Care Research  
The George Institute 
PO Box M201 
Camperdown  NSW  2050 
 
 
 
Dear Dr Peiris, 
 
RE: 778/11 - TORPEDO Study -Treatment of cardiovascular risk in primary care  
                        with electronic decision support (Health Tracker)  
 
I refer to the correspondence received 8
th
 March 2014 providing an Annual Progress Report 
and extension request for this project that has already been approved by the AH&MRC 
Ethics Committee.   
 
The Committee has agreed to approve an extension for the study until 30
th
 June 2015. 
If you require any further extension it will be subject to provision of an annual progress 
report prior to this date. Please find attached an Annual Progress Report pro forma for use at 
the end of the term. 
 
Thank you also for submitting the manuscript titled, ‘Effect of a computer-guided, quality 
improvement program for cardiovascular disease risk management in primary health care: 
The TORPEDO cluster-randomised trial’ for review by the Committee.  
 
The Ethics Committee has reviewed the manuscript and have no objection to its publication.  
 
The conditions of approval contained in the original approval letter will continue to apply. 
 
 
On behalf of the AH&MRC Ethics Committee, 
 
 
Yours sincerely 
Val Keed 
Chairperson  
AH&MRC Ethics Committee 
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APPENDIX C: Participant Consent Forms 
 
a)  Health professional information sheet and consent form  
b)  General practitioner video recording information sheet and consent form 
c)   Patient video-recording and interview information sheet and consent form 
i. Participants recruited from general practice 
ii. Participants recruited from ACCHS 
iii. Participant opt out form  
d)  Survey information sheet and consent form 
 
 
The TORPEDO Study Evaluation 
Health Professional Qualitative Interview 
Information and Consent Sheet  
 
 
Health Professional Qualitative Interview Information and Consent_V2_10Feb2013  
Page 1 of 4 
 
 
Participant Information Sheet 
 
You are invited to take part in the evaluation of a new electronic decision 
support tool that has been implemented as a part of a research trial at your 
health service.  Before you decide whether or not to participate, it is important 
for you to understand why the research is being done and what is involved. 
Please take time to read the following information carefully. You are entirely 
free to decide whether or not to take part in this study and you are free to 
discontinue your involvement with the study at any time by informing us. If 
there is anything that is not clear, or if you would like more information, please 
do not hesitate to ask. If you agree to take part, you will be asked to sign the 
attached Participant Consent Form.  
 
What is the TORPEDO study? TORPEDO stands for the ‘Treatment of 
cardiovascular risk in primary health care using electronic decision support’. 
Several months ago your health service agreed to participate in this project. 
We provided an electronic decision support tool to assist health staff in the 
management of cardiovascular disease (CVD) risk. This tool is called 
HealthTracker. It aims to improve the uptake of best practice evidence by 
giving management advice to health staff and patients based on national 
guidelines. 
 
How is HealthTracker being evaluated overall? The HealthTracker 
software has been randomly allocated to 30 health services with an additional 
30 health services who did not receive HealthTracker acting as a comparison 
group. There are three parts to evaluating whether HealthTracker improves 
quality of care for CVD risk management. 
1. Health service audits were done at baseline and again at the end of 12 
months (±6 months). Anonymous data is collected on appropriate 
screening of cardiovascular risk factors and guideline based prescribing of 
recommended medicines for people at high risk of heart attack or stroke. 
Comparisons will be made between the group who received 
HealthTracker and the group that did not. 
2. Interviews with selected health staff and patients are being conducted to 
understand the usefulness and acceptability of HealthTracker. 
3. Video recording of some healthcare consultations between doctors and 
patients will be conducted to better understand how HealthTracker is 
actually used in practice. 
 
Who can participate in the interview? 
 
Health professionals who have had access to the HealthTracker tool and/or 
Clinical Audit Tool (CAT) will be randomly selected to participate in the 
interview evaluation.  
 
What will the interview involve? 
Interviews will be conducted by a research team member and will take 
approximately 40 to 60 minutes. If you participate in the interview, we will ask 
you about your experience in using HealthTracker and/or Clinical Audit Tool 
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(CAT). We seek to explore any impact it may have had on the care you provided. We will ask you 
what you found beneficial and to identify any problems associated with its use. We will explore 
with you the factors that might influence uptake of the tool as a part of your routine care with your 
patients. All interviews will be digitally recorded, professionally transcribed and your name and 
personal details will be removed for analysis purposes.  You will be identified by a unique ID 
number. 
 
The interview process is informal and flexible as our main aim is to encourage you to articulate 
your experiences and views. We appreciate your work commitments and will fit with your schedule 
 
We will use the data received from the interviews for this study and any secondary analysis 
required in the future. At the conclusion of the research, data will be stored for 7 years minimum in 
accordance with ethics and governance regulations. 
 
Costs 
Participation in the health professional qualitative interviews will not cost you anything, nor will you 
be paid. 
 
Confidentiality 
We will ask you for your contact details in order to communicate with you if the need arises.  This 
information will be treated as strictly confidential and not released to anyone outside the research 
team.  The information provided to the researchers will not include any personal information and 
will be identified by a unique study number only.  
 
Study management  
This is an independent study managed by The George Institute for Global Health, University of 
Sydney, in collaboration with several partner organisations. Funding is provided by the National 
Health and Medical Research Council.  
 
Ethics Approval 
This study has been approved by The University of Sydney Human Ethics Administration 
Committee. Any person with concerns or complaints about the conduct of this study may contact 
The Manager, Human Ethics Administration on +61 2 8627 8176 (telephone);  +61 2 8627 8177 
(fax); or email ro.humanehtics@sydney.edu.au 
 
This study has been approved by the Aboriginal Health & Medical Research Council (AH&MRC) 
of New South Wales. Any person with concerns or complaints about the conduct of this study may 
contact The Chairperson, on 9212 4777 and quote protocol number (778/11). 
 
~~~ Thank you for your participation ~~~  
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Consent Form 
 
Before you sign this form please be sure that you understand what it means 
to be part of the study. Please read (or have read to you) the Participant 
Information Sheet (Version 2; dated 10Feb2013). Please ask the study team 
member to answer any questions you have. 
 
It is important to understand: 
 You may decide not to take part in the study. There will be no 
penalty against you at work. 
 You can stop taking part at any time. 
 Information you give will be used for this study and any post-study 
analysis required in the future. It will be stored in a secure place. 
Only study team members will have access.  
 Your name and details will not be made public. Nothing written in 
reports will link you personally to the study.    
 If interviewed, you agree that the interview will be audio taped and 
some words (not your name) can be used in the study reports.   
 
Participant to complete: 
 
 
 
 
  
 
 
 
 
 
 
 
I have a copy of the study information sheet and have 
had an opportunity to ask questions about the study 
yes    
□ 
no   
□ 
 
I agree to take part in an interview for the study. yes    
□ 
no   
□ 
 
I agree that the interview be audiotaped yes    
□ 
no   
□ 
 
   
I agree that some of my words (not my name) may be 
used in the study reports 
yes    
□ 
no   
□ 
 
I understand that I have the right to withdraw my 
consent and cease involvement in the study at any 
time without penalty, either financially or personally 
yes    
□ 
no   
□ 
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Participant to complete: 
 
I, _________________________________________________________________________ 
(name), of  
___________________________________________________________________________ 
(address),  
hereby consent to take part in this study. 
 
 
Signature: 
 
                                             Date: 
 
Interviewer’s name:   
I have explained the nature and purpose of the study to the above participant and have 
answered their questions. 
 
 
Signature: 
 
                                             Date: 
 
 
 
Contact details: 
If you have any questions regarding this research project please contact: 
 
Dr  David Peiris          (02) 9993 4513  
The George Institute For Global Health     
Level 10, King George V Building 
Missenden Rd Camperdown NSW 2050 
 
The Manager                     (02) 8627 8177  
Human Ethics Administration 
The University of Sydney 
Level 6 Jane Foss Russell Building 
Camperdown NSW 2006 
 
The Chairperson        (02) 9698 1099  
AH&MRC Ethics Committee 
PO Box 1565 Strawberry Hills NSW 2012 
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Participant Information Sheet 
 
 
You are invited to take part in the evaluation of a new electronic decision 
support tool that has been implemented as a part of a research trial at your 
health service.  Before you decide whether or not to participate, it is important 
for you to understand why the research is being done and what is involved. 
Please take time to read the following information carefully. You are entirely 
free to decide whether or not to take part in this study and you are free to 
discontinue your involvement with the study at any time by informing us. If 
there is anything that is not clear, or if you would like more information, please 
do not hesitate to ask. If you agree to take part, you will be asked to sign the 
attached Participant Consent Form.  
 
What is the TORPEDO study? TORPEDO stands for the ‘Treatment of 
cardiovascular risk in primary health care using electronic decision support’. 
Several months ago your health service agreed to participate in this project. 
We provided an electronic decision support tool to assist health staff in the 
management of cardiovascular disease (CVD) risk. This tool is called 
HealthTracker. It aims to improve the uptake of best practice evidence by 
giving management advice to health staff and patients based on national 
guidelines. 
 
How is HealthTracker being evaluated overall? The HealthTracker 
software has been randomly allocated to 30 health services with an additional 
30 health services who did not receive HealthTracker acting as a comparison 
group. There are three parts to evaluating whether HealthTracker improves 
quality of care for CVD risk management. 
1. Health service audits were done at baseline and again at the end of 12 
months (±6 months). Anonymous data is collected on appropriate 
screening of cardiovascular risk factors and guideline based prescribing of 
recommended medicines for people at high risk of heart attack or stroke. 
Comparisons will be made between the group who received 
HealthTracker and the group that did not. 
2. Interviews with selected health staff and patients are being conducted to 
understand the usefulness and acceptability of HealthTracker. 
3. Video recording of some healthcare consultations between doctors and 
patients will be conducted to better understand how HealthTracker is 
actually used in practice. 
 
Who can participate in the interview? Doctors who have had access to the 
HealthTracker tool will be randomly selected to participate in the video 
recording of their patient consultation.  Health care consultation recording 
requires informed consent from both you and your patient. 
 
What will the video recording involve?  If you agree to participate in the 
video recordings of healthcare consultations we will organise recording 
facilities to be set up at your health service over a maximum one week period. 
You will control when the recording starts and finishes. The analysis will focus 
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on how you use the HealthTracker tool and communicate information to your patients. After the 
recording day is completed we will ask you a debrief question at the end of each day of how you 
felt about being video-taped. During this time some of the health care consultation recordings may 
be played back to you to explore further how you used the tool in practice. 
 
Recording healthcare consultations may be uncomfortable to some individuals. To minimise any 
potential unwanted effects and to provide safeguards for you the following will be undertaken: 
 
 You and your patients will decide which aspects of the consultation are recorded and you will 
have the option of turning off the recording at any time. 
 You and your patients will have the option of reviewing the recorded data and if you feel that 
any footage should not be used (for any reason) we will not use this for any analysis.  
 The data will be analysed by a small team of experienced researchers and will be stored on a 
secure, password protected folder accessible only to the researchers. 
 We seek permission to use quotes from your interview and/ or recorded consultations in our 
reports but none of this information will allow identification of an individual person.   
 We will use the data received from the video recording for this study and any secondary 
analysis required in the future. 
At the conclusion of the research, data will be stored for 7 years minimum in accordance with 
ethics and governance regulations. 
 
We appreciate your work commitments and will fit with your schedule 
 
Costs 
Participation in the health professional qualitative interviews will not cost you anything, nor will you 
be paid. 
 
Confidentiality 
We will ask you for your contact details in order to communicate with you if the need arises.  This 
information will be treated as strictly confidential and not released to anyone outside the research 
team.  The information provided to the researchers will not include any personal information and 
will be identified by a unique study number only.  
 
Study management  
This is an independent study managed by The George Institute for Global Health, University of 
Sydney, in collaboration with several partner organisations. Funding is provided by the National 
Health and Medical Research Council.  
 
Ethics Approval 
This study has been approved by The University of Sydney Human Ethics Administration 
Committee and . Any person with concerns or complaints about the conduct of this study may 
contact The Manager, Human Ethics Administration on +61 2 8627 8176 (telephone);  +61 2 8627 
8177 (fax); or email ro.humanehtics@sydney.edu.au. 
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This study has been approved by the Aboriginal Health & Medical Research Council (AH&MRC) 
of New South Wales. Any person with concerns or complaints about the conduct of this study may 
contact The Chairperson, on 9212 4777 and quote protocol number (778/11). 
~~~ Thank you for your participation ~~~  
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Consent Form 
 
Before you sign this form please be sure that you understand what it means 
to be part of the study. Please read (or have read to you) the Participant 
Information Sheet (Version 2; dated 10Feb2013). Please ask the study team 
member to answer any questions you have. 
 
It is important to understand: 
 You may decide not to take part in the study. There will be no 
penalty against you at work. 
 You can stop taking part at any time. 
 Information you give will be used for this study and any post-study 
analysis required in the future. It will be stored in a secure place. 
Only study team members will have access.  
 Your name and details will not be made public. Nothing written in 
reports will link you personally to the study.    
 If interviewed, you agree that the interview will be taped and some 
words (not your name) can be used in the study reports.   
 
Participant to complete: 
  
 
 
 
 
 
 
 
 
 
 
 
I have a copy of the study information sheet and have 
had an opportunity to ask questions about the study 
yes    
□ 
no   
□ 
 
I agree to take part in an interview for the study. yes    
□ 
no   
□ 
 
I agree that the interview be audiotaped yes    
□ 
no   
□ 
 
   
I agree that some of my words (not my name) may be 
used in the study reports 
yes    
□ 
no   
□ 
 
I understand that I have the right to withdraw my 
consent and cease involvement in the study at any 
time without penalty, either financially or personally 
yes    
□ 
no   
□ 
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Participant to complete: 
I, _________________________________________________________________________ 
(name), of  
___________________________________________________________________________ 
(address),  
hereby consent to take part in this study. 
 
 
Signature: 
 
                                             Date: 
 
 
Interviewer’s name:   
I have explained the nature and purpose of the study to the above participant and have 
answered their questions. 
 
Signature: 
 
                                             Date: 
 
 
Contact details: 
 
If you have any questions regarding this research project please contact: 
 
Dr  David Peiris          (02) 9993 4513  
The George Institute For Global Health     
Level 10, King George V Building 
Missenden Rd Camperdown NSW 2050 
 
The Manager                     (02) 8627 8177  
Human Ethics Administration 
The University of Sydney 
Level 6 Jane Foss Russell Building 
Camperdown NSW 2006 
 
The Chairperson        (02) 9698 1099  
AH&MRC Ethics Committee 
PO Box 1565 Strawberry Hills NSW 2012 
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Participant Information Sheet 
 
You are invited to take part in the evaluation of a new electronic decision 
support software tool that has been implemented as a part of a research trial 
at your health service.  Before you decide whether or not to participate, it is 
important for you to understand why the research is being done and what is 
involved. Please take time to read the following information carefully. You are 
entirely free to decide whether or not to take part in this study and you are free 
to discontinue your involvement with the study at any time by informing us. If 
there is anything that is not clear, or if you would like more information, please 
do not hesitate to ask. If you agree to take part, you will be asked to sign the 
attached Consent Form.  
 
What is the TORPEDO study? TORPEDO stands for the ‘Treatment of 
cardiovascular risk in primary health care using electronic decision support’. 
Several months ago your health service agreed to participate in this project. 
We provided an electronic decision support software tool to assist health staff 
in the management and prevention of heart disease and stroke. This software 
tool is called HealthTracker. It aims to promote best practice care by giving 
management advice to health staff and patients based on national guidelines. 
 
How is HealthTracker being evaluated? The HealthTracker software has 
been randomly allocated to 30 health services with an additional 30 services 
who did not receive HealthTracker acting as a comparison group. There are 
three parts to evaluating whether HealthTracker improves the quality of care 
provided. 
1. Health service audits were done at the beginning and again at the end of 
12 months. Anonymous data is collected on how well heart disease risk 
factors are measured and whether people at high risk of heart attack or 
stroke are being prescribed the recommended medicines. Comparisions 
will be made between the group who received the HealthTracker software 
and the group that did not. 
2. Interviews with selected health staff and patients are being conducted to 
understand the usefulness and acceptability of HealthTracker. 
3. Video recording of some healthcare consultations between doctor and 
patients will be conducted to better understand how HealthTracker is 
actually used in practice. 
 
We are inviting you to have your doctor consultation video recorded and 
participate in the interview evaluation. You have the option of doing either the 
video recording of your consultation and interview or just the video recording 
of your consultation, depending on your preference. Health care consultation 
recording requires informed consent from both you and your doctor.   
 
What will the evaluation involve? 
Interviews will be conducted by a research team member and will take around 
30 to 45 minutes. We will explore your opinions about the HealthTracker tool. 
We are interested in any impact it may have had on the care you received and 
whether it assisted you in making decisions about your health. We will ask you 
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if there were any benefits, and if there were any problems associated with its use. Interviews will 
be digitally recorded, professionally transcribed and your name and personal details will be 
removed when we analyse the information you provide.  You will be identified by a unique 
identification number. 
 
Health care consultation video recording will take place at your doctor’s room or clinic. If you 
agree to participate in the video recording of your health care consultation, you and your doctor 
will decide when the recording starts and finishes. After the recording, a research team member 
will arrange a time and a place to conduct an interview with you. During this interview some of 
your health care consultation recording may be played back to explore further your opinions on 
how the tool was used.  
 
Recording healthcare consultations may be uncomfortable to some individuals. To minimise any 
potential unwanted effects and to provide safeguards for you the following will be undertaken: 
 
 You and your doctor will decide which aspects of the consultation are recorded and you will 
have the option of turning off the recording at any time. 
 You and your doctor will have the option of reviewing the recorded data and if you feel that 
any footage should not be used (for any reason) we will not use this for any analysis.  
 The data will be analysed by a small team of experienced researchers and will be stored on a 
secure, password protected folder accessible only to the researchers. 
 We seek permission to use quotes from your interview and/ or recorded consultations in our 
reports but none of this information will allow identification of an individual person, and will 
only be identified by a unique ID number. 
At the conclusion of the research, the information collected will be securely stored for 7 years 
minimum in accordance with ethics regulations. 
 
Costs 
Participation in the health care consultation video recording and/or interviews will not cost you 
anything, nor will you be paid. 
Confidentiality 
We will ask you for your contact details in order to communicate with you if the need arises.  This 
information will be treated as strictly confidential and not released to anyone outside the research 
team.  The information provided to the researchers will not include any personal information and 
will be identified by a unique study number only.  
Study management  
This is an independent study managed by The George Institute for Global Health, University of 
Sydney, in collaboration with several partner organisations. Funding is provided by the National 
Health and Medical Research Council.  
Ethics Approval 
This study has been approved by The University of Sydney Human Ethics Administration 
Committee. Any person with concerns or complaints about the conduct of this study may contact 
The Manager, Human Ethics Administration on +61 2 8627 8176 (telephone);  +61 2 8627 8177 
(fax); or email ro.humanehtics@sydney.edu.au 
 
~~~ Thank you for your participation ~~~  
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Consent Form 
 
Before you sign this form please be sure that you understand what it means to 
be part of the study. Please read (or have read to you) the Participant 
Information Sheet (Version 3; dated 10February2013). Please ask the study 
team member to answer any questions you have. 
 
It is important to understand: 
 You may decide not to take part in the study. There will be no penalty 
against you at work. 
 You can stop taking part at any time. 
 Information from the video-recording and/or interviews will be used for 
this study and any additional post-study analysis required in the future.  
 All data received from you (videotapes generated and interview data) 
will be stored in a secure place. Only study team members will have 
access.  
 Your name and details will not be made public. Nothing written in 
reports will link you personally to the study.      
 If interviewed, you agree that the interview will be audio taped and 
some of your words (not your name) can be used in study reports. 
 
 
 
I have a copy of the study information sheet and have 
had an opportunity to ask questions about the study. 
yes    
□ 
no   
□ 
 
I agree to take part in an interview for the study. yes    
□ 
no   
□ 
 
I agree that the interview be audiotaped. yes    
□ 
no   
□ 
 
I agree to have my health care consultation with my 
doctor video taped. 
yes    
 
no   
 
 □ □ 
   
I agree that some of my words (not my name) may be 
used in the study reports. 
yes    
□ 
no   
□ 
 
I understand that I have the right to withdraw my 
consent and cease involvement in the study at any 
time without penalty, either financially or personally. 
yes    
□ 
no   
□ 
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Participant to complete: 
I, _________________________________________________________________________ (name), of  
___________________________________________________________________________ (address),  
hereby consent to take part in this study. 
 
 
Signature: 
 
                                             Date: 
 
 
Interviewer’s name:   
I have explained the nature and purpose of the study to the above participant and have answered their 
questions. 
 
 
Signature: 
 
                                             Date: 
 
 
Contact details 
If you have any questions regarding this research project please contact: 
 
Dr  David Peiris       
The George Institute For Global Health   
Level 10, King George V Building 
Missenden Rd Camperdown NSW 2050 
(02) 9993 4513 (Telephone) 
(02) 9993 4502  (Fax) 
 
 
 
 
  
 
The Manager     
Human Ethics Administration 
The University of Sydney 
Level 6 Jane Foss Russell Building 
Camperdown NSW 2006 
 
 
(02) 8627 8176  (Telephone) 
(02) 86278177   (Fax) 
ro.humanehtics@sydney.edu.au 
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Participant Information Sheet 
 
You are invited to take part in the evaluation of a new electronic decision 
support software tool that has been implemented as a part of a research trial 
at your health service.  Before you decide whether or not to participate, it is 
important for you to understand why the research is being done and what is 
involved. Please take time to read the following information carefully. You are 
entirely free to decide whether or not to take part in this study and you are free 
to discontinue your involvement with the study at any time by informing us. If 
there is anything that is not clear, or if you would like more information, please 
do not hesitate to ask. If you agree to take part, you will be asked to sign the 
attached Consent Form.  
 
What is the TORPEDO study? TORPEDO stands for the ‘Treatment of 
cardiovascular risk in primary health care using electronic decision support’. 
Several months ago your health service agreed to participate in this project. 
We provided an electronic decision support software tool to assist health staff 
in the management and prevention of heart disease and stroke. This software 
tool is called HealthTracker. It aims to promote best practice care by giving 
management advice to health staff and patients based on national guidelines. 
 
How is HealthTracker being evaluated? The HealthTracker software has 
been randomly allocated to 30 health services with an additional 30 services 
who did not receive HealthTracker acting as a comparison group. There are 
three parts to evaluating whether HealthTracker improves the quality of care 
provided. 
1. Health service audits were done at the beginning and again at the end of 
12 months. Anonymous data is collected on how well heart disease risk 
factors are measured and whether people at high risk of heart attack or 
stroke are being prescribed the recommended medicines. Comparisions 
will be made between the group who received the HealthTracker software 
and the group that did not. 
2. Interviews with selected health staff and patients are being conducted to 
understand the usefulness and acceptability of HealthTracker 
3. Video recording of some healthcare consultations between doctor and 
patients will be conducted to better understand how HealthTracker is 
actually used in practice. 
 
We are inviting you to have your doctor consultation video recorded and 
participate in the interview evaluation. You have the option of doing either the 
video recording of your consultation and interview or just the video recording of 
your consultation, depending on your preference. Health care consultation 
recording requires informed consent from both you and your doctor.   
 
What will the evaluation involve? 
Interviews will be conducted by a research team member and will take around 
30-45 minutes. We will explore your opinions about the HealthTracker tool. We 
are interested in any impact it may have had on the care you received and 
whether it assisted you in making decisions about your health. We will ask you 
 
 
 
 
 
 
     
 
 
 
 
 
      
 
 
 
 
 
 
 
 
 
 
 
 
The TORPEDO Study Evaluation 
Patient Information and Consent Sheet  
 
 
ACCHS Patient Information and Consent_Version 3_10Feb2013 
 Page 2 of 5 
 
 
if there were any benefits and if there were any problems associated with its use. Interviews will 
be digitally recorded, professionally transcribed and your name and personal details will be 
removed when we analyse the information you provide. You will be identified by a unique 
identification number. 
 
Health care consultation video recording will take place at your doctor’s office or health service.  If 
you agree to participate in the video recording of your health care consultation, you and your 
doctor will decide when the recording starts and finishes. After the recording we will arrange a 
time and place to conduct an interview with you. During this interview some of your health care 
consultation recording may be played back to explore further your opinions on how the tool was 
used.  
 
Recording healthcare consultations may be uncomfortable to some individuals. To minimise any 
potential unwanted effects and to provide safeguards for you the following will be undertaken: 
 
 You and your doctor will decide which aspects of the consultation are recorded and you will 
have the option of turning off the recording at any time. 
 You and your doctor will have the option of reviewing the recorded data and if you feel that 
any footage should not be used (for any reason) we will not use this for any analysis and will 
erase the recorded data. 
 The data will be analysed by a small team of experienced researchers and will be stored on a 
secure, password protected folder accessible only to the researchers. 
 We seek permission to use quotes from your interview and/ or recorded consultations in our 
reports but none of this information will allow identification of an individual person, and will 
only be identified by a unique ID number.   
At the conclusion of the research, the information collected will be securely stored for 7 years 
minimum in accordance with ethics regulations. 
 
Costs 
Participation in the health care consultation video recording and/or interviews will not cost you 
anything, nor will you be paid. 
Confidentiality 
We will ask you for your contact details in order to communicate with you if the need arises.  This 
information will be treated as strictly confidential and not released to anyone outside the research 
team.  The information provided to the researchers will not include any personal information and 
will be identified by a unique study number only.  
Study management  
This is an independent study managed by The George Institute for Global Health, University of 
Sydney, in collaboration with several partner organisations including the Aboriginal Health & 
Medical Research Council and the Queensland Aboriginal and Islander Health Council. Funding is 
provided by the National Health and Medical Research Council.  
Ethics Approval 
This study has been approved by the Aboriginal Health & Medical Research Council (AH&MRC) 
of New South Wales. Any person with concerns or complaints about the conduct of this study may 
contact The Chairperson, on 9212 4777 and quote protocol number (778/11). 
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~~~ Thank you for your participation ~~~  
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Consent Form 
 
Before you sign this form please be sure that you understand what it means to 
be part of the study. Please read (or have read to you) the Participant 
Information Sheet (Version 3; dated 10February2013). Please ask the study 
team member to answer any questions you have. 
 
It is important to understand: 
 You may decide not to take part in the study. There will be no penalty 
against you at work. 
 You can stop taking part at any time. 
 Information from the video-recording and/or interviews will be used for 
this study and any additional post-study analysis required in the 
future.  
 All data received from you (video tapes and interview data) will be 
stored in a secure place. Only study team members will have access.  
 Your name and details will not be made public. Nothing written in 
reports will link you personally to the study.      
 If interviewed, you agree that the interview will be audio taped and 
some of your words (not your name) can be used in the study reports. 
 
 
 
I have a copy of the study information sheet and have 
had an opportunity to ask questions about the study. 
yes    
□ 
no   
□ 
 
I agree to take part in an interview for the study. yes    
□ 
no   
□ 
 
I agree that the interview be audiotaped. yes    
□ 
no   
□ 
 
I agree to have my health care consultation with my 
care provider video taped 
yes    
 
no   
 
 □ □ 
   
I agree that some of my words (not my name) may be 
used in the study reports? 
yes    
□ 
no   
□ 
 
I understand that I have the right to withdraw my 
consent and cease involvement in the study at any 
time without penalty, either financially or personally. 
yes    
□ 
no   
□ 
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Participant to complete: 
I, _________________________________________________________________________ (name), of  
___________________________________________________________________________ (address),  
hereby consent to take part in this study. 
 
 
Signature: 
 
                                             Date: 
 
 
 
 
Interviewer’s name:   
I have explained the nature and purpose of the study to the above participant and have answered their 
questions. 
 
 
Signature: 
 
                                             Date: 
 
 
 
 
 
 
Contact details: 
 
If you have any questions regarding this research project please contact: 
 
Dr  David Peiris          (02) 9993 4513  
The George Institute For Global Health     
Level 10, King George V Building 
Missenden Rd Camperdown NSW 2050 
 
The Chairperson        (02) 9698 1099  
AH&MRC Ethics Committee 
PO Box 1565 Strawberry Hills NSW 2012 
 
The Treatment of Cardiovascular Risk in 
Primary Care Using Electronic Decision 
Support, TORPEDO project 
 
Request to not include information in 
audits of health records 
 
I, ____________________________________________(name), of                        
_____________________________________________(address),                          
have reviewed the information about this project.  
 I understand that my health service will conduct audits of health 
records to look at the quality of health care provided.  These 
audits are computer generated and will not include any personal 
details such as names and addresses.  
 I do not wish to have my health information included in these 
audits.  
 I understand that my decision will not have any effect on the 
health care that I receive. 
 
Signature_____________________________________________ 
                                                                                                                                                                                   
   
 
If you have any further questions regarding this project 
please contact: 
 
Dr  David Peiris          (02) 9993 4513  
The George Institute For Global Health     
Level 10, King George V Building 
Missenden Rd Camperdown NSW 2050 
 
The Chairperson        (02) 9698 1099  
AH&MRC Ethics Committee 
PO Box 1565 Strawberry Hills NSW 2012 
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TORPEDO STUDY 
 
 
 
 
TORPEDO Study: Team Climate Inventory and Job Satisfaction Surveys  
 
INFORMATION FOR PARTICIPANTS 
 
Introduction 
You are invited to take part in two surveys that are trying to understand if team environment and job 
satisfaction at general practices or Aboriginal Community Controlled Health Services predict better 
management and prevention of cardiovascular disease. 
The surveys will be undertaken as part of the TORPEDO study that is testing whether HealthTracker-
CVD tool, an electronic decision support tool, used by healthcare providers helps people manage and 
prevent cardiovascular disease. 
 
What is required? 
If you participate you will be asked to complete two surveys.  
Survey 1: Team Climate Inventory questionnaire 
There are a series of questions which ask about the climate or atmosphere in your practice or health 
service.  It asks about how people tend to work together in your practice/health service, how 
frequently you interact, the organisation’s aims and objectives, and how much practical support and 
assistance is given towards the implementation of new and improved ways of doing things.   
Survey 2: Job Satisfaction questionnaire 
This section has questions about how satisfied you are with your job.   
Both questionnaires together usually take around 15-20 minutes to complete. There are no right or 
wrong answers, and no-one other than the researchers will see your answers.  The information you 
give will be de-identified.  
 
Ethical considerations 
Any personal information that is collected will be de-identified (i.e. no names will be used and the 
practice/ health service will not be identified in any analyses).  Your responses will remain confidential 
and will be available only to authorised research staff working on the TORPEDO study. 
Participation is entirely optional.  You do not have to take part in it.  If you do take part, you can 
withdraw at any time without having to give a reason.  Whatever your decision, please be assured 
that it will not affect your work/job.  Please sign the consent form only if you want to participate in the 
surveys and only after you have had a chance to ask your questions and have received answers that 
you are happy with.  
 
A research study to see if an electronic decision support tool (HealthTracker-CVD) 
prevents and treats Cardiovascular Disease  
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Who can help you with further information? 
Investigator:  Associate Professor David Peiris   
The George Institute for Global Health  
PO Box M201 Missenden Rd, Sydney NSW 2050  
Tel: 02 9993 4500 
Fax: 02 9993 4502 
 
Ethics Approval 
The surveys have been approved by The University of Sydney Human Ethics Administration Committee, 
and Aboriginal Health and Medical Research Council Ethics Committee.   Any person with concerns or 
complaints about the conduct of this study may contact The Manager, Human Ethics Administration on 
02 8627 8176 or the AH&MRC Executive Officer on 02 9212 4777. 
 
 
This information sheet is for you to keep. 
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TORPEDO STUDY 
 
 
                           
     
TORPEDO Study: Team Climate Inventory and Job Satisfaction Surveys  
 
PARTICIPANT CONSENT FORM 
 
 
 I have read the participant information sheet 
 
 I feel free to accept or refuse to participate in the surveys 
 
 I have had a chance to ask questions and all of my questions have been answered to my 
satisfaction 
 
 I have been given and I understand the information on the surveys concerning its nature, 
purpose, and duration  
 
 By signing this form, I give my free and informed consent to take part in these surveys as 
outlined in the information sheet and this consent form. I understand that I am free to 
withdraw from the surveys at any given time. I have been given a copy of this consent form. 
By signing this form I have not given up my legal rights. 
 
 
 
PARTICIPANT NAME …………………………………………………………........................................................... 
 
PARTICIPANT SIGNATURE: …………………………………………………………...Date:…..…………………… 
 
 
I have explained the nature and purpose of the study to the above participant and have answered their 
questions. 
 
INTERVIEWER NAME: …….………………………………………………………………………………….………… 
 
INTERVIEWER SIGNATURE: …………………………………………………………...Date:…..…………………… 
 
A research study to see if an electronic decision support tool (HealthTracker-CVD) 
prevents and treats Cardiovascular Disease  
 
300 
APPENDIX D: Instruments and Tools 
 
a) Health professional interview guide (see chapter 5) 
b) Patient interview guide 
c) Surveys 
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TORPEDO Study  
Patient interview guide (Intervention) 
 
 
Introductions  
 
Thank you for agreeing to be interviewed.   
 
We are studying doctor-patient communication, especially in relation to how heart disease risk, management and treatment are communicated, and how patients may 
understand this information.  
 
Everything you say will be strictly confidential.  We will make a transcript from the audio recording of this interview, but your name and identifying details will be removed.  
You will be identified by a unique ID number.  The interview will take around 30-45 minutes.  If you would not prefer to answer some questions, or would like to stop the 
interview at any time, that’s fine, just let me know.  
 
Do you have any questions before we start? 
 
 
Review of video-
recording of GP 
consultation 
I’d like to play back a few segments from your consultation with the doctor 
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Area of Interest Initial Broad 
Descriptive Questions 
Possible Probing Questions  
(These are a guide only. Depending on what the patient tells you, you do not have to ask all these questions or use 
the words exactly as written.) 
HealthTracker-CVD 
tool and shared 
decision making 
Has HealthTracker had 
any impact on the 
decisions you made 
about your health?  If 
yes, what were they? 
- HealthTracker is a  decision support tool that your GP used on the computer during you consultation 
o Here are two screenshots of HealthTracker  
- Lifestyle changes 
- use of medicines 
- involvement of other care providers 
- impact on family 
- social life 
How do you prefer your 
doctor to make decisions 
about your heart disease 
risk and treatment? 
- To what extent would you like to be involved? 
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Experience using 
HealthTracker tool 
What was your opinion of 
HealthTracker the doctor 
used during your visit? 
- How useful did you find the tool? 
- How did you find the recommendations given to you from the tool?   
o Reliable 
o Helpful 
- How easy was it to understand the information in HealthTracker? 
o How did you find the colour coded information? 
- Did the information given to you from the tool have an impact on your health care consultation? 
- How did you find the Heart Age risk graph? 
o Was the graph easy to understand? If yes, what was it that made it easy?  If no, what was that made it difficult 
or confusing? 
o How was your experience in being presented the heart disease risk graph in this format? 
 Heart age 
 Risk projection 
 % risk of heart attack 
 Use of colour coded risk categories 
 Traffic light recommendations 
 Summary print out 
 Recommended guidelines 
 
Management of 
Heart disease 
How could your health 
care be improved? 
 
What about specifically 
heart health? 
 
 
- How does your GP care for the health of your heart?   
o Blood pressure, cholesterol, smoking, diet, or exercise 
- Have you had any discussions with your doctor about heart disease risk? If yes, what type of discussions did you 
have? 
- Treatment/mediations, diet, smoking, exercise? 
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CVD risk and heart 
age 
communication 
What has the doctor said 
about your risk of 
cardiovascular disease? 
- Cardiovascular disease also means heart disease and some terms he may have used are high blood pressure, high 
cholesterol, stroke, heart attack. 
- How did your doctor explain your risk of heart disease to you? 
- Did the doctor tell you that you need to be on medication for heart disease?  If yes, how did you feel about starting new 
treatment?   
- Do you remember the percentage risk your doctor told you? 
o  
How would you describe 
your chance/risk of 
having heart disease?   
- Would you say you are low risk, medium risk, or high risk?  Why 
- Have you heard about heart age, and if yes, what do you know about it? 
o  
Shared Decision 
making 
How do you prefer your 
doctor to make decisions 
about your heart disease 
risk and treatment? 
- To what extent would you like to be involved in the decision making? 
Actions Did your doctor 
recommend any changes 
to reduce your heart risk? 
Are you planning to make 
any (lifestyle) changes as 
a result of this 
consultation? 
- Smoking 
- Control of BP or Cholesterol by medications 
- Lifestyle 
 
Health care 
experience 
Do you feel that your 
health needs were 
adequately met in the 
time you spent with your 
GP? 
- How is your health in general? 
- What are some of the good/bad things about your health care? 
- Why did you go visit your doctor?  What were your health needs? 
- Did you discuss heart disease, such as high blood pressure and cholesterol? If yes, is this discussed regularly at your 
doctor visit? 
For Patients aged 
75+ 
Please complete Vulnerable Elders Survey (VES-13)  
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Ongoing 
management of 
heart disease risk 
What types of resources 
would you like your 
doctor to provide to help 
manage your heart 
disease? 
- What would you like from your GP to improve management and prevention of heart disease? 
- Would you like to see a tool like this for use in your home on your computer? 
 
Note: Some questions in the guidelines will be modified in response to participant’s answers and themes emerging from the data. 
 
 
 
I would like to finish this interview by asking a few general questions about you. This will be used to describe the whole participant group. 
 
1. What is your age? 
 
 
2. What is your postcode?  
3. Gender Male  
Female 
 
 
 
4. Ethnicity   
       (tick as many as apply to you) 
Aboriginal   
Torres Strait Islander   
Both Aboriginal and Torres Strait Islander  
Other (please specify):  
5. What language(s) do you speak at home? 
 
 
 
 
6. Where are you currently living? Own home/ flat   
A home/flat owned by family   
A rented home/flat  
A friend’s house/flat  
A hostel/ other temporary accommodation  
Other (please specify):  
7. What is your current relationship status? Married  
Divorced/ Separated  
Widowed  
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De facto/ long term partner  
Single  
Other relationship (please specify): 
 
 
 
8. What is your highest level of school 
education?  
 
Year 10 or below                                                        
Year 11-12                    
College diploma or similar                         
Undergraduate university degree               
Postgraduate university degree           
 
9. What is your employment status?  
       (tick as many as apply) 
Full-time work  
Part-time/ Casual work  
Full or part-time study  
Unpaid/ Volunteer work  
Unemployed  
Other (please specify): 
 
 
 
10. Do you have regular access to the following:  
Phone 
Yes 
 
No 
 
Car   
Computer   
Internet   
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For patients aged 75+ (VES-13) 
 
The Vulnerable Elders Survey (VES-13) is a simple function-based tool for screening community-dwelling populations to identify older persons at risk for health deterioration. The 
VES considers age, self-rated health, limitations in physical function, and functional disabilities. 
 
1. Age 1 POINT FOR AGE 75-84 
3 POINTS FOR AGE ≥ 85 
2. In general, compared to other people your 
age, would you say that your health is: 
 
Poor,* (1 POINT)  
Fair,* (1 POINT)  
Good,  
Very good, or  
Excellent  
  
3. How much difficulty, on average, do you 
have with the following physical activities: 
SCORE: 1 POINT FOR EACH * RESPONSE 
IN Q3a THROUGH f . MAXIMUM OF 2 
POINTS. 
      
 No 
difficulty 
A little 
difficulty 
Some 
difficulty 
A lot of 
difficulty 
Unable to 
do 
a. stooping, crouching or kneeling?    * * 
b. lifting, or carrying objects as heavy as 
10 pounds? 
   * * 
c. reaching or extending arms above 
shoulder level? 
   * * 
d. writing, or handling and grasping small 
objects? 
   * * 
e. walking a quarter of a mile?    * * 
f. heavy housework such as scrubbing floors or 
washing windows? 
   * * 
      
4. Because of your health or a physical 
condition, do you have any difficulty: 
SCORE: 4 POINTS FOR ONE OR MORE * RESPONSES IN Q4a 
THROUGH Q4e 
      
a. shopping for personal items (like toilet items or medicines)?   
  Yes  do you get help with shopping? Yes * No  
  No   
  Don’t do  is that because of your health? Yes * No  
   
b. managing money (like keeping track of expenses or paying bills)?   
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 Yes  do you get help with managing money? Yes * No  
 No   
 Don’t do  is that because of your health? Yes * No  
   
c. walking across the room? USE OF CANE OR WALKER IS OK.   
 Yes  Do you get help with walking? Yes * No  
 No   
 Don’t do  is that because of your health? Yes * No  
   
d. doing light housework (like washing dishes, straightening up, or light cleaning)? 
 
  
 Yes  Do you get help with light housework? Yes * No  
 No   
 Don’t do  is that because of your health? Yes * No  
   
e. bathing or showering?   
 Yes  Do you get help with bathing or showering? Yes * No  
 No   
 Don’t do  is that because of your health? Yes * No  
 
 
Thank you for your participation. 
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Interview Staff only 
 
Participant category 
 
Regular client with CVD/CKD/Diabetes  
Regular client without CVD/CKD/Diabetes  
Family of Client  
Non-user/ infrequent user of the health service  
 
Notes: 
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TORPEDO Study  
Patient interview guide (Usual Care) 
 
 
Introductions  
 
Thank you for agreeing to be interviewed.   
 
We are investigating doctor-patient communication, especially in relation to how heart disease risk, management and treatment are communicated, and how patients may 
understand this information 
 
Everything you say will be strictly confidential.  We will make a transcript from the audio recording of this interview, but your name and identifying details will be removed.  
You will be identified by a unique ID number. 
 
The interview will take around 30-45 minutes.  If you would not prefer to answer some questions, or would like to stop the interview at any time, that’s fine, just let me know.  
Do you have any questions before we start? 
 
 
Area of Interest Initial Broad 
Descriptive Questions 
Possible Probing Questions  
(These are a guide only. Depending on what the patient tells you, you do not have to ask all these questions or use 
the words exactly as written.) 
Review of video-
recording of GP 
consultation 
I’d like to play back a few segments from your consultation with the doctor  
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Management of 
Heart disease 
How could your health 
care be improved? 
 
What about specifically 
heart health? 
 
 
- How does your GP care for the health of your heart?   
o Blood pressure, cholesterol, smoking, diet, or exercise 
- Have you had any discussions with your doctor about heart disease risk? If yes, what type of discussions did you 
have?* 
- Treatment/mediations, diet, smoking, exercise? 
 
CVD risk and heart 
age 
communication 
What has the doctor said 
about your risk of 
cardiovascular disease? 
- Cardiovascular disease also means heart disease and some terms he may have used are high blood pressure, high 
cholesterol, stroke, heart attack. 
- How did your doctor explain your risk of heart disease to you? 
- Did the doctor tell you that you need to be on medication for heart disease?  If yes, how did you feel about starting new 
treatment?   
- Do you remember the percentage risk your doctor told you? 
o  
How would you describe 
your chance/risk of 
having heart disease?   
- Would you say you are low risk, medium risk, or high risk?  Why 
- Have you heard about heart age, and if yes, what do you know about it? 
 
Shared Decision 
making 
How do you prefer your 
doctor to make decisions 
about your heart disease 
risk and treatment? 
- To what extent would you like to be involved in the decision making? 
Actions Did your doctor 
recommend any changes 
to reduce your heart risk? 
Are you planning to make 
any (lifestyle) changes as 
a result of this 
consultation? 
- Smoking 
- Control of BP or Cholesterol by medications 
- Lifestyle 
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Health care 
experience 
Do you feel that your 
health needs were 
adequately met in the 
time you spent with your 
GP? 
- How is your health in general? 
- What are some of the good/bad things about your health care? 
- Why did you go visit your doctor?  What were your health needs? 
- Did you discuss heart disease, such as high blood pressure and cholesterol? If yes, is this discussed regularly at your 
doctor visit? 
Ongoing 
management of 
heart disease risk 
What types of resources 
would you like your 
doctor to provide to help 
manage your heart 
disease? 
- What would you like from your GP to improve management and prevention of heart disease? 
- Would you like to see a tool like this for use in your home on your computer? 
 
For Patients aged 
75+ 
Please complete Vulnerable Elders Survey (VES-13) 
Note: Some questions in the guidelines will be modified in response to participant’s answers and themes emerging from the data. 
 
I would like to finish this interview by asking a few general questions about you. This will be used to describe the whole participant group. 
 
1. What is your age? 
 
 
2. What is your postcode?  
3. Gender Male  
Female 
 
 
 
4. Ethnicity   
       (tick as many as apply to you) 
Aboriginal   
Torres Strait Islander   
Both Aboriginal and Torres Strait Islander  
Other (please specify):  
5. What language(s) do you speak at home? 
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6. Where are you currently living? Own home/ flat   
A home/flat owned by family   
A rented home/flat  
A friend’s house/flat  
A hostel/ other temporary accommodation  
Other (please specify):  
7. What is your current relationship status? Married  
Divorced/ Separated  
Widowed  
De facto/ long term partner  
Single  
Other relationship (please specify): 
 
 
 
8. What is your highest level of school 
education?  
 
Year 10 or below                                                        
Year 11-12                    
College diploma or similar                         
Undergraduate university degree               
Postgraduate university degree           
 
9. What is your employment status?  
       (tick as many as apply) 
Full-time work  
Part-time/ Casual work  
Full or part-time study  
Unpaid/ Volunteer work  
Unemployed  
Other (please specify): 
 
 
 
10. Do you have regular access to the following:  
Phone 
Yes 
 
No 
 
Car   
Computer   
Internet   
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For patients aged 75+ (VES-13) 
 
The Vulnerable Elders Survey (VES-13) is a simple function-based tool for screening community-dwelling populations to identify older persons at risk for health deterioration. The 
VES considers age, self-rated health, limitations in physical function, and functional disabilities. 
 
1. Age 1 POINT FOR AGE 75-84 
3 POINTS FOR AGE ≥ 85 
2. In general, compared to other people your 
age, would you say that your health is: 
 
Poor,* (1 POINT)  
Fair,* (1 POINT)  
Good,  
Very good, or  
Excellent  
  
3. How much difficulty, on average, do you 
have with the following physical activities: 
SCORE: 1 POINT FOR EACH * RESPONSE 
IN Q3a THROUGH f . MAXIMUM OF 2 
POINTS. 
      
 No 
difficulty 
A little 
difficulty 
Some 
difficulty 
A lot of 
difficulty 
Unable to 
do 
a. stooping, crouching or kneeling?    * * 
b. lifting, or carrying objects as heavy as 
10 pounds? 
   * * 
c. reaching or extending arms above 
shoulder level? 
   * * 
d. writing, or handling and grasping small 
objects? 
   * * 
e. walking a quarter of a mile?    * * 
f. heavy housework such as scrubbing floors or 
washing windows? 
   * * 
      
4. Because of your health or a physical 
condition, do you have any difficulty: 
SCORE: 4 POINTS FOR ONE OR MORE * RESPONSES IN Q4a 
THROUGH Q4e 
      
a. shopping for personal items (like toilet items or medicines)?   
  Yes  do you get help with shopping? Yes * No  
  No   
  Don’t do  is that because of your health? Yes * No  
   
b. managing money (like keeping track of expenses or paying bills)?   
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 Yes  do you get help with managing money? Yes * No  
 No   
 Don’t do  is that because of your health? Yes * No  
   
c. walking across the room? USE OF CANE OR WALKER IS OK.   
 Yes  Do you get help with walking? Yes * No  
 No   
 Don’t do  is that because of your health? Yes * No  
   
d. doing light housework (like washing dishes, straightening up, or light cleaning)? 
 
  
 Yes  Do you get help with light housework? Yes * No  
 No   
 Don’t do  is that because of your health? Yes * No  
   
e. bathing or showering?   
 Yes  Do you get help with bathing or showering? Yes * No  
 No   
 Don’t do  is that because of your health? Yes * No  
 
 
Thank you for your participation. 
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Interview Staff only 
 
Participant category 
 
Regular client with CVD/CKD/Diabetes  
Regular client without CVD/CKD/Diabetes  
Family of Client  
Non-user/ infrequent user of the health service  
 
Notes: 
 
  
  
WARR-COOK-WALL Job Satisfaction Scale_November 26, 2012  
 
 
GP and Non-GP Staff: 
Treatment of cardiovascular risk in primary care with electronic decision support 
(TOPREDO) 
WARR-COOK-WALL SCALE OF JOB SATISFACTION 
Name:   ...........................................     Date of Birth:   ......................    Today’s date:   ...................  
How long have you been working in your present job?  …………………………… (years) 
Please answer the following questions about your job.  There are no right or wrong answers 
no-one other than the researchers will see your answers.   The information you give will be 
de-identified to keep it completely CONFIDENTIAL, so please be as honest as you can.  Do 
not confer with anyone else when completing the questionnaire. 
Looking at your current job, how satisfied are you with each of the following? 
Please fill in (using a black or blue pen) the appropriate box (for example: ) on the 
scale, ranging from "extremely dissatisfied” to "extremely satisfied":  
 
LOOKING AT YOUR CURRENT JOB, HOW 
SATISFIED ARE YOU WITH EACH OF THE 
FOLLOWING? 
E
x
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y
 
D
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S
a
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1.  The amount of responsibility you are 
given        
2.  The freedom to choose your own 
method of working        
3.  The amount of variety in your job        
4.  Your colleagues and fellow workers        
5.  The physical work conditions        
6.  Your opportunity to use your abilities        
7.  Your income        
8.  The recognition you get for your work        
9.  Your hours of work        
10. Taking everything into consideration, 
how do you feel about your job?        
 
OFFICE USE 
ONLY: 
Researcher ID: Practice ID #: Staff ID #: Date Sent: Data Checked? Date entered 
      
 
  
Team Climate Inventory_TOPREDO 
Version 1.0_26Nov2012 
 
     
Role of GP and Non-GP staff at General Practice: 
Treatment of cardiovascular risk in primary care with electronic decision 
support (TOPREDO) 
 
Team Climate Inventory Questionnaire 
 
 
 
NAME: 
 
 
 
GENERAL PRACTICE NAME: 
 
 
 
DATE OF BIRTH: 
 
 
___ ___/___ ___ ___/___ ___ ___ ___ 
 D   D     M   M   M      Y   Y   Y   Y 
 
 
TODAY’S DATE: 
 
 
___ ___/___ ___ ___/___ ___ ___ ___ 
 D   D    M   M   M      Y   Y   Y   Y 
 
GENDER:    Male    Female 
 
ROLES (checks one & answer any respective questions for your role, if applicable):    
 
  General Practitioner   
Country of Graduation ______________________Year of Graduation __________________ 
Do you consult in language other than English?   No  Yes 
If Yes, what language ________________________________ 
 
   Nurse – Are you involved in patient care?  No  Yes 
Country of Graduation _____________________ Year of Graduation __________________ 
Do you consult in language other than English?   No  Yes 
If Yes, what language ________________________________ 
 
   Aboriginal Health Worker – Are you involved in patient care?  No  Yes 
   Practice Manager 
   Receptionist 
   IT staff 
   Other ___________________________________________________________________ 
 
Years at current General Practice: __________________ 
……………………………………………………………………………………………………………………………………………………. 
INSTRUCTIONS 
This questionnaire asks about the climate or atmosphere in your work group or practice.  It asks about 
how people tend to work together in your practice, how frequently you interact, the practice’s aims and 
objectives, and how much practical support and assistance is given towards the implementation of new 
and improved ways of doing things.  There are no ‘right’ or ‘wrong’ answers to any of the questions – 
it is more important that you give an accurate and honest response to each question.  Do not spend too 
long on any one question.  First reactions are usually best.  For each question consider how your 
practice tends to be in general or how you feel in general about the climate within your practice.  
Please fill in the appropriate box using a black or blue pen: for example  
 
OFFICE USE 
ONLY: 
Researcher ID: Practice ID #: Staff ID #: Date Checked: Date entered: 
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 PART I    
COMMUNICATION AND 
INNOVATION 
 
Strongly 
disagree 
 
Disagree 
 
Neither 
agree nor 
disagree 
 
Agree 
 
Strongly 
agree 
1 We share information generally in the 
practice rather than keeping it to 
ourselves. 
 
 
 
 
 
 
 
 
 
 
2 
The programme or area in which I work 
functions well and does not have any 
aspects which need changing 
 
 
 
 
 
 
 
 
 
 
 
3 
Assistance in developing new ideas is 
readily available. 
 
 
 
 
 
 
 
 
 
 
4 We all influence each other.      
 
5 
The practice always functions to the best 
of its capability. 
 
 
 
 
 
 
 
 
 
 
 
6 
We keep in regular contact with each 
other. 
 
 
 
 
 
 
 
 
 
 
 
7 
In this practice we take the time needed to 
develop new ideas. 
 
 
 
 
 
 
 
 
 
 
8 There’s nothing that I really need to 
change about the way I do my job to be 
more efficient. 
 
 
 
 
 
 
 
 
 
 
 
9 
People feel understood and accepted by 
each other. 
 
 
 
 
 
 
 
 
 
 
 
10 
Everyone’s view is listened to, even if it is 
in a minority. 
 
 
 
 
 
 
 
 
 
 
 
11 
People in the practice never feel tense 
with one another. 
 
 
 
 
 
 
 
 
 
 
 
12 
The practice is open and responsive to 
change. 
 
 
 
 
 
 
 
 
 
 
 
13 
People in the practice co-operate in order 
to develop and apply new ideas. 
 
 
 
 
 
 
 
 
 
 
 
14 
Being part of the practice team is the most 
important thing at work for the people 
who work here. 
 
 
 
 
 
 
 
 
 
 
15 I’ve been thinking that I might want to 
help change something about the 
programme or area in which I work. 
 
 
 
 
 
 
 
 
 
 
16 We have a ‘we are in it together’ attitude.      
17 We interact frequently.      
 
18 
The practice is significantly better than 
any other in its field. 
 
 
 
 
 
 
 
 
 
 
 
19 
People keep each other informed about 
work-related issues in the practice. 
 
 
 
 
 
 
 
 
 
 
20 I plan to be involved in changing the 
programme or area in which I work. 
 
 
 
 
 
 
 
 
 
 
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21 
 
Members of the practice provide and share 
resources to help in the application of new 
ideas. 
 
 
 
 
 
 
 
 
 
 
22 
There are consistently harmonious 
relationships between people in the 
practice. 
 
 
 
 
 
 
 
 
 
 
 
23 
There is a lot of give and take. 
 
 
 
 
 
 
 
 
 
 
24 I am working hard to help improve aspects 
of the programme or area in which I work. 
 
 
 
 
 
 
 
 
 
 
 
25 
We keep in touch with each other as a 
practice. 
 
 
 
 
 
 
 
 
 
 
 
26 
People in this practice are always 
searching for fresh, new ways of looking 
at problems. 
 
 
 
 
 
 
 
 
 
 
 
27 
The practice consistently achieves the 
highest targets with ease. 
 
 
 
 
 
 
 
 
 
 
 
28 
There are real attempts to share 
information throughout the practice. 
 
 
 
 
 
 
 
 
 
 
 
29 
This practice is always moving towards 
the development of new answers. 
 
 
 
 
 
 
 
 
 
 
 
30 
Practice members provide practical 
support for new ideas and their 
application. 
 
 
 
 
 
 
 
 
 
 
 
31 
Members of the practice meet frequently 
to talk both formally and informally. 
 
 
 
 
 
 
 
 
 
 
32 
We are trying to make sure we keep 
changes/improvements my program/area 
has made. 
 
 
 
 
 
 
 
 
 
 
 
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 PART II    
OBJECTIVES 
 
Not at all 
 
 
 
 
Somewhat 
 
 
 
Completely 
33 How clear are you about what your 
practice objectives are? 
 
 
 
 
 
 
 
 
 
 
 
34 
 
To what extent do you think they are 
useful and appropriate objectives? 
 
 
 
 
 
 
 
 
 
 
 
35 
 
How far are you in agreement with 
these objectives? 
 
 
 
 
 
 
 
 
 
 
 
36 
 
To what extent do you think other 
practice members agree with these 
objectives? 
 
 
 
 
 
 
 
 
 
 
 
37 
 
To what extent do you think your 
practice’s objectives are clearly 
understood by other members of the 
practice? 
 
 
 
 
 
 
 
 
 
 
 
38 
 
To what extent do you think your 
practice’s objectives can actually be 
achieved? 
 
 
 
 
 
 
 
 
 
 
 
39 
 
How worthwhile do you think these 
objectives are to you? 
 
 
 
 
 
 
 
 
 
 
40 How worthwhile do you think these 
objectives are to the organisation? 
 
 
 
 
 
 
 
 
 
 
41 How worthwhile do you think these 
objectives are to the wider society? 
 
 
 
 
 
 
 
 
 
 
 
42 
 
To what extent do you think these 
objectives are realistic and can be 
attained? 
 
 
 
 
 
 
 
 
 
 
 
43 
 
To what extent do you think members 
of your practice are committed to these 
objectives? 
 
 
 
 
 
 
 
 
 
 
Team Climate Inventory Questionnaire 
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 PART III 
TASK STYLE 
 
To a very 
little extent 
 
 
 
To some 
extent 
 
 
 
To a very 
great extent 
44 Do your practice colleagues provide 
useful ideas and practical help to enable 
you to do the job to the best of your 
ability? 
 
 
 
 
 
 
 
 
 
 
 
45 
 
Do you and your colleagues monitor 
each other so as to maintain a higher 
standard of work? 
 
 
 
 
 
 
 
 
 
 
 
46 
 
Are practice members prepared to 
question the basis of what the practice is 
doing? 
 
 
 
 
 
 
 
 
 
 
 
47 
 
Does the practice critically appraise 
potential weaknesses in what it is doing 
in order to achieve the best possible 
outcome? 
 
 
 
 
 
 
 
 
 
 
 
48 
 
Do members of the practice build on 
each other’s ideas in order to achieve 
the best possible outcome? 
 
 
 
 
 
 
 
 
 
 
 
49 
 
Is there a real concern among practice 
members that the practice should 
achieve the highest standards of 
performance? 
 
 
 
 
 
 
 
 
 
 
 
50 
 
Does the practice have clear criteria 
which members try to meet in order to 
achieve excellence as a practice? 
 
 
 
 
 
 
 
 
 
 
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Name of General Practitioner:  
 
Name of Participating Health Service 
(GP/ACCHS): 
 
________________________________________ 
 
 
 
We are collecting this information to evaluate our electronic decision support tool, HealthTracker-CVD. Your 
responses to the questions below will give us important background information about you and your practice 
and will take about 15 minutes to complete. All responses are private and confidential. Your assistance is 
greatly appreciated. 
 
Section 1: Your Background 
 
1.1 What is your age? 
  20-29 
  30-39 
  40-49 
  50-59 
  60 or over 
1.2 
 
What is your gender? 
 
 Male 
 Female 
1.3 
 
What is the primary language you speak at home?  
1.4 
 
What country were you born in?  
1.5 
 
 
 
From which university did you obtain your medical degree?   
 
 Year graduated: 
1.6 
 
Are you vocationally registered? 
 
 Yes 
 No 
1.7 How many sessions per week do you work at this practice?  
1.8 How many sessions per week do you work elsewhere?  
 
1.9 
 
How often do you participate in research?  
Never Sometimes Often Very often 
    
1.10 How often do you conduct your own research?     
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Section 2: Opinions on HealthTracker-CVD: Electronic Decision Support Tool 
 
2.1 
 
For patients over 45 years (or over 35 years for Indigenous patients), on average how often would you use 
HealthTracker-CVD?  
 
Always  
More than  
50% of the time  
Less than  
50% of time Never 
    
2.2 
 
 
 
Please indicate your agreement or disagreement with the following statements about HealthTracker-CVD 
tool. 
 
 
 
Strongly 
Disagree Disagree Neutral Agree Strongly agree 
Overall, HealthTracker-CVD was easy to use       
 
Calculation of the cardiovascular risk score  
helped me to improve the quality of care      
The recommendations for screening helped 
me to improve the quality of care      
The recommendations for treatment helped 
me to improve the quality of care      
The CVD Risk projection graph increased 
patient’s awareness of the health of their heart       
 
       
 
     
 
     
 
        
 
Overall, HealthTracker-CVD increased the  
quality of my interaction with the patient during 
the consult      
 
I would like to use HealthTracker-CVD after 
the study finishes      
 
 
Section 3: Practice Characteristics 
  
3.1 
 
 
 
 
 
 
 
 
 
Which of the following best describes access to bulk-
billing at your practice?  (please choose one) 
 
 
 
 
 
 
 
Exclusively bulk-billing  
Selective bulk-billing (e.g. children, 
seniors, concession card holders)  
No bulk-billing  
Other  billing arrangements (please specify): 
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Section 4: Use of Information Technology 
  
4.1 
 
 
 
 
 
 
 
 
 
How often do you use the Internet for personal and/or 
professional use, including e-mail from home, work, or another 
location? 
 
 
Several times a day  
Daily  
Weekly  
Monthly   
Less than month or not at all  
  
 
4.2 
 
 
 
 
Overall how satisfied are you with 
the computer systems at your 
practice? 
 
 
Very 
Unsatisfied 
 
Unsatisfied 
 
Neutral 
 
Satisfied 
 
Very 
Satisfied 
 
     
4.3 
 
How much of a barrier is each of the following to successful implementation of computer systems at your 
practice? 
  
Not a barrier 
 
Minor barrier 
 
Major barrier 
 
 Staff training    
 Privacy/ Security concerns 
 
 
 
 
 
 
 Medical software limitations 
 
 
 
 
 
 
 
Technical limitations (e.g. slow  response 
time of computers, poor technical support 
 
 
 
 
 
 
 
 
Costs (e.g. additional RAM, server, computer (s), 
upgrade, etc.) 
 
 
 
           
 
            
 
 
Frequency of technology changes (e.g. 
technology adaptation such as EMRs, SideBar, 
Clinical Audit Tool, Doctor’s Control Panel, PCEHR, 
etc.) 
 
                       
 
                        
        
            
4.4 Please indicate how positive the impact of computer systems has been for each of the areas below. 
  
Very 
negative 
Somewhat 
negative No effect 
Somewhat 
positive Very positive 
 The practice of evidence based medicine       
 Patient-doctor communication       
 Patient privacy       
 TORPEDO Study 
End of Study Evaluation  
(Intervention)                
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 Practice cost efficiencies      
 
Overall patient safety  
(e.g. reduction in medication errors)      
 
 
  
 
 
  
If there is anything further you would like to discuss or clarify please contact: 
 
Bindu Patel  
Project Manager 
PO Box M201 Missenden Rd, NSW 2050 
bpatel@georgeinstitute.org.au;  
Telephone: 02 99934546; Mobile: 0420317195 
 
Thank you for your participation!  
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Name of General Practitioner:                      
 
Name of Participating Health Service 
(GP/ACCHS): 
 
_________________________________________ 
 
We are collecting this information to evaluate our electronic decision support tool, HealthTracker-CVD. Your 
responses to the questions below will give us important background information about you and your practice 
and will take about 15 minutes to complete. All responses are private and confidential. Your assistance is 
greatly appreciated. 
 
Section 1: Your Background 
 
1.1 What is your age? 
  20-29 
  30-39 
  40-49 
  50-59 
  60 or over 
1.2 
 
What is your gender? 
 
 Male 
 Female 
1.3 
 
What is the primary language you speak at home?  
1.4 
 
What country were you born in?  
1.5 
 
 
 
From which university did you obtain your medical degree?   
 
 Year graduated: 
1.6 
 
Are you vocationally registered? 
 
 Yes 
 No 
1.7 How many sessions per week do you work at this practice?  
1.8 How many sessions per week do you work elsewhere?  
 
1.9 
 
How often do you participate in research?  
Never Sometimes Often Very often 
    
1.10 How often do you conduct your own research?     
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Section 2: Practice Characteristics 
  
2.1 
 
 
 
 
 
 
 
 
 
Which of the following best describes access to bulk-
billing at your practice?  (please choose one) 
 
 
 
 
 
 
 
Exclusively bulk-billing  
Selective bulk-billing (e.g. children, 
seniors, concession card holders)  
No bulk-billing  
Other  billing arrangements (please specify): 
 
 
 
Section 3: Use of Information Technology 
  
3.1 
 
 
 
 
 
 
 
 
 
How often do you use the Internet for personal and/or 
professional use, including e-mail from home, work, or another 
location? 
 
 
Several times a day  
Daily  
Weekly  
Monthly   
Less than month or not at all  
 
3.2 
 
 
 
 
Overall how satisfied are you with 
the computer systems at your 
practice? 
 
 
Very 
Unsatisfied 
 
Unsatisfied 
 
Neutral 
 
Satisfied 
 
Very Satisfied 
 
     
3.3 
 
How much of a barrier is each of the following to successful implementation of computer systems at your 
practice? 
  
Not a barrier 
 
Minor barrier 
 
Major barrier 
 
 Staff training    
 Privacy/ Security concerns 
 
 
 
 
 
 
 Medical software limitations 
 
 
 
 
 
 
 
Technical limitations (e.g. slow  response 
time of computers, poor technical support 
 
 
 
 
 
 
 
 
Costs (e.g. additional RAM, server, computer (s), 
upgrade, etc.) 
 
 
 
           
 
            
 
 
Frequency of technology changes (e.g. 
technology adaptation such as EMRs, SideBar, 
Clinical Audit Tool, Doctor’s Control Panel, PCEHR, 
etc.) 
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3.4 Please indicate how positive the impact of computer systems has been for each of the areas below. 
  
Very 
negative 
Somewhat 
negative No effect 
Somewhat 
positive Very positive 
 The practice of evidence based medicine       
 Patient-doctor communication       
 Patient privacy       
 Practice cost efficiencies      
 
Overall patient safety  
(e.g. reduction in medication errors)      
 
 
  
 
 
  
If there is anything further you would like to discuss or clarify please contact: 
 
Bindu Patel  
Project Manager 
PO Box M201 Missenden Rd, NSW 2050 
bpatel@georgeinstitute.org.au;  
Telephone: 02 99934546; Mobile: 0420317195 
 
Thank you for your participation!  
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Cardiovascular diseases (CVDs) are the greatest contribu-tors to the global burden of disease, and finding ways to 
reduce this burden are a major challenge faced by health sys-
tems worldwide.1 Most guidelines recommend that the decision 
to use vascular disease preventive drug therapy should be on the 
basis of a patient’s overall or absolute cardiovascular risk.2 The 
broader application of risk-based care with safe, effective treat-
ments has the potential to reduce disease burden substantially 
Background—Despite effective treatments to reduce cardiovascular disease risk, their translation into practice is limited.
Methods and Results—Using a parallel arm cluster-randomized controlled trial in 60 Australian primary healthcare centers, 
we tested whether a multifaceted quality improvement intervention comprising computerized decision support, audit/
feedback tools, and staff training improved (1) guideline-indicated risk factor measurements and (2) guideline-indicated 
medications for those at high cardiovascular disease risk. Centers had to use a compatible software system, and eligible 
patients were regular attendees (Aboriginal and Torres Strait Islander people aged ≥35 years and others aged ≥45 years). 
Patient-level analyses were conducted using generalized estimating equations to account for clustering. Median follow-up 
for 38 725 patients (mean age, 61.0 years; 42% men) was 17.5 months. Mean monthly staff support was <1 hour/site. For the 
coprimary outcomes, the intervention was associated with improved overall risk factor measurements (62.8% versus 53.4% 
risk ratio; 1.25; 95% confidence interval, 1.04–1.50; P=0.02), but there was no significant differences in recommended 
prescriptions for the high-risk cohort (n=10 308; 56.8% versus 51.2%; P=0.12). There were significant treatment escalations 
(new prescriptions or increased numbers of medicines) for antiplatelet (17.9% versus 2.7%; P<0.001), lipid-lowering 
(19.2% versus 4.8%; P<0.001), and blood pressure–lowering medications (23.3% versus 12.1%; P=0.02).
Conclusions—In Australian primary healthcare settings, a computer-guided quality improvement intervention, requiring 
minimal support, improved cardiovascular disease risk measurement but did not increase prescription rates in the high-
risk group. Computerized quality improvement tools offer an important, albeit partial, solution to improving primary 
healthcare system capacity for cardiovascular disease risk management.
Clinical Trial Registration—URL: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=336630. Australian 
New Zealand Clinical Trials Registry No. 12611000478910.    
(Circ Cardiovasc Qual Outcomes. 2015;8:87-95. DOI: 10.1161/CIRCOUTCOMES.114.001235.)
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and has been shown to be highly cost-effective.3,4 However, 
there has been a failure to implement such a strategy adequately 
for both primary and secondary CVD prevention globally.5–7 
Even in high-income countries, the use of recommended medi-
cines in people with established CVD may be as low as 50% 
after 6 months of therapy, with only around one third of people 
achieving treatment goals.8,9 In Australian general practice and 
Aboriginal Community Controlled Health Service (ACCHS) 
settings, ≈50% of routinely attending adults lacked sufficient 
recorded information to evaluate vascular risk and only ≈40% 
to 50% of people at high CVD risk were prescribed optimal 
guideline-indicated medicines.10,11
Strategies to address these gaps in care are generally 
complex, multifaceted, and target barriers at the system, 
provider, and patient levels.12 Quality improvement (QI) 
interventions can take many forms and most of the evi-
dence about effectiveness is based on observational stud-
ies, which have major limitations. Two main strategies that 
have been more extensively evaluated are first, clinical 
decision support systems and second, audit and feedback 
systems. Although both systems have been demonstrated 
to confer modest improvements in practitioner perfor-
mance,13–17 few trials have targeted CVD risk management 
and most of these have focused on single risk factors with 
varying results and with little attention to patient outcomes 
or intervention costs.15,18
The Treatment of Cardiovascular Risk using Electronic 
Decision Support (TORPEDO) study was a cluster randomized 
trial that tested whether a computer-guided QI intervention 
comprising point-of-care electronic decision support, audit and 
feedback tools, and clinical workforce training improved CVD 
risk management when compared with usual care.
Methods
Study Design
Parallel arm cluster-randomized controlled trial in 60 Australian pri-
mary healthcare centers.
Included Patients and Health Services
Health services were eligible to participate if there was exclusive use 
of 1 of the 2 compliant software systems to record risk factor informa-
tion, pathology test results and prescribe medications and a willing-
ness from all clinical staff to use the intervention. The eligible patient 
population was based on Australian guideline vascular risk screening 
recommendations19 and defined as all Aboriginal and Torres Strait 
Islander people ≥35 years and all others ≥45 years (no upper age limit) 
who had attended the service ≥3× in the previous 24-month period and 
at least once in the previous 6-month period. The outcome evaluation 
cohort included patients who met these criteria at both baseline and 
end of study data extractions.
Study Setting
General practices were recruited from the Sydney region with as-
sistance from primary healthcare organizations known as Medicare 
Locals. ACCHSs were recruited through collaboration with 2 state 
representative bodies from NSW and Queensland and included urban, 
rural, and remote services. A $500AUD reimbursement to all partici-
pating sites was made to assist with study-related activities. All license 
costs and technical support associated with the intervention were pro-
vided free to intervention sites. The costs associated with patient care 
occurred as per usual practice. Australia has a universal health insur-
ance scheme (Medicare), which subsidizes primary healthcare consul-
tations on a predominantly fee for service basis. General practices can 
charge patients above the Medicare rebate at their discretion. ACCHS 
do not charge above the rebate and receive additional state and fed-
eral funding for provision of other primary healthcare services beyond 
general practice care.
Randomization and Allocation Concealment
Randomization was in a 1:1 allocation to the intervention or usual care 
stratified at 3 levels: (1) ACCHS versus general practices; (2) service 
size (<500 patients meeting eligibility criteria versus ≥500); and (3) 
current participation in a national or state QI program. Permuted block 
randomization was performed centrally, and outcome analyses were 
conducted blinded to randomized allocation. Participating services 
did not make any special provisions to advertise the trial and their al-
location status to patients; however, it would be reasonable to assume 
that when the tools were used during a consultation patients may have 
been aware of the intervention.
Intervention
Full details of the intervention have been published and are also sum-
marized in the Appendix in the Data Supplement.20 In brief, a sin-
gle screening and management algorithm were developed and then 
validated, based on a synthesis of recommendations from several 
screening and management guidelines for CVD, kidney disease, and 
diabetes mellitus.21 The algorithm interfaces with 2 clinical practice 
software systems that together comprise ≈80% of primary healthcare 
record systems in Australia. Data from the patient record prepopulate 
the tool. Point-of-care recommendations based on that patient’s ab-
solute CVD risk are provided. If the patient is receiving suboptimal 
WHAT IS KNOWN
•	 Effective treatments to reduce cardiovascular disease 
risk exist, but their use in routine clinical practice is 
limited, and as few as 50% of people at high car-
diovascular disease risk are prescribed appropriate 
treatments.
•	 Computerized clinical support tools are a promising 
strategy to improve healthcare quality.
•	 Clinical trials in this area are variable in quality, 
tend to lack data on clinical parameters, and are not 
scalable.
WHAT THE STUDY ADDS
•	 This Australian cluster-randomized trial, involving 
>38 000 people and 60 health services, tested a deci-
sion support system, combined with audit and feed-
back strategies.
•	 The intervention results in a 10% absolute improve-
ment in screening for cardiovascular disease risk.
•	 However, there were no significant improvements 
in prescribing recommended medicines to people at 
high cardiovascular disease risk although there were 
significant improvements in treatment escalation 
(new prescriptions or increased numbers of medi-
cines) of recommended medicines.
•	 The findings suggest that computerized tools may 
play an important role in preventative treatments; 
however, there is an important opportunity to 
improve clinical management further.
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screening or management, a series of traffic light prompts alert the 
practitioner to suggested recommendations. A risk communication 
tool also assists patients to understand their CVD risk, including 
how overall risk is affected by changes in individual risk factors.22 
Identification of screening and management gaps for the whole patient 
population was also built into a commonly used audit tool. This tool 
allows health services to audit health records, identify performance 
gaps, and establish recall/reminder prompts rapidly. It also allows for 
deidentified data to be exported to a Web-based portal where health 
services can view peer-ranked performance data benchmarked against 
other participating trial sites.
Clinical staff were trained in use of the tools and received access 
to a technical support desk. One face-to-face training visit was sup-
plemented with ad hoc visits to resolve technical issues as required. 
Bimonthly Webinars were offered with a focus on the practical dem-
onstrations of the tools. Sites allocated to the control arm continued 
usual care without access to the intervention tools or training. Services 
in both arms participating in existing QI initiatives continued with 
these programs at their discretion. Intervention was for a minimum 
of 12 months.
Data Collection
Deidentified data extracts were obtained for all patients who met the 
eligibility criteria with an encrypted identifier code attached to each 
patient’s data to allow for longitudinal comparisons. Data extraction 
was performed using a validated extraction tool at 1 month before 
randomization to check data quality, at randomization and at the end 
of the study.23
Outcomes
Coprimary outcomes were defined as follows:
1.  The proportion of eligible patients who received appropriate 
screening of CVD risk factors by the end of study. This was defined 
as having recorded: smoking status at least once, systolic blood 
pressure (BP) in the previous 12 months, total cholesterol and high-
density lipoprotein cholesterol in the previous 24 months.
2.  The proportion of eligible patients defined at baseline as being at 
high CVD risk, receiving recommended medication prescriptions 
at the end of study. This was defined as (1) current prescription for 
≥1 BP-lowering drugs and a statin for people at high risk with-
out established CVD, (2) current prescription for ≥1 BP-lowering 
drugs and a statin and an antiplatelet agent (unless contraindicated 
by oral anticoagulant use) for people with established CVD, or (3) 
lowering of calculated 5-year CVD risk to ≤15%.
High CVD risk is defined in Australian guidelines as (1) history of 
CVD (diagnosis of coronary heart disease, cerebrovascular disease, 
peripheral vascular disease); (2) the presence of any guideline-stip-
ulated clinically high-risk conditions (diabetes mellitus and age >60 
years, diabetes mellitus and albuminuria, stage 3B chronic kidney dis-
ease, or extreme individual risk factor elevations: systolic BP ≥180 
mm Hg, diastolic BP ≥110 mm Hg, total cholesterol >7.5 mmol [290 
mg/dL])19; or (3) a calculated 5-year CVD risk of >15% using the 
1991 Anderson Framingham equation.24
Secondary outcome measures included (1) measurements of indi-
vidual CVD risk factors (smoking status, BP, lipids, body mass index, 
estimated glomerular filtration rate, and albuminuria); (2) escalation 
of drug prescription among patients at high CVD risk (either newly 
prescribed or additional numbers of antiplatelet, BP-lowering and 
lipid-lowering agents); (3) BP and serum lipid levels among people 
at high CVD risk; and (4) newly recorded CVD-related diagnoses.
Sample Size
Randomization of 60 services (30 per arm) was calculated to provide 
90% power to detect a ≥10% absolute higher occurrence in each pri-
mary study outcome among services receiving the intervention. This 
assumed for the coprimary outcomes a 10% absolute improvement 
in the control arm as a result of study participation, an average clus-
ter size of 750 patients with 30% of these at high CVD risk, base-
line rates of risk factor measurement and appropriate prescribing of 
50%,10 2α=0.05 and an intraclass correlation coefficient of 0.05. The 
intraclass correlation coefficient was based on data from 3 recent 
cross-sectional studies in Australian general practices and ACCHSs 
conducted by our group.10,11
Data Analysis
Patient-level data analysis was performed using SAS enterprise guide 
5.1 (SAS Institute Inc, Cary, NC) on an intention-to-treat basis us-
ing generalized estimating equations with an exchangeable correla-
tion structure to account for clustering of patients within services. The 
population defined for the primary analyses was a cohort of eligible 
patients whose health record data were extracted at both randomization 
and end-of-study periods. Analyses were conducted using Gaussian 
and log-binomial generalized estimating equation regressions for con-
tinuous and binary outcomes, respectively. The intervention effects are 
expressed as unadjusted rate ratios for binary end points and mean dif-
ference for continuous end points with 95% confidence intervals (CIs) 
and P values. Subgroup analyses were performed using the 3 random-
ization strata. For each subgroup, the primary analysis was repeated 
with the addition of the subgroup variable along with its interaction 
with treatment. Heterogeneity was assessed based on the significance 
of the interaction term. Although formal adjustments for multiple tests 
were not made, findings are interpreted in the light of the number of 
comparisons made and the level of significance of the result.25
Ethical Considerations
The study was approved by the University of Sydney Human Research 
Ethics Committee and the Aboriginal Health and Medical Research 
Council Human Research Ethics Committee. Individual consent 
waiver was granted, given data collection was based on deidentified 
extracts from the electronic health record system. Signed agreements 
with participating sites were obtained.
Results
Recruitment
Sixty-four services were recruited from September 2011 to 
May 2012 (Figure 1) with 61 randomized (31 to intervention 
and 30 to usual care). One small intervention general practice 
site (n=152 eligible patients) withdrew from the study shortly 
after randomization. This left 60 randomized services and 
on outcome evaluation cohort of 38 725 eligible patients that 
included 10 308 patients defined as high CVD risk at baseline. 
Median follow-up for intervention and control arms was 17.3 
and 17.7 months, respectively. Almost all intervention services 
(27 sites) used the audit tool to conduct data extractions and 
submissions to the Web portal ≥50% of the time (ie, on average 
data were submitted at least bimonthly). Intervention practices 
received an average of 48-minute support per month compris-
ing on-site training, remote clinical Webinars, and helpdesk 
services. A detailed description of this support is provided in 
the Appendix in the Data Supplement. Table 1 shows the ser-
vice level characteristics, and Table 2 shows the baseline car-
diovascular risk profile of the sample.
Primary and Secondary Outcomes
During follow-up, patients in intervention sites were more 
likely to receive appropriate screening for CVD risk (62.8% 
versus 53.4% risk ratio [RR], 1.25; 95% CI, 1.04–1.50; P=0.02; 
Figure 2). Improvements were mainly driven by improvements 
in total/high-density lipoprotein cholesterol measurement and 
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BP recording. There was a trend to heterogeneity of effect 
based on whether these risk factors were measured at base-
line (Figure 3). For the high-risk cohort (n=10 308), baseline 
prescription rates of recommended medications were 46.7% 
(intervention) and 52.8% (control; Table 2). At end-of-study 
comparison, there were no statistically significant improve-
ments in prescription of recommended medications (56.8% 
versus 51.2%; RR, 1.11; 95% CI, 0.97–1.27; P=0.12). The 
intervention was most strongly associated with escalation 
of medications for patients at high risk (new prescriptions 
or increased numbers of medications) with respect to anti-
platelet medications (17.9% versus 2.7%; RR, 4.80; 95% CI, 
2.47–9.29; P<0.001), lipid-lowering medications (19.2% ver-
sus 4.8%; RR, 3.22; 95% CI, 1.77–5.88; P<0.001), and BP-
lowering medications (23.3% versus 12.1%; RR, 1.89; 95% 
CI, 1.08–3.28; P=0.02).
For the intervention arm site that withdrew from the study, 
a sensitivity analysis was conducted assuming that there was 
no improvement in the coprimary outcomes at end of study for 
this site and this had negligible effect on the findings. Because 
of likely effect modification relating to initial levels of the 
coprimary outcome, we did not conduct adjusted analyses for 
baseline differences. As is more appropriate in the presence of 
effect modification, we interpreted the effect of the interven-
tion based on stratified results.
In the high-risk cohort, there were no clear effects on 
mean systolic BP (−2.3 versus −1.5 mm Hg; difference, −0.8 
mm Hg; 95% CI, −2.0 to 0.4; P=0.20) and low-density lipo-
protein cholesterol (−0.14 versus −0.09 mmol/L; difference, 
−0.05 mmol/L; 95% CI, −0.12 to 0.01; P=0.08). There was a 
higher proportion attaining guideline BP targets in the inter-
vention group versus control (61.0% versus 55.0%; RR, 1.10; 
95% CI, 1.00–1.20; P=0.05). There were no differences in the 
proportion attaining lipid targets (P=0.61). There were also no 
significant differences in prescribing rates for BP, statin, and 
Table 1. Baseline Service Characteristics
Intervention  
(n=30; n=19 385)
Usual Care  
(n=30; n=19 340)
Eligible population
  <500 15/30 (50%) 15/30 (50%)
  ≥500 15/30 (50%) 15/30 (50%)
Type of service
  ACCHS 10/30 (33%) 10/30 (33%)
  General Practice 20/30 (67%) 20/30 (67%)
Current participation in a QI initiative
  No 17/30 (57%) 16/30 (53%)
  Yes 13/30 (43%) 14/30 (47%)
Medical software used
  Best Practice 10/30 (33%) 11/30 (37%)
  Medical Director 20/30 (67%) 19/30 (63%)
IT support
  Both local and 
external
5/30 (17%) 11/30 (37%)
  External 17/30 (57%) 14/30 (47%)
  Local 8/30 (27%) 5/30 (17%)
Staff currently using data extraction tools
  Most 1/30 (3%) 1/30 (3%)
  Some 18/30 (60%) 19/30 (63%)
  None 11/30 (37%) 10/30 (33%)
ACCHS indicates Aboriginal Community Controlled Health Service; IT, 
information technology; and QI, quality improvement.
64 health services agreed to participate
62 health services assessed for software 
requirements and had pre-randomisation data 
extractions performed
2 services decided not to 
participate on further 
consideration
61 health services randomised  
•31 sites randomised to intervention 
(21GPs, 10 ACCHS)
•28 sites received the intervention as randomised 
•2 sites used only the audit tool and quality 
improvement portal 
•1 site (GP) withdrew from the study shortly after 
randomisation (152 patients)
•Data extraction cohort
•19,385 patients median 498 /site (IQR 326- 755))
•5392 patients at high CVD risk- median 139 /site 
(IQR 93 - 238))
•30 sites randomised to usual care 
•Ps, 10 ACCHS)
•30 sites received usual care as randomised
•Data extraction cohort
•19,340 patients  at baseline (median 495 /site 
(IQR 349- 962))
•4916 patient at  high CVD risk- (median 135 /site 
(IQR 74- 219))
1 service did not meet technical 
software requirements
•30 sites analysed at end of study 
•Median follow-up 17.3 months (IQR 15.3-18.0)
•30 sites analysed at end of study
•Median follow-up 17.7 months (IQR 14.3-18.3)
Figure 1. Study flow diagram. ACCHS indicates Aboriginal Community Controlled Health Service; CVD, cardiovascular disease; GP, 
general practice; and IQR, interquartile range.
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antiplatelet medicines for those at low risk of CVD (<10% at 
5-year risk; all P>0.55). There were no differences in the pro-
portion with newly recorded CVD diagnoses (P=0.72).
There were greater improvements in risk factor screening in 
smaller when compared with larger health services (P interac-
tion=0.02), but no other significant differences were observed 
for either primary outcome for any prespecified subgroup 
(Figure 3).
In a post hoc analysis, there was a significant heterogeneity 
of effect according to whether patients were prescribed recom-
mended medicines at baseline (interaction P=0.03) with those 
not prescribed medicines (n=5090) showing a large improvement 
(38.3% versus 20.9%; RR, 1.59; 95% CI, 1.19–2.13; P<0.001).
Discussion
TORPEDO contributes new evidence on the effect of tech-
nology-assisted interventions to improve healthcare qual-
ity. It address a recent US Community Prevention Services 
Taskforce recommendation that multicomponent service 
delivery interventions, combining electronic health record–
integrated decision support with performance feedback, are 
needed for CVD prevention.17 TORPEDO demonstrated that a 
Table 2. Baseline Patient Characteristics
Intervention (Sites=30; n=19 385) Usual Care (Sites=30; n=19 340)
Available Data n (%) or Mean (SE) Available Data n (%) or Mean (SE) P Value
Age, y, mean (SD) 19 382 60.7 (12.4) 19 339 61.3 (12.7) 0.66
Men 19 377 7729 (40.0%) 19 305 8536 (44.0%) 0.03
Aboriginal/Torres Strait Islander 19 385 3624 (18.7%) 19 340 3292 (17.0%) 0.66
Current smoker/ex-smoker in the past 12 mo 16 539 3524 (21.4%) 16 464 3537 (21.4%) 0.94
Systolic blood pressure, mm Hg, mean (SD) 17 497 129.9 (17.5) 18 092 129.9 (16.4) 0.61
Total cholesterol, mmol, mean (SD) 16 383 5.00 (1.08) 14 544 5.00 (1.13) 0.40
High-density lipoprotein, mmol, mean (SD) 15 422 1.40 (0.43) 12 761 1.40 (0.41) 0.69
HbA1c for those with recorded diagnosis of 
diabetes mellitus, %, mean (SD)
3224 8.0 (4.6) 2942 7.5 (1.8) 0.16
Body mass index >30 kg/m2 12 981 4949 (36.3%) 13 647 4900 (37.8%) 0.32
Albuminuria* 3942 1025 (25.7%) 3996 1181 (30.0%) 0.79
Estimated glomerular filtration  
rate† <60 mL/min per 1.73 m2
16 415 1476 (9.9%) 14 876 1896 (11.6%) 0.87
Recorded diagnoses
  Coronary heart disease 19 385 2170 (11.2%) 19 340 1914 (9.9%) 0.31
  Cerebrovascular disease 19 385 570 (2.9%) 19 340 525 (2.7%) 0.92
  Peripheral vascular disease 19 385 160 (0.8%) 19 340 206 (1.1%) 0.51
  Diabetes mellitus 19 385 3555 (18.3%) 19 340 3250 (16.8%) 0.95
  Left ventricular hypertrophy 19 385 34 (0.2%) 19 340 95 (0.5%) 0.01
  Atrial fibrillation 19 385 724 (3.7%) 19 340 657 (3.4%) 0.85
  Heart failure 19 385 354 (1.8%) 19 340 287 (1.5%) 0.84
CVD risk information
  5-y CVD risk‡
   Missing information 19 385 5678 (29.3%) 19 340 7101 (36.7%) 0.19
   <10% 19 385 7197 (37.1%) 19 340 6493 (33.6%) 0.40
   10%–15% 19 385 1118 (5.8%) 19 340 830 (4.3%) 0.29
   >15% 19 385 505 (2.6%) 19 340 398 (2.06%) 0.30
Clinically high risk condition§ 19 385 2249 (11.6%) 19 340 2094 (10.8%) 0.94
Established CVD║ 19 385 2638 (13.6%) 19 340 2424 (12.5%) 0.61
Primary outcomes at baseline
  Patients with appropriate CVD risk screening 19 385 10 110 (52.2%) 19 340 8558 (44.3%) 0.47
  Patients at high CVD risk with appropriate 
medical management
5392 2516 (46.7%) 4916 2598 (52.8%) 0.17
HbA1c indicates glycated hemoglobin.
*Urinary albumin:creatinine ratio >2.5 men and >3.5 women.
†Calculated using the Chronic Kidney Disease Epidemiology Collaboration formula.
‡Calculated using the 1991 Anderson Framingham risk equation.
§Any of the following based on Australian guidelines: diabetes mellitus and age >60 year, diabetes mellitus and albuminuria, estimated glomerular filtration rate 
<45 mL/min per 1.73 m2, systolic blood pressure (BP) ≥180 mm Hg, diastolic BP ≥110 mm Hg, total cholesterol >7.5 mmol/L.
║Any of the following: coronary heart disease, cerebrovascular disease, and peripheral vascular disease.
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computer-guided intervention comprising point-of-care deci-
sion support, audit and feedback tools, training and support 
improved cardiovascular risk factor screening. The interven-
tion did not improve the prescription of appropriate preven-
tive drugs in the overall high-risk cohort. The improvements 
identified in the high-risk individuals inadequately treated at 
baseline suggest that this is the group most likely to benefit 
from the intervention; however, this was a post hoc analy-
sis. The escalation in guideline-based care indicates that the 
intervention was effective in reducing practitioner therapeutic 
inertia (the failure to initiate or increase therapy when treat-
ment goals are not being met) although it must be emphasized 
that absolute rates of treatment remained unacceptably low.26 
The observed improvements in care were equally apparent in 
ACCHSs and in general practices; this is especially pertinent 
to addressing Indigenous health inequities in Australia, which 
are largely driven by excess CVD burden.
Despite more than a decade of CVD guidelines recommend-
ing medical management on the basis of overall cardiovascu-
lar risk, most implementation strategies have focused on the 
management of single risk factors and there are few strategies 
that have been shown to be effective in changing practitioner 
behavior toward risk-based management. The US Community 
Prevention Services Taskforce review of 44 randomized 
controlled trials on effectiveness of cardiovascular decision 
support systems found median absolute improvements of 
3.2% for screening and 4.0% for test ordering.18 In the area 
of audit and feedback, a systematic review of 49 studies (not 
CVD specific) found a median absolute improvement in per-
formance of 4.3%.17 TORPEDO demonstrated 3-fold greater 
improvements than these for screening and test ordering. Key 
features of the TORPEDO interventions that are known to be 
drivers of change included work flow integration, alignment 
with usual decision-making processes in the patient consulta-
tion, provision of treatment recommendations rather than just 
assessments, and repeated audit and feedback with explicit 
recommendations.14,17
Importantly, however, TORPEDO was less successful 
in shifting prescribing behavior, which is consistent with 
small intervention effect sizes found in the US Community 
Prevention Services Taskforce systematic review (only a 2% 
absolute improvement).18 Consequently, there remains much 
scope for further improvements if such QI strategies are to 
translate into tangible health benefits. Berwick27 has com-
mented that QI is not a single, testable answer. Rather it is a 
complex process driven by a range of factors at the level of 
the patient, provider, health service, and the broader health 
system.28 For diabetes mellitus care, QI strategies that have 
targeted both prescriber and patient behavior change in combi-
nation seem to be associated with greater success.29 Similarly, 
for CVD risk management, patient-focused strategies may be a 
critically important additional element to improving outcomes. 
Despite the bold promise of consumer-focused technologies to 
increase patient engagement, few trials have been conducted 
1571/2697 (58.3%) 1311/2422  (54.1%) 1.09  (0.97, 1.22) 0.16
Current prescription for at least one BP medicine, a statin
and an antiplatelet medicine for people with CVD
0.121459/2638 (55.3%) 1172/2424  (48.4%) 1.14  (0.97, 1.35) 0.10
Escalation of antiplatelet medicines for people 
with CVD
470/2638 (17.8%) 65/2424  (2.7%) 4.79  (2.47, 9.29) <.001
Escalation of lipid-lowering medicines 1026/5335 (19.2%) 226/4846  (4.7%) 3.22  (1.77, 5.88) <.001
Escalation of BP-lowering medicines 1243/5335 (23.3%) 586/4846   (12.1%) 1.89  (1.09, 3.28) 0.02
Intervention Usual care
Risk ratio
(95% CI) p -value
Favours
Usual care
Favours
Intervention
0.42
0.57
0.06
0.49
ICC
CVD risk screening (n=38,275)
Primary outcome
Proportion receiving appropriate and timely 
measurement of CVD risk factors 12164/19385 (62.8%) 10317/19340  (53.4%) 1.25  (1.04, 1.50) 0.02
Secondary outcomes
Smoking status recorded 17596/19385    (90.8%) 17227/19340  (89.1%) 1.04  (0.96, 1.13) 0.35
Systolic BP recorded in previous 12 months 16433/19385 (84.8%) 15587/19340  (80.6%) 1.08  (0.99, 1.18) 0.09
Total & HDL cholesterol recorded in the 
previous 24 months
14641/19385  (75.5%) 12855/19340  (66.5%) 1.19  (1.03, 1.37) 0.02
BMI measurement in previous 12 months 9780/19385  (50.5%) 9559/19340  (49.4%) 0.97  (0.77, 1.23) 0.79
Urinary ACR measured in the previous 24 months 5196/19385  (26.8%) 4281/19340  (22.1%) 1.23  (0.84, 1.80) 0.29
eGFR measured in the previous 24 months 16230/19385  (83.7%) 15494/19340  (80.1%) 1.06  (0.97, 1.15) 0.20
Primary outcome
Proportion receiving guideline recommended 
medication prescriptions 
3030/5335 (56.8%) 2483/4846  (51.2%) 1.11  (0.97, 1.27) 0.12
Secondary outcomes
Current prescription for at least one BP lowering medicine 
and a statin for people at high risk without CVD
0.09
0.06
0.11
0.09
0.15
0.05
0.08
0.08
Medication management for people at high CVD risk (n=10,308)
Figure 2. Cardiovascular disease (CVD) risk factor screening and medication management end points. ACR indicates albumin:creatinine 
ratio; BMI indicates body mass index; BP, blood pressure; CI, confidence interval; eGFR, estimated glomerular filtration rate; HDL, high-
density lipoprotein; and ICC, intraclass correlation coefficient.
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to examine their effectiveness, costs, and optimal delivery 
mechanisms. New studies are required that combine such con-
sumer-focused approaches with provider-focused approaches, 
each designed in a way that takes careful account of health 
service and system characteristics. Given the particularly large 
unmet need for quality improvement interventions in low- and 
middle-income countries, such regions should also be a major 
focus for attention.30
The strengths of this study include the pragmatic implemen-
tation of a randomized study within usual day-to-day prac-
tice, the large sample size, the clinical outcome data, scalable 
intervention components, and the low level of implementation 
support required. Another strength is the representativeness of 
participating general practices and ACCHSs. All general prac-
tices included in TORPEDO were recruited from urban set-
tings (in which ≈70% of all Australian general practices are 
based) and had site characteristics that were broadly represen-
tative of general practice in Australia.31 The ACCHSs repre-
sented urban, rural, and remote regions and comprised ≈20% 
of all ACCHSs that provide medical services in Australia. The 
TORPEDO ACCHS sites also demonstrated service character-
istics that were similar to the sector at large.32 Furthermore, the 
baseline rates for key outcome measures were similar to those 
found in previous Australian studies in both general practice 
and ACCHSs.10,11
The main study limitation is that it was not powered for clin-
ical outcomes. This needs to be balanced against the pragmatic 
nature of the trial and a focus on increasing prescription of 
treatments of known efficacy, which is a critical first step in 
maximizing the full benefits of such treatments. Data link-
age studies with national hospitalization and mortality data-
bases are currently being planned and will help to ascertain 
the effect on hard outcomes. Although not a limitation per se, 
the intervention is ideally suited for implementation in set-
tings where there are high adoption rates of electronic health 
records. Australia has among the highest rates of electronic 
health record adoption in the world (>90%); however, uptake 
is increasing internationally with the majority of high-income 
countries in Europe now achieving rates in excess of 80% 
and substantial implementation occurring in North America, 
spearheaded by the Medicare and Medicaid meaningful use 
program.33,34 Intervention programs such as that tested by 
TORPEDO are therefore well placed for large-scale imple-
mentation in high-income countries. Indigenous governed 
community health services operating within other high-income 
country settings, such as United States and Canada, may also 
be well suited to adopting this intervention. These findings 
may also have broader relevance to the management of cardio-
vascular risk in other resource-poor settings and in other rural 
and remote communities.
The implications of effective QI tools and strategies are 
substantial. Improving health system performance by even a 
small margin has the potential to make a major effect on dis-
ease burden if improvements can be delivered at scale. Taking 
CVD risk screening by subgroup (n=38,275)
(Proportion receiving appropriate and timely measurement of CVD risk factors)
Type of service
ACCHS 2904/4812 (60.4%) 1579/3459 (45.7%) 1.29  (0.98, 1.70) 0.76
General Practice 9260/14573 (63.5%) 8738/15881 (55.0%) 1.22  (0.97, 1.55)
Service size at baseline
Small (<500) 2652/4436 (59.8%) 1620/4343 (37.3%) 1.63  (1.17, 2.26) 0.02
Large (>=500) 9512/14949 (63.6%) 8697/14997 (58.0%) 1.03  (0.87, 1.23)
Participation at baseline in a national 
quality improvement program
No 7576/11839 (64.0%) 5113/9843 (52.0%) 1.35  (1.00, 1.82) 0.41
Yes 4588/7546 (60.8%) 5204/9497 (54.8%) 1.16  (0.94, 1.43)
Medication management for people at high CVD risk (n=10,308) by subgroup
(Proportion receiving guideline recommended medication prescriptions)
Type of service
ACCHS 1112/1622 (68.6%) 787/1195 (65.9%) 1.05  (0.97, 1.14) 0.45
General Practice 1918/3713 (51.7%) 1696/3651 (46.5%) 1.14  (0.96, 1.35)
Service size at baseline
Small (<500) 757/1315 (57.6%) 800/1390 (57.6%) 1.04  (0.86, 1.24) 0.35
Large (>=500) 2273/4020 (56.5%) 1683/3456 (48.7%) 1.18  (0.98, 1.41)
Participation at baseline in a QI program
No 1583/3151 (50.2%) 1021/2209 (46.2%) 1.13  (0.92, 1.39) 0.91
Yes 1447/2184 (66.3%) 1462/2637 (55.4%) 1.11  (0.98, 1.26)
Intervention Usual care
Risk ratio
(95% CI)
p-value
interaction
Favours
Usual care
Favours
Intervention
0.07
0.09
0.09
0.05
0.08
0.01
0.06
0.11
0.06
0.14
0.07
0.13
ICC
Figure 3. Screening and medication management end points by prespecified subgroups. ACCHS indicates Aboriginal Community 
Controlled Health Service; CI, confidence interval; CVD, cardiovascular disease; ICC, intraclass correlation coefficient; and QI, quality 
improvement.
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a conservative estimate that 5% of people in Australia have at 
least a 20% 5-year CVD risk,35 and using published data on 
risk reductions from treatment interventions,36–38 a 2 mm Hg 
mean systolic BP reduction, 0.1 mmol low-density lipoprotein 
reduction, and a 10% increase in aspirin adherence together 
could lead to around a 10% relative risk reduction and ≈20 000 
fewer events >5 years. Such improvements highlight the great 
potential for the primary healthcare sector to make a larger 
contribution to reduction of the CVD burden. Scalable and 
effective systems that require minimal support to implement 
could make major improvements in primary healthcare system 
performance and health outcomes globally.
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Intervention components 
Component 1: Point of care decision support for use in clinical consultations 
A risk assessment score and traffic light dashboard would appear when the HealthTracker assessment was opened. If essential information was 
missing to calculate risk then the risk bar would be in greyscale, an alert would state that risk cannot be calculated because essential information 
is missing and a traffic light prompt would alert the practitioner to the variables that were missing. 
Pen Computers Sidebar 
application automatically 
extracts data from the 
primary care health record
Health Tracker- CVD 
screening and management 
panel.
Traffic light treatment 
recommendations based on 
national guidelines
Risk factor information 
extracted from the patient’s 
health record
The patients GP health 
record
A resource link providing 
access to clinical guidelines
Risk of heart attack or stroke 
in the next 5 years
Recommended screening 
tests based on national 
guidelines
Component 2: Risk communication tool 
This tool enables health care providers to discuss the risk score with patients and to perform “what if” scenarios to illustrate changes in risk score 
and trajectory with particular risk factors available. It draws on a similar approach taken in a New Zealand risk communication tool and 
incorporates a “heart age” calculation to show the user at what age their risk score would be similar to a person with “optimal” risk factor 
control. The tool was only used for primary prevention and would not appear for those with established cardiovascular disease. 
Component 3: Clinical Audit Tool 
This data extraction tool allowed clinic staff to monitor performance and identify patients that were not being appropriately managed according 
to guidelines. Four sets of graphs were provided (screening gaps, risk profile, prescribing gaps for the high risk population and meeting guideline 
targets for blood pressure and lipids). For each of the graphs the practitioner can click on the red section of the column (eg. those without a 
cholesterol test performed) and the patients in that section would pop up as a list. Customised bubble alerts can then be set each time that patient 
record is opened or clinic administration staff can set up recall and reminder alerts/ letters to notify the patient to attend for a consultation. 
Component 4: Peer-ranked performance portal 
Each month, clinics were asked to send de-identified aggregated data extracts for six performance indicators to a central secure facility. For each 
indicator the clinic would be able to securely log on to this facility and identify on a histogram their performance (in red) against all other 
participating sites for that reporting period. They would also be able to access a trend graph of their changes over time compared to the average. 
Component 5: Staff training and support 
All contact time to support intervention implementation was logged on a standardised reporting template. There were three types of intervention 
support: 
1. On site- support. All intervention arm sites received an initial face-to-face visit either at randomisation or shortly after randomisation to
familiarize themselves with the intervention. Additional on-site support was provided at the request of the participating service with most
sites receiving at least one follow-up visit. The median support time per site for the whole intervention period was 300 minutes (interquartile
range (IQR) 172-510 minutes)
2. Remote clinical support was provided via training webinars, remote desktop connection and phone support. This was ad hoc and provided
either at the request of the participating service or via a training webinar which was advertised to particular services. Only 14 of the 30
intervention arm services used remote clinical support. The median remote support time for these 14 sites for the whole intervention period
was 38 minutes (IQR 16-112 minutes)
3. Technical support comprised helpdesk support provided by the software company for installation, assistance with user registration and
password recoveries, software updates and any general issues with software performance. All of this support was provided by phone and
remote desktop log in. The median technical support time for the whole intervention period for 28 sites with data available was 320 minutes
(IQR 209-386 minutes)
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ABSTRACT
Background: Large gaps exist in the implementation
of guideline recommendations for cardiovascular
disease (CVD) risk management. Electronic decision
support (EDS) systems are promising interventions to
close these gaps but few have undergone clinical trial
evaluation in Australia. We have developed
HealthTracker, a multifaceted EDS and quality
improvement intervention to improve the management
of CVD risk.
Methods/design: It is hypothesised that the use of
HealthTracker over a 12-month period will result in:
(1) an increased proportion of patients receiving
guideline-indicated measurements of CVD risk factors
and (2) an increased proportion of patients at high risk
will receive guideline-indicated prescriptions for
lowering their CVD risk. Sixty health services
(40 general practices and 20 Aboriginal Community
Controlled Health Services (ACCHSs) will be
randomised in a 1:1 allocation to receive either the
intervention package or continue with usual care,
stratified by service type, size and participation in
existing quality improvement initiatives. The
intervention consists of point-of-care decision
support; a risk communication interface; a clinical
audit tool to assess performance on CVD-related
indicators; a quality improvement component
comprising peer-ranked data feedback and support to
develop strategies to improve performance. The control
arm will continue with usual care without access to
these intervention components. Quantitative data will
be derived from cross-sectional samples at baseline
and end of study via automated data extraction.
Detailed process and economic evaluations will also
be conducted.
ARTICLE SUMMARY
Article focus
▸ The development of a multifaceted decision
support tool and quality improvement (QI)
intervention.
▸ The methods to test the effectiveness of this inter-
vention in improving guideline-recommended
screening for cardiovascular risk and management
for individuals identified at high risk.
Key messages
▸ This study tests a novel intervention that incor-
porates point of care decision support, risk
communication and resources for patients,
health service audit tools and use of data for
supporting QI initiatives.
▸ In addition to assessing practitioner perform-
ance on indicators correlated with improved
health outcomes, the study also includes
detailed process and economic evaluations.
Strengths and limitations of this study
▸ The strengths of the study are that it assesses an
innovative complex intervention that is implemen-
ted in routine primary healthcare settings. It will
provide rigorous evidence on process, clinical and
economic outcomes and addresses an important
issue facing health systems worldwide—namely
scalable interventions that are able to achieve
improvements in performance.
▸ The main limitation is that it is conducted in one
country, Australia, and thus its generalisability
may be influenced by the prevailing health
system context.
Peiris D, Usherwood T, Panaretto K, et al. BMJ Open 2012;2:e002177. doi:10.1136/bmjopen-2012-002177 1
Open Access Protocol
 group.bmj.com on June 14, 2014 - Published by bmjopen.bmj.comDownloaded from 
Ethics and dissemination: The general practice component of the
study is approved by the University of Sydney Human Research
Ethics Committee (HREC) and the ACCHS component is approved by
the Aboriginal Health and Medical Research Council HREC. Formal
agreements with each of the participating sites have been signed.
In addition to the usual scientific forums, results will be
disseminated via newsletters, study websites, face-to-face feedback
forums and workshops.
Trial registration: The trial is registered with the Australian Clinical
Trials Registry ACTRN 12611000478910.
BACKGROUND
Cardiovascular disease burden in Australia
Despite recent gains, cardiovascular disease (CVD)
remains Australia’s biggest killer accounting for 18%
of the total disease burden and 11% of health system
expenditure in Australia.1 Aboriginal and Torres Strait
Islander peoples experience around ﬁve times greater
CVD burden than other Australians.2 Current estimates
project that by 2030 annual CVD expenditure will rise by
around 100% to $16 billion.3 Primary care-based strat-
egies that improve the uptake of best-practice recom-
mendations could substantially reduce both the
Indigenous and non-indigenous CVD burden and help
improve health system efﬁciencies.
Evidence-practice gaps in CVD prevention
In addition to lifestyle modiﬁcation, a number of drug
therapies have been shown to be highly effective in pre-
venting cardiovascular events, primarily through modiﬁ-
cation of blood pressure, lipids and platelet function.4–8
However, there is compelling evidence of the failure of
current clinical practice to adequately implement such
treatments, and to translate current knowledge into
maximally improved health outcomes. Three recently
completed cross-sectional studies of CVD risk manage-
ment in Australian general practice and Aboriginal
Community Controlled Health Service (ACCHS) set-
tings9–11 demonstrated that 50% of routinely attending
adults lacked sufﬁcient recorded information to compre-
hensively evaluate vascular risk. For those identiﬁed at
high vascular risk, only around 40% were prescribed
guideline-indicated medicines. Similar ﬁndings have
been noted in other Australian studies.12–15 These
surveys have demonstrated failure to adequately imple-
ment the ‘absolue risk’ paradigm for CVD prevention.
Numerous tools are now available to estimate an indivi-
dual’s 5-year or 10-year absolute risk of coronary heart
disease and/or CVD.16–21 Despite their availability, only
a minority of Australian general practitioners (GPs) use
these risk assessment tools, and then primarily for
patient education, rather than to guide management
decisions.9 22 23 Australia’s ﬁrst absolute risk assessment
guideline was released in 2009 by the National Vascular
Disease Prevention Alliance (NVDPA)17 and in 2012 this
was augmented by a single management guideline.24
Despite these guidelines now becoming available, there
remain substantial challenges in effectively implement-
ing their recommendations. We have found that
CVD-risk assessment and treatment work best when
negotiated as part of a shared decision-making
approach, taking an average of 15 min even where only
one guideline needs to be consulted.25
The role of electronic decision support in closing evidence
practice gaps
Electronic decision support (EDS) systems are among
the most promising interventions to improve uptake of
guideline-based recommendations in clinical practice. In
ﬁve systematic reviews on the effectiveness of EDS,
around two-thirds of studies demonstrated improvement
in practitioner performance.26–30 One systematic review
identiﬁed four decision support system features asso-
ciated with improved performance: incorporation in
routine work ﬂow, provision at the time and location of
patient consultation, use of computer-based tools and
provision of treatment recommendations rather than
just assessments.28 Of 32 systems that incorporated all of
these elements, signiﬁcant improvements in perform-
ance were noted in 30. There are relatively few con-
trolled evaluations of EDS systems that are integrated
with electronic health records (EHRs) in the area of
CVD.31–35 Effect sizes vary greatly depending on the vari-
ables studied and the type of EDS system. In one system-
atic review of on-screen point-of-care reminder systems
the absolute improvements ranged from 1% to 24% for
test ordering and from 3% to 28% for medication pre-
scribing.27 In New Zealand, an EDS system that is fully
integrated with the country’s most popular primary care
software has been successfully implemented.36 To date,
we are unaware of an EDS system aimed at assisting com-
prehensive cardiovascular risk management based on
Australian guidelines. Furthermore, we are not aware of
any randomised evaluations of such systems in Australian
primary care settings. Globally, few examples exist and
the evidence base remains poor.
INTERVENTION DEVELOPMENT
HealthTracker is a novel EDS system to facilitate
guideline-based assessment and management of CVD
risk. Outlined below are the key steps taken in the devel-
opment of the intervention.
Algorithm development and validation
A single screening and management algorithm was
developed based on a synthesis of recommendations
from several primary care screening and management
guidelines (table 1). The algorithm calculates a person’s
5-year absolute CVD risk based on the Framingham risk
equation and NVDPA recommendations 17 20 and pro-
vides management recommendations based on the
guidelines listed in table 1. In 2008–2009, a β-version of
HealthTracker was developed in a stand-alone software
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system and independently validated for accuracy and
compliance with the prevailing guidelines.22 In 2011,
the algorithm was extensively revised to incorporate
recommendations from newly published guidelines.
A similar validation process was then conducted consist-
ing of three levels:
▸ Level 1 was an iterative process where each of the cal-
culations programmed in the algorithm were tested
to ensure they were consistent with recommendations
from the guidelines. This was conducted using dei-
dentiﬁed data from 337 patients involved in the pilot.
Programming modiﬁcations were made where neces-
sary and all variables were retested to ensure they
were programmed correctly.
▸ Level 2 involved giving a plain language summary of
the algorithm to a research fellow who had not been
involved in the development of the algorithm. She
independently programmed the algorithm into a statis-
tical software package. Using data from 9077 patients
from three representative cross-sectional general prac-
tice surveys,9–11 we then assessed whether the outputs
from HealthTracker correlated with those generated
from the independently programmed version. For 60
of the 63 output variables HealthTracker achieved
perfect correlation with the independently pro-
grammed version. For the remaining three variables
minor programming errors were identiﬁed and
corrected.
▸ Level 3 involved user acceptance testing and scrutiny
of the algorithm by the study investigators, 20 health
professionals working in both General Practice
and ACCHSs and three national professional
organisations—the NVDPA, the Royal Australian
College of General Practitioners and the National
Prescribing Service. Following this feedback, a
number of minor algorithm and user interface
changes were incorporated into the ﬁnal version of
the tool. The level 2 testing process was repeated
following these changes and perfect correlation
between HealthTracker and the independently pro-
grammed version was achieved for all variables.
Integration of HealthTracker with the primary care
electronic health record and quality improvement tools
HealthTracker interfaces with the two Australian clinical
practice software systems most commonly used in general
practice and ACCHS settings (Medical Director and Best
Practice). There are four components to the system:
▸ Point-of-care decision support: HealthTracker is built in
the Pen Computer Systems PrimaryCareSidebar,
third-party software that interacts with the primary
EHR system. Figure 1 shows the HealthTracker user
interface and its integration with the
PrimaryCareSidebar and the EHR. A prompt function
is used to encourage health professionals to conduct
a cardiovascular assessment if guideline recom-
mended. Where possible, the tool populates with
information from the patient’s record. If essential
information required for the calculation of absolute
risk is missing or out-of-date, a trafﬁc light prompt
alerts the health professional and updated informa-
tion can be entered. If the patient is receiving subopti-
mal treatment then a trafﬁc light recommendation is
made to consider initiation of treatment or additional
agents. Information about eligibility for the Australian
Government Pharmaceutical Beneﬁts Scheme subsidy
is provided if lipid lowering medicines are recom-
mended. All outputs are qualiﬁed by statements
emphasising that the ﬁnal decision to commence or
change therapy should be made by the health profes-
sional based on all available information.
Table 1 Guidelines used in the HealthTracker algorithm
Professional organisation Guideline
National Vascular Disease Prevention Alliance Guidelines for the Assessment of Absolute Cardiovascular Disease Risk
2009
National Heart Foundation Reducing Risk in Heart Disease 2008
Guide to Management of Hypertension 2008- Updated Aug 2009
Aspirin for cardiovascular disease prevention 2003
National Heart Foundation/ Cardiac Society of
Australia and New Zealand
The Lipid Position Statement 2005
National Stroke Foundation Clinical Guidelines for Stroke Management 2010
Royal Australian College of General
Practitioners
Guidelines for preventive activities in general practice 2009
Diabetes Australia Diabetes Management in General Practice 2010/2011
NHMRC Evidence Based Guidelines for Type 2 Diabetes 2009- Case
Detection and Diagnosis
NHMRC Evidence Based Guidelines for Type 2 Diabetes 2009- Diagnosis,
Prevention and Management of Chronic Kidney Disease
Kidney Health Australia Chronic Kidney Disease Management (CKD) in General Practice 2007
Department of Health and Aging Schedule of Pharmaceutical Benefits Scheme 2011 General Statement for
Lipid Lowering Drugs
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▸ A patient-oriented risk communication interface: A key
ﬁnding from the pilot evaluation was the role of the
output in risk communication. GPs wanted to inter-
actively alter current risk factors and perform ‘what
if’ scenarios to demonstrate to patients the effects of
current and altered risk over time. This functionality
has been built into HealthTracker and uses the
concept of ‘Heart Age’ to demonstrate to patients the
discrepancy between current risk and an ideal risk
based on well-controlled risk factor levels. Figure 2
shows an example of how a patient’s heart age
changes with the effect of smoking cessation.
▸ A data extraction tool: This provides health professionals
with immediate feedback on their performance on
screening and management of CVD risk for their
entire patient population. Figure 3 shows an example
of screening performance for a range of CVD risk
factors. Practitioners can use this tool to identify
speciﬁc patients in whom there may be a particular
risk factor measurement missing or a potential pre-
scribing gap. Customised point-of-care prompts can
then be created. When a patient record is opened an
alert is provided to notify the practitioner of the par-
ticular management issue and this can then be
actioned.
▸ A quality improvement (QI) component: This is aligned
with the methods of the Improvement Foundation of
Australia (IFA) Australian Primary Care
Collaboratives (APCC) programme. Deidentiﬁed data
extracts of clinical performance are securely exported
to a web-based central repository managed by the
IFA. This repository provides access to site-speciﬁc
feedback reports on performance compared with
other anonymised sites. Figure 4 shows an example of
how this information is presented.
STUDY OBJECTIVES
The TORPEDO study will test HealthTracker’s perform-
ance in assisting health professionals and patients in
making evidence-based management decisions to help
prevent heart attack, stroke and related conditions.
Hypotheses
Using a cluster randomised, controlled trial design, two
speciﬁc hypotheses will be tested. Compared with
control practices, those practices randomised to receive
HealthTracker will have:
1. An increased proportion of patients receiving appro-
priate (guideline-indicated) measurements of their
CVD risk factors.
2. An increased proportion of patients at high risk
receiving appropriate (guideline-indicated) prescrip-
tions for the management of their CVD risk.
These aims will be augmented by formal economic
and process evaluations to provide crucial information
on large-scale implementation and sustainability.
Figure 1 HealthTracker_user interface.
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STUDY DESIGN
HealthTracker will be evaluated using a cluster
randomised, controlled trial design. At end of study,
HealthTracker will be made available to both the inter-
vention and control arms for a further 12 months free of
any licence fees. The study schema including site and
patient eligibility criteria are highlighted in ﬁgure 5.
Eligibility criteria
Health service
1. Use of Medical Director or Best Practice for EHR
management.
2. Exclusive use of these systems to record risk factor
information, pathology test results and prescribe
medications.
3. Agreement by all GPs and other designated staff to
use HealthTracker.
Services that do not have a compliant software system
will be excluded from participation. Services using
‘hybrid’ paper and electronic systems for recording risk
factor information, pathology results and medication
prescription will also not be eligible to participate.
Patients
1. Aboriginal and Torres Strait Islander people 35+
years and all others 45+ years (age criteria are based
on NVDPA guideline screening recommendations37).
2. Attendance at the general practice or ACCHS at least
three times in the previous 24-month period AND at
least once in the previous 6-month period.
Site recruitment
Participating general practices have been recruited
from the Sydney region in collaboration with primary
healthcare organisations known in Australia as Medicare
Locals. Participating ACCHSs have been recruited in
partnership with two state representative bodies for
ACCHSs, the Aboriginal Health & Medical Research
Council (AH&MRC) of NSW and the Queensland and
Aboriginal Islander Health Council (QAIHC).
A $500AUD reimbursement to participating sites will be
made to partially compensate for health service staff
time commitment to study-related activities. Sites rando-
mised to the intervention will receive training support in
use of the system predominantly via face-to-face visits
and webinars. All licence costs and technical support
associated with the intervention will be provided free to
the intervention sites in the ﬁrst 12 months and to all
sites for the following 12 months after completion of
the trial. A newsletter and networking web site will be
provided to participating sites. Royal Australian College
of General Practitioners Quality Assurance and
Continuing Professional Development points will be
offered to participating GPs in both arms of the trial.
Figure 2 HealthTracker—cardiovascular disease-risk communication interface.
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Randomisation
Sixty services (40 general practices and 20 ACCHSs) will
be randomised in a 1:1 allocation to use HealthTracker
or ‘usual care’ for 12 months. Clusters will be stratiﬁed
at three levels:
1. ACCHS versus general practices.
2. Service size (<500 patients meeting eligibility criteria
vs >=500).
3. Participation in existing QI programmes (current
involvement in one of ﬁve national and state pro-
grammes involving regular audit and feedback versus
past or never involved in these programmes).
A site assessment survey will be administered to all
sites to assess for service eligibility and these stratifying
variables. Permuted block randomisation will be cen-
trally performed using a web-based form. As this is a
pragmatic trial, allocation will be single blinded with
outcome analyses conducted blinded to treatment
allocation.
Intervention group
The intervention arm will receive the four components
of the system described above (point-of-care decision
support software, risk communication tools, data extrac-
tion tools and access to the QI portal). Clinical staff will
be given training in use of the tools and a support
service will be available for any technical queries. One
initial face-to-face training visit and subsequent site visits
and webinars targeting strategies to improve quality of
care will be provided. Unless requested by health ser-
vices the intervention will not be modiﬁed or
discontinued. Reasons for discontinuation will be out-
lined and all analyses will be conducted on an
intention-to-treat basis (see below).
Control group
Sites allocated to this arm will continue usual practice
with their current systems without the implementation
of HealthTracker. As the George Institute holds exclusive
rights to the distribution of the system, there is no possi-
bility of control sites having access to HealthTracker. If
these sites already routinely use data extraction tools for
assessing their quality of care then this will continue as
normal. As with the intervention arm, services participat-
ing in any QI initiatives will continue participation as
usual. For those sites not routinely using data extraction
tools, the automated data extraction tool will be tempor-
arily installed for data collection purposes only and then
uninstalled that same day. A feedback report on per-
formance will be provided at study completion only.
Quantitative data collection
Cross-sectional data will be collected in an automated
manner for all patients who satisfy the eligibility criteria
at each service (ﬁgure 5). These data will then be sent
securely to the George Institute via an export function
for the analysis of primary and secondary outcomes.
Prerandomisation: 1 month prior to randomisation, dei-
dentiﬁed data will be collected from all sites. These data
will be fed back to all sites as a formal report highlight-
ing areas where data quality issues may occur.
Figure 3 Sample output of performance in cardiovascular disease-risk factor screening.
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Randomisation: Baseline data will be collected and sites
will be randomised to intervention or control.
End of intervention period: At the end of 12 months,
data will be collected in both study arms.
Primary outcomes
▸ Change in the proportion of eligible patients receiv-
ing appropriate measurements of their CVD risk in
the previous 12 months (measured at randomisation
and at 12 months).
▸ Change in the proportion of eligible patients assessed
at high CVD risk receiving appropriate prescriptions
for their CVD risk factors in the previous 12 months
(measured at randomisation and 12 months).
Appropriate measurement of CVD risk factors is
deﬁned as having recorded or updated all the essential
risk factors for the measurement of CVD risk (smoking
status, blood pressure (BP) in the previous 12 months,
total cholesterol and high-density lipoprotein (HDL)
cholesterol in the previous 24 months) among those in
whom risk assessment is guideline indicated. Unless
explicitly recorded, diagnoses of diabetes or left ven-
tricular hypertrophy will be assumed to be absent.
High CVD risk is deﬁned as a calculated 5-year CVD
risk of >15%, a history of CVD or the presence of any
clinically high-risk conditions (as per NVDPA recom-
mendations). Based on audit data, this is expected to
comprise ∼30% of the patient population.10 11
Appropriate prescriptions is deﬁned as a prescription
for one or more BP lowering drugs and a statin for
people at high risk without CVD; or a prescription for
one or more BP lowering drugs and a statin and an anti-
platelet agent (unless contraindicated by oral anticoagu-
lant use) for people with established CVD.
Secondary outcomes
▸ Change in the measurement of individual risk factors
separately (smoking status, BP, cholesterol, other
non-Framingham risk factors—BMI, chronic kidney
disease (CKD) screening with urinary Albumin
to Creatinine ratio, estimated Glomerular Filtration
Rate);
Figure 4 Sample display from the quality improvement portal.
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▸ Intensiﬁcation of existing medication regimes among
patients at high CVD risk (additional BP and
lipid-lowering agents);
▸ Changes in mean systolic BP, total cholesterol, LDL
cholesterol and HDL cholesterol;
▸ New CVD and CKD diagnoses.
Statistical considerations
Randomisation of 60 services (30 per arm) will provide
90% power to detect a ≥10% absolute higher occur-
rence in each primary study outcome among practices
receiving HealthTracker. The following assumptions are
based on our three audits in ACCHSs and mainstream
general practices9–11 and include an assumed improve-
ment of 10% in the two primary outcomes in control
practices as a result of study participation.
1. Cluster size of eligible population will range from 200
in a small service through to 2000 in a large service.
An average cluster size of 750 is assumed.
2. Recording rates of essential risk factors needed for
risk assessment in the target group (ﬁrst primary
outcome) average 50%.10 11
3. Thirty per cent of the cluster will be either be at high
CVD risk or have established CVD (n=250) and
prescription of appropriate medicines to high-risk
patients (second primary outcome) is 50%. This is
based on our published data on drug prescriptions
for individuals with and without established CVD.9–11
4. An intraclass correlation coefﬁcient of 0.05 for both
primary outcomes based on our audit data.9–11
5. Two-sided α=0.05
Data analysis will be performed on an intention-to-
treat basis using generalised estimating equations.38
Subgroup analyses will be carried out using the three
prespeciﬁed strata: (1) ACCHS versus general practices,
(2) service size (small vs large) and (3) current partici-
pation in QI programmes vs past or no involvement in
these programmes.
Economic evaluation
The economic evaluation will have a trial-based compo-
nent and a modelled evaluation of long-term costs and
outcomes. The incremental cost will be based on soft-
ware, training and other costs incurred with transition-
ing practices to using HealthTracker. This will help
determine the cost barriers experienced by different
practices in adopting the system. Data on medications,
laboratory tests, consultations and newly recorded diag-
noses of CVD events incurred by eligible patients during
the trial will be obtained from the data extraction tools.
Costs will be calculated from prevailing Medicare rates
and standard Australian National Diagnosis Related
Groups cost weights for CVD hospitalisations. The incre-
mental cost consequences of the HealthTracker system
in achieving each of the primary outcomes will then be
estimated, for example, cost per eligible patients
assessed at high CVD risk receiving appropriate prescrip-
tions. Trial-based data, however, cannot capture costs
and outcomes beyond the trial. To address this, a mod-
elled economic evaluation will enable quality of life and
survival to be examined and allow incremental cost-
effectiveness ratios to be calculated in terms of cost per
Quality Adjusted Life Years gained. Using a Markov
model, the eligible patient population in both study
arms will be hypothetically tracked over an extended
period. Transition between various deﬁned health states,
costs and quality of life attached to various health states
and the projected long-term intervention effects from
that observed in the trial will be based on published evi-
dence. With appropriate discounting, estimates of long-
term costs and outcomes will fold out of the model.
Sensitivity analyses will be conducted on discount rate,
uncertainty in outcome estimates and assumptions made
in costing (eg, varying efﬁciencies with different patient
practice ratios to those of the trial setting). This will
better inform policy makers as to the resource conse-
quences of rolling out this programme to scale.
Process evaluation
The qualitative evaluation of the β-version of
HealthTracker suggested that a critical factor affecting
the uptake of EDS interventions is whether and how
Figure 5 TORPEDO study schema.
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they become embedded in routine healthcare.22 In the
TORPEDO trial we will build on this observation
through a detailed process evaluation to better appreci-
ate the factors that might inﬂuence sustainability beyond
the trial setting. Two qualitative methods will be used to
explore these factors.
Semistructured interviews with health professionals and staff
A maximum variation sample will be taken to ensure
diverse opinions are gained from patients, clinical and
managerial health staff and sites with low and high
uptake of the intervention.39 Key issues to be explored
will include (1) how practitioners use HealthTracker;
(2) what effects it has on organisational practices and
personnel and (3) what are patients’ experiences of
being presented with HealthTracker outputs and what
impact does this have on the healthcare encounter.
Individual informed consent will be sought and data will
be collected towards the end of the intervention period
so as not to unduly inﬂuence trial outcomes.
Audio/video ethnography
A key component of understanding barriers/enablers to
use of HealthTracker is a better appreciation of how
practitioners and patients use it at the point of care.
Data collection using audio/video recording will capture
how technological innovations are actually used in prac-
tice.40 Ethnographic analysis will greatly augment the
interview accounts and will particularly shed important
light on (1) how the intervention impacts on the ﬂow of
the clinical encounter; (2) how risk information is com-
municated between health professional and patient and
(3) how the patient receives and interprets the informa-
tion and the role it may play in shared decision-making
processes. Although audio/video recorded clinical
encounters are commonly used for primary care teach-
ing purposes, such a technique can be potentially sensi-
tive and therefore will be restricted to a small number of
sites. Recordings will be conducted toward the end of
the intervention period when both health staff and
patients are thoroughly familiar with the system. This
will occur over a 1-week period at each site. Participants
who are approached for an interview will be invited to
participate in this component. They will be given the
option of having their healthcare encounter audio or
video recorded. A follow-up interview will be arranged
with these participants (both staff and patients) where
the recording is played back for participant interpret-
ation of the data.
These data will be supplemented by project ofﬁcer
ﬁeld notes to identify any key processes, events, stafﬁng
and other resource issues occurring during the
intervention period that may be relevant in gaining a
better understanding of barriers and facilitators to
implementation.
A multidisciplinary research team will guide the ana-
lysis process. As is common with qualitative inquiry, data
analysis will commence early and be conducted
contemporaneously with data collection. This method
allows for interview content to be reﬁned for subsequent
data collection and to actively pursue emergent themes
of interest. Although interviewing will continue until
thematic saturation is achieved and therefore the exact
number of interviews is unknown, we anticipate from
prior experience that around 80 interviews (40 patients
and 40 staff) will provide sufﬁciently rich data to meet
our objectives.
Interview data will be digitally recorded, and profes-
sionally transcribed. NVivo 9 (QSR International
Melbourne, Victoria, Australia) will be used to assist with
data organisation and coding for key themes. Video data
will be directly analysed and coded for key themes
within NVivo. Feedback of ﬁndings to participants will
be provided by a variety of methods, including work-
shops, summary reports, newsletters and via the study
website.
ETHICAL CONSIDERATIONS
The general practice component of the study is
approved by the University of Sydney Human Research
Ethics Committee (HREC) and the ACCHS component
is approved by the Aboriginal Health and Medical
Research Council HREC. Formal agreements with each
of the participating sites have also been signed.
Quantitative data will be obtained from deidentiﬁed clin-
ical audits. Ethical approval to grant waiver of the usual
requirement to obtain individual patient consent has
been obtained. In participating ACCHS sites, eligible
patients can request to ‘opt out’ from having data in the
clinical audit data extracts exported. Data exports will be
compliant with privacy legislation, centrally managed by
the George Institute and held in strict conﬁdence. Some
individual health professionals (GPs, practice nurses,
etc) and patient participants will have their informed
consent taken at the site to allow data collection
through semistructured in-depth interviews and/or
the use of audio/videotaped healthcare encounters.
Participation in this component will be optional. Patient
information statements and consent forms have been
approved by each ethics committee and formatted in
accordance with their own guidelines and requirements.
The study will be conducted in accordance with the
principles set out in the National Health and Medical
Research Council and the NSW Aboriginal Health and
Medical Research Council guidelines. Speciﬁc effort will
be taken to respect the autonomy and governance of
participating ACCHSs. The intellectual property rights
of ACCHSs will be recognised and preserved. It is also
recognised that ACCHSs have rights and responsibilities
regarding the use of health-related information for their
attending clients. Collaborators on the TORPEDO study
will be encouraged to disseminate information from the
project in a manner that supports health improvement
for Aboriginal and Torres Strait Islander peoples and
local beneﬁt to participating ACCHSs.
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DISCUSSION
The TORPEDO study will seek to provide reliable evi-
dence about the effectiveness of QI interventions
incorporating EDS in Australian primary care settings.
The implications of use of such systems for CVD risk
management extend well beyond being a point-of-care
clinical resource. Improving health system performance
is central to the aims of this initiative and this is espe-
cially pertinent to addressing Aboriginal health inequi-
ties where the CVD burden is ﬁve-fold greater. There is
potential for substantially better health outcomes
from CVD in Australia with improved implementation of
existing evidence in primary healthcare, where most of
the opportunity to manage cardiovascular risk occurs.
The strategy proposed is the ﬁrst of its kind in Australia
and is strongly aligned with national strategy recom-
mendations for health system reform. If effective,
HealthTracker could have widespread applicability
for the prevention and management of other chronic
diseases.
Strengths and limitations of this study
The strengths of the study are that it assesses an in-
novative complex intervention that is implemented in
routine primary healthcare settings. It will provide rigor-
ous evidence on process, clinical and economic out-
comes and addresses an important issue facing health
systems worldwide—namely scalable interventions that
are able to achieve improvements in performance.
The main limitation is that it is conducted in one
country, Australia, and thus its generalisability may be
inﬂuenced by the prevailing health system context.
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research
There is growing interest in the use of 
primary healthcare data for multiple 
purposes, including health professional 
audits, quality improvement programs and 
research. A critical enabling factor is the 
availability of data extraction tools to audit 
patient databases for information such 
as patient demographics, data quality, 
disease profiles, risk factor measurements, 
pathology testing, immunisation and 
cancer surveillance, use of medicines and 
Medicare item uptake. Several extraction 
tools are now available that interface 
with the major primary healthcare 
software systems. These tools are used 
by healthcare providers for practice 
audits and by many organisations such as 
Medicare Locals, Aboriginal Community 
Controlled Health Services (ACCHSs), 
the Australian Primary Care Collaborative 
(APCC) program and the National 
Prescribing Service.1–3 These tools are 
also being used for national indicator 
programs, including the former Divisions 
of General Practice indicator program,4 
the Queensland Aboriginal and Islander 
Health Council indicator program,5 the 
Northern Territory and the National 
Key Performance Indicator programs.6,7 
Increasingly, researchers are also using 
these tools to facilitate data collection.8 
Few studies have assessed the validity 
of these tools in Australia and generally 
these have been secondary considerations 
to the main objectives.9–11 
In this study, we assessed how accurately 
one of the most commonly used audit tools 
extracted data from patient record systems. 
The study forms part of the Treatment Of 
cardiovascular Risk in Primary care using 
Electronic Decision suppOrt (TORPEDO) study. 
TORPEDO is a cluster randomised controlled trial 
examining the effectiveness of a multi-faceted 
quality improvement intervention to improve 
cardiovascular disease (cVD) risk screening 
and management. sixty health services are 
participating (40 general practices and 20 
Acchss) in New south Wales and Queensland. 
Full details of the study protocol have been 
published elsewhere.12 
Methods
TORPEDO involves extracting clinical data for all 
regularly attending patients (three visits in the 
previous 2 years and one visit in the previous 6 
months) in whom national guidelines recommend 
cVD risk screening (>35 years if Aboriginal and 
Torres strait Islander and >45 years for all others). 
Participating sites need to be exclusively using 
either Medical DirectorTM or best PracticeTM for 
their electronic health records (EhR) without any 
use of paper or hybrid paper/electronic recording. 
These software products currently comprise 
the majority of EhR systems used in Australia. 
Extractions are performed at baseline and end of 
study. Two de-identified data files are generated: 
(1) an individual patient data file that is sent 
to the coordinating research institute for trial 
analyses via a secure file transfer protocol; and 
(2) an aggregated data file that is sent to a web-
based portal via an identical mechanism as that 
used in the APcc program. Intervention arm sites 
can perform these extractions monthly and can 
view peer-ranked performance feedback data.
Variables are extracted on patient 
demographics, recorded diagnoses of chronic 
diseases, chronic disease risk factors, pathology 
tests and medications. We assessed the validity 
of the data extraction tool in detecting these 
variables from the two previously described EhR 
systems via a two-stage process.
Background
We assessed how accurately a 
common general practitioner (GP) 
audit tool extracts data from two 
software systems. 
Methods
First, pathology test codes were 
audited at 33 practices covering nine 
companies. Second, a manual audit of 
chronic disease data from 200 random 
patient records at two practices was 
compared with audit tool data.
Results 
Pathology review: all companies 
assigned correct codes for cholesterol, 
creatinine and glycated haemoglobin; 
four companies assigned incorrect 
codes for albuminuria tests, precluding 
accurate detection with the audit tool. 
Case record review: there was strong 
agreement between the manual audit 
and the tool for all variables except 
chronic kidney disease diagnoses, 
which was due to a tool-related 
programming error.
Discussion
The audit tool accurately detected 
most chronic disease data in two GP 
record systems. The one exception, 
however, highlights the importance 
of surveillance systems to promptly 
identify errors. This will maximise 
potential for audit tools to improve 
healthcare quality.
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Manual record audit
Table 1 highlights the patient characteristics 
for the 200 records audited. Table 2 outlines 
the level of agreement/correlation for the 
23 variables manually audited. Overall, the 
majority of variables achieved perfect or near 
perfect agreement/correlation. There was, 
however, one notable exception related to 
chronic kidney disease (cKD). criteria for cKD 
were based on national guideline definitions 
and included a recorded diagnosis of cKD or 
proteinuria or an estimated glomerular filtration 
rate (eGFR) < 45ml/min/1.73m2. There were 
several cases where the extraction tool seemed 
Results
Pathology audit
Thirty-three sites had pathology data audited 
covering nine laboratories in New south Wales and 
Queensland. All laboratories were using the correct 
lOINc codes for total cholesterol, high-density 
lipoprotein cholesterol, low-density lipoprotein 
cholesterol, triglycerides, creatinine and hbA1c. There 
were, however, marked variations in codes used 
for uAcR. Four laboratories used incorrect codes, 
precluding accurate extraction of results for these 
tests. All pathology companies were notified and 
instructed on the correct codes to use for this test.
Stage 1: Pathology review
For extraction tools to accurately collect 
pathology data, laboratories must submit test 
results in a standard format (health level 
seven [hl-7]) and assign a unique code per 
test (logical Observation Identifiers Names 
and codes [lOINc]). Prior to validating the tool 
itself, we reviewed pathology reporting for 
plasma cholesterol, creatinine and glycated 
haemoglobin (hbA1c), and urinary albumin 
to creatinine ratio (uAcR). As a condition of 
participating in TORPEDO we mandated that 
all sites have their pathology reported in hl-7 
format. We then reviewed pathology extracts 
from a sample of health services covering all 
the laboratories in the TORPEDO study. These 
extracts identified what lOINcs were being 
reported for the tests in question and from 
these data we determined whether they were 
concordant with those searched for with the 
data extraction tool.
Stage 2: Manual case record 
audit at two general practices
Two hundred records (100 per practice) from 
patients in the eligible age range for TORPEDO 
were randomly selected. The two sites were 
urban sydney practices participating in the 
intervention arm of TORPEDO. One site used 
Medical DirectorTM and the other used best 
PracticeTM. Audits were conducted as part of a 
12-month follow-up visit. both sites had shown 
some mild improvement in data quality over the 
intervention period. A research assistant reviewed 
the following sections of the record: demographic 
details, diagnoses, past medical history, physical 
risk factor measurements, current medications 
and pathology results, encompassing 23 chronic 
disease-related variables. Free text entries in 
progress notes were not reviewed. A fresh data 
extraction was simultaneously performed and 
securely sent to the research institute. Data 
entered from the manual record audit and that 
obtained from the individual patient data extract 
were compared. Kappa statistics were used 
for categorical variables and bland–Altman 
plots were constructed for continuous variables 
with the mean differences and 95% limits of 
agreement reported.13 Analyses were conducted 
using sAs Enterprise Guide (v. 4.5; sAs Institute, 
cary, Nc, usA)
Table 1. Patient characteristics obtained from the manual case record 
audit tool (n = 200)
Risk factor measurement Mean (SD) or 
n (%) in those 
with available 
information
No of records 
with available 
information      
(% total)
Demographic information
Age (years) 66.2 (12.5) 200 (100)
Male 93 (47) 200 (100)
Risk factor measurements 
Current smoker 29 (20) 145 (73)
BMI (kg/m2) 31.5 (8.8) 97 (49)
Systolic blood pressure (mmHg) 129.1 (15.4) 179 (90)
Diastolic blood pressure (mmHg) 79.1 (10.0) 179 (90)
Pathology laboratory measurements 
Total cholesterol (mmol/L) 5.1 (1.2) 157 (79)
HDL cholesterol (mmol/L) 1.4 (0.4) 155 (78)
LDL cholesterol (mmol/L) 2.8 (0.9) 153 (77)
Triglycerides (mmol/L) 1.9 (1.2) 157 (79)
Urinary albumin to creatinine ratio (mg/
mmol)
6.8 (24.3) 93 (47)
Creatinine (umol/L) 78.7 (28.3) 147 (74)
HbA1c (%) 6.4 (1.3) 112 (56)
Past medical history n (%)
Coronary heart disease 30 (15)
Ischaemic stroke/transient ischaemic 
attack
15 (7.5)
Peripheral vascular disease 6 (3)
Left ventricular hypertrophy 0 (0)
Atrial fibrillation 11 (5.5)
Heart failure 11 (5.5)
Diabetes 41 (20.5)
Abbreviations: BMI = body mass index; HbA1c = glycated haemoglobin; HDL = 
high-density lipoprotein; LDL = low-density lipoprotein; SD = standard deviation
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as a result of this study, was identified to be a 
programming error and subsequently fixed. We 
also found wide discrepancies in the coding of 
cKD-related test results by various laboratories. 
This affects the ability of any data extraction tool 
to accurately detect pathology test results for this 
condition. 
An important study limitation is that it was 
‘fit for purpose’ for the chronic disease-related 
variables used in TORPEDO and for the population 
recommended for cVD risk screening. We cannot 
make any assumptions, therefore, about validity 
for other disease areas. Another limitation is that 
we looked at interaction between one extraction 
tool and two GP EhR systems. Although these are 
the most commonly used systems in Australia, 
we cannot extrapolate findings to other systems. 
A final limitation is that we only included data 
that could potentially be extracted from the 
EhR. If a practitioner is making free text entries 
rather than in codable sections of the record 
then neither the extraction tool nor our manual 
case record reviewer would have detected those 
entries. 
The Australian health care system is 
rapidly evolving to incorporate an information 
communication technology (IcT) infrastructure 
that will enable data to be shared across 
multiple platforms. The primary health care 
sector is a leading driver of this change. GPs 
and Acchss were early adopters of EhRs and 
are now leading developments in use of data for 
quality improvement, key performance indicator 
reporting, secure messaging, and the personally 
controlled e-health record. The ability to extract 
data reliably and consistently is central to 
supporting these activities. 
There are two clear recommendations from 
the study. First, there is a critical need for 
consistent reporting of pathology tests across 
all laboratories. second, the lack of agreement 
for variables associated with cKD recording, 
although in retrospect was able to be explained, 
highlights the importance of establishing regular 
surveillance procedures that are independent of 
any validation work conducted by the software 
vendors themselves. Whenever new code is 
written, either for the extraction tools or within 
the EhR system itself, there is potential for errors 
in the data extraction process. National programs 
such as the APcc are well placed to establish 
to inappropriately assign a diagnosis of cKD 
where no such criteria could be identified from 
the manual record review. This was subsequently 
identified to be a problem in the way the tool 
extracted eGFR values from one pathology 
company. If the result reported a non-integer 
value (eg. >90 ml/min), this defaulted to a zero 
value and hence met one of the cKD criteria 
(eGFR <45 ml/min). The software company was 
notified and a fix was put in place. There was 
also low agreement with uAcR tests. This is 
likely to not be a problem related to the tool per 
se, but related to incorrect lOINc coding by one 
of the pathology companies used at that practice.
Discussion
In this study we found that data extraction using 
one of the most commonly used tools in Australia 
was highly consistent with manual reviews of the 
data for all variables except cKD recording which, 
Table 2. Agreement/correlation statistics between the audit tool and 
manual case record audit for 200 patient records from two general 
practices 
Variable Agreement (kappa) (95% CI where applicable)
Aboriginal status 1.00
Smoking status 1.00
Recorded diagnoses
Coronary heart disease 0.95 (0.90–1.00)
Peripheral vascular disease 1.00
Stroke 0.96 (0.89–1.00)
Atrial fibrillation 1.00
Left ventricular hypertrophy 1.00
Congestive heart failure 0.95 (0.85–1.00
Diabetes 1.00
Gestational diabetes 1.00
Chronic kidney disease 0.24 (0.00–0.48)
Chronic disease risk factor 
measurements
Mean difference* (95% 
limits of agreement 
where applicable)
No of readings 
where difference > 
2SD (%)†
Weight (kg) 0.001 (–0.51–0.51) 2 (1.0)
Height (cm) 0 0 (0)
Waist circumference (cm) 0 0 (0)
Systolic blood pressure (mmHg) 0.06 (–1.8–1.6) 3 (1.5)
Diastolic blood pressure (mmHg) 0.14 (-4.9–5.2) 2 (1)
Total cholesterol (mmol/l) 0.02 (–0.37–0.34) 6 (3)
HDL  (mmol/l) 0.002 (–0.03–0.04) 0 (0)
LDL (mmol/l) 0.03 (–0.52–0.46) 2 (1)
Triglycerides (mmol/l) 0.02 (–0.65–0.62) 6 (3)
Creatinine (µmol/l) 0.7 (–10.1–8.8) 5 (2.5)
HbA1c (%) 0.001 (–0.18–0.19) 2 (1)
Urinary albumin to creatinine 
ratio (mg/mmol)
9.7 (–71.7–91.0) 0 (0)
Abbreviations: SD = standard deviation
*The mean difference between the readings obtained from the manual audit vs the 
audit tool with zero indicating perfect agreement for all readings
†Derived from constructing Bland–Altman plots for each variable
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such surveillance systems. This program receives 
monthly aggregated data from a large number 
of practices. Automated warning systems for 
unexpected deviations in these routinely collected 
data would enable early detection of potential 
problems. A sentinel network of practices that 
routinely extracted data could complement such a 
surveillance system. As we become increasingly 
reliant on IcT systems for both clinical care and 
system improvements, it is important that action 
be taken to ensure these systems are robust.
Implications for general 
practice
•	The audit tool used in this study was reliable 
for most chronic disease-related measurements 
with the exception of cKD diagnoses.
•	 Inaccurate pathology data extracted from audit 
tools is due to laboratories assigning incorrect 
codes to test results.
•	National initiatives to independently and 
regularly review the quality of data obtained 
from data extraction tools are needed.
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Abstract. The aim of this study is to investigate the utilisation of Medicare Beneﬁt Scheme items for chronic disease in
the management of cardiovascular disease (CVD) in general practice and to compare characteristics of CVD patients
with and without a General Practice Management Plan (GPMP). Subgroup analysis of Treatment of Cardiovascular
Risk using Electronic Decision Support (TORPEDO) baseline data was collected in a cohort comprising 6123 patients
with CVD. The mean age (s.d.) was 71 (13) years, 55% were male, 64% had a recorded diagnosis of coronary heart
disease, 31% also had a diagnosis of diabetes and the mean number of general practice (GP) visits (s.d.) was 11 (9) in
12 months. A total of 1955/6123 (32%) received a GPMP in the 12 months before data extraction; 1% received a Mental
Health Plan. Factors associated with greater likelihood of receiving a GPMP were: younger age, had a diagnosis of
diabetes, BMI > 30 kgm–2, prescription of blood pressure-lowering therapy and more than ten general practice visits.
Enhancing utilisation of existing schemes could augment systematic follow up and support of patients with CVD.
Received 21 December 2016, accepted 30 May 2017, published online 27 July 2017
Introduction
Cardiovascular disease (CVD), including coronary heart disease
(CHD), is a leading cause of morbidity and mortality globally
(World Health Organization 2014). In recent decades, mortality
associated with CHD has decreased substantially in developed
countries due to the improving pharmacological therapies,
revascularisation procedures and prevention programs (World
Health Organization 2014). However, patients with prior CVD
are at high risk of recurrent events and approximately one-
quarter will be readmitted to hospital within 1 year of an index
event (Briffa et al. 2011). In 2010, more than 25 000 Australian
hospital separations were associated with repeat cardiovascular
admissions at a cost of more than A$600million in direct
costs alone (Deloitte Access Economics 2011). The associated
challenge is that more people are surviving cardiovascular
events, hospital stays are becoming much shorter and there
are growing numbers of people living with CVD requiring
ongoing secondary prevention (Redfern et al. 2011). Secondary
prevention strategies (including lifestyle change and adherence
to evidence-based medication) provide an effective way of
reducing CVD morbidity and mortality (Clark et al. 2005).
However, once people leave hospital, only ~50% adhere to
recommended medicines (Rasmussen et al. 2007) and, at best,
30% achieve lifestyle modiﬁcation (Chow et al. 2010). Therefore,
a more systematic approach is needed to improve the quality of
ongoing care for people living with CVD.
Primary health care can be described as the frontline of
Australia’s healthcare system, and that CVD is a chronic disease
requiring lifelong management; this offers the ideal environment
for closing evidence-practice gaps. Research suggests that a
strong primary care system is associated with reduced costs,
increased efﬁciency, lower rates of hospitalisations, increased
patient satisfaction and better health outcomes (Department of
Health 2013). In 2016, the Australian Government identiﬁed the
need for development of a ‘Medicare payment system to reward
and encourage best practice and quality improvement in chronic
disease prevention and management’ (Department of Health
2016). Later in 2016, a consultation paper was released by the
Department of Health that outlines how and why the practice
incentive payment (PIP) could be redesigned with a greater focus
on quality improvement with better use of data (Department of
Health 2016). The redesign aligns with previous calls from the
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House of Representatives identifying the need for a Medicare
payment system to reward and encourage quality in chronic
disease prevention and management (Department of Health
2016). These discussions are likely to see opportunities for
changes in how chronic conditions such as CVD are supported
and managed, and hence understanding existing models and
services and their utilisation is important at this time.
In Australia, the publically funded universal health insurance
scheme, known as the Medicare Beneﬁts Scheme (MBS), is the
primary fundingmechanism for primary health care. The scheme
includes subsidies for treatment and services (identiﬁed through
Item Numbers) provided by suitably qualiﬁed professionals such
as (but not limited to) medical practitioners, nurse practitioners
and allied health providers (Department of Health 2015). The
scheme includes several Item Numbers intended to support
ongoingmanagement of people with chronic medical conditions.
These Item Numbers provide an opportunity to plan and monitor
care in an ongoing and regular way. The Chronic Disease
Management (formerly Enhanced Primary Care) MBS Items
enable GPs to plan and coordinate the health care of patients with
chronic or terminal medical conditions, including patients with
these conditions who require multidisciplinary, team-based
care from a GP and at least two other health or care providers
(Department of Health 2015). To be eligible, patients must
have a chronic or terminal medical condition (with or without
multidisciplinary care needs), where a ‘chronicmedical condition’
is one that has been or is likely to be present for at least 6 months
(Department of Health 2015). The Chronic DiseaseManagement
Items include a GP Management Plan (GPMP) and Team Care
Arrangements (TCA), which are designed to support those with
complex conditions who require coordinated and multidisciplinary
care. They are intended to be provided and coordinated by the
patient’s usual GP. However, despite these Items being introduced
with the aim of improving care of people with chronic disease,
their rate of implementation and use in a CVD population
remains unexplored.
Additional MBS Items support access to allied health
and mental health services. These include services from
individual allied health providers, including (but not limited
to) physiotherapists, Indigenous health workers, occupational
therapists and psychologists (Department of Health 2015). The
TCA Item supports the GP in working with other providers
and for the care provided by those providers to be renumerated
through the MBS (Department of Health 2015). There are also
MBS Items that support access to psychological care and
professionals with expertise in behaviour modiﬁcation among
others. Previous research has suggested that care plans can
improve outcomes for people with chronic conditions including
diabetes (Zwar et al. 2007; Mitchell et al. 2008; Comino et al.
2015). Increasing our understanding about the utilisation of these
Items for people living with CVD could inform opportunities for
system-level improvements that may also inﬂuence outcomes.
The aim of this study is to conduct a subanalysis of existing
baseline study data to investigate the utilisation of MBS Items to
support the management of CVD in people presenting to primary
care and to compare demographic and clinical characteristics
of those with and without a GPMP.
Methods
This study is a subanalysis of Treatment of Cardiovascular
Risk using Electronic Decision Support (TORPEDO) Study
data relating to use of chronic disease Medicare Items to support
chronic disease management. Details of themethods and primary
results of the TORPEDO Study are reported elsewhere (Peiris
et al. 2012, 2015) In brief, the TORPEDO Study was a parallel
arm, cluster-randomised controlled trial involving 40 general
practices and 20 Aboriginal Medical Services across NSW,
Australia. Primary care services were eligible to participate if
there was exclusive use of one of the two compliant software
systems to record MBS Items numbers claimed, risk factor
information, pathology test results and prescribed medications,
and a willingness from all staff to use the intervention (Peiris
et al. 2012). The TORPEDO Study aimed to assess whether
a multifaceted quality-improvement intervention comprising
point-of-care electronic decision support, audit and feedback
tools, and clinical workforce training, improved CVD risk
management when compared with usual care (Peiris et al.
2012). The full TORPEDO cohort comprised 38 725 patients
(10 308 high CVD risk at baseline). At follow up, the proportion
of patients with recommended CVD risk factor measurements
was higher in the intervention than control arm (63 v. 53%,
P = 0.02) (Peiris et al. 2015). There were also signiﬁcant
treatment escalations (new prescriptions or increased numbers
of medicines) for antiplatelet (17.9 v. 2.7%; P < 0.001), lipid-
lowering (19.2 v. 4.8%; P < 0.001) and blood pressure-lowering
medications (23.3 v. 12.1%; P= 0.02) (Peiris et al. 2015). The
TORPEDO Study has ethics approval from the University of
Sydney Human Research Ethics Committee (HREC) and the
Aboriginal Health and Medical Research Council HREC.
Individual consent waiver was granted given data collection was
based on de-identiﬁed extracts from electronic health records
(Peiris et al. 2012, 2015).
Participants with CVD and Medicare data available
The eligible population for this subanalysis, of baseline data
was deﬁned as all Aboriginal and Torres Strait Islander people
35 years and all others 45 years (based on vascular risk
screening recommendations; Anderson et al. 1991) who had
a documented diagnosis of established CVD (diagnosis of
CHD, cerebrovascular disease, peripheral vascular disease)
and attended the primary care service at least three times in the
previous 24 months, including at least once in the previous
What is known about the topic?
* Despite the potential value and importance of government-
funded primary care chronic disease management items,
their rate of utilisation in a CVD population remains
unexplored.
What does this paper add?
* Only one-third of patientswith diagnosedCVD received
a GPMP, and enhancing utilisation of existing schemes
could facilitate systematic follow up and support for
patients living with CVD.
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6-months. All MBS Items claimed for the 12 months before
the date of data extraction were available from 44 of the primary
care sites (16 sites did not use compliant software billing
systems). The total number of participants from these sites with
documented CVD provided a cohort of 6123 participants for
the present subanalysis. Importantly, only allied health service
usage could be obtained for those services claimed via MBS
where a service was delivered within the practice.
Data collection
For the TORPEDO Study, de-identiﬁed data extractions from
databases at participating practices were completed using a
validated data extraction tool for all patients who met the
eligibility criteria (Peiris et al. 2013). These extracts were
securely uploaded to the coordinating research institute’s study
database (Peiris et al. 2015). An encrypted identiﬁer code was
attached to each patient extract to allow for longitudinal
comparisons and subsequent extraction of MBS data from GP
electronic records using third-party software. One month before
primary data collection, an extraction was performed to assess
data quality. A brief report was sent to all services highlighting
areas where data quality issues may have been occurring.
Following this quality check, data were extracted for all eligible
patients at all participating practices. The extraction provided
clinical and demographic data at an individual level.
Statistical analysis
Data extracted at baseline for the TORPEDO Study were
used for this subanalysis. Descriptive statistics are means
(standard deviations), frequencies or proportions as appropriate.
Independent t-test or Chi-Square tests were computed to compare
demographic and clinical characteristics. Patient- and practice-
level data analysis was performed to explore the factors
associated with increased likelihood of receiving a GPMP (Item
#721), in the previous 12 months, for CVD patients using
multiple adjusted multilevel logistic regression model with
random intercept to account for clustering of patients within
services. A list of independent variables was chosen to be
included in the multivariable model if they were statistically
signiﬁcant on univariate testing at an a-level of 0.2, and then
according to the clinical signiﬁcance, some variables were
included or excluded regardless of their statistical signiﬁcance.
The patient-level variables included in the model were: age
divided into four quartiles (<61, 61–71, 72–81 and >81 years),
gender, CHD, diabetes, Aboriginal or Torres Strait Islander
status, body mass index (BMI) (>30 kgm–2 v. not), systolic
blood pressure (SBP) (>140mmHg v. not), total cholesterol (TC)
(>4.5mmolL1 v. not), anticoagulant, antiplatelet, blood pressure
(BP)-lowering statin or other lipid-lowering medication and GP
visit (>10 v.10 visits), and the practice-level variable included
was participation in a structured quality improvement initiative
outside the context of the study. Examples of structured quality
improvement initiatives included (but were not limited to)
the Australian Primary Care Collaboratives Program, Divisions
of General Practice Indicator Programs and the Audit and
Best Practice for Chronic Disease Extension Project. The odds
ratios and the corresponding 95% conﬁdence intervals from
the multivariable model were plotted on a forest plot. Data were
analysed using SAS, ver. 9.4, for Windows (SAS Institute Inc.
Cary, NC, USA).
Results
Demographic and clinical characteristics of those
with and without care plans
Demographic and clinical characteristics for those with (n=1955)
and without (n= 4168) a GPMP are presented in Table 1. The
mean age (s.d.) of the total cohort (n= 6123) was 71 13.1
years; 55% were male, 64% had a documented diagnosis of
CHD and 31% had a documented diagnosis of diabetes. The
mean number of GP visits in the 12 months was 11.4 8.8
(Table 1). Regarding CVD risk factors, 17% were current or
recent smokers, the mean TC (s.d.) was 4.36 1.11mmol L1,
the mean SBP (s.d.) was 132.2 18.3mmHg and 29% had
a BMI > 30 kgm–2. A diagnosis of CHD, peripheral vascular
disease, diabetes, BMI > 30 kgm–2 and prescription of lipid-
lowering, antiplatelet medication, BP lowering medication,
as well as those who saw their GP more frequently, were
associated with a signiﬁcantly higher rate of receiving a care plan
than not receiving a care plan (Table 1).
Utilisation of MBS items
A total of 1955 (32%) patients with CVD had a GPMP
prepared in the 12 months before data extraction. For the
Indigenous subgroup (n = 1296), a total of 458 (35%) of the
patients had a GPMP in the 12 months prior (Table 1). We
also calculated the number of patients who had a GPMP or
a review and found it was 2676/6123 (44%). Although the
categories are not mutually exclusive, the majority of recorded
GP consultations were of standard length (87%) rather than
extended (12%) or short (20%) (Table 2). Patients with a
GPMP compared to those without a GPMP were signiﬁcantly
more likely to have standard (GPMP: 93% v. no GPMP: 84%,
P < 0.001) and long consultations (GPMP: 18% v. no GPMP:
10%, P < 0.001). A total of 24% of patients received a GPMP
review and 28% received a TCA (Table 2). There were very
few claims for the suite of mental health services (Table 2) and
also very few in-practice consultation claims with an allied
health provider (exercise physiologist, dietitian, occupational
therapist, physiotherapist all <1%) through the Medicare system
where the most commonly claimed service was for podiatry
at 3%.
We also compared utilisation of GPMPs based on practice
level characteristics. We found that there was no signiﬁcant
difference in the proportion of patients receiving a GPMP
based on whether they attended an ACHS or a primary care
practice (GPMP: 500/1510, 33% v. no GPMP: 1455/4613, 31%,
P=0.256) and the size of the practice (large: 1020/3247, 31% v.
small: 935/2876, 33%, P= 0.3582). Practice-level variation
in GPMP rate ranged from 0 to 75% (Mean (s.d.): 34% (19.3);
median (IQR): 33% (17.5, 47.5)). However, in this unadjusted
analysis, we found that practices who had participated in
quality improvement had a signiﬁcantly greater proportion of
patients with GPMPs (709/1955, 36%) than practices that
had not participated in quality improvement (1182/4168, 28%,
P< 0.001).
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Factors associated with the likelihood of receiving
a GPMP
The adjusted odds ratios (ORs) and 95% conﬁdence intervals
(CIs) describing the likelihood of receiving a GPMP are presented
in Fig. 1. Patient-level factors independently associated with
greater likelihood of receiving a GPMP were younger age,
diagnosis of diabetes, BMI 30 kgm–2, prescription of blood
pressure-lowering therapy and more frequent GP consultations.
Following adjustment, factors such as gender, diagnosis of
CHD, SBP and TC were not associated with receipt of a
GPMP. With adjusted analyses, practice-level characteristics,
including quality improvement, also were not signiﬁcantly
associated with receipt of a GPMP (Fig. 1).
Discussion
In this analysis of Medicare data from 6123 patients diagnosed
with CVD, we found that only one-third had received a GPMP
in the preceding 12 months. We did, however, ﬁnd that 44%
of the cohort had either a GPMP or a review in the 12-month
period. We also found that factors such as diagnosis of CHD
(compared to other CVD-related diagnoses) and high levels of
risk factors such as cholesterol and BP were not associated with
Table 1. Demographic and clinical characteristics of the cohort with established cardiovascular disease
GPMP, General Practice Management Plan (MBS Item #721); s.d., standard deviation; HDL, high-density lipoprotein; TG, triglyceride; LDL, low-density
lipoprotein; HbA1c, glycosylated haemoglobin ; BMI, bodymass index; SBP, systolic blood pressure; GP, general practice. P-values are the difference between
those with a GPMP and those without a GPMP
Variable GPMP (N= 1955) No GPMP (N= 4168) Total cohort (N= 6123) P value
Age, mean (s.d.) (years) 70.2 (12.3) 71.1 (13.4) 70.8 (13.1) 0.014
Male, N (%) 1093 (56) 2254 (54) 3347 (55) 0.169
Aboriginal or Torres Strait Islander, N (%) 458 (23) 838 (20) 1296 (21) 0.003
Coronary heart disease diagnosis, N (%) 1283 (66) 2625 (63) 3908 (64) 0.045
Cerebrovascular disease diagnosis, N (%) 367 (19) 750 (18) 1117 (18) 0.462
Peripheral vascular diagnosis, N (%) 154 (8) 223 (5) 377 (6) <0.001
Diagnosis of diabetes, N (%) 746 (38) 1174 (28) 1920 (31) <0.001
Atrial ﬁbrillation diagnosis, N (%) 453 (23) 975 (23) 1428 (23) 0.849
Diagnosis of chronic heart failure, N (%) 207 (11) 446 (11) 653 (11) 0.894
Cardiovascular risk factors
Current smoker, N (%) 313 (18) 596 (17) 909 (17) 0.414
SBP (mm Hg), mean (s.d.) 131.6 (17.9) 132.5 (18.5) 132.2 (18.3) 0.089
SBP > 140 mm Hg, N (%) 480 (26) 1032 (28) 1512 (27) 0.148
Total cholesterol (mmol), mean (s.d.) 4.35 (1.1) 4.37 (1.1) 4.36 (1.11) 0.598
Total cholesterol> 4.5, N (%) 593 (37) 1237 (38) 1830 (37) 0.539
HDL (mmol), mean (s.d.) 1.26 (0.4) 1.30 (0.4) 1.28 (0.41) 0.005
TG (mmol), mean (s.d.) 1.68 (1.02) 1.60 (1.4) 1.63 (1.3) 0.041
LDL (mmol), mean (s.d.) 2.36 (1.1) 2.38 (0.9) 2.38 (1.0) 0.466
HbA1c for those with diabetes, mean (s.d.) 7.44 (4.5) 7.39 (4.5) 7.41 (4.5) 0.803
BMI > 30 kg m–2, mean (s.d.) 694 (35) 1072 (26) 1766 (29) <0.001
Cardiovascular medications prescribed
Statins or other lipid lowering, N (%) 1500 (77) 2919 (70) 4419 (72) <0.001
Antiplatelet, N (%) 1336 (68) 2701 (65) 4037 (66) 0.007
Blood pressure-lowering, N (%) 1738 (89) 3462 (83) 5200 (85) <0.001
Anticoagulant, N (%) 335 (17) 678 (16) 1013 (17) 0.394
GP visits
Mean number of visits (s.d.) 13.7 (9.0) 10.4 (8.5) 11.4 (8.8) <0.001
>10 visits in 12 months, N (%) 1092 (56) 1602 (38) 2694 (44) <0.001
Table 2. Health service utilisation according to MBS item claims by
the cohort with established CVD
CVD, cardiovascular disease;MBS,Medicare Beneﬁts Scheme; GP, General
Practitioner; GPMP, General Practice Management Plan; TCAs, Team Care
Arrangements
Total cohort, N (%)
(Practices = 44, n= 6123)
General practice consultations
MBS Item 3 – Brief GP consult 1224 (20)
MBS Item 23 – Standard GP consult 5304 (87)
MBS Item 36 – Long GP consult 3321 (54)
MBS Item 44 – Extended GP consult 764 (12)
Chronic disease management and team care arrangements
MBS Item 721 – Preparation of a GPMP 1955 (32)
MBS Item 732 – Review of GPMP or TCA 1453 (24)
MBS Item 723 – Coordination of TCA 1687 (28)
Mental health and psychology items
MBS Item 2713 – Mental Health Treatment
Consultation
159 (3)
MBS Items 2700, 2701, 2715, 2717, 2712 –
Preparation or review of a GP Mental
Health Treatment Plan
77 (1)
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an increased likelihood of receipt of a GPMP. Overall, there
appears to be a signiﬁcant gap in the utilisation of Medicare-
funded Items for this population of Australian patients with
CVD who were attending primary care.
Our results align with previous Australian chronic disease
studies. One study reported only 50% of patients with chronic
disease were receiving optimal management and that a change
in the health system, both in policies and in attitudes, was
required (Infante et al. 2004). Further studies have reported that
GPs were often discouraged from using the chronic disease
management (CDM) items. Reported barriers have included
time constraints and reported difﬁculty in staying up to date
with changing eligibility criteria (Blakeman et al. 2002). Other
reported barriers include inadequate infrastructure, lack of items
that nurses can use to assist with implementation and lack of
available allied health staff, particularly in rural areas (Holden
et al. 2012). Importantly, a systematic review of comprehensive
primary healthcare models found that CDM items were
associated with patients reporting increased quality of care,
improved clinical measures (e.g. BP and blood cholesterol) and
increased knowledge of conditions and management, as well as
GPs reporting greater patient satisfaction (McDonald et al.
2006). A recent study of diabetic patients (n = 20 433) found
that claims for annual cycles of care and review of GPMPs or
TCAs were associated with reduced likelihood of hospitalisation
(Comino et al. 2015). However, secondary prevention of CVD
in primary care is not speciﬁcally incentivised in a similar way
to schemes available for other conditions such as diabetes.
In the case of CVD, ongoing secondary prevention is
recommended in all the major national and international
guidelines (Aroney et al. 2006;Steg et al. 2012). These guidelines
recommend use of evidence-based medications, risk factor
management, lifestyle modiﬁcation (including physical activity,
diet and smoking cessation), screening for psychosocial factors,
as well as education and provision of monitoring and support
(Aroney et al. 2006; Steg et al. 2012). Clearly, if the World
Health Organization global targets are to be met, an overall
‘strengthening’ of prevention is needed in terms of planning,
service delivery and policy (Perel et al. 2015). Initiatives aimed
at supporting primary care to better enable delivery of ongoing
prevention are of pivotal importance (Redfern and Chow
2013). The Bettering the Evaluation and Care of Health
program (BEACH) report in Australia found that 12% of current
problems managed by GPs are cardiovascular related (Britt
et al. 2015). An Australian study in a small acute coronary
syndrome (ACS) cohort (n= 108) found the majority of
patients visited their GP on at least ﬁve occasions (85%) and
a cardiologist at least once (63%) in the 12 months after
hospital discharge (Redfern et al. 2010). Similar results have
been reported based on the CONCORDANCE Registry, where
Age (4 Groups) Group 1 v. Group 4
Group 2 v. Group 4
Group 3 v. Group 4
Age (4 Groups)
Age (4 Groups)
Gender
Indigenous
Statin or other lipid lowering therapy
Antiplatelet
Blood pressure lowering therapy
Anticoagulant
Body mass index > 30 kg m–2
Total cholesterol > 4.5 mmol L–1
Systolic blood pressure > 140 mm Hg
Diagnosis of coronary heart disease
Diagnosis of diabetes
GP visit >10
Quality improvement
.5 1 2 3
1.14 (0.58, 2.27)
2.25 (1.94, 2.61)
1.49 (1.27, 1.74)
1.04 (0.88, 1.21)
0.90 (0.76, 1.05)
1.04 (0.89, 1.21)
1.17 (1.01, 1.37)
1.05 (0.84, 1.32)
1.46 (1.17, 1.83)
1.08 (0.91, 1.30)
1.18 (0.99, 1.42)
1.01 (0.74, 1.38)
1.03 (0.89, 1.19)
1.27 (1.03, 1.56)
1.38 (1.11, 1.71)
1.14 (0.90, 1.45)
Odds ratio (95% CI)
Fig. 1. Factors associated with increased likelihood of receiving a General Practice Management Plan (GPMP) plan (after adjustment for all other
included variables).
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96% of patients visited their GP at least once within the 6 months
after their index event, and 35% visited their GP more than ﬁve
times during the same period (Hyun et al. 2016). These studies
indicate that the majority of patients present frequently to their
GP and each of these visits offers an opportunity to support
CVD prevention and management.
It is difﬁcult to pinpoint exactly why patients with CVD are
not receiving more systematic care via existing MBS Items. It
is likely to be a multidimensional issue. The case is somewhat
different for diabetes, where there are complimentary activities
available to GPs including PIPs, annual cycles of care and
speciﬁc roles for Diabetes Educators. Historically, management
of diabetes has required these services to enable access to
subsidised services for such aspects of care such as foot care and
glycaemic control. However, people with CVD also require risk
factor management for aspects such as blood pressure and
cholesterol management and access to allied health services
such as dietary and physical activity advice and support. This
present research highlights an evidence-practice gap for CVD
management, and it is anticipated that the results will help
facilitate primary care strengthening in the area of CVD
management. It is possible that GPs assume that CVD
management is the role of cardiologists, leaving some patients
to miss out receiving a GPMP. All of these together may be
important drivers of why CVD management of patients lacks
systematic care. Qualitative research could also help inform
current knowledge.
Our results show that despite the availability of MBS Items
to support chronic disease management, these are not commonly
utilised for patients with CVD. Perhaps one strategy for making
CVD management more systematic is better use of routinely
collected data with support for practice-level quality improvement
(Department of Health 2016). For example, electronic medical
record systems and third party software systems usually have
built-in ability to set recall and reminder alerts that enable
practices to identify missed claiming opportunities and be
proactive about managing patients with chronic diseases such
as CVD. Such an approach, which aligns with the current
government focus on strengthening primary care, and the
potential for improved service delivery through increased
utilisation of existing MBS Items, is a potential strategy for
improving management of CVD (Department of Health 2016).
The concept also identiﬁes potential importance for strategies
such as Health Care Homes, which will provide bundled upfront
and quarterly payments to recognise the time and effort that
GPs and nurses invest into patients with chronic conditions.
There are several study limitations to this research. First, the
services recruited for the TORPEDO study did not represent a
random sample of primary healthcare services in Australia. All
of the general practices were located in urban areas, whereas
~30% of Australian general practices are in rural or remote
areas. Second, the study population for the TORPEDO study
was restricted to regular attendees of the primary healthcare
service. Regular attendees are commonly used in the denominator
for quality improvement indicators and for the purposes of
the randomised trial; it was important to deﬁne a fairly stable
population to test the effect of the intervention. Our data do
not capture primary care attendances at practices outside the
participating sites. However, this means that we are unable
to extrapolate the ﬁndings to infrequent attenders who may
exhibit different demographic, health and healthcare seeking
characteristics. Third, we were unable to capture attendance at
privately funded and non-practice allied health services such
as physiotherapy and dietetics for the management of CVD risk
factors. However, despite a signiﬁcant proportion potentially
attending non-Medicare-funded allied health providers, our
results highlight opportunities to improve access to care and
Medicare-funded services provided by dietians, physiotherapists
and exercise physiologists, etc. We also acknowledge that some
of the independent variables included in the regression could be
somewhat interdependent, and our data do not enable speciﬁc
determination of the relationships. This includes the potential
that unobserved variables may be driving practice-level variation
such as practice management structure, team environment
and provider leadership. Further research, including collection
of qualitative data, would enhance our understanding of
why provision of systematic care appears to be suboptimal for
patients with CVD and to explore the rate of allied health service
utilisation.
Conclusion
Only one-third of patients with diagnosed CVD and who
frequently attend primary care had received a chronic disease
management plan from theirGPat a practice studied inTORPEDO
in the preceding 12 months. This study provides unique insights
into the utilisation of MBS Items related to chronic disease
management and highlights signiﬁcant opportunities for enhanced
utilisation of existing health service-funded management plan
systems. Findings also suggest that those with CHD and who
have diabetes or are overweight are most likely to receive a
management plan. Enhancing utilisation of existing services
funded through Medicare could reduce the CVD burden and
enhance systematic follow up and support for these patients.
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